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ABSTRACT 
 
Proinsulin is an auto-antigen in type 1 diabetes in the Non-obese Diabetic (NOD) 
mouse. The CD8+ T cell clone, G9C8, which utilises a T cell receptor (TCR) 
comprising TRAV8-1*01TRAJ9 and TRBV19*01TRBD1TRBJ2-3,  recognises insulin 
B15-23 presented by H-2Kd, escapes negative selection and rapidly causes 
diabetes upon adoptive transfer into immunocompromised NODscid mice. 
To understand how these insulin B15-23 reactive CD8+ T cells develop, G9C8-
derived single TCR TRAV8-1*01TRAJ9 chain transgenic NOD mice were generated. 
These mice were bred with different proinsulin-expressing NOD mice to generate 
proinsulin1 deficient, proinsulin2 deficient, proinsulin2 over-expressing and 
proinsulin1 and 2 deficient mice with a mutated proinsulin transgene, preventing 
G9C8 antigen recognition. 
Although proinsulin-specific CD8+ TCR repertoire changes in TRBV19 were seen in 
these mice, the proportion of insulin B15-23 reactive CD8+ T cells was unaffected 
by proinsulin expression. Interestingly, TCR clonotyping of these insulin B15-23 
reactive T cells revealed minimal shared sequences between the strains, with 
mice exhibiting individual clonal expansions. However, by isolating TRBV19-
expressing insulin B15-23-responsive T cells, shared sequences across the 
different proinsulin-expressing mice were identified, with a requirement of 
TRBJ2-3 for insulin recognition (used by the original G9C8 T cell clone).  
Furthermore, male proinsulin2 deficient TRAV8-1*01TRAJ9 mice developed 
diabetes, with a higher incidence seen upon antibiotic administration. Although 
the TCR repertoire was unaffected by antibiotics, the gut microbial diversity was 
greatly reduced in all the mice with age, independent of antibiotic use, with 
firmicutes bacteria comprising 90-97% of the microbiota.  
In summary, proinsulin expression and antibiotics modify diabetes susceptibility; 
however, insulin B15-23 reactive T cells develop independently of antigen 
expression and are not directly affected by antibiotics. This data suggests that 
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non-antigen dependent mechanisms exist in controlling the development of 
auto-reactive T cells, but T cell activation and pathogenicity is influenced 
indirectly by a combination of antigen expression and gut microbiota. 
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CHAPTER 1: INTRODUCTION 
1.1 T CELL DEVELOPMENT  
1.1.1 EARLY T CELL PROGENITOR DEVELOPMENT IN THE BONE 
MARROW 
Lymphocyte development initiates from haematopoietic stem cells (HSC) within 
the bone marrow. Notch1 signalling, either dependently or independently of 
ligands, promotes HSC self-renewal maintaining a pool of lymphocyte progenitors 
(Stier et al., 2002). Upon receiving differentiation signals, these HSC differentiate 
into common lymphoid progenitors (CLPs), which are phenotypically 
characterised by Lin-IL-7R+Thy-1-Sca-1loc-Kitlo (Kondo et al., 1997). These 
progenitors further differentiate to form progenitors of two distinct lymphocyte 
lineages – T cells and B cells.  
Differentiation factors influencing CLPs to differentiate into B Cells include the 
proto-oncogene LRF, encoded by Zbtb7a (Maeda et al., 2007) and Pax5 in B 
lymphopoeisis, which represses Notch1 activation (Horcher et al., 2001, Souabni 
et al., 2002). T cell lineage commitment requires Notch-dependent signalling 
(Radtke et al., 1999, Han et al., 2002, Sambandam et al., 2005) and Hedgehog 
receptor signalling (El Andaloussi et al., 2006) to ensure T cell survival, 
proliferation and differentiation.     
Upon receiving T cell differentiation signals, these T cell progenitors are recruited 
to the thymus. This recruitment involves migration and cell adhesion molecules 
including P-selectin/P-selectin glycoprotein ligand 1, vascular cell adhesion 
molecule 1, CD44, intercellular adhesion molecule 1 and chemokine receptors, 
such as CCR9 (Scimone et al., 2006, Rajasagi et al., 2009). 
1.1.2 THYMIC T CELL DEVELOPMENT 
Early thymus progenitors (ETPs) are the earliest detectable population in the 
thymus, which differentiate into T cells (Allman et al., 2003), with similar cells 
identified in the adult blood, possibly acting as an extra-thymic reservoir of 
progenitors (Schwarz and Bhandoola, 2004). Recently, progenitors which give rise 
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to ETPs, lose megakaryocyte-erythroid potential but still retain T cell, B cell and 
granulocyte-megakaryocyte potential as they enter the thymus (Luc et al., 2012). 
The formation of single positive T cells is dependent on a number of 
developmental stages mediated by CD25 (IL-2 Receptor α chain) and CD44 
(adhesion molecule) expression (Godfrey et al., 1993), as shown in FIGURE 1. 
Briefly, the Pro-T Cell (Double negative 1; DN1) expresses CD44 and Kit (Stem Cell 
Factor Receptor), with CD25 expression upregulated as the cell develops into the 
Double negative 2 (DN2) stage. In DN2, the T cell receptor β (TCRβ) chain 
rearrangement begins (as do the T cell receptor γ genes (Livák et al., 1999)), 
downregulating CD44, characterising cells in double negative stage 3 (DN3). Once 
the TCRβ chain is fully formed, it pairs with a pre-T cell receptor α (TCRα) chain, 
forming a pre-TCR complex in the double negative 4 (DN4) stage (Saint-Ruf et al., 
1994), and is expressed at the cell surface, driving T cell proliferation and 
expansion. DN4 T Cells, post-proliferation, shrink in size and activate RAG-1 and 2 
gene transcription to allow TCRα chain rearrangement. CD4 and CD8 co-receptors 
are expressed forming Double Positive T Cells (DP), involving both Notch 
signalling and CXCL2, while IL-7 inhibits DP T cell generation (Yasuda et al., 2002, 
Schmitt et al., 2004, Tussiwand et al., 2011). Interestingly, the TCRβ chain 
rearrangement is vital for DN T cells to become DP T cells (Mombaerts et al., 
1992a). Further T cell differentiation occurs at the DP stage involving 
commitment to either the αβ or γδ T cell lineage (Petrie et al., 1992). Finally, 
single positive (SP) T cells are formed, expressing either CD4 or CD8 co-receptors, 
regulated by transcription factors e.g. T-helper-inducing POZ/Kruppel-like factor 
(Th-POK) (He et al., 2005). In addition, while co-receptor signalling strength does 
not determine which SP T cell develops (Bosselut et al., 2001), the duration of the 
TCR signalling can dictate which co-receptor is expressed on the T cell (Yasutomo 
et al., 2000). 
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FIGURE 1: T CELL DEVELOPMENT IN THE THYMUS  
 
 
 
 
 
 
 
 
 
FIGURE 1: DN1 T cell progenitors initially express CD44 and Kit (Stem Cell Factor Receptor) with the T cell Receptor (TCR) DNA in the native 
germline state. As cells move through the thymic cortex, CD25 becomes expressed (DN2) and the TRBV chain DNA begins recombination. 
Reduction in CD44 and Kit expression allows the TRBV chain DNA to completely rearrange and pair with a pre-TCRα chain (DN3). Cell surface 
expression of the pre-TCR results in a loss of CD25, CD44 and Kit expression, allowing the T cell to undergo proliferation. Adapted from 
(Godfrey et al., 1993). 
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FIGURE 2: Chromatin packaging of DNA enables vast numbers of genes to be 
encoded in a spatially restricted manner. tcra and tcrb loci undergo 
rearrangement catalysed by the RAG-1 and RAG-2 proteins through recognition 
of recombination signal sequences (RSS) located at the ends of each V, D and J 
segment (Schatz et al., 1989, Oettinger et al., 1990). The RAG protein forms a 
synaptic complex enabling 2 RSS to be brought into proximity to create a double-
stranded DNA break (excising the DNA located between the 2 RSS sites). This 
break creates a 3’OH that attacks a phosphodiester bond in the opposite DNA 
strand, which forms a 5’ phosphate and hairpin DNA structure (McBlane et al., 
1995, van Gent et al., 1996). This cleavage works best when the sequence has a 
23 base pair spacer that is brought together with a 12 base pair spacer, known as 
the 12/23 rule (van Gent et al., 1996). Recruitment of proteins such as Artemis 
with DNA-dependent protein kinases enable the hairpin DNA structure to be 
opened up and form 5’ and 3’ overhanging regions allowing non-homologous 
DNA joining (Ma et al., 2002). RAG expression occurs solely in DN and DP 
thymocytes ensuring no other rearrangements can occur (Wilson et al., 1994). 
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1.1.3 T CELL RECEPTOR  
1.1.3.1 TCR GENE REARRANGEMENT 
Recombination-activating gene (RAG) enzymes are upregulated in T cells and B 
cells to enable TCR or Immunoglobulin (Ig) rearrangement. If either RAG-1 or 
RAG-2 enzymes are deficient, T cell and B cell development is blocked early into 
the TCR or IG rearrangements, preventing the development of mature 
lymphocytes (Mombaerts et al., 1992b, Shinkai et al., 1992). RAG expression 
during T cell development occurs at 2 time points, the DN2 and the DP stages 
coinciding with TCR gene rearrangements (Wilson et al., 1994, Monroe et al., 
1999).  In DN2, the TCRβ chain locus (tcrb loci) undergoes recombination (FIGURE 
2) (Godfrey et al., 1994). Briefly, this involves RAG enzymes which cleave the DNA 
to join a Diversity (D) and Joining (J) gene together and subsequently recombine 
the DJ gene segment with a Variable (V) gene segment in DN3 (Schatz et al., 
1989, Oettinger et al., 1990, Schatz et al., 1992). In DN4, the rearranged TCRβ 
chain recombines with an invariant TCRα chain, forming the pre-TCR complex, 
inhibiting RAG expression and thus further rearrangement (Wilson et al., 1994, 
Saint-Ruf et al., 1994). Upregulation of CD4 and CD8 (DP) re-stimulates RAG 
expression and tcra loci rearrangement to form a VJ segment (Wilson et al., 
1994). Once the final rearranged TCR is expressed, RAG gene expression is 
repressed. This repression may occur through through erk and abl kinases (Roose 
et al., 2003) or through NFATc1 directly binding to the RAG locus (Patra et al., 
2006).  
Unlike the TCRβ chain, the TCRα chain can undergo multiple rearrangements 
prior to formation of the final expressed TCR, ensuring successful T cell 
development (Petrie et al., 1993, Wang et al., 1998). 
1.1.3.2 TCR DIVERSITY 
During recombination, a large TCR diversity is generated. This occurs through 
combinatorial diversity whereby the RAG enzymes select a single V, D and/or J 
gene segment from a number of possible candidates (TABLE 1). Additionally, the 
recombination event lacks proof-reading capabilities and thus nucleotides may be 
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lost or added through terminal deoxynucleotidyl transferases (Cabaniols et al., 
2001). These processes ensure the developing T lymphocytes exhibit a broad TCR 
repertoire (Robins et al., 2009, Genolet et al., 2012), ensuring reactivity to 
potential foreign antigens, while in some cases predisposing to autoimmunity.  
 
TABLE 1: THE TOTAL NUMBER OF FUNCTIONAL T CELL RECEPTOR GENES FOR 
TCRαβ T CELLS  
 
 
 
 
 
 
TABLE 1: Data obtained from the IMGT website whereby pseudogenes were 
excluded from the data while genes containing coding regions with an open 
reading frame present were included. 
 
1.1.3.3 αβTCR STRUCTURE & SIGNALLING 
T cell Receptors (TCRs) comprise an alpha and a beta chain (40-45kDa 
glycoproteins), each encoded by a series of genes that have undergone 
rearrangement, as discussed previously, linked by disulphide bonds (Minami et 
al., 1987b). CD3 molecules also associate with the TCR structure as shown in 
FIGURE 3. These CD3 molecules include CD3ζ homodimers (16kDa each) linked 
together by disulphide bonds, while the CD3γε and CD3δε heterodimers are non-
covalently linked (Minami et al., 1987b). This association with TCR and CD3 occurs 
intracellularly prior to cell surface expression (Koning et al., 1988) with TCRαβ 
heterodimer formation required for CD3 molecule association, cell surface 
expression and functional competence (Saito et al., 1987, Sussman et al., 1988, 
Sancho et al., 1989). These CD3 molecules are joined specifically to the TCR 
TCR GENE NUMBER OF GENES 
TRAV 112 
TRAJ 51 
TRAC 1 
TRBV 23 
TRBD 2 
TRBJ 13 
TRBC 2 
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whereby CD3δε localise to a transmembrane 8 amino acid motif within the TCRα 
chain, and CD3δ with the TCRβ chain (Manolios et al., 1994). However the CD3ε 
molecule interacts with the extracellular region of the TCRβ chain, while CD3ζ 
does not interact with the TCRβ chain (Manolios et al., 1994).  
Upon antigen binding to the TCR complex, the immunoreceptor tyrosine-based 
activation motifs (ITAMS) are phosphorylated by tyrosine kinases; Lck (Abraham 
et al., 1991, van Oers et al., 1996), which interacts with the co-receptors (CD4 or 
CD8 (Veillette et al., 1988, Rudd et al., 1988)) and Fyn, which associates with the 
TCR CD3 complex (Samelson et al., 1990). Upon ITAM phosphorylation, ZAP-70 is 
recruited to the phosphorylated tyrosine sequence and becomes activated (Chan 
et al., 1991, Straus and Weiss, 1993, van Oers et al., 1996), phosphorylating LAT 
and SLP-76, which bind and activate phospholipase C-γ (PLC-γ) (Bubeck 
Wardenburg et al., 1996, Zhang et al., 1998, Yablonski et al., 2001). PLC-γ then 
cleaves phosphatidylinositol bisphosphate producing diacylglycerol and inositol 
trisphosphate, which activate other protein kinases and increase intracellular 
calcium concentration (Truneh et al., 1985, Pantaleo et al., 1987, Granja et al., 
1991, Chakrabarti and Kumar, 2000, Zhong et al., 2003). This subsequently leads 
to transcription factor activation including NF-κB, NFAT and AP-1 which transcribe 
genes responsible for cell proliferation and differentiation, enabling cells to 
respond to their stimulus (Sen and Baltimore, 1986, Shaw et al., 1988, Shibuya 
and Taniguchi, 1989, Rincón and Flavell, 1994). TCR signalling is dependent on 
ITAM phosphorylation and PLC activation (Mustelin et al., 1990, June et al., 1990) 
and antigen-dependent TCR signalling is sensitive to cyclic AMP (cAMP) 
regulation (Klausner et al., 1987) and can be recycled from the cell surface 
(Minami et al., 1987a). 
The tyrosine phosphatase CD45 receptor is one of the critical factors in T cell 
receptor signalling and due to the presence of splice variants, controlled through 
hetereogeneous nuclear riboprotein L (hnRNP L) (Gaudreau et al., 2012), 8 CD45 
isoforms exist. CD45 is important in TCR signalling through interacting with the 
CD4 and CD8 co-receptor-associated Lck kinase and activating TCR signalling 
(Leitenberg et al., 1996, Dornan et al., 2002, McNeill et al., 2007). In addition, 
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CD8 co-receptor interaction with p:MHC also triggers TCR signalling through 
phosphorylation of the TCRζ chain (Purbhoo et al., 2001). The CD8 co-receptor 
can also interact with p:MHC and activate T cells without p:MHC:TCR interactions 
(Wooldridge et al., 2010a, Clement et al., 2011). CD8:pMHC:TCR interactions are 
important for controlling T cell responses to altered peptide ligands (Yachi et al., 
2006) and cross-reactivity (Wooldridge et al., 2010b, Wooldridge et al., 2012). 
1.1.3.4 COMPLEMENTARITY DETERMINING REGIONS 
The TCRα and β chains each encode 3 complementarity determining regions 
(CDR) each and dictate the peptide:MHC specificity. CDR1 and CDR2 regions are 
encoded within the germline variable gene chosen during V(D)J recombination, 
whereas the third CDR is encoded by the region spanning the V(D)J gene 
segments and thus tends to be the most diverse due to imprecise gene segment 
joining. While the CDR3 is the most diverse, enabling recognition and maximum 
contact with the peptide(s), the CDR1 and CDR2 residues are also involved in 
interacting with the MHC ((Danska et al., 1990, Rubtsova et al., 2009, Nakayama 
et al., 2012) and reviewed by (Goldrath and Bevan, 1999)). In addition, non-CDR3 
regions can also provide important peptide interactions allowing the TCR to 
recognise different peptides (Garcia et al., 1998, Maynard et al., 2005). These 
CDR regions in both the TCRα and β chains show amino acid sequence bias 
providing peptide-specific recognition (Prochnicka-Chalufour et al., 1991) and 
they can also be used to identify the clonality or immunodominance of an 
immune response (Luciani et al., 2013). In addition, the size of these 
hypervariable CDR regions can vary, altering the recognition of peptides by the 
TCR, however the CDR3 loops of most TCRαβ chains are constrained in size and 
unaffected during the thymic T cell selection process (Rock et al., 1994, Hughes et 
al., 2003).  
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FIGURE 3: THE STRUCTURE OF THE αβ T CELL RECEPTOR AND CD3 COMPLEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3: The T cell receptor (TCR) comprises variable, joining and diversity 
regions, which interact extracellularly with peptide presented by MHC complexes. 
Upon antigen recognition, the TCR signals intracellularly through the CD3 
complex (comprising ε,γ,δ and ζ subunits). 
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1.1.3.5 NON-PEPTIDE:MHC-DEPENDENT T CELL ACTIVATION SIGNALS 
In order for T cells to fully become activated they require 2 further signals in 
addition to the TCR:p:MHC interaction – costimulatory signals and 
cytokines/chemokine secretion. A number of these T cell:APC interactions are 
shown in FIGURE 4. Costimulatory activation signals are received through CD28, 
on the T cell, and B7.1/B7.2 (CD80/86) on the APC. When B7 molecules were 
over-expressed,  providing T cell activation signals, disease could be accelerated 
(Wong et al., 1998). In addition, T cells receive activation signals from multiple 
signalling molecules including the 4-1BB receptor interacting with its ligand, 4-
1BBL (Hurtado et al., 1995), ICOS interacting with its ligand ICOSL (B7H/B7RP-1) 
(Dong et al., 2001), CD2 signalling (Hünig et al., 1987, Bachmann et al., 1999), 
ICAM-3 interacting with DC-SIGN (CD209) (Geijtenbeek et al., 2000) and LFA-1 
interacting with ICAM-1/2 (Marlin and Springer, 1987, Staunton et al., 1989). 
Upon activation, T cells quickly upregulate CTLA-4 (Cytotoxic T Lymphocyte 
Antigen 4) where it outcompetes CD28, due to higher binding affinity, for binding 
to CD80/CD86 on the APC, preventing further TCR signalling (Chikuma et al., 
2003). Both CTLA-4 and PD-1 (Programmed death 1), on the T cell, inhibit T cell 
activation and promote tolerance (Walunas et al., 1994, Fife et al., 2009). 
Regulation of T cell activation is needed to terminate an immune response to 
protect the host from further immune-mediated damage. In addition, CTLA-4 
expression with the B7-independent isoform (li-CTLA-4), also reduce effector T 
cell cytokine production and the ability to cause disease (Stumpf et al., 2013). B7x 
delays the onset of disease and protect against disease when B7x is over-
expressed (Lee et al., 2012b). However, the role of B7x was only investigated in 
the context of transgenic mice and therefore it may play an alternate role for 
other T cell specificities.  In addition, T cells can also interact with each other T 
cells through trogocytosis, where the p:MHCII complexes from APCs can be 
transferred to CD8+ T cells to promote CD4+ T cell activation (Romagnoli et al., 
2013).  
Finally, T cell activation also relies upon the production and signalling mediated 
by cytokines and chemokines and their receptors. When the T cell is activated 
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through the TCR and costimulatory molecules, the cell rapidly proliferates, 
mediated by IL-2 acting autologously through the IL-2 receptor. Depending on the 
cytokines and chemokines present, the T cell can differentiate into a number of 
different subtypes (FIGURE 5).  
CD8+ T cells, once they have become activated and differentiated into effector T 
cells, can secrete perforin and granzymes (regulated by IL-2 (Janas et al., 2005)), 
which form pores in the membrane and activate apoptosis of the target cell 
(reviewed in (Trapani and Smyth, 2002). 
1.1.4 ANTIGEN PRESENTATION WITHIN THE THYMUS 
1.1.4.1 CELLS PRESENT IN THE THYMUS 
In addition to T cells, other cells are present to aid successful T cell development. 
These include, cortical and medullary thymic epithelial cells, B cells, bone-marrow 
derived dendritic cells and macrophages (Pearse, 2006). They all express peptide 
presented by Major Histocompatibility Complex class I (MHCI) or class II (MHCII) 
molecules to T cells. These molecules were originally identified due to tissue graft 
rejection experiments (Barth et al., 1956) and were later shown to control the T 
cell antigen-directed immune response (Benacerraf and McDevitt, 1972). These 
MHC molecules present antigen to the developing thymocytes (Boyd et al., 1993, 
Douek and Altmann, 2000), which aid positive and negative selection (central 
tolerance), ensuring that the TCR is functional and that the developing T cell is 
not too easily activated or capable of recognising self-antigens as discussed later. 
They are also vitally important in antigen presentation to T cells in the periphery. 
12 
 
FIGURE 4: T CELL COSTIMULATION ACTIVATORY AND INHIBITORY MOLECULE INTERACTIONS 
 
 
 
 
 
 
 
 
 
FIGURE 4: T cell interactions with antigen presenting cells (APCs) are needed to provide additional support to T cells. This support can enable T 
cell activation by signalling through many molecules including CD2, CD28, ICOS, 4-IBB, ICAM-3 and LFA-1 or regulation and inhibition of T cell 
activation by signalling through CTLA-4 and PD-1. In addition, while CD8+ T cells do not express p:MHCII molecules, through trogocytosis, they 
are capable of expressing p:MHCII and presenting antigens to CD4+ T cells.  
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FIGURE 5: CYTOKINE-MEDIATED T CELL DIFFERENTIATED SUBSETS 
 
 
 
 
 
 
 
 
 
FIGURE 5: For T cell activation, survival and differentiation, the cytokine environment is very important. The presence of cytokines, as well as 
TCR signalling and costimulation, enables T cells to develop into a variety of T cell subsets, some of which are shown. While there are many 
cytokines known to impact T cell differentiation and function, only a few are shown. Data extracted from (Sad et al., 1995, Luckheeram et al., 
2012).   
14 
 
1.1.4.2 MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) MOLECULES 
PRESENT PEPTIDES TO T CELLS 
MHC molecules present peptide to developing thymocytes and cells in the 
periphery. MHCI and MHCII present peptides to CD8+ T cells and CD4+ T cells 
respectively via their TCR molecules. For MHCI peptide presentation, the single 
chain of MHCI (α chain) is transported into the endoplasmic reticulum where 
chaperone proteins enable β2 microglobulin association and allow antigenic 
peptides to bind within the MHC groove prior to cell surface expression (Moore 
et al., 1988, Degen et al., 1992), as shown in FIGURE 6. For MHCII peptide 
presentation, antigens are taken up into endocytic vesicles and transported to 
the endosomes and lysosomes, where the extracellular proteins are degraded by 
proteases to produce peptides capable of binding to the MHCII molecules (Dunn 
et al., 1989, Dunn and Maxfield, 1992). However, both endogenous and 
exogenous peptide-processing pathways can be used by both MHCI and MHCII 
molecules to bind peptide (Carbone and Bevan, 1990, Dani et al., 2004). 
These peptides are produced by proteases degrading the proteins intracellularly. 
However, the function and availability of specific proteases can change the 
peptide repertoire, both centrally and peripherally and therefore, depending on 
the peptide presented, the TCR repertoire can be modified, influencing disease 
susceptibility (Murata et al., 2007, Nitta et al., 2010, Viret et al., 2011a, Viret et 
al., 2011b, Zanker et al., 2013). In addition, for longer peptides (i.e. MHCII 
peptides), the peptide may be able to bind in a different register(s), known as 
register shifting, once again modifying disease susceptibility (Scott et al., 1998, He 
et al., 2002, Mohan et al., 2011).  
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FIGURE 6: PEPTIDE ASSOCIATION WITH MHCI 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6: MHCI α chain is translocated into the ER lumen where calnexin 
stabilises the molecule prior to β2 microglobulin binding. Upon binding, calnexin 
is released and other chaperone proteins are recruited (Erp57, Calreticulin, 
Tapasin), further stabilising the complex until peptide binds. Peptide is derived 
from intracellularly-degraded cytosolic proteins by proteasomes, where the 
peptide products traffic into the ER lumen via TAP proteins. Once the peptide has 
bound, the pMHC complex buds from the ER to the cell surface via vesicle 
trafficking. Upon arrival at the cell surface the pMHC complex awaits interactions 
with the TCR of CD8+ T cells (reviewed by (Germain, 1994)). 
16 
 
1.1.4.3 ANTIGEN EXPRESSION IN THE THYMUS 
During T cell development in the thymus, tissue restricted self-antigens are 
expressed under a transcription factor called the autoimmune regulator (AIRE), 
predominantly in medullary thymic epithelial cells (Zuklys et al., 2000, Derbinski 
et al., 2001). AIRE was identified in 1997 with mutations in the Aire gene found in 
patients with autoimmune polyendocrinopathy-candidiasis-ectodermaldystrophy 
(APECED) (Nagamine et al., 1997). When Aire is not expressed APECED develops, 
characterised by a number of different clinical manifestations including oral 
candidiasis, hypoparathyroidism, vitiligo and leading to multi-organ autoimmune 
disease (Ahonen et al., 1990). AIRE is a master regulator ensuring tissue-
restricted antigens (TRAs), such as those targeted in APECED e.g. insulin, salivary 
proteins etc (Anderson et al., 2002). Aire is also highly conserved between 
humans and mice (Blechschmidt et al., 1999) and is responsible for the 
expression of between ~100-300 different genes. In addition, AIRE expression 
was shown to be increased in an allele dose-dependent manner with each AIRE 
encoding allele expressed corresponding to increased TRA (tissue restricted 
antigen) expression in the thymus (Liston et al., 2004). However, TRA expression 
in the periphery was unaffected suggesting the thymic microenvironment played 
an important role in modulating AIRE (Liston et al., 2004, Kont et al., 2008).  
Aire expression enables developing T cells to encounter TRAs, ensuring any T cells 
that recognise these antigens strongly are deleted by negative selection, 
preventing autoimmunity (Liston et al., 2003). Without AIRE, auto-reactive T cells 
escape and cause autoimmune disease seen in APECED. Additionally, in 
autoimmune-disease prone NOD mice, thymic AIRE positive cells were shown to 
have abnormal morphology indicating the importance of normal morphology in 
antigen presentation and development of a healthy immune system (Heino et al., 
2000). Furthermore, autoreactive T cells may escape due to differences in antigen 
presentation as insulin, a TRA, has been shown to be post-translationally 
modified within the periphery, by the formation of a disulphide bond, enabling 
autoreactive T cells, which escape selection, to become activated within the 
periphery (Mannering et al., 2005). Other post-translational modifications of 
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antigens include transglutamination, citrullination, phosphorylation and 
ubiquitination (reviewed in (Doyle and Mamula, 2012, Dunne et al., 2012)).  
1.1.4.4 T CELL SELECTION IN THE THYMUS 
As alluded to previously, T cell development requires the formation of a 
functional TCR that can recognise peptide presented in the thymus and relies on 
the central tolerance processes known as positive and negative selection. In 
order to assess if the T cell is functional, positive selection occurs whereby, 
developing T cells are stimulated for further development if they are able to 
recognise peptide presented in the context of MHC (Ashton-Rickardt et al., 1993, 
Ashton-Rickardt et al., 1994, Hogquist et al., 1994, Sebzda et al., 1994). No 
positive selection can occur when tyrosine kinases (Lck or Zap70) or the tyrosine 
phosphatase, CD45, are inactivated (Negishi et al., 1995, Byth et al., 1996, 
Hashimoto et al., 1996). When there is defective positive selection, T cell 
lymphopenia, correlated with fewer single positive thymocytes, as well as 
increased autoimmunity, occurs (Fischer et al., 1995, Trop et al., 2000, Zou et al., 
2008, Wang et al., 2012a).  In addition, T cells that have a high affinity TCR to self-
antigens (i.e. a TCR that recognises p:MHC strongly) enable positive selection and 
the development of CD4+ Tregs (Lee et al., 2012a). In addition, any T cell that is 
unable to interact with p:MHC complexes dies by apoptosis referred to as “death 
by neglect” in the thymic cortex (Surh and Sprent, 1994).  
Positively selected T cells may also be negatively selected whereby T cells 
expressing TCRs that recognise p:MHC strongly are deleted, by apoptosis, to 
prevent the development of autoimmunity. This process only occurs within the 
thymic medulla (Douek and Altmann, 2000). Depending on the concentration of 
antigen, either FAS-mediated (Kishimoto and Sprent, 2001) or FAS-independent 
apoptosis is stimulated (Kishimoto and Sprent, 2000). However, strong TCR 
signalling can increase cFLIP (caspase-8-homologous FAS-associated death-
domain-like interleukin 1β-converting enzyme-inhibitory protein) and thus semi-
mature auto-reactive thymocytes can escape from negative selection (Kishimoto 
and Sprent, 2001). In addition, low affinity interactions enable auto-reactive T 
cells to escape central tolerance (Zehn and Bevan, 2006, Yin et al., 2011, Enouz et 
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al., 2012). The presence of antigen is very important and, in some cases, 
susceptible mice/individuals fail to express enough e.g. in EAE (Klein et al., 2000) 
and T1D (Bennett et al., 1995), allowing auto-reactive T cells to escape negative 
selection. Once the thymocytes have migrated out of the thymus, they continue 
their maturation in the periphery (Boursalian et al., 2004).  
1.1.5 PERIPHERAL T CELL ACTIVATION AND REGULATION 
While mTECs present antigen to developing T cells in the thymus; peripheral 
antigen can be expressed by many cell types including APCs i.e. dendritic cells 
(DCs) and stromal cells. Peripheral antigen expression enables T cells to become 
activated, tolerised, anergic (become unresponsive) or even deleted (Hawiger et 
al., 2001, Fife et al., 2006, Lee et al., 2007, Fletcher et al., 2010, Lukacs-Kornek et 
al., 2011). In addition, MHC expression (Tsai et al., 2013a, Tsai et al., 2013b), lack 
of costimulation (Chang et al., 1999, Girvin et al., 2000) and the presence of 
tolerogenic cytokines e.g. IL-10 or TGF-β (Horwitz et al., 2003) can all enable T cell 
suppressive effects. 
Regulatory T cells (expressing CD25+FoxP3+) can exert suppressive effects on 
pathogenic T cells, such as islet-reactive T cells  (Martinez et al., 2005). Tregs can 
be classified into natural Tregs and induced Tregs (converted T cells that have 
switched to become Tregs) and have many roles including preventing 
autoimmunity, inducing tolerance to dietary antigens, fetal antigens during 
pregnancy and commensal bacterial antigens, while also suppressing allergic 
responses and pathogen-mediated pathology (reviewed in (Corthay, 2009)). 
While some studies have shown that conventional CD4+ T cells do not convert 
into Tregs (Wong et al., 2007a, Hindley et al., 2011, Relland et al., 2012), others 
have shown that they are capable of conversion (Fousteri et al., 2012). When 
CD4+CD25+ T cells were depleted, various autoimmune diseases were seen 
(Sakaguchi et al., 1995). Furthermore, Tregs have been shown to induce self-
tolerance to many auto-antigens, preventing autoimmune diseases such as 
experimental autoimmune encephalomyelitis (McGeachy et al., 2005), 
rheumatoid arthritis (Ehrenstein et al., 2004) and autoimmune diabetes (Tang et 
al., 2004, Montane et al., 2011). Interestingly, in the non-obese diabetic (NOD) 
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mouse model, infection with parasitic Schistosoma mansoni soluble egg antigen 
(SEA; containing the glycoprotein ω-1) prevents diabetes through inducing Tregs, 
which upregulate FoxP3 in a TGF-β-dependent manner with TGF-β responses 
increased through Toll-like receptor 2 (TLR-2; a cell surface receptor aiding in 
pathogen recognition) stimulation (Cooke et al., 1999, Zaccone et al., 2009, 
Burton et al., 2010, Zaccone et al., 2011).  
In addition to the classic CD4+CD25+FoxP3+ T cells, other subsets of regulatory 
cells have been identified, including CD8αα+TCRαβ+ T cells (Lu et al., 2008, Kim et 
al., 2010), CD8+CD122+ T cells (Rifa'i et al., 2004, Lee et al., 2008) and Tr1 cells 
(Apetoh et al., 2010), all of which mediate immune regulation. 
For naïve auto-reactive CD8+ T cells, they can be peripherally deleted by “suicidal 
emperipolesis”, whereby auto-reactive CD8+ T cells actively invade the 
hepatocytes and are rapidly degraded in lysosomes (Benseler et al., 2011), or 
destroyed after an immune response in the liver (John and Crispe, 2004). 
However, not all auto-reactive T cells can be tolerised effectively and therefore T 
cells become activated and cause disease.  
As mentioned, it is the TCR which dictates the antigen specificity of the T cell and 
therefore understanding how the T cell, expressing a specific TCR, is able to 
escape tolerance and cause disease, is important. By following the development 
of T cells i.e. through using antibodies to the TCRVα and/or TCRVβ chains, the 
selection of specific TCR chains could be investigated. This enabled researchers to 
investigate the TCR repertoire to identify if there was any TCR chain bias 
associated with T cells escaping tolerance and causing disease. 
1.1.6 T CELL RECEPTOR REPERTOIRE IN DISEASE 
1.1.6.1 TCR REPERTOIRE ANALYSIS METHODS 
Investigation of the T cell receptor repertoire enables identification of the TCR 
chains used by antigen-specific populations of T cells. There are currently 2 main 
ways of identifying the TCR repertoire. These include using an antibody-based 
flow cytometry method and using a gene-based approach. In addition, for a more 
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detailed repertoire study, sequencing the complementarity determining region 3 
(CDR3) will identify the portion of the TCR that determines antigen specificity. 
This effectively identifies the clonotype of a T cell, providing information on the 
V-(D)-J rearrangement and can provide clearer insight into how the TCR engages 
with peptide:MHC complexes. 
1.1.6.1.1 FLOW CYTOMETRIC METHODS 
Assessing TCR repertoire by flow cytometry provides a protein-based approach 
and enables not only the TCR variable alpha/beta chain to be studied but also 
other cellular markers e.g. activation markers. In addition, this also allows 
identification of specific TCR-expressing T cells within a heterogeneous 
population of cells. The number of cellular markers to be investigated depends on 
the flow cytometer available. This information provides both qualitative and 
quantitative information about the variable region of the TCR which can be useful 
in assessing cell populations with age or treatment. Prior to new advancements in 
technology, this method was the only way to quantitatively assess the TCR 
repertoire. Unfortunately, there are also limitations including the lack of 
availability of antibodies specific to the TCR variable chains e.g. for murine TRBV 
chains there are currently 14 antibodies available; however for the TRAV chains 
there are only 4. In addition, this provides a very limited approach with respect to 
assessing junctional diversity as well as the inability to identify polymorphisms 
within the TCR repertoire. 
1.1.6.1.2 GENE-BASED APPROACHES  
Gene-based approaches such as the use of PCR can identify the TCR chain usage. 
This is invaluable when developing transgenic mouse models i.e. genotyping but 
may also be used to follow the TCR repertoire diversity following therapy (Douek 
et al., 1998). Initial genetic approaches to TCR repertoire involved individual 
specific primers for each chain, identifying if the chain was present or not. The 
development of quantitative real-time PCR strategies further advanced the field 
whereby specific primers can be used for the variable and junctional regions 
(Wettstein et al., 2008) or may be bound to the constant region of the TCR. This 
provides the ability to study the TCR repertoire diversity in great detail, as it not 
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only identifies the variable chain but also the diversity and junctional regions too. 
CDR3 spectratyping is also a powerful technique for investigating the CDR3 region 
length, shown by peaks, which can change following immunisation (Cochet et al., 
1992). These techniques provide greater insight into the TCR repertoire, including 
how the T cells recognise antigen, and prove very important when antibodies are 
not available. However, while initially this technique was semi-quantitative, it has 
become much more quantitative providing clonal frequencies, but no other 
cellular information on the cells, unlike the data obtained by flow cytometry. In 
addition, depending on the technique used, individual T cell clones may not be 
identified at the nucleotide level. Microarray techniques have also been pursued 
at the single cell level though this relies on data from previous spectratyping 
experiments (Bonarius et al., 2006).  
1.1.6.1.3 NEXT GENERATION SEQUENCING AND CLONOTYPING 
Coupling flow cytometry-based cell sorting on a specific population of cells with 
gene-based approaches can provide numerous advantages while reducing the 
limitations discussed. In order to get the best nucleotide sequence and therefore 
the best resolution of the TCR repertoire diversity, Sanger sequencing techniques 
can be used following PCR amplification of the cDNA and bacterial cloning 
(although cloning into TCR negative cell lines also works too and may help 
identify rare antigen-specific clones (Kobayashi et al., 2013)). This specifically 
enables information to be gathered on the TCR diversity and how it may be 
modified (Weinstein et al., 2009), providing very detailed information about the 
repertoire including the identification of shared TCRs (public TCRs) and private 
TCRs (individual-specific TCRs). This information provides the TCR clonotype, 
which refers to a “unique nucleotide sequence that arises during the gene 
rearrangement process for that receptor” (Yassai et al., 2009). However, these 
techniques have disadvantages including time (although new techniques suggest 
it can take as little as 10 days (Kobayashi et al., 2013)) and also cost, although 
costs are reduced as higher-throughput sequencers are developed. 
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1.1.6.2 TCR REPERTOIRE IN DISEASE 
TCR repertoire is important as specific TCR chains/clonotypes may be influential 
in driving, or protecting mice or individuals, from disease. It has also been 
acknowledged that TCR repertoire diversity is advantageous to health, with public 
TCRs providing targets for vaccination and immunotherapy. In addition, as 
healthy individual’s age, there is a reduction in the diversity of the TCR repertoire. 
While some studies have suggested this does not occur before 75 years of age 
(Naylor et al., 2005, Pfister et al., 2006), more advanced deep TRBV sequencing 
has shown a significant reduction present by 40 years of age (Britanova et al., 
2014). Analysing the TRBV repertoires and clonotypes in the study by Britanova 
and colleagues also revealed a reduction in the most abundant public TCRs with 
age, an important finding for future work on vaccinations in the elderly. 
1.1.6.2.1 TCR REPERTOIRE IN INFECTION 
Anti-viral CD8+ TCR repertoire is dependent on the recognition of specific 
antigenic peptides, whereby a single MHC type is capable of presenting different 
peptides of the same virus and super-imposed epitopes enabling the recruitment 
of cells with different TCRs (Koning et al., 2013, Sun et al., 2014). In addition, 
polymorphisms within the MHC can alter antigen presentation, which can affect 
the TCR repertoire diversity and avidity of CD8+ T cells resulting in either a 
protective or a pathogenic response (Messaoudi et al., 2002, Gras et al., 2009). It 
is this avidity for antigen, which in turn selects the CD8+ T cell clone which 
dominates the immune response (Price et al., 2005). 
In human CMV infections, Smith and colleagues showed that exposure to genetic 
variants of the virus enabled strain-specific T cells to expand prior to the 
subsequent influx of cross-reactive T cells for CMV peptides (Smith et al., 2014). 
Interestingly, the initial strain-specific T cells were shown to be unique, with an 
oligoclonal repertoire within individuals. However, the cross-reactive CD8+ T cells 
were shown to express a public TCR repertoire that was highly conserved due to 
the flexibility of the TCR to recognise peptide variants.  In addition, a cross-
reactive CMV-specific CD8+ T cell had been identified which recognised peptides 
presented by HLA-A*02:01 and alleles of HLA-B27 (Nguyen et al., 2014). 
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TRAV3TRAJ31 and TRBV12-4TRBJ1-1 chains formed this TCR with these specific T 
cells becoming immunodominant following a bilateral lung transplant in the CMV 
seropositive recipient prior to CMV reactivation. Therefore, this suggested that 
TCR monitoring in patients may identify clinically relevant changes and provide 
targets for therapy. 
In C57BL/6 mice, a HSV-1 epitope was used to investigate the HSV-1 specific CD8+ 
T cell repertoire. This showed a TCRVβ10 (TRBV4) bias dominating the response 
and TCRVβ8 (TRBV13) being sub-dominant (Cose et al., 1995). In a subsequent 
study, age was shown to increase TCRVβ10+ (TRBV4+) HSV-1 specific CD8+ T cells 
while reducing TCRVβ8 (TRBV13) (Rudd et al., 2011). Specific investigation of 
these TCRVβ10+ (TRBV4+) T cells revealed retention of the identified WG motif 
within the CDR3β sequence at all ages, although the CDR3β length was shown to 
be shorter in neonatal mice than adult mice. While identifying this bias, they 
reported shared clonotypes between the mice but within individual mice they did 
not find the same dominant clonotype. 
There are also TCR repertoire biases within CD4+ T cells in relation to viral 
infection. This can be seen in mice infected with the Friend virus (a retrovirus) 
whereby virus-specific CD8+ T cells enable a specific expansion of CD4+ Tregs 
expressing TCRVβ5 (TRBV12), which reduce the acute response but allow a 
chronic infection to be established (Myers et al., 2013).  
1.1.6.2.2 TCR REPERTOIRE IN CANCER 
In cancer, there is an increased presence of Tregs, which enable the survival of 
the carcinoma. In mouse carcinogen-induced tumour models there is an 
increased presence of TGF-β and Tregs. Through investigation of the TCR 
repertoire, Tregs and conventional CD4+ T cells were compared. This revealed 
distinct TCR repertoires between the subsets. This lack of TCR repertoire sharing 
indicated that the two populations of T cells had arisen independently and, there 
was no conversion from conventional T cells into Tregs (Hindley et al., 2011). This 
has also been shown in relation to foreign antigens (Relland et al., 2012). In a 
mouse tumour cell injection model, the CD4+FoxP3+ T cells showed TCRVβ8.1 
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(TRBV13-3) and TCRVβV6 (TRBV19) were found to be elevated intra-tumorally 
compared to non-tumour tissue but also that the CDR3 sequences used were 
biased towards public sequences (Sainz-Perez et al., 2012), suggesting these 
could be targeted therapeutically. 
In human ovarian cancer, freshly isolated tumour-infiltrating T cells (TILs) were 
shown to have a heterogeneous TRVB repertoire; however, following in vitro 
expansion of CD8+ T cells, a bias was identified with a predominance of Vβ2 and 6 
(Peoples et al., 1993). When targeted by TCRVβ monoclonal antibodies, both 
TCRVβ populations were unable to cause tumour cytotoxicity, highlighting the 
importance of these TILs and their repertoire bias in targeting cancer. Culturing 
TILs from renal and ovarian carcinoma in IL-2 also revealed a preferential 
expansion of T cells utilising Vβ5 and 6 (Halapi et al., 1993). Subsequent high-
throughput sequencing of TCRs in ovarian cancer revealed a homogeneous TRBV 
repertoire intra-tumorally that was distinct from peripheral blood (Emerson et 
al., 2013). There were also repertoire differences noted between TIL in 
hepatocellular carcinoma and PBMCs (Weidmann et al., 1992). However, in 
colorectal tumours, this trend was reversed with a greater diversity intra-
tumorally than in adjacent mucosal tissue (Sherwood et al., 2013). In breast 
cancer there were no reported TRBV repertoire changes (Mathoulin et al., 1993). 
Identifying bias within the TCR repertoire provides information on how these cells 
develop and if they clonally expand in response to a specific tumour antigen. 
TCR repertoire can also be important clinically, as reduced TCR repertoire 
diversity with lymphopenia indicates poor survival following chemotherapy for 
metastatic breast cancer (Manuel et al., 2012). Furthermore, through TRBV CDR3 
spectratyping, murine TCRVβ1+, TCRVβ6+ and TCRVβ13+ (TRBV5+, TRBV19+ and 
TRBV14+) CD8+ T cells were identified as having a response to a tumour antigen 
(MMC6) without any Graft vs Host disease (GVHD) (Fanning et al., 2013). As 
TCRVβ13+ (TRBV14+) expressing CD8+ T cells were able to recognise the antigen 
using 3 different CDR3 sized-lengths, they showed through pre-exposing these T 
cells to MMC6, they induced a beneficial graft vs leukaemia effect with minimal 
GVHD, highlighting the importance of the immune repertoire in cancer therapy. 
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1.1.6.2.3 TCR REPERTOIRE IN AUTOIMMUNE DISEASE 
As discussed in relation to cancer and virus infection, TCR repertoire studies have 
shown little or no bias towards specific TRAV or TRBV segments in some cases but 
in others, have revealed important information on cell development with the 
potential for use in therapy. This is also the case with regard to autoimmune 
disease. 
In rheumatoid arthritis the TRAV and TRBV repertoire has been investigated in 
the synovia of patients (Olive et al., 1991, Sioud et al., 1992), showing 
populations of polyclonal T cells with little or no bias. However, in early stages of 
rheumatoid arthritis there was preferential Vα17 gene usage (Fischer et al., 1996) 
but this TCR repertoire bias was lost in cases with juvenile (Sioud et al., 1992) and 
adult (Olive et al., 1991) rheumatoid arthritis. This suggested recruitment of 
other T cells with disease progression, as also seen in a mouse model of Sjogren’s 
disease (Hayashi et al., 1995). In the collagen-induced mouse model of arthritis, 
type II collagen is administered intradermally with CFA (complete Freund’s 
adjuvant), which activates antigen-specific T cells causing autoimmune arthritis. 
These type II collagen-specific T cells were fused with hybridoma partners (lacking 
a TCR) to investigate the TCR repertoire. Both the TCRα and TCRβ chains 
exhibited a restricted TCR repertoire including Vα8, 11 or 22 with Jα24, 32, 37 or 
42 while the TCRVβ was limited to TCRVβ1, TCRVβ6 and TCRVβ8 (TRBV5, TRBV13 
and TRBV19). This TCR restriction provided a target for antibody immunotherapy; 
upon anti-TCRVβ8.2 (TRBV13-2) antibody administration, the incidence of 
arthritis was reduced by 60% (Osman et al., 1993). However, studies investigating 
the repertoire of total T cells, which may respond to many different antigens or 
peptides, may not provide the most accurate results and therefore antigen-
specific repertoire studies may provide greater evidence of a TCR repertoire bias. 
As for the CD4+ Treg population in rheumatoid arthritits, transfer of polyclonal 
Tregs induced disease prevention. However, using Tregs expressing a clonotypic 
TCR for hemagglutinin expressed as an auto-antigen, only prevented antigen-
specific pathogenic T cells for the same hemagglutinin antigen and was unable to 
stop the Th17 T cell accumulation and disease (Oh et al., 2012). 
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In a limited TCR repertoire mouse model of arthritis, Wong and colleagues 
investigated how the TCR repertoire was altered in response to self-antigen 
expression within the CD4 compartment (Wong et al., 2007b). They showed that 
CD4+ T cells had a fixed TCRVβ5 (TRBV12) chain and a TCRα chain minilocus 
encoding TCRVα2.3 and either Jα2 or 26. Interestingly, differences within the 
TCRα chain CDR3 region were observed whereby Tregs tended to have a higher 
positive charge than conventional CD4+ T cells. This CDR3α chain difference was 
dependent on self-peptide presentation, as when H2-DM was mutated, fewer 
peptides were presented. The CDR3 repertoires were much more similar but also 
shorter, indicating a need for peptide presentation to ensure TCR repertoire 
diversity and effective Treg repertoire development. 
In addition to CD4+ Tregs, CD8+CD122+ IL10-producing Tregs, important in 
inflammatory bowel disease and experimental autoimmune encephalitis (EAE), 
have also been shown to preferentially use TCRVβ13 (TRBV14) to mediate their 
suppressive activity (Okuno et al., 2013). These T cells also exhibited the most 
common CDR3 sequence (ASSYRGAEQF) suggesting preferential expansion of 
these cells. 
Additionally, in experimental autoimmune encephalomyelitis (EAE), a mouse 
model for multiple sclerosis, those mice that were susceptible to disease lacked a 
splice variant of the proteolipid protein (found in the myelin sheath) within the 
thymus, leading to a lack of tolerance and thus an auto-reactive TCR repertoire 
escaped (Klein et al., 2000). This auto-reactive repertoire showed a CD4+ T cell 
bias for TCRVβ8.2 (TRBV13-2), TCRVβ13 (TRBV14), TCRα2.3 and 4.3  (Urban et al., 
1988) and enabled immunotherapy using anti-TCR antibodies to treat the murine 
disease (Zaller et al., 1990). CD4+TCRVβ8+ (TRBV13+) TCR repertoire bias, and to a 
lesser extent TCRVβ6 (TRBV19), has also been reported in the MRL/lpr model of 
Sjogren’s disease (Hayashi et al., 1995).  
In autoimmune thyroid diseases there have been reports showing skewing of the 
TRAV repertoire in thyroid infiltrating T cells, where only 2-6 TRAV chains were 
detected in each patient, with each patient expressing an individual dominant 
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TRAV chain (Davies et al., 1991). Investigation of the TRBV repertoire revealed 
greater diversity with no apparent skewing (Davies et al., 1992). However, with 
the advancement of technology, in particular CDR3 spectratyping, a significantly 
higher skewing within the CD8+ TCRβ CDR3 region was identified in the peripheral 
blood of patients with Hashimoto’s thyroiditis but not in patients with Graves’ 
disease or healthy controls (Okajima et al., 2009). While no specific TRBV bias was 
noted for any particular chain, it illustrated that some TCRβ chains had a CDR3 of 
a specific length, especially in patients with disease longer than 5 years and 
receiving hormone replacement therapy. Disease duration can also influence the 
TCR repertoire, as seen in patients with early-stage Graves’ disease in whom a 
preference for specific TRBV repertoire (TCRVβ3, 5 and 8) was seen in thyroid-
infiltrating T cells (Zhang et al., 2006).  
1.1.6.2.4 TCR REPERTOIRE IN TYPE 1 DIABETES 
TCR repertoire has been investigated in type 1 diabetes in a variety of models, 
including the Non-Obese Diabetic (NOD) mouse, which develops spontaneous 
autoimmune disease similarly to humans (see section 1.2). Expressing protective 
transgenes for I-E and I-Ag7 protected NOD mice from diabetes but failed to alter 
the level of CD4+ or CD8+ TCRVβ5 (TRBV12), TCRVβ6 (TRBV19), TCRVβ8 (TRBV13) 
and TCRVβ11 (TRBV16) expressing T cells (Lund et al., 1990). NOD mice and NOD 
I-E expressing mice were also screened for 14 TRBV chains to see if any 
differences were responsible for the protective effect, although none were found 
(Parish et al., 1993). In addition, even NOD mice, which were engineered to 
genetically lack TCRVβ5, 8, 9, 11, 12 and 13 (TRBV12, 13, 17, 16, 15 and TRBV14), 
still developed spontaneous autoimmune disease (Shizuru et al., 1991). However, 
through advancements in technology, with studies designed to specifically follow 
a given treatment or antigen-specific T cells, TCR repertoire changes have been 
identified. 
Polyclonal B cell reconstitutions in NOD.Igµnull mice, which lack B cells, show a 
pancreas-specific TRBV expansion that becomes more diverse with age (Vong et 
al., 2011). In addition after the B cell reconstitution, if the mice were treated with 
cyclophosphamide, the TRBV repertoire showed a reduction within the pancreas 
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of TCRVβ1-, 8- and 11- (TRBV5, TRBV13 and TRBV16) expressing T cells but an 
increase in others e.g. TCRVβ4, 5.2, 9, 16, 17, 18, 19 and 20 (TRBV2, TRBV12-1, 
TRBV17, TRBV3, TRBV24, TRBV30, TRBV21 and TRBV23). 
Investigation of islet-reactive CD8+ T cells from infiltrated islets of young 5-6 week 
old NOD mice were isolated and examined for any TCR repertoire bias (DiLorenzo 
et al., 1998). TCRVβ8 (TRBV13) was found to be predominant, having been 
identified in 5 T cell lines (AI11.B2, AI12.B1p, AI15.A3, AI15.A10 and AI15.F5) but 
the TRBV repertoire was quite diverse. More noticeable was the prevalence of 
TCRVα17 members and TCRJα42 which resulted in similar CDR3α loop size and 
this was suggested to be important for antigen recognition.  
Another study, in NOD female islets at 7 weeks, showed a bias in TCRVβ3 and 
TCRVβ7 (TRBV26 and TRBV29) (Galley and Danska, 1995), despite the presence of 
the mouse mammary tumour virus which deletes T cells expressing TCRVβ3 
(TRBV26) (Fairchild et al., 1991). However, this TCRVβ3 deletional effect is only 
mediated when NOD mice express I-E (Parish et al., 1993), which normal NOD 
mice lack. 
In islet-infiltrating T cells, TCRVβ5 and TCRVβ8 (TRBV12 and TRBV13) were shown 
to be preferentially used in pre-diabetic NOD male and female mice, although 
these T cells were not clonal and varied in CDR3 length (Berschick et al., 1993). 
Interestingly, the TCRVβ5+ (TRBV12+) T cells had a preference for associating with 
TCRJβ2.6 (TRBJ2-6; 30-40%) and lacked any association with TCRJβ1.6 (TRBJ1-6); 
however these preferences were shared with non-islet tissues including spleen 
and lymph nodes. As for TCRVβ8+ (TRBV13+) T cells, there was no selective 
pressure on the TRBJ chains although, in male NOD islet-infiltrating T cells, there 
was an increased association of TCRJβ1.1 (TRBJ1-1; 23% vs 5% in females). 
However, these T cells encompassed both CD4+ and CD8+ T cells and were of 
unknown antigen specificity, which may suggest reasons why no clonal 
expansions were identified.  
Investigation of antigen-specific TCR repertoire showed a greater TCR α/β chain 
bias. One antigen, recognised by both humans and mice, is GAD65 (Kaufman et 
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al., 1993, Endl et al., 1997). In NOD mice, there are two GAD65 epitopes 
recognised by auto-reactive CD4+ T cells; these are amino acids 530-543 and 524-
538, which provide dominant GAD65 reactivity in naïve young NOD mice or 
immunised NOD mice respectively. Adaptations in TRBV repertoire are 
responsible for this change in peptide dominance, whereby TCRVβ4+ (TRBV2+) T 
cells are preferentially expanded in naive young NOD mice, whereas upon 
immunisation, TCRVβ12+ (TRBV15+) CD4+ T cells are preferentially found (Quinn 
et al., 2001a). In addition, this repertoire change also corresponds to a functional 
difference resulting in a shift from effector T cells to regulatory T cells.  
By generating a single chain TCRβ transgenic mouse expressing TCRVβ8.1, used 
by the β cell cytotoxic NY8.3 CD8+ T cell clone in NOD mice (Nagata et al., 1994a), 
Verdaguer and colleagues were able to identify the role of an antigen-specific 
CD8+ T cell in disease but also determine which TCRα chains pair to enable islet 
antigen recognition (Verdaguer et al., 1996). Interestingly, in these single chain 
transgenic mice, they showed specific increased CD8+ T cell pancreatic 
infilitration, resulting in greater β cell destruction and accelerated diabetes (from 
8 weeks) compared to non-transgenic mice and NOD controls, while CD4+ T cells 
were unaffected. By using this TCRβ chain they showed, in 4/5 oligoclonal lines, a 
preferential selection of the TCRα chain used by the NY8.3 T cell clone. This T cell 
clone was later shown to recognise a peptide of IGRP (Lieberman et al., 2003), 
however, it does demonstrate the bias in TCR repertoire for recognising β cell 
antigens.  
Insulin B9-23-reactive CD4+ T cells show a TCRα chain bias in inducing anti-insulin 
autoimmunity. TCRCα-/- single chain transgenic mice for TRAV5D-4*04TRAJ53, the 
TCRα chain of the insulin-reactive BDC12.4.1 clone, were shown to dictate insulin 
auto-reactivity as mice transgenic for TCRVβ2 (TRBV1; the TCRβ chain of the 
BDC12.4.1 T cell) failed to develop insulin auto-reactivity (Kobayashi et al., 2008). 
In addition, mice expressing TRAV5D-4*04 but with variable CDR3α regions were 
shown to induce insulin auto-antibodies, insulitis and respond to peptide in vitro 
(Nakayama et al., 2012). However, insulin auto-reactivity was abrogated when 
mutating an amino acid in each of the CDR1 (asparagine at position 5) and CDR2 
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(arginine at position 2) sequences encoded by the TRAV5D-4*04 chain, 
suggesting other interactions are important in stimulating an antigen-specific 
response. 
Interestingly, islet-reactive TCRs, when sequenced, showed a surprising similarity 
to the insulin receptor and glucagon receptor, in both humans and NOD mice, as 
well as to each other (Root-Bernstein, 2009). Therefore, developing novel 
therapeutics focussing on the interactions between TCRs and their target will 
have to be very specific to prevent any unwanted effects on the Insulin or 
glucagon receptor.  
TCR repertoire changes can be targeted for use in therapy. For example, in the 
bio-breeding diabetes prone (BBDP) rats and LEW.1WR1 rats, diabetes could be 
prevented or reduced through administering an anti-TCRVβ13 (TRBV14) 
monoclonal antibody treatment, depleting TCRVβ13+ T cells (Liu et al., 2012). In 
addition, when diabetic NOD splenocytes were depleted of each of TCRVβ5, 6, 8 
and 11 (TRBV12, TRBV19, TRBV13 or TRBV11) and transferred into young NOD 
recipients, only the TCRVβ6 (TRBV19) depletion reduced the transfer of diabetes 
(Edouard et al., 1993). Therefore the TCR repertoire has an important function in 
aiding the progression of disease. However, further antigen-specific data for CD4 
and CD8 T cells are required, together with the TCR repertoire, in order to further 
understand how antigen expression can shape that specific auto-reactive 
repertoire, prior to the recruitment of more heterogeneous T cells (Candéias et 
al., 1991b). One such study investigated the development of IGRP206-214 reactive 
CD8+ T cells in the NY8.3 TCR transgenic NOD mouse. Here, Han and colleagues 
demonstrated that, in the early stages of disease, low avidity T cells accumulate 
in the islets causing inflammation (Han et al., 2005). However, this inflammatory 
environment preferentially expands higher avidity diabetogenic T cells (and 
outcompetes lower avidity T cells), through avidity maturation, enabling these T 
cells to contribute to the progression of disease. Therefore, when antigens are 
released in an inflammatory setting (e.g. β cell destruction), the immune 
response selects for better responding T cells; thus, while these T cells utilise the 
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same TCR, the avidity for their antigen changes. However, it is unknown if avidity 
maturation is also seen in CD8+ T cells that recognise other auto-antigens. 
1.2 TYPE 1 DIABETES 
1.2.1 HUMAN TYPE 1 DIABETES 
Type 1 diabetes is characterised by a loss of insulin production mediated by 
pancreatic infiltration of auto-reactive T cells causing concomitant destruction of 
the insulin-producing β cells. This autoimmune disease is increasing in incidence, 
particularly in children (Gillespie et al., 2004, Bessaoud et al., 2006, Harjutsalo et 
al., 2008a, Evertsen et al., 2009), with both genetic and environmental factors 
influencing disease progression, some of which are discussed in relation to the 
NOD mouse model of type 1 diabetes. 
1.2.2 NON-OBESE DIABETIC MOUSE MODEL 
1.2.2.1 ANIMAL MODELS 
There are two main rodent models of autoimmune diabetes; one is the non-
obese diabetic (NOD) mouse model developed by Makino et al (Makino et al., 
1980) and the other is the Bio-breeding (BB) rat (Nakhooda et al., 1977). While 
both models develop spontaneous autoimmune diabetes similarly to humans, 
only the NOD mouse model will be discussed in further detail.  
1.2.2.2 NATURAL HISTORY OF DIABETES IN THE NOD MOUSE 
Initially, the pancreatic islets of NOD mice are free from cellular infiltration; 
however, as the disease progresses the islets become infiltrated by a variety of 
cells including antigen presenting cells and lymphocytes.  
From 4-5 weeks of age, macrophages, neutrophils and dendritic cells (DCs) are 
seen infiltrating the pancreas of NOD mice (Jansen et al., 1994, Diana et al., 
2013). From 7 weeks, macrophages and DCs begin to surround the islets with aid 
from increased chemokines (CCL19 and CCL21) and enhanced adhesion to 
fibronectin (Bouma et al., 2005). However, these macrophages are defective at 
clearing apoptotic debris (O'Brien et al., 2006) and when selectively depleted, 
through silica injections, prevent insulitis and diabetes (Lee et al., 1988). This 
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indicates that macrophages are likely to play a role. Importantly, communication 
between innate and adaptive immune cells is vital for the initiation and 
progression of type 1 diabetes (Diana et al., 2013). 
During the pathogenesis of type 1 diabetes, B lymphocytes also play a critical 
role. They are found within the islets and can recognise antigens including GAD 
(De Aizpurua et al., 1994) and insulin (Pontesilli et al., 1987, Michel et al., 1989), 
to produce auto-antibodies. These auto-antibodies develop from 3 weeks and 
can help identify potential diabetes risk (Ziegler et al., 1989), as they are 
associated with islet inflammation but not necessarily diabetes progression 
(Robles et al., 2003). In addition, NOD B-1a cells (CD5+CD19+CD1dmed) are capable 
of producing anti-nuclear IgG antibodies during diabetes pathogenesis 
(Humphreys-Beher et al., 1993) and may activate DCs during the initiation 
process (Diana et al., 2013). Furthermore, B cell deficient NOD mice, in general, 
do not develop diabetes (Serreze et al., 1996, Wong et al., 1998) although a few 
can develop disease (Yang et al., 1997). This relationship is complex however, as 
B cells alone are unable to induce diabetes in B cell deficient mice, but can do so 
when repopulated with syngeneic bone marrow (Serreze et al., 1998). 
Between 4-6 weeks CD4+ and CD8+ T lymphocytes are detectable within the 
pancreas, with increasing age associated with severe infiltration of the islets 
(Miyazaki et al., 1985). Both CD4+ and CD8+ T cells are required for diabetes. This 
has been shown through genetic mutations in NOD mice (Serreze et al., 1994, 
Wicker et al., 1994a), in vivo transfers into nude athymic mice (Yagi et al., 1992, 
Matsumoto et al., 1993) or NODscid mice (Christianson et al., 1993), through 
antibody immunotherapy to CD8 (Wang et al., 1996), MHC I or II (Boitard et al., 
1988, Taki et al., 1991, Nagata et al., 1994a), CD4 (Charlton and Mandel, 1989) or 
CD3 (Chatenoud et al., 1992). The recruitment of CD4+ and CD8+ T cells enables 
destruction of the insulin-producing β cells leading to a lack of insulin and the 
onset of diabetes. While both are important, CD8+ T cells, have shown they can 
cause β cell-specific lysis in NOD mice (Nagata et al., 1989, Hayakawa et al., 1991) 
and can recognise islet antigens in the context of H-2kd (Nagata et al., 1989) and 
inhibit islet-derived insulin release (Timsit et al., 1988). In addition to these αβ T 
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cells, there are also γδ T cells, of which CD27-CD44hi γδ T cells have also been 
implicated as effectors of type 1 diabetes through IL-17 secretion (Markle et al., 
2013b).  The αβ T cells target many pancreatic antigens, leading to activation and 
destruction of the β cells, as will be discussed later. 
Approximately 70% of female and 20% of male NOD mice develop diabetes by 35 
weeks, but this varies in different colonies around the world (Pozzilli et al., 1993). 
Interestingly, sexual dimorphism can be altered by castration, whereby male NOD 
mice become more susceptible to diabetes development and female castration 
reduced the diabetes incidence (Makino et al., 1981, Hawkins et al., 1993). In 
addition, testosterone treatment of female NOD mice was shown to reduce 
diabetes incidence and protect from the development of disease (Fox, 1992). The 
role of androgens was further highlighted by the observation that female NOD 
mouse thymocytes were shown to have decreased apoptosis compared to male 
mice, and when male mice were castrated, thymocyte responses to apoptotic 
signals were reduced (Casteels et al., 1998). This suggested T cell development or 
selection was affected by androgens. More recently, this gender dichotomy has 
been further investigated with both androgens and gut microbiota capable of 
modifying NOD diabetes susceptibility (Yurkovetskiy et al., 2013, Markle et al., 
2013a). In addition, only male NOD mice develop autoimmune dacryoadenitis, 
where cells infiltrate the lachrymal glands, however both castration and 
testosterone treatment of male NOD mice increased the incidence (Takahashi et 
al., 1997). This suggests that androgens may have different effects in relation to 
different autoimmune diseases. 
Similarly, human diabetes involves cellular infiltration in the pancreas of patients 
with juvenile diabetes mellitus (Gepts, 1965), with macrophages, T cells (CD4+ 
and CD8+) and B cells shown to infiltrate the islets of patients with type 1 
diabetes (Foulis et al., 1986, Foulis, 1993, Willcox et al., 2009, Coppieters et al., 
2012). Although the patterns of infiltration may be different, nevertheless, there 
are sufficient parallels in the NOD mouse diabetes that indicate that the NOD 
mouse may give important insights to some aspects of human disease. 
34 
 
1.2.2.3 GENETIC SUSCEPTIBILITY TO DIABETES IN THE NOD MOUSE 
The most important genetic susceptibility factor in NOD mice is the MHC. NOD 
mice express MHC molecules H-2KdDb and I-Ag7, with a lack of the MHCII I-E 
molecule, due to a deletion in the promoter region of the α chain, associated 
with susceptibility to diabetes (Hattori et al., 1986, Nishimoto et al., 1987, Lund 
et al., 1990, O'Shea et al., 2006). In addition, NOD mice express I-Ag7 containing a 
serine at position 57 (i.e. a non-aspartic acid residue) of the IA-β chain (Acha-
Orbea and McDevitt, 1987), thus altering the charge enabling a site for auto-
antigens to bind e.g. WE14 peptide of chromogranin A (Stadinski et al., 2010b). 
This susceptibility is also seen in humans (Sato et al., 1999). When I-Ag7 was 
introduced into NOD mice with the wild type proline at position 56 instead of the 
histidine expressed in NOD mice, it protected them from disease (Lund et al., 
1990). Like NOD mice, the most important genetic susceptibility in human type 1 
diabetes comes from the MHC, encoded in the Insulin Dependent Diabetes 
Mellitus 1 (IDDM1) locus. The MHCII HLA DR3/4-DQ8 haplotypes provide the 
greatest genetic susceptibility to type 1 diabetes, with other HLA-DR and DQ 
alleles providing protection (Aly et al., 2006, Erlich et al., 2008). In addition, to 
MHCII susceptibilities, there are also MHCI genetic susceptibilities (Nejentsev et 
al., 2007). 
The second most important genetic susceptibility is a region upstream of the 
proinsulin gene, known as the insulin-dependent diabetes mellitus 2 (IDDM2) 
locus. In humans, a variable number of tandem repeats (VNTRs) related to the 
insulin gene,  give rise to protection or susceptibility depending on the number of 
repeats (140->200 repeats vs 26-63 repeats respectively) (Vafiadis et al., 1997). 
The greater the number of insulin VNTRs an individual has, the greater the level 
of thymic proinsulin expression, and thus auto-reactive T cells are more likely to 
be negatively selected, providing protection against type 1 diabetes (Pugliese et 
al., 1997). By generating NOD mice with graded insulin levels, it was shown that 
the more insulin was expressed in the thymus, the greater the degree of immune 
tolerance seen (Chentoufi and Polychronakos, 2002). 
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In addition to these genetic susceptibilities, there are other immune function 
genes that contribute to susceptibility to type 1 diabetes. These include genes 
encoding CTLA-4, which competes with CD28 for CD80/86 on the APC to induce T 
cell deactivation. NOD mice are protected from developing diabetes when splice 
variants are expressed (Vijayakrishnan et al., 2004, Gerold et al., 2011) and the 
variant encoding CTLA-4 is believed to contribute significantly to genetic 
susceptibility contained within the Idd5.1 locus (Hunter et al., 2007). Idd3 and 5 
are both required to restore complete tolerance to anti-islet reactive T cells by 
Tregs through preventing accumulation within the pancreatic lymph nodes 
(Martinez et al., 2005, Hamilton-Williams et al., 2012). In addition, Idd3 also 
provides protection from both spontaneous and cyclophosphamide-induced 
diabetes (Wicker et al., 1994b). Interestingly, genetic susceptibility at the Idd9 
locus alters the CD8+ T cell response to islet antigens (Chamberlain et al., 2006) 
and provides protection from late expansion of pathogenic CD8+ IGRP-specific T 
cells within the pancreas and draining lymph nodes (Hamilton-Williams et al., 
2010). There are many more genetic susceptibilities, but they are all involved in 
immune function, insulin secretion and metabolism, some of which have 
candidate/known genes, others currently do not.  
In humans, multiple genetic regions are also implicated in the susceptibility to 
type 1 diabetes (Concannon et al., 2009). These include similar genetic 
susceptibilities to the NOD mouse, such as genes associated with immune 
function and pancreatic β cell function, including the MHC (the most important 
genetic susceptibility factor), CTLA-4 and insulin expression (reviewed in 
(Polychronakos and Li, 2011)). Historically, only those at high genetic risk would 
develop T1D, however, individuals who are less genetically susceptible are now 
developing T1D (Gillespie et al., 2004). These changes have occurred too quickly 
to be due to genetic shift and therefore the environment has been suggested to 
play a role. 
1.2.2.4 ENVIRONMENTAL FACTORS INFLUENCING DIABETES IN NOD MICE 
In human diabetes, environmental factors have been implicated in the 
pathogenesis of T1D due for a number of reasons. These include the studies on 
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concordance of monozygotic twins with T1D where both twins developed 
diabetes in fewer than 30% of twin pairs (Hyttinen et al., 2003). If genetics were 
the sole factor in causing diabetes, the concordance would be 100%. In addition, 
geographical variation and migration also affect the incidence of T1D (Harjutsalo 
et al., 2008b, Hjern and Söderström, 2008), suggesting that environmental factors 
modify disease susceptibility. Furthermore, the incidence of type 1 diabetes 
worldwide is rising (Gillespie et al., 2004, Harjutsalo et al., 2008b, Evertsen et al., 
2009, Ehehalt et al., 2010), suggesting that something other than genetic 
susceptibility factors, such as environmental factors, are involved in disease 
pathogenesis. 
In the NOD mouse, environmental factors have been known to influence diabetes 
susceptibility. These include dietary factors (Schmid et al., 2004, Maurano et al., 
2005, Marietta et al., 2013), infections (Cooke et al., 1999, Zaccone et al., 2004, 
Drescher et al., 2004), antibiotics and the gut microbiota (Hansen et al., 2012, 
Mor and Cohen, 2013, Tormo-Badia et al., 2014). Interestingly, these factors are 
also similar to those impacting human diabetes (reviewed in (Akerblom et al., 
2002, Knip and Simell, 2012)). While many environmental factors cannot be 
controlled in humans, NOD mice can be housed in specific conditions, enabling 
assessment of the environmental factor(s) on disease. In order to assess 
environmental factors modifying disease susceptibility in humans, a large 
international study is currently underway investigating the environmental 
determinants of diabetes in the young (TEDDY), following a cohort of children 
over time (Group, 2008).  
In diabetes in both NOD mice and humans, the gut microbiota appears to play a 
key role with many environmental factors having direct or indirect effects on the 
gut microbiota. While it is unknown as to what triggers the autoimmune process, 
the role of gut microbiota has become more recently favoured.  
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1.2.2.4.1 THE EFFECT OF GUT MICROBIOTA ON THE INCIDENCE OF TYPE 1 
DIABETES 
During any immune response, the innate immune cells are the first to respond, 
interacting with components of foreign organisms, such as bacteria, through Toll-
like receptors (TLRs). There are currently 12 TLR family members, of which TLRs 3, 
7, 8 and 9 are expressed intracellularly and TLRs 1, 2, 4, 5 and 6 are expressed 
extracellularly (reviewed by (Akira et al., 2006)). Many TLRs use MyD88, an 
adaptor protein, for downstream signalling, resulting in stimulation of the 
production of NF-κB-dependent proinflammatory cytokines and chemokines, as 
well as costimulation molecule expression (Medzhitov et al., 1997). TLRs are 
expressed on many cell types, including antigen-presenting cells such as DCs and 
macrophages, which upon TLR signalling, can differentiate and become activated 
(Krutzik et al., 2005).   
Both TLRs and MyD88 signalling are important in shaping the immune response 
to gut microbiota through stimulating antimicrobial peptide release (reviewed in 
(Ganz, 2003)), IgA secretion (Shang et al., 2008), epithelial cell proliferation 
(Fukata et al., 2006) and ensuring epithelial tight junctions are maintained (Cario 
et al., 2004). These cellular responses maintain gut homeostasis and prevent 
opportunistic pathogen infections. 
As discussed TLR signalling is important for keeping invading organisms from 
infecting the host and causing disease. However, to understand the role that 
these TLRs play, TLR knock out mice were generated. For example, TLR2-/- mice 
had increased bacterial loads, associated with increased pathology (Wooten et 
al., 2002, Echchannaoui et al., 2002), while TLR4-/- mice exhibited decreased 
myosin-specific CD4+ T cell proliferation (TCRVβ8.1 and 8.2), due to increased 
apoptosis compared to TLR4 sufficient mice, suggesting a role for TLR4 signalling 
in experimental autoimmune myocarditis (Gonnella et al., 2008).  
In NOD mice, TLRs have also been implicated in disease. For example, NOD mice 
lacking TLR2 or TLR9 were protected from the development of autoimmune 
diabetes whereas TLR3 or TLR4 had no influence on diabetes development (Kim 
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et al., 2007, Wong et al., 2008). The protective effect of TLR9-/- was mediated 
through inhibition of the activation of diabetogenic CD8+ T cells (Zhang et al., 
2010) and expanded CD73+ immune cells, which were immunosuppressive (Tai et 
al., 2013). Diabetes-resistant NOD mice downregulate TLR1 gene expression, 
resulting in diminished regulatory and effector CD4+ T cell proliferation and 
proinflammatory cytokine production compared to diabetes susceptible NOD 
mice (Vallois et al., 2007). Interestingly, inducing TLR2 tolerance (through 
Pam3CSk4) with dipeptidyl peptidase 4 inhibitors, which prevent the destruction 
of incretin, thereby increasing insulin production, were able to reverse recent-
onset diabetes in NOD mice. This was due to increased beta cell mass and 
proliferation, while reducing BDC2.5 CD4+ diabetogenic T cell proliferation in the 
PLN (Kim et al., 2012).  
There have also been human studies investigating the role of TLRs in diabetes. 
For example, a Korean study showed humans with a particular TLR2 
polymorphism were associated with increased protection from type 1 diabetes 
(Park et al., 2004). Additionally, TLR2 and 4 expression was increased on 
monocytes from human type 1 diabetes patients with microvascular 
complications compared to both patients without complications or normal 
control subjects (Devaraj et al., 2011a). This association suggested that TLR 
signalling was exacerbating the proinflammatory response and disease (Devaraj 
et al., 2011b, Devaraj et al., 2011c). These observations highlight the role of TLR-
dependent signalling in containing microbial infections, but also in determining 
prevention of, or susceptibility to, autoimmunity. 
While models investigating TLRs and their individual roles have been discussed, 
others focused on the downstream signalling molecules e.g. MyD88. MyD88-/- 
mice were protected from diabetes both on the NOD, and the C57BL/6 
background, even when the latter expressed islet costimulatory molecules (Wen 
et al., 2008, Alkanani et al., 2014). Interestingly, specific pathogen free (SPF) 
NODMyD88-/- mice, were protected from disease but when the mice were 
rederived into a germ-free environment, nearly all mice developed diabetes by 30 
weeks of age (Wen et al., 2008). By repopulating the gut bacteria using specific 
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commensal bacteria, diabetes was reduced to below 40% (Wen et al., 2008). This 
suggested that bacteria were involved in stimulating TLR signalling and the 
subsequent immune responses that develop and importantly, could modify the 
susceptibility to development of autoimmune diabetes. In addition, those NOD 
mice lacking MyD88 also had a different bacterial gut composition to those 
sufficient in MyD88. By transferring the gut microbiota from the protected 
NODMyD88-/- mice into NOD MyD88 sufficient mice, insulitis was reduced and 
the onset of diabetes delayed (Peng et al., 2014). Investigation of the microbiota 
within the gut revealed increases in Clostridiaceae and Lachnospiraceae with a 
decrease in lactobacillaceae, while also identifying higher concentrations of 
luminal TGF-β and IgA, associated with increases in CD8αβ+ and CD8+CD103+ T 
cells. This work highlighted the importance of gut bacteria and the innate 
immune system in shaping the diabetogenic potential of the adaptive immune 
system.  
The altered gut microbiota noted in these NODMyD88-/- mice, was also seen in 
other TLR deficient mice, with the additional observation that this altered 
microbiota can be maternally transmitted to the offspring (Ubeda et al., 2012).   
Bacterial interactions with the innate immune system are important, not only for 
stimulation of the innate immune response, but also for innate immune cell 
communication with the adaptive immune system. This connection may 
therefore be important for responses mediated by the adaptive immune system 
and lead to immunopathology and autoimmune disease such as type 1 diabetes. 
In the NOD mouse, it has been shown that diabetogenic T cells can be activated 
in the gut and pancreatic lymph nodes (Jaakkola et al., 2003) and that this 
activation is dependent on mucosal addressin cell adhesion molecule-1, which 
enables lymphocyte homing into mucosal lymphoid tissue (Hänninen et al., 
1998). When the mucosal addressin molecule was blocked, the investigators 
observed a reduction in diabetes incidence from approximately 50% to 9%, but 
only when the mice were treated before 3 weeks of age. Therefore, diabetogenic 
T cells can encounter antigen that could be natively expressed or produced by 
components within the gut. Furthermore, mucosal inflammation can be seen in 
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NOD mice prior to the development of autoimmune diabetes. This inflammation 
could lead to a “leaky” mucosal epithelium allowing the microbiota to interact 
with the immune system, which may also be important (Vaarala et al., 2008). This 
highlights the adaptive immune system can be activated in the gut and that this 
activation may be modified by the bacteria present, either directly or indirectly, 
through modification of the innate immune system. 
Other studies investigating the role of the gut microbiota include work in the Bio-
Breeding diabetes-prone (BBDP) and diabetes-resistant (BBDR) rats, which also 
highlighted gut bacterial differences. Here, the investigators found a greater 
presence of Lactobacillus and Bifidobacterium in those resistant to developing 
diabetes (Roesch et al., 2009). Interestingly, these two genera have probiotic 
activity, unlike the three most abundant genera (Bacteroides, Eubacterium and 
Ruminococcus) found in BBDP rats. Similarly, in humans with T1D, specific 
bacteria may predispose susceptible individuals to the development of 
autoimmune diabetes. The proportion of bacteria from the Bacteroidetes phylum 
was found to be increased (mainly due to Bacteroides ovatus) while bacteria from 
the Firmicutes phylum decreased, compared to microbiota in age and genotyped 
matched non-T1D individuals (Giongo et al., 2011). In addition, in children with β 
cell autoimmunity, there was a lack of Bifidobacterium adolescentis and 
Bifidobacterium pseudocatenulatum and an increase in the Bacteroides genus 
when compared to those without β cell autoimmunity (de Goffau et al., 2013).  
Antibiotic treatment of NOD mice has also yielded interesting results. NOD 
female mice treated from birth to 28 days with Vancomycin have showed 
reduced diabetes incidence (~80% vs 95% in controls) and when treated from 8 
weeks also show diminished insulitis in comparison to non-treated controls 
(Hansen et al., 2012). Investigations into the gut microbiota revealed an increase 
in Akkermansia muciniphila species (in the Verrucomicrobia phylum), while also 
increasing proinflammatory CD4+ T cells in the small intestine of neonatally-
treated adult NOD female mice. This once again illustrates that altering the gut 
microbiota reduces diabetes in a polyclonal NOD mouse susceptible to disease. 
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Furthermore, antibiotic treatment of pregnant female NOD mice was also shown 
to impact the development of the gut in the offspring (Tormo-Badia et al., 2014). 
In addition, oral administration of heat-inactivated Lactobacillus casei reduced 
diabetes incidence in NOD mice treated at 4 weeks, as did treatment with an oral 
probiotic mix VSL#3 (80% in controls vs 20-25% in the treatment cohort) 
(Matsuzaki et al., 1997, Calcinaro et al., 2005). Genetically modified Lactococcus 
lactis, engineered to secrete human proinsulin and IL-10, administered with low-
dose anti-CD3 treatment to NOD mice, reverted diabetes in approximately 50% of 
the NOD mice and induced proinsulin-specific tolerance (Takiishi et al., 2012). 
Similarly, genetic modification of Lactococcus lactis to facilitate secretion of 
GAD65370-575 and IL-10, administered with low-dose anti-CD3 treatment, 
stabilised insulitis and preserved islet β cell mass as well as reversing 
hyperglycaemia in recently diagnosed NOD mice (Robert et al., 2014). This 
prevention of further autoimmunity was shown to be mediated by an increase in 
the number of CD4+FoxP3+CD25+ regulatory T cells present. This work highlights 
the importance of gut mucosal tolerance and how it can be adapted to develop 
antigen-specific therapies even after the onset of disease. 
As mentioned previously, female NOD mice have a higher incidence of diabetes 
but when males and female mice are germ-free, or the males are castrated, the 
incidence of diabetes in both male and female mice is similar (Yurkovetskiy et al., 
2013). In addition, upon faecal transfer from male NOD mice into young female 
NOD mice, there was an alteration in the microbiota with an increase in 
testosterone, which was associated with decreased islet inflammation and type 1 
diabetes protection (Markle et al., 2013a). This suggests that the gut microbiota, 
androgens and the immune system all interact to help shape protection from, or 
susceptibility to, type 1 diabetes. 
There are a number of mechanisms by which these auto-reactive T cells become 
activated, including bystander activation, where the T cells become non-
specifically activated, and molecular mimicry. In molecular mimicry, a bacterial 
component mimics a component of self, in order to avoid being destroyed; 
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however, this can inadvertently lead to T cells becoming activated in response to 
the bacteria and subsequently cause destruction of the self-antigen expressing 
target i.e. the pancreatic islets. Interestingly, in human diabetes, rotavirus VP7 
peptides have significant sequence similarity to IA-2805-817 and GAD65115-127 
(Honeyman et al., 2010), while Coxsackie virus P2-C peptides have high sequence 
similarity to GAD65247-279 (Atkinson et al., 1994). Both studies showed T cell 
proliferation to the diabetes-related antigen as well as the mimic; however, it is 
unknown if this is causal in the development of diabetes. 
While these studies have focused on diabetes development, only a small number 
have focused on auto-antigen-specific T cells; however none have shown the gut 
microbiota cause diabetes. Therefore, to further understand the role of gut 
microbiota, more work has to be done to identify which T cells are being affected 
and if that effect is direct/indirect or specific/non-specific.  
1.2.2.5 AUTO-ANTIGENS TARGETED IN NOD MICE 
There are many auto-antigen targets of T cells during diabetes development. 
These targets include insulin (Wegmann et al., 1994, Zekzer et al., 1997, Wong et 
al., 1999, Lamont et al., 2014), islet glucose-6-phosphatase related subunit 
protein (IGRP) (Lieberman et al., 2003), GAD65 (Kaufman et al., 1993, Quinn et 
al., 2001b), Chromogranin A (Stadinski et al., 2010a) and Zinc transporter 8 (ZnT8) 
(Nayak et al., 2014). Some of the auto-reactive CD4+ and CD8+ T cell clones 
identified are shown in TABLE 2 and TABLE 3 respectively. Interestingly in humans 
with type 1 diabetes, similar auto-antigens are targeted including insulin (Schloot 
et al., 1998, Semana et al., 1999, Arif et al., 2004, Bulek et al., 2012), GAD65 
(Panina-Bordignon et al., 1995, Nepom et al., 2001), IGRP (Yang et al., 2006, 
Jarchum et al., 2008) and ZnT8 (Énée et al., 2012), while also targeting other 
auto-antigens including islet amyloid precursor protein (IAPP) (Panagiotopoulos 
et al., 2003) and glial fibrilliary acidic protein (GFAP) (Standifer et al., 2006). 
In human diabetes, CD8+ T cell responses to preproinsulin and GAD dominate 
early in diagnosis but this immunodominance is replaced by subdominant IA-2 
and IGRP responses over time (Martinuzzi et al., 2008). Even in healthy newborn 
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individuals, naïve proinsulin and GAD reactive T cells can be detected (Heninger 
et al., 2013). In addition, HLA-A*0201 patients with recent onset type 1 diabetes 
also showed frequently detectable populations of CD8+ T cells reactive to 
preproinsulin15-24, Insulin B10-18 and IGRP265-273 (Velthuis et al., 2010). However, in 
NOD mice insulin B15-23 reactive CD8
+ T cell responses are low, with IGRP-reactive 
T cells dominating the auto-reactive T cell populations as early as 5 weeks of age 
(Lieberman et al., 2004). However, these IGRP-reactive CD8+ T cells are 
dependent on prior insulin autoimmunity, as when NY8.3 TCR transgenic mice 
(recognising IGRP206-214) were crossed to NOD mice over-expressing proinsulin 2, 
the mice were protected from developing diabetes (Krishnamurthy et al., 2008). 
In human type 1 diabetes, B cells were found to recognise a number of auto-
antigens resulting in the production and secretion of auto-antibodies to insulin 
(Palmer et al., 1983), GAD (Baekkeskov et al., 1990), insulinoma antigen 2 (IA-2) 
(Bonifacio et al., 1995), IA-2β (Lu et al., 1996) and ZnT8 (Wenzlau et al., 2008a, 
Wenzlau et al., 2008b). In the NOD mice, auto-antibodies were only found against 
Insulin (Michel et al., 1989), but not to GAD (Velloso et al., 1994) or Insulinoma 
antigen 2 (IA-2) (DeSilva et al., 1996). While auto-antibodies are present in NOD 
mice, they provide a marker of inflammation and not necessarily diabetes 
development (Robles et al., 2003). However, in humans the more auto-antibodies 
present in an individual, the more likely they will develop disease (Ziegler et al., 
2013). 
While there are many auto-antigens identified in diabetes, insulin is believed to 
have a prime role in the development of diabetes. 
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TABLE 2: AUTO-REACTIVE CD4+ T CELL CLONES AND THEIR EPITOPES 
CLONE ANTIGEN PEPTIDE 
SEQUENCE 
TCRα CHAIN TCRβ CHAIN REFERENCES 
2H6 Insulin B Chain 12-25/9-
23 
VEALYLVCGERGFF/ 
SHLVEALYLVCGERG 
Vα6, Jα45 Vβ14, Jβ2.3 (Zekzer et al., 1997) 
BDC4-7.2 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.3, Jα45 Vβ1, Jβ1.3 (Simone et al., 1997) 
BDC6-4.3 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.3, Jα45 Vβ2, Jβ1.1 (Simone et al., 1997) 
BDC6-6.4 Insulin B chain 9-23 SHLVEALYLVCGERG Vα8, Jα48 Vβ10, Jβ2.5 (Simone et al., 1997) 
BDC8-1.1 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.3, Jα47 Vβ12, Jβ2.6 (Simone et al., 1997) 
BDC8-1.3 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.1, Jα34 Vβ6, Jβ1.6 (Simone et al., 1997) 
BDC8.1.9 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.3, Jα34 Vβ4, Jβ1.1 (Simone et al., 1997) 
BDC12-1.19 Insulin B chain 9-23 SHLVEALYLVCGERG Vα10, Jα9 Vβ6, Jβ1.1 (Simone et al., 1997) 
BDC12-2.35 Insulin B chain 9-23 SHLVEALYLVCGERG Vα1, Jα1 Vβ8.3, Jβ1.6 (Simone et al., 1997) 
BDC12-4.1 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.3, Jα45 Vβ2, Jβ2.6 (Simone et al., 1997) 
BDC12-4.4 Insulin B chain 9-23 SHLVEALYLVCGERG Vα13.3, Jα45 Vβ12, Jβ1.3 (Simone et al., 1997) 
B16.3 GAD65 286-300 KKGAAAIGIGTDSVI Vα4.5, Jα6 Vβ1, Jβ2.7 (Chao et al., 1999, Tarbell et al., 
2002) 
BDC2.5 Chromogranin A 
WE14 359-372 
WSRMDQLAKELTAE Vα1, Jα17 Vβ4, Jβ1.2 (Candéias et al., 1991a, Katz et 
al., 1993, Stadinski et al., 2010a) 
BDC10.1 Chromogranin A 
WE14 359-372 
WSRMDQLAKELTAE Vα9.2 Vβ15 (Stadinski et al., 2010a, Burton 
et al., 2008) 
NY4.1 Unknown Unknown Vα4.1, Jα33 Vβ11, Jβ2.4 (Schmidt et al., 1997) 
 
NOTE: All CD4+ T cell clones recognise peptides presented by MHC Class II I-Ag7 due to a lack of I-E. 
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TABLE 3: AUTO-REACTIVE CD8+ T CELL CLONES AND THEIR EPITOPES IN DIABETES 
CLONE MHC 
RESTRICTION 
ANTIGEN PEPTIDE 
SEQUENCE 
TCRα CHAIN TCRβ CHAIN REFERENCES 
P4.10* Unknown Proinsulin 2 25–34 FYTPMSRREV Unknown Unknown (Ejrnaes et al., 2005) 
AI4 H-2Db Insulin A Chain 
14-20 
YQLENYC Vα8, Jα52 Vβ2, Jβ1.3 (DiLorenzo et al., 1998, Lamont 
et al., 2014) 
G9C8 H-2Kd Insulin B Chain 
15-23 
LYLVCGERG Vα18, Jα8 Vβ6, Jβ2.3 (Wong et al., 1996) 
A1* H-2Kd Insulin B Chain 
15-23 
LYLVCGERG Unknown Vβ13 (Ejrnaes et al., 2005) 
R1* H-2Kd GAD65 515-524 WFVPPSLRTL Unknown Vβ8.2 (Videbaek et al., 2003) 
C2* H-2Kd GAD67 515-524 WYIPQSLRGV Unknown Vβ6 (Bowie et al., 1999) 
NY8.3 H-2Kd IGRP 206-214 VYLKTNVFL Vα17, Jα42 Vβ8.1, Jβ2.4 (Nagata et al., 1994a, Lieberman 
et al., 2003) 
NY2.3 H-2Db Unknown Unknown Vα4, Jα45 Vβ11, Jβ2.1 (Nagata et al., 1994a) 
YNK1.3 H-2Kd Unknown Unknown Unknown Vβ8 (Yoneda et al., 1997) 
 
NOTE: * Isolated by peptide immunisations prior to the cloning procedure 
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1.2.2.5.1 INSULIN 
Proinsulin is the prohormone of the active Insulin. This is cleaved to produce the 
active hormone insulin, composed of 2 chains (A and B) joined by disulphide 
bonds (FIGURE 7). Insulin, in its metabolic form, is secreted by the β cells in the 
islets of Langerhans within the pancreas in response to glucose stimulation and is 
a known auto-antigen in type 1 diabetes. In NOD mice, there are 2 proinsulin 
genes – Proinsulin 1 and Proinsulin 2, which are highly homologus and differ by 
only 2 amino acids in the B chain and 3 amino acids in the C peptide. However, 
they appear to be expressed differently. Within the thymus, proinsulin is 
expressed under the AIRE promoter (Anderson et al., 2002), enabling developing 
T cells that would recognise insulin to be negatively selected and thus prevent 
autoimmunity. This role of proinsulin in T cell selection is believed to be driven by 
proinsulin 2, as it is predominantly expressed in the thymus and is believed to be 
important in tolerance (Chentoufi and Polychronakos, 2002, Chentoufi et al., 
2004, Faideau et al., 2004, Palumbo et al., 2006). In NOD mice deficient in 
proinsulin 2, nearly all mice developed robust accelerated diabetes (Thébault-
Baumont et al., 2003), while over-expression of proinsulin 2 protected mice from 
diabetes (French et al., 1997, Jaeckel et al., 2004). In addition, proinsulin 2 
mediates tolerance in non-autoimmune mice shown in 129SV/Pas mice, where all 
insulin-reactive T cells were deleted; however, in proinsulin 2 deficient 129SV/Pas 
mice immunised with proinsulin 2, a T cell response was detected and islet 
infiltration was identified (Faideau et al., 2004). Furthermore, the protective 
effect of proinsulin 2 was shown to be mediated by thymic epithelial cells (Jaeckel 
et al., 2004, Faideau et al., 2006). However, proinsulin 2 expressed solely in bone-
marrow derived cells was not influential in protecting proinsulin 2 deficient NOD 
mice, suggesting that thymic tolerance was the most important factor in shaping 
the immune response (Martin-Pagola et al., 2009). However, whether proinsulin 
1 is expressed in the thymus remains a source of contention with some studies 
suggesting it is present, while others do not; although all agree that both 
proinsulin 1 and 2 are expressed in the pancreas. Unlike, proinsulin 2 deficient 
mice, proinsulin 1 deficient NOD mice were protected from developing diabetes 
(Moriyama et al., 2003). Not surprisingly, given the sequence homology between 
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proinsulin 1 and 2, proinsulin 1-reactive T cells were shown to cross-react with 
proinsulin 2 epitopes (Jaeckel et al., 2004). However, proinsulin 1 9-23 (B chain) 
and 49-66 (C chain) peptides were able to stimulate a proliferative response. This 
suggested that these insulin cross-reactive T cells, expressing specific TCRs, were 
selected for by proinsulin 2 and that both proinsulins can allow proinsulin-specific 
populations to be expanded. Recently, NOD mice lacking both proinsulin 1 and 2, 
but containing a mutant insulin transgene, where position 16 of the insulin B 
chain was substituted from a tyrosine to an alanine, were generated (Nakayama 
et al., 2005a). This mutation prevented both insulin B9-23 and insulin B15-23 
peptides from being recognised by these insulin-reactive T cells, due to poor MHC 
binding of the peptide, and these mice were protected from diabetes suggesting 
that insulin was an important antigen in initiating the auto-reactive T cell 
response. Furthermore, this mutated insulin was unable to prevent insulin 
autoimmunity and diabetes when expressed in the thymus of NOD mice lacking 
proinsulin 2 (Nakayama et al., 2005b). This suggested tolerance was mediated by 
the native proinsulin epitopes and is required to effectively delete auto-reactive T 
cells recognising epitopes overlapping the site of mutation in the proinsulin gene.   
In spite of the fact, NOD mice express 2 proinsulin genes; insulin-reactive T cells 
are able to escape from thymic negative selection. For insulin B9-23 reactive CD4
+ T 
cells, it has been suggested the peptide binds to the MHC (I-Ag7) in two 
conformations; register 1-recognising T cells (type A insulin-specific T cells) 
respond weakly upon TCR stimulation by p:MHC whereas register 2 T cells (type B 
insulin-specific T cells) react to intra-islet DC presentation of peptide and are 
capable of inducing diabetes (Mohan et al., 2010). This difference in peptide 
binding has been suggested as a mechanism for the escape from negative 
selection of the insulin-reactive CD4+ T cells. For insulin A14-20 reactive CD8
+ T cells 
(AI4), the MHC (H-2Db) allows peptides lacking C terminal amino acids i.e. the 
anchor at position 9, to avoid negative selection, yet become activated within the 
periphery (Lamont et al., 2014). The reason that the insulin B15-23 reactive CD8+ 
T cells (G9C8) escape negative selection is likely to be due to the low affinity 
interaction, whereby insulin B15-23 binds weakly to H-2Kd (Wong et al., 1999).  
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FIGURE 7: Mus musculus preproinsulin II protein sequence is shown. Letters 
highlighted in red indicate sequence differences between preproinsulin II and 
preproinsulin I, while the red box identifies 2 amino acids missing in preproinsulin 
I. Initially, preproinsulin is translated by a ribosome at the ER, where the leader 
sequence (in green) is removed by proprotein convertase II (Davidson et al., 
1988). This proinsulin molecule is then folded and transported out of the ER via 
the Golgi. The C peptide is then cleaved (in red) to produce the active hormone 
insulin, where the A (in blue) and B (in yellow) chains are bound by disulphide 
bonds. This cleavage is carried out by proprotein convertase I (Davidson et al., 
1988). These proprotein convertase enzymes are only able to convert 
preproinsulin into insulin within the pancreatic β cells (Neerman-Arbez et al., 
1994). 
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FIGURE 7: PREPROINSULIN CLEAVED TO PRODUCE INSULIN 
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1.2.2.6 G9C8 CLONE 
1.2.2.6.1 G9C8 ANTIGEN IDENTIFICATION 
G9C8 CD8+ T cell lines were generated from islets of pre-diabetic female NOD 
mice (Wong et al., 1996). In order to identify the islet antigen recognised by the 
CD8+ T cell, a NOD-derived pancreatic islet cDNA library was ligated into the pEAX 
expression vector and transfected into COS cells (Wong et al., 1999). cDNA 
translation to protein and the subsequent MHC association enabled G9C8 CD8+ T 
cell hybridomas to recognise their putative antigen. Detection of the clones 
recognising their antigen was through using a reporter gene, lacZ, under the 
NFAT element of the IL-2 enhancer. Upon addition of X-Gal, the lac-Z encoded β-
galactosidase catalysed the conversion of X-Gal, with any positive cells seen as 
blue-coloured. Any hybridomas recognising antigen were then screened further, 
eventually identifying peptides from preproinsulin 1 and 2 to be stimulating the 
cells. Through generating overlapping peptides spanning the length of 
preproinsulin 1, the G9C8 TCR was found to specifically recognise the insulin B 
chain amino acids 15-23 (LYLVCGERG).  
Insulin B15-23 was shown to be restricted to H-2Kd through in vitro cytotoxicity 
experiments, whereby the G9C8 T cell clones could only respond to antigen 
presented by NOD and BALB/C islets but not C57BL/6 islets (Wong et al., 1996, 
Wong et al., 1999). NOD mice express H-2DbKd, BALB/C mice express H-2DdKd and 
C57BL/6 mice express H-2DbKb. The only detectable T cell responses were 
between NOD and BALB/C islets suggesting that the shared H-2Kd was presenting 
the antigen and not H-2Db. In vivo adoptive transfer experiments also confirmed 
this MHC restriction as the CB17-SCID (H-2KdDd) developed diabetes but the B6-
SCID (H-2KbDb) mice did not (Wong et al., 1996). Furthermore, using an anti-Kd 
antibody and subsequently preventing peptide presentation, T cell proliferation 
and cytokine production were inhibited (Wong et al., 1999). 
The G9C8 TCR was initially characterised through monoclonal antibodies 
identifying the TCRVβ chain as Vβ6 (later referred to as TRBV-19*01). Further 
sequence analysis revealed that the G9C8 TCRβ chain expressed TCR Vβ6, Dβ1.1, 
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Jβ2.3 (later referred to as TRBV-19*01, TRBD1.1, TRBJ2-3), while the partnered 
TCRα chain was identified as Vα15 initially due to homology with the published 
TCRα chain designated Vα15. This TCRα chain was later renamed Vα18 with Jα8 
(later redesignated as TRAV8-1*01 and TRAJ9) (Wong et al., 1996).  
Interestingly, Insulin B chain 15-23 (LYLVCGERG) binds poorly to H-2Kd, reducing 
the avidity of the TCR:p:MHC interaction (Wong et al., 2002). By introducing 
single alanine mutations at positions 1, 2, 3, 4 and 6 along the cognate peptide, T 
cell recognition was lost with a mutation at position 8 very weakly stimulating the 
T cells. However, alanine mutations at positions 5, 7 and 9 were able to stimulate 
almost equivalent T cell recognition to the native peptide. Through modelling the 
p:MHC, a tyrosine at position 2 of the cognate peptide was identified as the 
primary anchor with a glycine at position 9 providing a secondary anchor. At the 
amino terminus of the peptide, several MHC derived heavy chain residues enable 
the peptide to bind and interact with many polar residues. Peptide interactions 
with MHCI amino acids 97R-99F and the 74F/116F pair force the insulin peptide 
backbone to curve upwards (in relation to the β sheet of the MHC groove) 
enabling the small glycine at position 9 to bind, but not fill, the MHCI groove. This 
binding is enhanced through hydrogen bonds between residues 143T and 146K. 
In a later modelling paper, it was suggested that MHC amino acids 73W and 
147W create a barrier, which forces the peptide to curve upwards instead 
(Petrich de Marquesini et al., 2008).  
Through molecular modelling, potential TCR contact residues within the p:MHC 
complex including p3L, p4V, p5C, p6G and p8R with a partial interaction at p1L 
have been identified (Wong et al., 2002). Depressions at position 3, between 
positions 5 and 6 and around positions 7 and 9 within the peptide suggest sites 
the TCR may bind. It is believed that little interaction between the TCR and 
peptide p7E can occur due to the amino acid pointing towards the MHCI α2 helix 
(Petrich de Marquesini et al., 2008). Interactions between p:MHCI force the 
insulin peptide backbone to curve enabling the TCR to make contacts with both 
p6G and p8R, both of which are required for TCR selection as no substitutions at 
these positions in the peptide allow the G9C8 T cells to become stimulated 
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(Wong et al., 2002, Petrich de Marquesini et al., 2008). However, while modelling 
is useful, without a specific p:MHC:TCR structure to analyse, it may not be 
entirely accurate. 
Recently this p:MHC structure was crystallised revealing that the amino acids at 
position 1, 3, 6, 7 and 8 of the peptide were exposed potentially for TCR 
recognition (Motozono et al, in submission). Interestingly, glutamic acid and 
arginine (positions 7 and 8 of the peptide) extended the furthest out of the MHC 
groove, suggesting that these amino acids are most likely to contact the TCR. 
However, further work is needed to crystallise the TCR in order to identify how 
the p:MHC:TCR interact with one another. 
1.2.2.6.2 G9C8 HETEROCLITIC PEPTIDE INTERACTIONS 
The cognate Insulin B15-23 glycine at position 9 is small and unable to completely 
fill the binding pocket within the MHCI (Wong et al., 2002). This weak interaction 
can be enhanced through substituting the amino acid at p9 with A/V/L/I, which 
stabilise binding through van der Waals interactions. Modelling these 
substitutions does not displace the peptide backbone structure and thus the 
interactions with MHC/TCR are equal or enhanced. Identification of the minimal 
cognate peptide also identified a weak decamer (LYLVCGERGF) capable of 
stimulating G9C8 T cell clones but at higher concentrations to the cognate 
nonamer. In addition, proliferation and IFN-γ production were reduced 
approximately 10-fold, as was the cytotoxic response, requiring 25 times more 
peptide to obtain a similar response to the cognate nonamer (Wong et al., 2002).  
Primary TCR anchor contacts within the cognate B15-23 peptide involve p6G and 
p8R (Wong et al., 2002). Through substituting these amino acids, antagonism can 
be induced whereby T cell function can be altered in a non-competitive MHC-
binding way between native and altered peptides (Petrich de Marquesini et al., 
2008). Altered peptide ligands with substitutions at p6 (G6H, G6I, G6L) induced 
over 50% antagonism at 0.1µg/ml, resulting in IFN-γ inhibition. Antagonism was 
also induced, albeit to a lesser extent in substitutions involving p8 (R8L). These 
altered peptide ligands correspond to reduced TCR affinity and thus antagonism 
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through changing TCR main contacts i.e. p6H reduces the contact space for the 
TCR to engage and raises the p8R side chain making it difficult for the cognate 
TCR to interact. Even in peptides encoding p8L, where the only difference 
between cognate peptide and altered peptide is the lack of a guanidine group 
with a charged nitrogen, reduced TCR recognition. 
Through p:MHC crystallisation, it was noted between the native LYLVCGERG and 
altered LYLVCGERV peptides, there are similar interactions at the C terminal end 
of the peptide to the MHC, however; the avidity is altered due to reduced 
hydrogen bonding at the N terminus of the peptide (Motozono et al, in 
submission). Furthermore, the arginine at postion 84 of the MHCα1 chain, 
accompanied by the tyrosine at position 84, were able to adopt a different 
confirmation enabling the phenylalanine at position 10 of the LYLVCGERGF 
peptide to fit into the groove. This movement is likely to reduce the stabilisation 
of the p:MHC. 
1.2.2.6.3 G9C8 T CELL PHENOTYPE AND FUNCTIONAL ABILITIES 
Monoclonal antibodies to a panel of activation and adhesion cell surface markers 
revealed G9C8 CD8+ T cells expressed activation markers CD28 and CD44, and 
adhesion molecules α-4 integrin and ICAM-1 but were HSA and CD69 negative 
(Wong et al., 1996).  
In vitro, G9C8 T cells could be stimulated by NOD islets to express 
proinflammatory cytokines, IFN-γ, TNF-α and TNF-β, and the effector molecule 
perforin (Wong et al., 1996). In addition, other cytokines were tested for by RT-
PCR but were shown not to be expressed by the G9C8 clone, including IL-2, IL-4, 
IL-5, IL-12 and TGF-β. In order to assess, the G9C8 T cells ability to destroy 
antigen-specific targets, mimicking the in vivo ability to destroy the insulin-
producing β cells, a cytotoxicity assay was set up. This involved culturing G9C8 T 
cells with MHC-Kd expressing pancreatic islets, which were specifically destroyed, 
while the control target was unaffected (Wong et al., 1996). In addition Insulin B 
chain 15-23 loaded P815 cells (PKH labelled target cells) could also be specifically 
lysed by the G9C8 T cells (Wong et al., 1999, Wong et al., 2002). 
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In addition, G9C8 T cells could be identified using tetrameric complexes 
expressing MHC-Kd bound to Insulin B chain 15-23 with an attached fluorescent 
dye detected using a flow cytometer (Wong et al., 1999). Studies with the 
tetramer p:MHC complex showed that predominant insulin B15-23 tetramer 
positive G9C8-like populations were detectable in 4-week old NOD islets but were 
shown to decrease with age, as other antigen specificities became 
immunodominant (Wong et al., 1999, Lieberman et al., 2004). 
In adoptive transfer studies, activated G9C8 T cells were able to cause rapid 
diabetes in irradiated NOD mice without CD4+ T cell help within 10 days (Wong et 
al., 1996). Investigation of these NOD islets revealed extensive islet destruction 
with all cells expressing Vβ6. In addition, fluorescent labelled G9C8 T cells homed 
to, and invaded, the islets within 24 hours post-transfer, confirming that the cells 
clearly targeted the islets, contributing to their highly diabetogenic phenotype. 
1.2.2.7 G9Cα-/- TRANSGENIC MICE 
1.2.2.7.1 DEVELOPMENT OF G9Cα-/- TRANSGENIC MICE 
Cloned G9C8 T cell genomic DNA was isolated identifying the G9C8 TCR 
comprising TCR Vα18 and Jα8 (TRAV8-1*01TRAJ9) and TCRβ chain Vβ6, Dβ1.1 and 
Jβ2.3 (TRBV19*01TRBD1-1TRBJ2-3) (Wong et al., 1996). Each chain of the TCR 
was purified and cloned into individual TCR cassette vectors (Kouskoff et al., 
1995), with expression dependent on natural TCR regulatory elements. Single TCR 
transgenic founders were generated through injection of the constructs into NOD 
ova, producing three independent single chain TCRα and TCRβ founders, which 
were then crossed to generate G9C8 transgenic mice (Wong et al., 2009) (FIGURE 
8).  
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FIGURE 8: SCHEMATIC REPRESENTATION OF THE DEVELOPMENT OF G9Cα-/- 
TRANSGENIC MICE 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8: NOD mice expressing the G9C8 TCRα chain (G9C8 TCRα chain mice) 
were crossed to NOD mice lacking TCRα chains (NOD.TCRCα-/- mice). This 
generated single chain G9C8 TCRα mice that only expressed the clonotypic TCRα 
chain. These mice were then crossed to G9C8 TCRβ restricted NOD mice (lacking 
other TCRβ chains) to generate the clonotypic G9C8 TCR-expressing NOD mice 
(G9Cα-/-TCRαβ mice).  
 
 
 
 
 
 
  X G9C8 TCRα chain mice NOD.TCRCα-/- 
G9C8 TCRαCα-/- mice 
G9Cα-/- TCRαβ mice 
G9C8 TCRβ mice X 
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1.2.2.7.2 T CELL SELECTION IN G9Cα-/- TRANSGENIC MICE 
Despite natural thymic proinsulin expression, T cells in G9Cα-/- mice are selected 
in the thymus and expand in the peripheral tissues (Wong et al., 2009). These 
transgenic mice exhibit a CD8+ T cell bias both in the thymus and the periphery 
(TABLE 4). Interestingly, even when these G9Cα-/- mice were crossed with mice 
deficient in proinsulin 1 or proinsulin 2 or mice lacking native insulin and 
expressing the mutant proinsulin with alanine replacing tyrosine at position 16 in 
the B chain (see section 1.2.2.5.1), preventing the G9 TCR epitope from being 
recognised, all mice exhibited a CD8+ T cell bias and there was no difference in 
the frequency of G9C8 CD8+ T cells that were selected in the thymus (Terri 
Thayer, personal communication, manuscript in progress). Thus, there was no 
evidence of negative selection of the G9C8 CD8+ T cells in the thymus. Even when 
G9Cα-/- mice were crossed to mice over-expressing proinsulin 2, there was no 
apparent deletion of these cells in the thymus; however in the periphery, G9C8 T 
cells were reduced. This suggests that for this particular antigen specificity, 
peripheral tolerance is more important than central tolerance.  
TABLE 4: CD8+ AND CD4+ T CELL PROPORTIONS IN G9C8 TCR TRANSGENIC MICE 
TISSUE % CD8+ % CD4+ 
THYMUS 5.1 (+/- 1.6) 1.43 (+/- 0.42) 
SPLEEN 21.14 (+/- 4.62) 8.28 (+/- 1.35) 
LYMPH NODES 52.18 (+/- 9.26) 6.28 (+/- 0.57) 
 
1.2.2.7.3 T CELL FUNCTION IN G9Cα-/- TRANSGENIC MICE 
G9Cα-/- T cells isolated directly ex vivo can elicit antigen-specific cytotoxicity 
although this can be greatly enhanced when cells are co-cultured with antigen 
indicating these T cells are relatively naïve. In addition, similarly to the G9C8 T cell 
clones, the G9Cα-/- derived T cells proliferate in response to Insulin B chain 15-23 
and produce IFN-γ and TNF-α in response to stimulation (Wong et al., 1996, 
Wong et al., 2009). Interestingly, when these G9Cα-/- mice were crossed with 
mice deficient in proinsulin 2 (G9Cα-/-PI2-/- mice) or lacking native insulin 
expression (G9Cα-/-PI1-/-PI2-/-Y16Atg mice), with a transgenic mutant insulin 
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(where the tyrosine at position 16 of the B chain is replaced by an alanine 
(Nakayama et al., 2005a)) expressed, there were no differences in T cell selection 
in the thymus, but there were functional differences (Terri Thayer, personal 
communication, manuscript in progress). Interestingly in the native proinsulin 
deficient G9Cα-/-PI1-/-PI2-/-Y16Atg mice, the CD8+ T cells exhibited the greatest 
antigen response in vitro, in terms of proliferation and cytotoxicity with increased 
cytokine production, followed by G9Cα-/-PI2-/- mice and finally the native 
proinsulin expressing G9Cα-/- mice. Therefore, while alterations in proinsulin 
expression do not change the T cell selection, the antigen is important for 
controlling the functional ability of these T cells.   
In the G9Cα-/- mice, only mice aged 15 weeks or older showed islet infiltration, 
with the majority of islets remaining intact (Wong et al., 2009). In addition, no 
spontaneous diabetes was seen by 35 weeks of age, even when CD4+CD25+ T cells 
(i.e. regulatory T cells) were depleted. However, on immunisation with insulin 
B15-23 and CpG adjuvant, the naïve phenotype was altered (downregulation of 
CD62L while CD44 was upregulated) and mice rapidly developed spontaneous 
diabetes (75-100% incidence 5-15 days post-immunisation) with many islets 
subject to extensive infiltration and destruction. Enhanced islet expression of the 
costimulatory molecule B7-1 (under the RIP), was also capable of inducing 
spontaneous diabetes in G9Cα-/- mice with ~90% incidence by 20 weeks (Wong et 
al., 2009). Even when purified CD4+ T cells were transferred from diabetic NOD 
donors into G9Cα-/- mice, spontaneous diabetes could be demonstrated (in ~75% 
mice) suggesting a requirement for activated, polyclonal CD4+ T cell help (Wong 
et al., 2009). However, CD4+ T cell independent diabetes could be induced when 
G9Cα-/- CD8+ T cells were activated in vitro (3 day co-culture with bone marrow-
derived DCs presenting antigen) and subsequently transferred into NODscid mice. 
However, naïve CFDA-SE-labelled G9Cα-/- CD8+ T cells, used directly ex vivo were 
unable to induce spontaneous diabetes when transferred into 4-6 week old NOD 
mice, although they showed specific homing and CD69+ T cell proliferation solely 
within the pancreatic lymph nodes. 
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1.3 THESIS INTRODUCTION 
T cell development involves the rearrangement of the T cell receptor (TCR) gene 
segments forming the mature TCR, which mediates the antigen specificity of the 
responding T cell. It is important that T cells develop with a broad TCR repertoire 
in order to protect the host from any potential infection; however, this broad 
repertoire may also include T cells with TCRs that recognise self-antigens. While 
there are processes to reduce likelihood that the repertoire of T cells in the 
periphery are not reactive to self-antigens, through central and peripheral 
tolerance, some T cells escape this control and may cause disease. One example, 
of many auto-reactive T cells, is the insulin B15-23 reactive G9C8 T cell, discussed 
in the previous sections, which can cause autoimmune diabetes in the NOD 
mouse. Insulin B15-23 peptide is specifically recognised by this T cell through its 
TCR comprising TRAV8-1*01TRAJ9 and TRBV19*01TRBD1-1TRBJ2-3, however, the 
recognition is weak, enabling the T cell to escape both negative and peripheral 
selection processes. As discussed in the previous section, proinsulin is thymically 
expressed, yet this expression alone, fails to stop all proinsulin/insulin-reactive T 
cells from escaping. However, central and peripheral tolerance are able to control 
proinsulin/insulin reactive T cells through deletion, anergy or inducing regulatory 
T cells. Therefore, antigen is important for shaping the TCR repertoire, whether 
through inducing protective responses or in the G9C8 T cell, leads to a 
proinflammatory response causing the destruction of the insulin-producing β 
cells in the islets of Langerhans within the pancreas. Therefore, understanding 
the role proinsulin plays in the T cell developmental process is important as it 
may identify novel ways to control inappropriate T cell activation and may enable 
new therapies leading to the prevention of autoimmune diabetes. In addition, 
even though antigen drives the immune response, other factors exist, which help 
control or prevent inappropriate responses from taking place. This may include 
regulatory cell subsets, the location the antigen is expressed (i.e. thymus, 
draining lymph nodes etc.) and factors influencing antigen expression, e.g. insulin 
responds to glucose stimulus and therefore factors affecting metabolism are 
important such as the gut microbiota. 
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The G9C8 T cell is a single insulin B15-23 reactive T cell and studies of this T cell 
has provided valuable insight into how the T cell causes diabetes and how 
proinsulin expression affects T cell development. However, it is only one T cell 
and it is highly likely, there are other insulin B15-23 reactive CD8+ T cells that 
have not been studied. Therefore, this study focuses on identifying other insulin 
B15-23 reactive T cells and examining how proinsulin expression is able to alter 
the TCR repertoire of those T cells which develop. This was investigated in single 
chain TRAV8-1*01TRAJ9 NOD transgenic mice, which utilised the same TCRα 
chain as the G9C8 T cell. Previous work on CD4+ insulin-reactive T cells revealed 
that the TCRα chain was more important in dictating antigen specificity than its 
TCRβ chain partner, but this has not been shown for insulin-reactive CD8+ T cells. 
In addition, using a known insulin-reactive TCRα chain would also enable us to 
potentially increase the number of insulin-reactive T cells compared to a non-TCR 
transgenic wild-type NOD mouse.  
The hypothesis for this study was: 
Genetically-manipulating proinsulin expression will mediate significant T cell 
receptor repertoire selection pressure on insulin B15-23 reactive T cells, while 
also influencing the functional development and/or the control of these auto-
reactive T cells in single chain TRAV8-1*01TRAJ9 transgenic NOD mice. 
This was be addressed by using single chain TCR transgenic NOD mice (expressing 
TRAV8-1*01TRAJ9), the same TCRα chain used by the insulin-reactive G9C8 T cell. 
These mice were then crossed to other NOD mice, lacking TCRα chains (TCRCα-/-) 
that were also genetically deficient in proinsulin 1 or 2, deficient in proinsulin 1 
and 2 with a mutant transgene expressed, or over-express proinsulin 2 under the 
MHCII promoter. By generating these mice we were able to answer: 
1. Does the expression of proinsulin influence the selection of the TCRβ 
chain paired to the restricted TCRα chain? This was investigated through 
flow cytometric methods using TCR monoclonal antibodies to the TCRVβ 
chains, as discussed in Chapter 3. 
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2. Does the expression of proinsulin influence the selection of the TCRβ 
chain paired to the restricted TCRα chain in insulin B15-23 reactive CD8+ T 
cells? This was investigated through molecular methods identifying the 
sequence of the TCRβ chain used by the insulin B15-23-reactive CD8+ T 
cells, as discussed in Chapter 3. 
3. Does the expression of proinsulin influence the function of the insulin 
B15-23-reactive CD8+ TCRs selected? This was investigated by cytokine 
production, proliferative ability and cytotoxicity responses of insulin B15-
23-reactive CD8+ T cells, as discussed in Chapter 4. 
4. Does altering the gut microbiota influence the TCR repertoire or the 
functional capabilities of the insulin B15-23 reactive T cells? This was 
investigated through flow cytometric methods using TCR monoclonal 
antibodies to the TCRVβ chains and memory markers, as well as through 
the detection of spontaneous autoimmune diabetes in the single chain  
TCRα restricted NOD mice, as discussed in Chapter 5.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 MICE 
2.1.1 GENERATION 
Single TCRα chain, A22Cα-/- mice, were generated using a transgene for the G9C8 
TCRα chain (TRAV8-1*01TRBJ9 referred to in this thesis as A22, deriving from 
mouse line 22) and a TCRCα gene knock out, preventing endogenous TCRα chain 
expression (Wong et al., 2009).  A22+/+ NOD mice, were generated using TRAV8-
1*01TRBJ9 DNA expressed in a TCR vector (originally provided by D.Mathis) 
(Kouskoff et al., 1995) and injected into NOD ova. The mice were crossed with 
TCRCα-/- NOD mice, derived from backcrossing TCRCα-/- mice on the B6/129 
background (Philpott et al., 1992) to the NOD background, to generate A22Cα-/- 
mice. The breeding for the generation of these mice (FIGURE 9), shows that 
within 3 generations, both A22+/+ and TCRCα-/- genes were homozygous in 25% of 
the offspring. Interbreeding of these homozygous mice resulted in fixing both 
genes to homozygousity. All mice used were on the NOD background and had 
native insulin 1 and 2 expression. To further generate mice expressing altered 
proinsulin levels, these A22Cα-/- mice were bred with other strains. For the 
generation of A22Cα-/-PI2tg mice, which over-expressed proinsulin 2 as a 
transgene under the MHCII promoter, A22Cα-/- mice were bred with NODPI2tg 
mice, which were provided by L. Harrison, WEHI, Australia (French et al., 1997). 
For A22Cα-/-PI1-/- mice and A22Cα-/-PI2-/- mice, the A22Cα-/- mice were bred with 
NODPI1-/- or NODPI2-/- mice, purchased from the Jackson Laboratory, respectively 
(Paronen et al., 2003). Finally, for the generation of A22Cα-/-PI1-/-PI2-/-Y16Atg 
mice, the A22Cα-/- mice were bred with NODPI1-/-PI2-/-Y16Atg mice, purchased 
from the Jackson Laboratory (Nakayama et al., 2005a). All these mice had already 
been generated at the start of this work. 
2.1.2 ANIMAL HUSBANDRY 
All mice were bred in specific pathogen-free isolators, except those used in 
Chapter 5, which were bred in scantainer facilites. All other mice, post-weaning, 
were then transferred to scantainers or filter top cages which were specific 
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pathogen-free. All procedures were carried out according to the Home Office 
guidelines, under PPL number 30/2766 and PIL number 30/9655. 
2.2 MOLECULAR TECHNIQUES 
2.2.1 GENOTYPING 
2.2.1.1 DNA ISOLATION 
Mice ear/tail clippings were placed into individual 1.5ml microfuge tubes, and 
were incubated in a Digest Buffer with 10μg pronase per sample overnight in a 
water bath at 55°C. Samples were then cooled at 4°C for 5 minutes, prior to the 
addition of 200μl saturated sodium chloride (~5.5M), which was mixed well and 
left to incubate for a further 5 minutes at 4°C. Samples were then centrifuged 
(14000rpm, 20 minutes, 4°C) with the nucleic acid-containing supernatant 
aliquotted into a new 1.5ml microcentrifuge tube. To this 80μg Ribonuclease A 
was then added (to remove RNA contamination), tubes were then inverted and 
incubated at 37°C for 15-20 minutes. 500μl of 100% ice-cold ethanol was then 
added to each tube before centrifugation. The supernatant was then discarded 
and the DNA pellet was then washed with 500μl of 70% ethanol (diluted in 
deionised water). The supernatant was discarded and tubes were left to dry at 
room temperature before resuspension in 50μl deionised water. Samples were 
then stored at 4°C until required. 
2.2.1.2 POLYMERASE CHAIN REACTION (PCR) 
A PCR mastermix comprising; deionised water, 10x Buffer, Primers, dNTPs and 
Taq DNA Polymerase was added to DNA pipetted into a 96 well plate. Plates were 
briefly centrifuged and placed into a PCR thermal cycler. Genotyping the mice 
required PCR reactions for different genes (2.9.2.3.1) which required different 
amplification programmes (2.9.2.3.2). 
2.2.1.3 GEL ELECTROPHORESIS 
An appropriate agarose gel was made in 1xTAE buffer for the PCR product of 
interest (2.9.2.3.4). The solution was microwaved at medium heat until the 
agarose was fully dissolved and allowed to cool to approximately 55-60°C prior to 
the addition of ethidium bromide (stains DNA). The solution was mixed well and 
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poured into an electrophoresis gel tray to further cool and solidify. Post-PCR, 
Orange G (DNA loading dye) was added to the PCR product and then loaded onto 
the agarose gel, with a 100bp ladder. The DNA was electrophoresed for 50 
minutes at 100V and subsequently visualised and photographed on a UV 
transilluminator. The band appearance and size was then used to determine the 
genotype of the given mouse. 
2.2.2 TCR CLONOTYPING 
Cells were sorted as described in 2.3.5.1 on a BD FACS ARIA into RNAlater®. 
2.2.2.1 mRNA ISOLATION 
Cells were thawed quickly at room temperature, then immediately pelleted by 
centrifugation (15000xg, 7 minutes, 4°C). The supernatant was then removed and 
replaced with 900μl Lysis/Binding buffer, provided in the μMACS isolation kit 
(2.9.1.4). Samples were then vortexed at high intensity for 1 minute and 
centrifuged (13000xg, 2 minutes, room temperature). Lysate was then 
transferred to a Lysateclear® column placed on top of a centrifugation tube and 
centrifuged (13000xg, 3 minutes, room temperature). 50µl Oligo(dT) beads per 
ml of lysate were added and mixed well prior to transfer onto a pre-rinsed MACS 
μ column enabling mRNA to bind. The column was then washed twice with 
Lysis/Binding buffer to remove proteins and DNA and then four times with Wash 
buffer (removing DNA and rRNA). mRNA was then eluted using two additions of 
70°C heated Elution buffer; an initial 27µl pre-elution to remove all Wash Buffer 
and then a 30µl addition, containing the mRNA. Samples were stored in a 1.5ml 
screw-topped microtube at -80°C until required. 
2.2.2.2 cDNA SYNTHESIS 
Into a 1.5ml screw-topped microtube, 1μl 5’CDS primer (oligo dT primer) and 6μl 
mRNA were added. The tubes were then incubated at 72°C for 3 minutes to 
denature the RNA, and then cooled to 42°C for 2 minutes to allow the primer to 
anneal. Post-incubation 7μl of the cDNA mastermix was added and mixed before 
further incubating at 42°C for 2 hours. The reverse transcriptase was then 
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deactivated by the addition of Tricine Buffer and incubated for 8 minutes at 72°C. 
cDNA was then stored at -80°C until required. 
2.2.2.3 AMPLIFICATION OF TCRβ CHAIN BY PCR 
Into a 0.2ml microcentrifuge tube, 13μl of cDNA was added to the TCRβ chain 
mastermix (to make a total volume of 50μl) and mixed well by pipetting. The 
sample was then incubated in a PCR thermal cycler on programme “TCRβ CHAIN 
AMPLIFICATION” (2.9.2.3.2) which amplified the TCRβ chain from the TCRβ 
constant region. 
2.2.2.4 ELECTROPHORESING TCRβ CHAIN cDNA PRODUCT ON A 1% 
AGAROSE TAE GEL  
After the TCRβ chain has been amplified, TrackIt buffer was added to each 
sample, mixed by pipetting and then all the samples was loaded into individual 
wells of a 1% agarose TAE gel with a 1Kb ladder. The samples were then 
electrophoresed at 65V at 180mA (per gel) for 50 minutes. Post-electrophoresis, 
15μl of SYBR Gold was added to the gel and 1xTAE solution and the sample was 
then covered with aluminium foil to protect the light-sensitive SYBR Gold. The gel 
and solution were then mixed on a plate rocker at approximately 25-30 rotations 
per minute for 25 minutes, allowing the SYBR Gold to bind to the DNA. The gel 
was then visualised under low UV light for approximately 3 seconds with positive 
bands identified between 500-700bp. 
2.2.2.5 GEL EXTRACTION OF TCRβ CHAIN cDNA  
The TCRβ chain DNA band was removed from the 1% agarose TAE gel using a 
sterile scalpel on a UV Box set to minimum intensity to avoid damaging the DNA. 
The gel was then placed into a sterile 1.5ml microtube, which were then weighed. 
To this, 2 volumes of NT1 buffer for every 1 volume of gel (i.e. 200μl per 100mg 
gel) were added. Samples were then incubated at 50°C for 10 minutes and 
vortexed every 2-3 minutes to dissolve the agarose. The NT1/Agarose solution 
was then pipetted onto a DNA binding column and centrifuged (11000xg, 30 
seconds, room temperature), with the flow-through discarded. The column was 
then washed using 700μl of NT3 buffer (containing ethanol) and centrifuged as 
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before, discarding the flow-through. The tube was then centrifuged again 
(11000xg, 1 minute, room temperature) to remove excess wash buffer. The DNA 
was then eluted into a clean microtube by the addition of 30μl of NE Buffer onto 
the filter prior to centrifugation as before. The eluted DNA from the column was 
then stored at -80°C until required. 
2.2.2.6 TCRβ CHAIN LIGATION INTO TOPO TA DH5α PLASMID VECTOR 
In a 1.5ml microtube 4μl of DNA was added to 1μl of salt solution and 1μl of Topo 
vector. The solution was mixed and incubated at room temperature for 30 
minutes, allowing each TCRβ chain amplicon, from the heterogeneous 
population, to be ligated into a vector. Following the incubation, the tubes were 
placed on ice to stop the reaction and samples were then prepared for 
immediate bacterial transformation. 
2.2.2.7 TCRβ CHAIN AMPLIFICATION USING CHEMICALLY COMPETENT 
E.COLI 
Max efficiency DH5α-T1R E.Coli were defrosted on ice and once thawed; 50μl was 
removed and added to the ligation mix prepared in the previous step. Samples 
were mixed gently and then incubated on ice for 30 minutes. Cells were then 
heat shocked for 30 seconds at 42°C and immediately placed on ice for a further 
2 minutes. Using sterile technique, 950μl of SOC media was then added to each 
tube with the samples then placed in a thermomixer at 750rpm for 90 minutes. 
100μl was then removed from each sample and spread over a pre-warmed 37°C 
LB-AIX plate using a glass L-shaped spreader (2 plates per sample). Plates were 
then inverted and incubated overnight (16-24 hours) in a 37°C incubator. 
2.2.2.8 FURTHER AMPLIFICATION OF TCRβ CHAIN CDR3 REGION 
The TCRβ chain amplicon was then amplified by PCR using the Colony PCR 
mastermix, in a 96-well PCR plate. Individual white bacterial colonies were then 
picked and transferred into a 96 well PCR plate with the PCR mastermix solution. 
The PCR plate was then sealed with a film lid, vortexed and centrifuged briefly 
and then placed in the PCR thermal cycler following the Colony PCR programme. 
After the PCR amplification, the wells were diluted 1:2 using sterile water, with 
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half then transferred into a new PCR plate. Plates were then sealed with foil lids 
and stored at -80°C. 
2.2.2.9 SEQUENCING TCRβ CHAIN CDR3 REGION 
The TCRβ chain was sequenced by single-pass PCR DNA sequencing (Beckman 
Coulter Genomics in Danvers, MA (USA)). Data were then analysed using 
Sequencher (Gene Codes Corporation), whereby sequences were aligned against 
the TCR genome using the IMGT website. Post-identification, sequences with 
their relative proportions were then calculated.  
2.2.3 BACTERIAL DNA EXTRACTION, SEQUENCING AND IDENTIFICATION 
Faecal pellets were collected from mice in Baytril-treated observational studies as 
discussed (see section 2.8). Samples were then shipped to Yale University for 
Bacterial DNA isolation, sequencing and classification. The following methods 
were conducted by Dr Jian Peng in Dr Li Wen’s laboratory. 
2.2.3.1 BACTERIAL DNA EXTRACTION 
Faecal pellets were resuspended in TE Buffer, vortexed and then digested with 
Proteinase K (200μg/ml) at 37°C. 0.3g of zirconium beads (diameter 0.1mm) were 
then added to the samples, which were then beaten with a mini bead beater 
shaker at 5000rpm for 3 minutes in a 50% phenol-chloroform isoamyl (PCI) 
solution. Samples were then pelleted and DNA was precipitated with isopropanol 
and subsequently washed in 70% ethanol. 
2.2.3.2 16S rRNA GENE SEQUENCING 
Bacterial DNA was amplified using primers specifically for the V2 region of the 
16S rRNA gene. Post-PCR, DNA was electrophoresed in a 1.2% agarose gel 
containing ethidium bromide and subsequently the DNA was cut from the gel 
using a sterile scalpel on a UV transilluminator. PCR products were then gel 
extracted (as discussed in 2.2.2.5) and DNA was quantified using a Nanodrop 
spectrophotometer. DNA was then resuspended at 1x109 molecules/μl in TE 
Buffer. 20μl of DNA was then used for pyrosequencing on a GS Junior Titanium 
Series 454 sequencing system (Roche).  
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2.2.3.3 BACTERIAL IDENTIFICATION 
Sequencing data were analysed using QIIME software version 1.6 where 
operational taxonomic units were assigned and low quality samples removed. 
Beta diversity was then calculated to enable comparisons between microbial 
communities. Data were then plotted as a principal component analysis (PCA). 
Post-sequencing data analysis identified bacterial phyla, shown as pie charts. 
2.2.4 QUANTITATIVE PCR (qPCR) 
2.2.4.1 ISOLATION AND DIGESTION OF CELLS FROM THE THYMUS AND PLN  
Thymus and PLN were removed from NOD mice aged 8 weeks (n=8-9) under 
sterile conditions and were placed in RPMI complete media. Cell suspensions 
were then made as outlined in 2.3.2, however, the entire stromal tissue was also 
used for the subsequent digestion. Cells were then pelleted (400xg, 5 minutes, 
4°C) and resuspended in Liberase-DNase I containing RPMI complete media. Cells 
were then incubated for 2 hours at 37°C, mixing frequently, with half the solution 
removed and placed into a 50ml tube on ice containing MACS Buffer. To the 
original tube, an equal volume of fresh enzyme solution was added. Post-
incubation, similar tissue and gender samples were pooled together. The cells 
were then pelleted as before and resuspended in MACS buffer for counting. Cells 
were then pelleted again and the CD45 MACS Miltenyi kit method was followed, 
depleting leukocytes. Briefly, cells were resuspended in 90μl MACS Buffer and 
10μl CD45 microbeads per 107 cells. Cells were incubated for 15 minutes at 4°C, 
then washed in MACS Buffer. Cells were then resuspended in MACS Buffer and 
then loaded onto a LS column held by a magnet. CD45- cells were found in the 
flow-through and the column was washed three times. The CD45- cells were then 
pelleted, resuspended in 500μl of Tri-reagent and frozen at -80°C overnight. 
2.2.4.2 RNA EXTRACTION 
Samples were defrosted on ice slowly and then 100μl of 1-bromo-3-
chloropropane was added. Samples were then vortexed and incubated at room 
temperature for 5 minutes and subsequently pelleted (12000xg, 15 minutes, 4°C). 
The upper colourless layer (containing RNA) was removed and transferred to a 
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new 1.5ml tube, to which 500μl of isopropanol was then added. Samples were 
then incubated for 5 minutes at room temperature and then pelleted as before. 
Supernatant was discarded and the RNA pellet was washed in 75% ethanol. 
Samples were vortexed and then pelleted (7500xg, 5 minutes, 4°C), from which 
the supernatant was removed and samples were incubated at room temperature 
for 5 minutes, enabling any remaining alcohol to evaporate. Samples were then 
resuspended in 20μl of ddH2O and measured on a Nanodrop spectrophotometer 
for their concentration and purity. 
2.2.4.3 GENERATION OF cDNA FROM RNA 
cDNA was made from 2.5μg RNA and superscript VILO mastermix (Invitrogen) and 
made up to 20μl using ddH2O. Samples were then incubated at 25°C for 10 
minutes, 42°C for 60 minutes and to terminate the reaction, 85°C for 5 minutes. 
2.2.4.4 qPCR REACTION 
cDNA was then plated in quadruplicate, into wells of a 96 well plate, where 
duplicates were assessed for Insulin 1 or Insulin 2 with either 18S or GAPDH 
expression using a qPCR mastermix. A total volume of 20μl was loaded into each 
well of the plate. An adhesive film lid was then placed over the wells and samples 
were then vortexed and briefly centrifuged. Plates were then loaded onto a ViiA7 
real-time qPCR machine for 100 minutes following the qPCR programme. 
2.2.4.5 QPCR ANALYSIS 
Data were analysed using Expression Suite software version 1.0.3 and plotted 
showing the change in reaction fluorescence concentration. 
2.3 FLOW CYTOMETRIC TECHNIQUES 
2.3.1 GENOTYPING TCRCα-/- AND G9Cα-/- MICE 
Mice were bled from the tail tip into Blood Buffer. Cells were then pelleted by 
centrifugation (400xg, 4°C, 5 minutes) and the supernatant was discarded. The 
genotyping antibody mastermix in FACS buffer (2.9.3.3.1) was then added and 
the cells were incubated at 4°C for 30 minutes. This antibody mastermix panel 
containing antibodies to CD8, CD19, TCRValphas and TCRVβ6, would identify if 
the TCRCα-/- was present and the degree of TCRβ restriction for the G9 T cells. 1ml 
68 
 
of prediluted (1:10) Lysis Buffer was then added and cells were further incubated 
for 10 minutes at room temperature in the dark. Cells were then washed in FACS 
Buffer and centrifuged as before with the supernatant discarded and the pellet 
resuspended in 100μl FACS Buffer. Samples were then stored at 4°C until 
measured on the BD FACS Calibur with data analysed using Flowjo version 7.6.5 
software (Treestar). 
2.3.2 STANDARD TRBV PHENOTYPING 
Thymus, spleen, pancreatic, mesenteric and para-aortic lymph nodes were 
removed from mice aged 4-7 weeks, 8-10 weeks and 12-16 weeks. Tissues were 
placed into 5mls of 1xPBS with the exception of the lymph nodes which were 
teased open in petri dishes using a 30G needle and pipetted into 4mls 1xPBS. 
Thymus and spleen were homogenised using loose-fit glass homogenisers. Cells 
were washed in 1xPBS and pelleted by centrifugation at 400xg for 5 minutes at 
4°C. Cells were then resuspended in FACS buffer, except the spleen, which 
required red blood cell lysis in 900µl H2O followed quickly by the addition of 
100µl 10xPBS and resuspended in 5mls 1xPBS. Post-lysis, the remaining cells were 
then washed, centrifuged as before and resuspended in FACS buffer. 100µl of 
each tissue were pipetted into each FACS tube, with the appropriate antibody 
mastermix (2.9.3.3.2). Cells were then stained at 4°C for 30 minutes prior to the 
addition of 500μl FACS FIX buffer and a further 30 minute incubation at 4°C. Post-
incubation, FACS buffer was added to each tube to remove any excess antibody. 
Cells were then pelleted as before and resuspended in 100µl FACS buffer and 
kept at 4°C until ready to be measured on a BD FACS CANTO II instrument.  
2.3.2.1 TRBV PHENOTYPING ANALYSIS 
Data were analysed using Flowjo software (Treestar), Version 7.6.5. FIGURE 10 
and FIGURE 11 show the gating strategy used to identify live single cell 
lymphocytes (both CD4+ and CD8+), from which the TRBV repertoire was then 
investigated within the T cell subsets. Data were then plotted in GraphPad 
Version 4 software. 
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2.3.2.2 TRBV PHENOTYPING STATISITCAL ANALYSIS 
Analyses were carried out using the statistical software, R (version 2.13.2, R 
Development Core Team 2012, Vienna, Austria), whereby an analysis of variance 
was conducted using gender, age, strain and tissue as variables with a stringent 
Bonferroni correction. This correction was calculated using the data below: 
Mice (6) x Gender (2) x Strains (5) x Age (2.69*) x Tissues (4.83**) x CD4/CD8 (2) x 
TCRVβ chains (14) = 21827.736 
For p=<0.05 then values below 0.0000022907 are significant (0.05/21827.736) 
For p=<0.01 then values below 0.0000004581 are significant (0.01/21827.736)  
*While 3 strains have 3 age groups, the A22Cα-/-PI1-/- and the A22Cα-/-PI1-/-PI2-/-
Y16Atg mice were only analysed at 2 age groups. Therefore a total of 13 age 
groups were compared resulting in an average of 2.69 age groups in total and 
therefore, this value was used.  
**In all strains, except the A22Cα-/-PI1-/- mice, 5 tissues were analysed and 
therefore, an average was taken of the total amount of tissues giving 4.83. 
2.3.3 PEYER’S PATCH TRBV PHENOTYPING 
As for 2.3.2, the PLN and MLN were prepared as discussed; however, they were 
kept in PP Buffer rather than 1xPBS. For isolation of the Peyer’s patches, the 
small intestine was dissected and flushed twice using 20mls PP Buffer injected 
using a 20G needle and syringe intra-luminally. Post-flush, Peyer’s patches were 
identified and removed from the small intestine using scissors and placed into a 
petri dish containing 1ml PP Buffer. Peyer’s patches were then teased open using 
a 30G needle, with excess tissue removed and pipetted into 3mls PP Buffer. Cells 
were then pelleted (400xg, 5 minutes, 4°C) and resuspended in 500μl FACS Buffer 
with 100μl aliquots transferred into new FACS tubes. The antibody mastermix 
was then added (2.9.3.3.3) and cells were fixed, washed and resuspended in FACS 
buffer as 2.3.2. Samples were kept at 4°C until ready to be measured on a BD 
FACS CANTO II instrument. 
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2.3.3.1 PEYER’S PATCH TRBV PHENOTYPING ANALYSIS 
Data were analysed as 2.3.2.1, however for Peyer’s patch TRBV repertoire 
staining there was an additional gate post-CD4 and CD8 gating, in which, CD8α vs 
CD8β was plotted enabling gating on the double positive CD8αβ+ lymphocytes. 
These cells were then investigated for the TRBV repertoire or activation status. 
TRBV data were then adjusted to X number of cells per 104 CD8αβ+ T cells in 
order to adjust for the proportional differences between the Peyer’s patches and 
the MLN and PLN. Data were then plotted using GraphPad Version 4 software. 
2.3.3.2 PEYER’S PATCH TRBV PHENOTYPING STATISITCAL ANALYSIS 
Analysis of variance was conducted using gender, age, strain and tissue as 
variables using the statistical software R (version 2.13.2, R Development Core 
Team 2012, Vienna, Austria). Data were then corrected using a stringent 
Bonferroni correction, calculated using the data below: 
Mice (5) x Gender (2) x Strains (1) x Tissues (3) x CD4/CD8 (2) x TCRVβ chains (14) 
= 840 
For p=<0.05 then values below 0.0000595238 are significant (0.05/840) 
For p=<0.01 then values below 0.00001190476 are significant (0.01/840)  
2.3.4 PEPTIDE:MHC TETRAMER STAINING 
Tissues were collected and prepared as in 2.3.2 or 2.3.3; however, Tetramer 
Wash Buffer was used instead of FACS Buffer. Live cells were then counted using 
a haemocytometer with Trypan blue staining, enabling exclusion of dead cells. 
1x106 cells were pipetted into FACS tubes, pelleted (400xg, 5 minutes, 4°C) and 
resuspended in Tetramer Wash Buffer containing Dasatinib (final concentration 
of 50nM). Cells were then incubated at 37°C for 30 minutes to allow Dasatinib to 
enter the cells and inhibit protein kinases, particularly Lck (Lee et al., 2010), and 
thus TCR recycling, allowing maximal detection of tetramer-reactive T cells. Post-
incubation cells were pelleted, supernatant was removed and cells were 
resuspended in 100µl Tetramer Wash Buffer containing 1µg tetramer. BV421-
conjugated tetramers were kindly provided by the Tetramer Core Facility, NIH, 
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USA. Cells were incubated for 15 minutes at 37°C and were subsequently washed 
in Tetramer Wash Buffer, to remove excess unbound tetramer, pelleted and 
resuspended in 100µl of antibody mastermix (2.9.3.3.5). Cells were antibody 
stained, fixed, washed and resuspended as 2.3.2 and then stored at 4°C until 
measured on a BD FACS CANTO II instrument.  
2.3.4.1 PEPTIDE:MHC TETRAMER STAINING ANALYSIS 
Data were analysed using the Flowjo (Treestar) Version 7.6.5 software. FIGURE 12 
shows the gating strategy for identifying live single cell lymphocytes which were 
CD8+CD19-CD11b-CD4-Tetramer+. Data were then corrected by subtracting the 
minimal binding tetramer from the native insulin B15-23 peptide tetramer and 
then plotted in GraphPad Version 4 software. 
2.3.5 FLOW CYTOMETRY SORTING 
2.3.5.1 PEPTIDE:MHC TETRAMER FLOW CYTOMETRY SORTING 
Splenocytes were prepared and stained as above (2.3.2) using panel 1 (2.9.3.3.5). 
Once the 30-minute antibody incubation had passed, cells were washed and 
taken for fluorescent activated cell sorting. Stringent gates were used to ensure 
the only cells sorted were tetramer positive (FIGURE 13). Cells were sorted on a 
BD FACS ARIA into RNAlater® and stored at -80°C. 
2.3.5.2 CD8+TRBV19+ (TCRVβ6) ANTIBODY BASED FLOW CYTOMETRY 
SORTING 
As 2.3.5.1; however, cells were sorted into RPMI complete media under sterile 
conditions prior to cell culture. 
2.4 CELL CULTURE 
2.4.1 PEPTIDE PREPARATION 
2.4.1.1 INSULIN B CHAIN AMINO ACIDS 15-23 PEPTIDE PREPARATION 
Peptide stock (5mg/ml) was diluted in RPMI complete media to 20μg/μl. This was 
then added to a round-bottomed 96-well plate/FACS tube and diluted 1:4 to 
provide a top peptide concentration of 5μg/μl. 
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2.4.1.2 DENATURED WHOLE INSULIN PREPARATION 
Actrapid Insulin (100 IU/ml equivalent to 3.5mg/ml, see 2.9.1.5) was diluted using 
ddH2O and heated to 60°C for 5 minutes. Post-denaturation, insulin was then 
further diluted, as mentioned for Insulin B15-23 peptide (2.4.1.1). 
2.4.2 ANTIGEN PRESENTING CELL PREPARATION 
2.4.2.1 HARVESTING AND CULTURING DENDRITIC CELLS 
Hind legs were dissected from NOD mice aged 6-10 weeks using sterile 
technique. Muscle was removed and clean bones were placed into a 5ml tube 
containing RPMI complete media. Bones were placed in a tissue culture dish in a 
laminar flow hood and then dissected at the knee joint and the ends of the bones 
to reveal the red bone marrow pulp using a scalpel. RPMI complete media was 
then injected into the bone cavity, using a 30G needle, flushing out the bone 
marrow into a new tissue culture dish. A single cell suspension was then made by 
flushing the cells through a clean 25G needle into a 50ml centrifuge tube 
containing a 40μm filter. Cells were then pelleted (400xg, 5 minutes, 4°C), 
resuspended in RPMI complete media and transferred into 75cm2 tissue culture 
flasks and incubated for 2 hours at 37°C. Post-incubation, the cell solution was 
carefully removed and transferred into a new 50ml tube. The tissue culture flask 
was gently washed ensuring no adherent cells were removed and then the cells 
were pelleted and counted using Trypan blue. Cells were then resuspended at 
5x106/ml and pipetted into a 6-well plate. RPMI complete media was added 
containing Granulocyte macrophage colony stimulating factor (GM-CSF) to a final 
concentration of 1x106/ml cells and 1.5ng/ml of GM-CSF. RPMI complete GM-CSF 
media was half-changed every three days. 
2.4.2.2 ACTIVATING AND PREPARING DENDRITIC CELLS FOR ASSAY 
6-9 days post-dendritic cell culture, RPMI complete GM-CSF-containing media 
was half changed with the addition of Lipolysaccharide (LPS: final concentration 
of 1μg/ml). Cells were then incubated for 18 hours at 37°C and then removed 
from each well using a cell scraper. Collected cells were then pelleted (400xg, 5 
minutes, 4°C) and washed in RPMI complete media twice to remove excess LPS. 
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DCs were then irradiated (3000 grays), pelleted and resuspended in RPMI 
complete media and counted. Dendritic cells were then plated at 0.2x106/ml. 
2.4.2.3 WHOLE SPLENOCYTE PREPARATION 
Single cell suspensions of splenocytes were freshly prepared (see 2.3.2) and 
irradiated (as in 2.4.2.2). Cells were then pelleted and resuspended in RPMI 
complete media for counting and resuspended at 1x106/ml. 
2.4.2.4 CULTURING P815 CELLS 
P815 cells (a murine lymphoblast-like mastocytoma cell line) were removed from 
liquid nitrogen storage and quickly thawed at room temperature. Pre-warmed 
(37°C) RPMI Complete media was then added to the tube and all cells were 
transferred into a new 10ml tube. Cells were then pelleted (400xg, 5 minutes, 
room temperature), supernatant was discarded and cells were washed with pre-
warmed RPMI complete media to remove DMSO contaminant from storage. Cells 
were then resuspended in pre-warmed media, transferred into a 25cm2 cell 
culture flasks and incubated at 37°C with 5% CO2 until the next day. Cells were 
checked daily under a light microscope and split i.e. diluted 1:10 when the cells 
reached approximately 80% confluency using pre-warmed RPMI complete media. 
Cells were grown until sufficient numbers were obtained for the required 
cytotoxicity assay. 
2.4.3 ISOLATION OF CD8+ T CELLS  
CD8+ T cells were isolated from the spleen or PLN and single cell suspensions 
were prepared as in 2.3.2. Isolated, viable CD8+ T cells were then counted, 
washed in MACS Buffer, and pelleted (400xg, 5minutes, 4°C). Supernantant was 
then discarded and CD8+ T cells were isolated using the MACS Miltenyi CD8+ T cell 
isolation protocol. Briefly, 107 cells were resuspended in 40μl MACS Buffer and 
10μl Biotin-antibody cocktail (containing anti-mouse monoclonal antibodies to 
CD4, CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, MHC Class II, Ter-
119, and TCRγ/δ) and the cells were incubated for 5 minutes at 4°C. Post-
incubation, 30μl MACS Buffer and 20μl anti-biotin microbeads were then added 
to the cells, which were then further incubated for 10 minutes at 4°C. Cells were 
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then pelleted as before, resuspended in 500μl per 107 cells and added to pre-
washed MACS columns held by a magnet. The CD8+ T cells flowed through the 
column, which was washed 3 times. Cells were counted and resuspended at 
1x106/ml. 
2.4.4 CYTOTOXICITY ASSAY 
This method was adapted from (Lee-MacAry et al., 2001). P815 cells were 
removed from the tissue culture flask and transferred into a 50ml falcon tube. 
Cells were pelleted (400xg, 5 minutes, room temperature), supernatant was 
discarded and cells were resuspended in serum-free RPMI media. Viable P815 
cells were counted using a haemocytometer and Trypan blue, with the required 
number of cells transferred into a new 50ml falcon tube (excess P815 cells were 
kept for use as compensation controls for flow cytometry) and washed in serum-
free RPMI media. Supernatant was then discarded and P815 cells were labelled 
by resuspension in PKH-26 cell dye diluted (1:250) in diluent C. Cells were then 
wrapped in aluminium foil, to protect from light, and incubated at room 
temperature for 90 seconds. Post-incubation, cell labelling was terminated by the 
addition of 500μl of sterile FBS per 1x106 cells. Cells were then incubated for a 
further minute at room temperature in the dark, then washed twice in 10mls of 
RPMI complete media. Cells were then resuspended in RPMI complete media, 
counted and resuspended at 0.2x106/ml. 10,000 P815 cells were then transferred 
into sterile FACS tubes. P815 cells and isolated CD8+ T cells (1:10) were incubated 
with Insulin B15-23 peptide for 16 hours overnight at 37°C in duplicate prior to 
assessment for cytotoxicity by flow cytometry on a BD FACS CANTO II. 20 seconds 
prior to measurement of cytotoxicity, TOPRO-3, a viability marker, was added to 
the FACS tubes. 5,000 PKH-26+ cells were recorded for each sample. Data were 
then analysed using Flowjo software Version 7.6.5 (Treestar) gating on single 
PKH-26+TOPRO-3+ cells indicating the proportion of P815 target cells lysed. Data 
were adjusted for background using the P815 cells and T cells without peptide. 
GraphPad Prism software Version 4 was then used to plot the data. 
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2.4.5 IN VITRO 3H-THYMIDINE INCORPORATION PROLIFERATION 
ASSAYS 
Insulin B15-23 peptide or whole insulin (2.4.1), CD8+ T cells (2.4.3) and Dendritic 
cells (2.4.2) were plated into a 96-well round bottomed plate at final 
concentrations of 100,000 T cells, 10,000 DCs and 5μg/ml peptide (prior to serial 
dilution). Cells were then incubated for 48 hours at 37°C. At this point half the 
supernatant was removed and stored in sterile 1.5ml microcentrifuge tubes at -
20°C for later analysis. 18.5KBq of 3H-thymidine were then added to each well 
and cells were then incubated for a further 18 hours at 37°C. Post-incubation, 
cells were harvested onto a filter mat, which was dried overnight. Wax was then 
melted onto the filter, in a heated cabinet, at 75°C for 3-4 minutes, prior to 
counting on a microbeta counter with 3H-thymidine incorporation measured in 
counts per minute (cpm). Counts were then corrected for background subtracting 
the cpm values for T cells and DCs without peptide. Data were plotted using 
GraphPad Prism Version 4 software. 
2.4.6 GENERATING INSULIN B15-23 REACTIVE CD8+ T CELL 
OLIGOCLONAL LINES 
2.4.6.1 ISOLATION AND INITIAL GROWING OF CD8+TRBV19+ T CELLS 
CD8+ T cells were isolated from murine splenocytes (see 2.4.3) and once purified, 
were antibody-stained and sorted by FACS for TRBV19+ (TCRVβ6) as outlined in 
2.3.5.2. Post-sorting, cells were resuspended RPMI complete media, resuspended 
at 1x106/ml and transferred into a 6-well plate containing 20,000/ml irradiated 
DCs (prepared as outlined in 2.4.2) and 80,000/ml irradiated whole splenocytes. 
The next day, insulin B15-23 peptide was added at a final concentration of 
1μg/ml and the day after 20U/ml IL-2 and 2μg/ml IL-7 were also added into the 
cultures. Cells were cultured for 3 weeks with half media changes (containing IL-7 
and IL-2) every 3 days with fresh irradiated DCs, splenocytes and peptide added 
every 6 days. 
76 
 
2.4.6.2 LIMITING DILUTION OF CD8+TRBV19+ T CELLS 
At 3 weeks, a limiting dilution of the CD8+TRBV19+ T cells was carried out. Cells 
were then pelleted (400xg, 5 minutes, 4°C), counted and resuspended at 300 
cells/ml, (30 cells/well) and diluted to 100 cells/ml (10 cells/well), 30 cells/ml (3 
cells/well) and 10 cells/ml (1 cell/well). The cells were then transferred into a 96-
well round-bottomed plate. Cells remaining from the limiting dilution were set up 
as bulk cultures in a 6-well plate and cultured as in 2.4.6.1.  
2.4.6.3 EXPANSION OF CD8+TRBV19+ T CELLS 
Any individual well cultures showing significant expansion were removed using a 
plastic Pasteur pipette and expanded into a larger 48-well plate with fresh media 
(and APCs if prepared). Cells expanding further were then plated into 24-, 12-, or 
6-well plates depending on the plate they were removed from. Once the 
oligoclonal lines were plated in 6-well plates, samples were frozen down and 
assessed for insulin B15-23 reactivity. 
2.4.6.4 NOMENCLATURE OF THE CD8+TRBV19+ OLIGOCLONAL CELL LINES 
Oligoclonal lines were named based upon the strain, the plate and the well they 
were derived from e.g. a culture from A22Cα-/- 30 cells/well plate, well D4 
became A22Cα-/- 30D4. 
2.4.6.5 PREPARATION OF CD8+TRBV19+ OLIGOCLONAL CELL LINES FOR 
FUNCTIONAL ASSAYS 
Cells were removed from the 6-well cultures and pelleted (400xg, 5 minutes, 
room temperature). They were then washed twice, resuspended in RPMI 
complete media and incubated at room temperature for 20 minutes (to ensure 
removal of the cytokines) prior to pelleting as before. Cells were then counted 
and resuspended at 1x106/ml.  
2.4.6.6 FREEZING CD8+TRBV19+ OLIGOCLONAL CELL LINES 
Cells were prepared as 2.4.6.5 except the cells were resuspended at 1-2x106/ml 
in Freezing medium and transferred into a 1.8ml cryotube. Tubes were then 
placed into an isopropanol-containing freezing box to ensure cells were gradually 
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frozen down to -80°C. The next day, tubes were removed from the -80°C freezer 
and transferred into liquid nitrogen for long-term storage. 
2.5 CYTOKINE ASSAYS 
2.5.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
2.5.1.1 MACROPHAGE INFLAMMATORY PROTEIN-1β (MIP-1β) 
A 96-well Maxisorp immuno plate was coated with 4μg/ml capture antibody and 
incubated overnight at room temperature. The next day, plates were washed 
with ELISA Wash Buffer three times using a plate washer and blotted against 
paper towels to fully remove any buffer. Plates were then blocked using Reagent 
Diluent for 1 hour at room temperature. During this time, standards and samples 
(supernatants from cell culture experiments) were thawed, with the standards 
diluted in Reagent Diluent to the appropriate concentration (2.9.5.3). Plates were 
washed and blotted as above and standards/samples were then added to the 
wells and incubated for 2 hours at room temperature. Post-incubation, plates 
were washed and blotted as before followed by the addition of the detection 
antibody (0.8μg/ml). Plates were further incubated for 2 hours at room 
temperature, then washed and blotted as before. Diluted streptavidin-HRP was 
then added to the wells and incubated in the dark for 20 minutes at room 
temperature. Plates were then washed and blotted dry. TMB Substrate Solution 
was then added to each well and incubated for 15-20 minutes until sufficient 
colour change was seen. Further substrate conversion was then prevented 
through the addition of 2N H2SO4. Optical density (OD) was then determined 
using a plate reader set to 450nm with a reference at 570nm (to subtract any 
optical imperfections within the plate). 
2.5.1.2 IFN-γ 
Protocol as above except; capture antibody was diluted in Carbonate Buffer and 
incubated at 4°C overnight, plates were blocked at 37°C for 1 hour and the 
detection antibody was incubated for 1 hour at room temperature. 
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2.5.1.3 ELISA ANALYSIS 
A standard curve was plotted using the OD values and the known concentrations 
of the standards. From this, the concentration of the samples was calculated by a 
linear regression. Samples were then corrected for the background using the 
concentration of cytokines in the absence of peptide.  
2.6 HISTOLOGY 
2.6.1 FIXING AND CRYOPRESERVING TISSUE  
Pancreas, salivary gland and partial spleen were fixed in PLP overnight at 4°C. The 
tissue was then washed using PB Buffer and infused with 10% sucrose-PB Buffer 
solution for 30 minutes at 4°C to cryoprotect the tissue. The tissue was then 
incubated for an additional 30 minutes at 4°C using 20% sucrose-PB Buffer 
solution. Tissue was then removed from the solution, transferred to a tissue 
mould, embedded in OCT embedding matrix, and frozen using an isopentane ice 
bath. Tissue blocks were then stored at -80°C. 
2.6.2 SECTIONING TISSUE BLOCKS  
8μm sections were cut using a cryostat with the following settings: cryobar -45°C, 
chamber temperature -25°C and the specimen at -19°C. Sections were then 
transferred to poly-lysine coated slides and were stored at -80°C. 
2.6.3 IMMUNOHISTOCHEMISTRY STAINING  
Slides were defrosted at room temperature until dry. A hydrophobic border was 
then drawn around the tissue using a PAP pen and when dry, the specimens were 
rehydrated for 45 minutes with 1xPBS. Solution was then removed and replaced 
with 1% hydrogen peroxide in 1xPBS, to neutralise endogenous peroxidise 
activity, for 15 minutes. Slides were then washed 3 times using Histology Wash 
Buffer and, to prevent non-specific binding, FC receptors were blocked using 5% 
rat serum in Histology Wash Buffer and incubated for 20 minutes at room 
temperature. Slides were then washed in Histology Wash Buffer prior to the 
addition of 2-3 drops of Avidin per section. Slides were incubated for 15 minutes 
at room temperature, rinsed with Histology Wash Buffer, then 2-3 drops of biotin 
per section were added and slides were incubated for a further 15 minutes. Slides 
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were then immersed in Histology Wash Buffer for 5 minutes and then incubated 
for 90 minutes with the appropriate primary biotinylated antibody (2.9.6.3), 
diluted in 1xPBS. Post-incubation, slides were immersed once in Histology Wash 
Buffer and twice more in 0.1M Tris Buffer (pH7.4) for 5 minutes each to remove 
excess unbound primary antibody. Slides were then incubated with 0.1M Tris 
Buffer (pH7.4) diluted Streptavidin-Alkaline Phosphatase (1:300) for 45 minutes 
and then washed three times in 0.1M Tris Buffer (pH7.4), incubating each wash 
for 5 minutes. The colour was then developed using an alkaline phosphatase 
substrate kit (diluted in 0.1M Tris, pH8.4), with slides incubated for 20 minutes in 
the dark at room temperature. Slides were then washed in 0.1M Tris Buffer 
(pH7.4) and incubated for 5 minutes and then in water for 5 minutes. 
Haematoxylin counter stain was conducted by submerging the slides in 
haematoxylin for 30 seconds; submerging in water for 5 minutes and then 
submerging in 1% ammonium chloride in water for 30 seconds prior to a 5 minute 
wash in water. Slides were then dried overnight followed by section dehydration 
in 70% ethanol, then 100% ethanol and finally in Histo-Clear. Sections were then 
mounted with a coverslip using DPX. 
2.6.4 HISTOLOGY SCORING 
Islets were counted and scored using a scale of 0-4 as follows: no cellular 
infiltration, score 0, peri-insulitis (cellular infiltration around the islet), score 1, 
<25% infiltration, score 2, <50% infiltration, score 3, >50% infiltration score 4. 
Scoring was blinded with 2 independent scorers. Data were then collated and 
presented in GraphPad Prism Version 4 software. 
2.6.5 HISTOLOGY IMAGING 
Slides were visualised using an Olympus BX51 light microscope and Axiovision LE 
software, with help kindly provided by Dr Christopher Von Ruhland within the 
Central Biotechnology Services of Cardiff University. 
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2.7 COMPETITIVE INSULIN AUTOANTIBODY RADIOIMMUNOASSAY 
2.7.1 SERUM PREPARATION 
Mice were culled by cervical dislocation with blood extracted by cardiac puncture 
using a 25G needle and syringe. Blood was left to clot at room temperature for 3 
hours, then stored overnight at 4°C. Blood was then centrifuged (2000xg, 10 
minutes, 4°C) and the serum was removed and transferred to a fresh 
microcentrifuge tube to be stored at -20°C. 
2.7.2 INSULIN 125I LABEL 
2.7.2.1 DILUTION OF STOCK INSULIN 125I LABEL     
125I insulin label stock (50Ci) was diluted in TBT buffer and left at room 
temperature for 30 minutes. The diluted stock was then aliquotted into 400l 
aliquots and stored at -80C in a lead container until needed.  
2.7.2.2 DILUTION OF INSULIN 125I LABEL FOR COMPETITION ASSAY 
125I insulin aliquots were thawed at room temperature within a lead container 
and once defrosted, 125I-labelled insulin was diluted in TBT-BSA. A 25l sample 
was removed and counted for 3 minutes on a gamma counter. Once the counts 
per minute reached 16,500 (+/- 500 counts), half the solution was transferred to 
a new universal tube. To this new tube, 80l/ml of cold insulin i.e. non 125I-
labelled insulin was added, while an equal volume of TBT-BSA buffer was added 
to the original diluted tube. A 25l sample of each solution was then counted as 
before with counts between 14,000-15,500cpm (+/- 500 counts of each other).   
2.7.3 PROTEIN G SEPHAROSE BEADS 
Protein G Sepharose (PGS) beads were blocked in ethanolamine. When required, 
PGS beads were washed 3 times (500xg, 4°C, 3 minutes) in TBT Buffer, to remove 
excess ethanolamine, and then resuspended in TBT and stored at 4°C until 
needed.  
2.7.4 COMPETITIVE INSULIN AUTOANTIBODY RADIOIMMUNOASSAY 
5µl of sample/standard/quality control serum was plated twice in duplicates into 
a 96-deep-well plate. To each well 25µl of 125I-labelled insulin (“hot”) or 125I-
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labelled insulin + non-labelled insulin (“cold”) was added. Plates were centrifuged 
(500xg, 4°C, 3 minutes) and then incubated at 4°C for 72 hours. Washed PGS 
beads were then added to the labelled plates and shaken on a digital plate shaker 
at 700rpm for 1 hour and 45 minutes. After PGS incubation, wells were washed 
with TBT Buffer and centrifuged as before. Wells were then manually aspirated 
and washed with TBT Buffer 4 times. Upon completion, wells were resuspended 
in 100μl of TBT Buffer, vortexed briefly and then the solution was transferred into 
1.2ml microtubes for counting on the gamma counter for 10 minutes/tube. 
2.7.4.1 ANALYSIS 
Standard counts per minute were plotted against their concentration to create a 
standard curve and using linear regression, samples and quality control serum 
competitive insulin autoantibody (cIAA) results were calculated. Values over 
0.0103 cIAA units were deemed positive with quality controls falling within their 
designated range. This threshold was set using the mean background level (plus 3 
standard deviations), detected in serum from C57BL/6 mice, which do not 
develop diabetes. Data were then presented in GraphPad Prism Version 4 
software. 
2.8 IN VIVO EXPERIMENTS 
2.8.1 NATURAL HISTORY OF DIABETES 
Post-weaning, mice were placed into observation groups and monitored bi-
weekly for glycosuria from 3 weeks of age using Glucostix strips. If positive, the 
mice were retested the next day and diabetes confirmed with a blood glucose 
reading, over 13.9mmol/L. In addition, for the gut microbiota experiments, 
weekly faecal pellets were also taken and placed into 1.5ml microcentrifuge 
tubes and stored at -80°C. Upon development of diabetes (6-10 weeks of age) or 
termination of the observation group (12-20 weeks of age), the pancreas, salivary 
gland and partial spleen were taken for histology and blood was collected for 
serum. Data were then presented using GraphPad Version 4 software. 
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2.8.2 PEPTIDE IMMUNISATIONS 
Mice were immunised with 50μl of Incomplete Freund’s Adjuvant (IFA) added to 
an equal volume of saline containing 50μg of CpG and 50μg of Insulin B15-23 
peptide/denatured insulin. The solution was then emulsified by vortex and then 
injected subcutaneously at the base of the tail into mice.   
2.8.3 SPLENOCYTE TRANSFERS 
Spleens were harvested from mice, homogenised using a loose glass 
homogenisers, lysed with 900μl of water, followed by the addition of 100μl of 
10xPBS (producing a 1xPBS solution). Cells were then resuspended in 9mls of 
1xPBS and then pelleted (400xg, 5 minutes, 4°C). Splenocytes were then 
resuspended and washed twice in sterile saline and counted. Cells were then 
resuspended at 10-20x106 per 200µl and injected intravenously into the tail vein 
of donor mice. Mice were then monitored for diabetes as detailed in 2.8.1. 
2.8.3.1 CFDA-SE LABELLED SPLENOCYTE TRANSFER 
Single cell splenocyte suspensions were prepared and counted as 2.8.3. CD8+ T 
cells were then isolated (2.4.3), pelleted (400xg, 5 minutes, 4°C) and resuspended 
in pre-warmed (37°C) sterile 1xPBS containing the CFDA-SE probe (5μM). Cells 
were then incubated at 37°C for 15 minutes in a waterbath. Post-incubation, cells 
were pelleted as before, and resuspended in pre-warmed (37°C) RPMI complete 
media to ensure complete modification of the probe. Cells were then further 
incubated for 30 minutes at 37°C, pelleted, washed in sterile saline twice, 
counted and resuspended at 10-20x106 cells per 200μl. They were then 
intravenously injected into the tail vein of recipient NODPI2tg mice. 
2.8.3.2 CFDA-SE IN VIVO PROLIFERATION ASSESSMENT 
Thymus, spleen, PLN and MLN were taken from the NODPI2tg mice, which 
received CFDA-SE labelled CD8+ T cells. Single cell suspensions were prepared, 
stained and fixed as 2.3.2, with the panel of antibodies as shown in 2.9.3.3.1. 
Cells were then measured on a BD FACS CANTO II and analysed on Flowjo 
(Treestar) Version 7.6.5 software, gating on CD8+CFDA-SE+ T cells. To assess those 
proliferating cells, a gate was placed on the cells with reduced CFDA-SE staining 
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i.e. proliferating cells, while excluding unproliferated, bright CFDA-SE labelled 
cells (FIGURE 14). Data were then presented using GraphPad Prism Version 4 
Software. 
2.8.4 BAYTRIL ADMINISTRATION 
Baytril (containing the active antibiotic enrofloxacin) was diluted 1:250 in sterile, 
autoclaved tap water. Water was changed bi-weekly with fresh Baytril-containing 
water made each time. In addition water bottles were replaced every week.  
2.8.5 INTRA-PERITONEAL GLUCOSE TOLERANCE TESTS (IPGTT) 
Mice were fasted overnight for a period of up to 16 hours. At this point, fasting 
blood glucose was measured using a blood glucose monitor and all mice were 
weighed. Sterile glucose (1.5g/kg) was then injected intra-peritoneally into the 
mice. At time points, 0, 15, 30, 60 and 90 minutes post-injection, mice were bled 
from a superficial cheek vein and blood glucose tested. At the end of the 
experiment mice were culled by cervical dislocation. Data were then presented 
using GraphPad Prism Version 4 software. 
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2.9 REAGENT DETAILS  
2.9.1 GENERAL REAGENT DETAILS 
2.9.1.1 IN-HOUSE BUFFERS  
BUFFER/SOLUTION NAME CONSTITUENTS 
BAYTRIL-CONTAINING 
WATER 
1:250 BAYTRIL DILUTED IN AUTOCLAVED TAP WATER 
BLOOD BUFFER 5% FBS, 0.02M EDTA, 0.08% SODIUM AZIDE IN  500ml 
1xPBS 
CARBONATE BUFFER 
(0.05M) 
1 TABLET/100mls DEIONISED WATER (pH9.6) 
DASATINIB SOLUTION 100nM DASATINIB IN TETRAMER WASH BUFFER 
DIGEST BUFFER 0.05M TRIS (pH8), 0.02M EDTA, 2% SDS IN DEIONISED 
WATER 
dNTPs DEIONISED WATER CONTAINING 5mM OF EACH dNTP 
ELISA WASH BUFFER 1xPBS in 0.05% TWEEN (pH7.2-7.4) 
ETHANOL (70%) 70% ETHANOL IN MOLECULAR BIOLOGY GRADE STERILE 
WATER 
ETHANOL (75%) 75% ETHANOL IN MOLECULAR BIOLOGY GRADE STERILE 
WATER 
FACS BUFFER 5g/L BSA, 0.01% SODIUM AZIDE in 1xPBS (pH7.3 (+/-
0.1)) 
FACS FIX 1% PARAFORMALDEHYDE IN 1xPBS (pH7.4) 
GENE RULER (100bp) 0.083μg/μl DNA LADDER IN 1xLOADING DYE 
HISTOLOGY WASH BUFFER 0.01% TRITON X-100 IN 1xPBS (pH7.3 (+/-0.2)) 
LYSIS BUFFER 1:10 DILUTION OF 10x FACS LYSING SOLUTION IN 
DEIONISED WATER 
MACS BUFFER 2mM EDTA, 0.5% BSA in 1xPBS 
ORANGE G (6x) 2.5mg/ml ORANGE G IN 30% GLYCEROL IN DEIONISED 
WATER  
PB BUFFER (0.1M) 3 PARTS 0.1M MONO-BASIC SODIUM PHOSPHATE 
(NaH2PO4), 1 PART 0.1M DI-BASIC SODIUM PHOSPHATE 
(NA2HPO4) (pH7.6) 
PLP 0.075M LYSINE, 1% PARAFORMALDEHYDE, IN 100ml OF 
0.1M PB BUFFER. ONCE pH7.1, 0.212g SODIUM META-
PERIODATE ADDED 
PP BUFFER 0.015M HEPES in 1xHBSS (pH7.2) 
REAGENT DILUENT 1% BSA in 1xPBS (pH7.2-7.4) 
TAE (1x) 0.02M TRIS, 1mM EDTA (pH8), 0.4% ACETIC ACID IN 
DEIONISED WATER 
TBT 50mM/L TRIS,  1% TWEEN in DEIONISED WATER 
(pH8.0) 
TBT-BSA 50mM/L TRIS,  1% TWEEN, 1% BSA in DEIONISED 
WATER (pH8.0) 
TETRAMER WASH BUFFER 2% FBS in 1xPBS 
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2.9.1.2 IN-HOUSE MEDIA  
 
2.9.1.3 OTHER CHEMICALS AND SOLUTIONS 
REAGENT SUPPLIER ITEM 
NUMBER 
ETHANOL THERMO FISHER SCIENTIFIC M/4400/17 
DOUBLE DEIONISED WATER 
(MOLECULAR BIOLOGY GRADE) 
THERMO FISHER SCIENTIFIC BP2819-1 
SODIUM CHLORIDE (99.85%) ACROS ORGANICS 7647-14-5 
100% GLACIAL ACETIC ACID SIGMA-ALDRICH 27225 
SODIUM DODECYL SULPHATE 
(SDS) 
SIGMA-ALDRICH L3771 
EDTA SIGMA-ALDRICH E7889 
1x PHOSPHATE BUFFERED SALINE 
(PBS) 
LIFE TECHNOLOGIES 10010023 
ISOPROPANOL SIGMA-ALDRICH I9516 
HYCLONE TRYPAN BLUE THERMO SCIENTIFIC SV30084.01 
PHENOL-CHLOROFORM ISOAMYL 
(PCI) ALCOHOL MIX 
SIGMA-ALDRICH 77617 
TRI-REAGENT SIGMA-ALDRICH T9424 
1-BROMO-3-CHLOROPROPANE SIGMA-ALDRICH B62404 
1M HEPES GIBCO 15630-056 
10xHBSS WITHOUT Ca2+, Mg2+ & 
SODIUM BICARBONATE 
SIGMA-ALDRICH H4385 
DMSO SIGMA-ALDRICH D2650 
ISOPENTANE SIGMA-ALDRICH M32631 
TRIS BASE SIGMA-ALDRICH 252859 
PARAFORMALDEHYDE SIGMA-ALDRICH P-6148 
TWEEN® 20 FISHER SCIENTIFIC BP337-500 
 
 
MEDIA NAME CONSTITUENTS 
FREEZING MEDIA 60% FBS, 30% RPMI 1640 MEDIA, 10% DIMETHYL SULFOXIDE 
(DMSO) 
LB-AIX AGAR 
MEDIUM 
32 AGAR CAPSULES/L (CONTAINING 10g TRYPTONE, 5g YEAST 
EXTRACT, 10g NaCl & 15g), 8μg/ml AMPICILLIN, 40μg/ml X-
GAL 
RPMI COMPLETE 
MEDIA 
2mM L-GLUTAMINE, 5000 UNITS PENICILLIN, 0.1mg/ml 
STREPTOMYCIN, 5% FBS, 0.05mM 2-MERCAPTOETHANOL IN 
RPMI 1640 MEDIA 
SERUM-FREE RPMI 
MEDIA 
2mM L-GLUTAMINE, 5000 UNITS PENICILLIN, 0.1mg/ml 
STREPTOMYCIN, 0.05mM 2-MERCAPTOETHANOL IN RPMI 
1640 MEDIA 
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2.9.1.4 REAGENT KITS 
KIT CONSTITUENTS SUPPLIER ITEM 
NUMBER 
AVIDIN/BIOTIN 
BLOCKING KIT 
AVIDIN SOLUTION, BIOTIN 
SOLUTION 
VECTOR 
LABORATORIES 
SP-2001 
ALKALINE 
PHOSPHATASE 
SUBSTRATE KIT I 
REAGENT 1, REAGENT 2, 
REAGENT 3 
VECTOR 
LABORATORIES 
SK-5100 
CD8α+ T CELL 
ISOLATION KIT 
CD8α+ T CELL BIOTIN-
ANTIBODY COCKTAIL, ANTI-
BIOTIN MICROBEADS 
MACS MILTENYI 
BIOTEC 
130-104-
075 
GEL EXTRACTION 
KIT 
CLEAN UP COLUMNS, 2ml 
COLLECTION TUBES, WASH 
BUFFER, STABILISATION 
BUFFER, ELUTION BUFFER 
QIAGEN 28706 
μMACS mRNA 
ISOLATION KIT 
OLIGO dT MICROBEADS, 
LYSIS/BINDING BUFFER, WASH 
BUFFER, ELUTION BUFFER, 
μMACS ISOLATION COLUMNS, 
LYSATECLEAR COLUMNS 
MACS MILTENYI 
BIOTEC 
130-075-
201 
MOUSE CCL4/MIP-
1β DUOSET ELISA 
DEVELOPMENT 
SYSTEM 
CAPTURE ANTIBODY, 
DETECTION ANTIBODY, 
STANDARD, STREPTAVIDIN-
HRP 
R&D SYSTEMS DY451 
NUCLEOSPIN GEL 
AND PCR CLEAN UP 
KIT 
NUCLEOSPIN GEL CLEAN UP 
COLUMNS, 2ml COLLECTION 
TUBES, BUFFER NT1, BUFFER 
NT2, WASH BUFFER NT3, 
ELUTION BUFFER NE 
MACHERY-
NAGEL 
740609.50 
PKH-26 RED 
FLUORESCENT 
CELL LINKER KIT 
FOR GENERAL CELL 
MEMBRANE 
LABELING 
PKH-26 DYE, DILUENT C SIGMA-ALDRICH PKH26GL-
1KT 
SMARTTM RACE 
cDNA 
AMPLIFICATION 
KIT 
5’CDS PRIMER (OLIGO dT 
PRIMER), REVERSE 
TRANSCRIPTASE, RNase 
INHIBITIOR, TRICINE BUFFER, 
dNTPs, 10x REACTION BUFFER, 
UNIVERSAL PRIMER MIX 
CLONTECH 
LABORATORIES 
634924 
TOPO TA CLONING 
KIT FOR 
SEQUENCING, WITH 
ONE SHOT MAX 
EFFICIENCY DH5α-
T1R E.Coli 
pCR™4-TOPO® TA VECTOR, 
SALT SOLUTION, PCR BUFFER, 
dNTPS, CONTROL TEMPLATE, 
PRIMERS, STERILE WATER, ONE 
SHOT® CHEMICALLY COMPETENT 
E. coli, S.O.C MEDIUM 
INVITROGEN K4595-01 
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2.9.1.5 PEPTIDES AND PROTEINS  
REAGENT SUPPLIER ITEM NUMBER 
125-LABELLED 
RECOMBINANT HUMAN 
INSULIN 
PERKIN-ELMER NEX420050UC 
ACTRAPID INSULIN NOVO NORDISK 8-0201-01-203-3 
INSULIN B15-23 PEPTIDE GL BIOCHEM (SHANGHAI) LTD 068592 
 
2.9.1.6 REAGENT TUBES 
REAGENT SUPPLIER ITEM NUMBER 
0.2ml PCR TUBES THERMO SCIENTIFIC AB-0337 
1.2ml MICROTUBES STAR LAB I14127400 
1.5ml MICROCENTRIFUGE EPPENDORF 0030119460 
1.8ml CRYOTUBE THERMO SCIENTIFIC 375418 
2ml MICROTUBE SARSTEDT 72.609 
5ml STERILE POLYSTYRENE 
ROUND-BOTTOMED FACS 
TUBES 
BD 352054 
15ml FALCON TUBE VWR 734-0451 
20ml STERILIN UNIVERSAL 
TUBE 
GREINER BIO-ONE 201151 
50ml CENTRIFUGE TUBE SIGMA-ALDRICH CLS430291 
 
2.9.1.7 NEEDLES AND SYRINGES 
REAGENT SUPPLIER ITEM NUMBER 
1ml SYRINGE BD 309628 
10ml SYRINGE BD SYR188 
20G NEEDLE BD 305175 
20ml SYRINGE BD 301625 
25G NEEDLE BD 300600 
27G NEEDLE BD 305109 
30G NEEDLE BD 304000 
MYJECTOR U100 INSULIN 
1ml SYRINGE 
TERUMO BS=05M2713 
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2.9.1.8 GENERAL MISCELLANEOUS REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
20mm TISSUE CULTURE 
DISHES 
FISHER SCIENTIFIC 08-772-E 
300mm PLASTIC PASTEUR 
PIPETTE 
FISHER SCIENTIFIC 12827625 
40μm CELL FILTER BD 352340 
BOVINE SERUM ALBUMIN FISCHER SCIENTIFIC BP 1600-100 
GLASS PASTEUR PIPETTE FISHER SCIENTIFIC 12710756 
LS COLUMNS MACS MILTENYI BIOTEC 130-042-401 
MS COLUMNS MACS MILTENYI BIOTEC 130-042-201 
PBS TABLETS (DULBECCO A) OXOID BR0014 
STERILE DISPOSABLE 
SCALPEL 
SWANN MORTON 05XX 
 
2.9.1.9 GENERAL EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
CENTRIFUGE EPPENDORF CENTRIFUGE 
5415R 
EPPENDORF 
HAEMOCYTOMETER BRIGHT-LINE HAUSSER 
SCIENTIFIC 
TISSUE HOMOGENISER  LOOSE FIT FISHER 
SCIENTIFIC 
INCUBATOR HERAcell 150i THERMO 
SCIENTIFIC 
MICROCENTRIFUGE 5415 R EPPENDORF 
VORTEX VORTEX GENIE 2 SCIENTIFIC 
INDUSTRIES 
WATER BATH ISOTEMP 215 FISHER 
SCIENTIFIC 
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2.9.2 MOLECULAR REAGENTS AND EQUIPMENT 
2.9.2.1 MOLECULAR REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
1Kb LADDER THERMO SCIENTIFIC SM0313 
10mM dNTP MIX LIFE TECHNOLOGIES 18427088 
10x PCR BUFFER SIGMA-ALDRICH P2192 
6x TRACKIT CYAN/ORANGE 
BUFFER 
INVITROGEN 10482-028 
96-WELL MICROAMP OPTICAL 
REACTION PLATES 
APPLIED BIOSYSTEMS 4346906 
ADVANTAGE 2 POLYMERASE MIX CLONTECH LABORATORIES 639201 
AMPICILLIN INVITROGEN 11593-027 
DNaseI ROCHE 11284932001 
dNTPs THERMO FISHER SCIENTIFIC 10234683 
ETHIDIUM BROMIDE SIGMA ALDRICH E1510 
GENERULERTM 100BP DNA 
LADDER 
THERMO FISHER SCIENTIFIC 11873953 
GLYCEROL SIGMA-ALDRICH G5516 
LB AGAR MEDIUM MP 3002-231 
LIBERASE TM RESEARCH GRADE ROCHE 05401119001 
MICROAMP OPTICAL ADHESIVE 
FILM 
APPLIED BIOSYSTEMS 4311971 
ORANGE G SIGMA-ALDRICH O-3756 
PCR PLATES (STANDARD) THERMO FISHER SCIENTIFIC 14-230-232 
PCR PLATE STRIP CAPS THERMO FISHER SCIENTIFIC 3418F 
PRONASE SIGMA-ALDRICH P6911 
PROTEINASE K SIGMA-ALDRICH P4850 
qPCR PRIMERS LIFE TECHNOLOGIES N/A 
RIBONUCLEASE A (FROM BOVINE 
PANCREAS) 
SIGMA-ALDRICH R4642 
RNAlater SIGMA-ALDRICH R0901 
RNAse OUT INVITROGEN 10777019 
SUPERSCRIPT II INVITROGEN 18064-014 
SUPERSCRIPT VILO MASTERMIX INVITROGEN 11755050 
SYBR GOLD INVITROGEN S11494 
TAQ DNA POLYMERASE (FROM 
THERMUS AQUATICUS) 
SIGMA-ALDRICH D1806 
TAQMAN UNIVERSAL MASTERMIX 
II, NO UNG (URACIL-N 
GLYCOSYLASE) 
APPLIED BIOSYSTEMS 4440040 
TRIS-EDTA BUFFER (TE BUFFER) SIGMA-ALDRICH 93283 
ULTRAPURE AGAROSE INVITROGEN 16500-500 
ULTRAPURE X-GAL (5-BROMO-4-
CHLORO-3-INDOLYL-β-D-
GALACTOSIDE) 
INVITROGEN 15520-034 
ZIRCONIUM BEADS BIOSPEC 11079105z 
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2.9.2.2 MOLECULAR EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
BEAD BEATER SHAKER MINI BIOSPEC 
PRODUCTS 
GEL ELECTROPHERESIS POWER 
SUPPLY 
POWER 608 FISHER SCIENTIFIC 
GEL TANKS DNA PLUS USA SCIENTIFIC 
GENE AMP PCR THERMOCYCLER 9700 APPLIED 
BIOSYSTEMS 
HEATING BLOCKS SBH130DC STUART 
MICROWAVE MICROCHEF SM11 PROLINE 
NANODROP 
SPECTROPHOTOMETER 
ND-1000 NANODROP 
PCR THERMAL CYCLER PTC-200 MJ RESEARCH 
qPCR MACHINE Viia-7 APPLIED 
BIOSYSTEMS 
SEQUENCING SYSTEM GS JUNIOR TITANIUM SERIES 
454 
ROCHE 
THERMOMIXER COMFORT EPPENDORF 
UV ILLUMINATOR BIODOC-IT IMAGING 
SYSTEM 
UVP 
 
2.9.2.3 POLYMERASE CHAIN REACTION REACTIONS, PROGRAMMES, 
MASTERMIXES AND PRIMERS 
2.9.2.3.1 PCR GENOTYPING REQUIRED FOR EACH STRAIN 
 
 
 
 
 
 
STRAIN PCR REACTIONS REQUIRED 
A22Cα-/- TCRCα-/-, TRAV8-1*01 
A22Cα-/-PI1-/- TCRCα-/-, PI1, PI1-/-, TRAV8-1*01 
A22Cα-/-PI2tg TCRCα-/-, PI2tg, TRAV8-1*01 
A22Cα-/-PI2-/- TCRCα-/-, PI2/PI2-/-, TRAV8-1*01 
A22Cα-/-PI1-/-PI2-/-Y16Atg TCRCα-/-, TRAV8-1*01, PI1, PI1-/-, PI2/PI2-/-, Y16Atg 
NODPI2tg PI2tg 
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2.9.2.3.2 PCR PROGRAMME LIST  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROGRAMME 
FOR PCR 
REACTIONS 
PROGRAMME DETAILS 
TEMPERATURE 
(°C) 
TIME 
(SECONDS) 
REPEATS 
TRAV8*1-01 
PI1-/- 
PI2-/- 
PI2tg 
Y16Atg 
94 
94 
55 
72 
72 
8 
180 
60 
60 
60 
300 
600 
 
 
35x 
TCRCα-/- 
PI1 
94 
94 
60 
72 
72 
8 
180 
45 
45 
45 
600 
600 
 
 
35x 
TCRβ CHAIN 
AMPLIFICATION 
95 
95 
72 
95 
70 
72 
95 
68 
72 
4 
30 
5 
120 
5 
10 
120 
5 
10 
120 
Forever 
 
5x 
 
 
5x 
 
 
35x 
COLONY PCR 95 
57 
68 
4 
30 
30 
180 
Forever 
 
35x 
qPCR 50 
95 
95 
60 
120 
600 
15 
60 
 
 
40x 
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2.9.2.3.3 PCR MASTERMIX CONSTITUENTS 
MASTERMIX NAME CONSTITUENTS PER SAMPLE 
cDNA 1μl SMARTer OLIGO, 2μl 5xRT BUFFER, 1μl DTT, 1μl 
RNAse OUT (RNAse INHIBITOR), 1μl SUPERSCRIPT II 
(REVERSE TRANSCRIPTASE) 
COLONY PCR 250μl 10x BUFFER, 50μl dNTPS, 100μl MI3R 
PRIMER, 100μl MI3F PRIMER, 5μl ADVANTAGE 2 
TAQ, 1995μl ddH2O 
qPCR MASTERMIX 45% TAQMAN UNIVERSAL MASTERMIX II, 10% 
PRIMERS (5% OF EACH PRIMER), 45% cDNA 
TCRβ CHAIN 5μl 10x BUFFER, 10μl UNIVERSAL PRIMER MIX, 1μl 
MuMBC PRIMER, 1μl dNTPs, 1μl ADVAN TAQ 2, 
19μl ddH2O 
 
2.9.2.3.4 GENOTYPING PRIMER SEQUENCES, BAND SIZE AND AGAROSE GEL 
REQUIREMENT 
*PRIMERS SYNTHESISED BY THERMO FISHER SCIENTIFIC 
 
GENE OF 
INTEREST 
PRIMER PRIMER SEQUENCE (5’ – 3’)* EXPECTED 
BAND SIZE 
AGAROSE 
GEL (%) 
TCRCα-/- F GCG GGA TCC AGA ACC CAG AAC CTG 
CTG TG 
900bp 3% 
R GGC GAA TTC CTG AAC TGG GGT AGG 
TGG CG 
TRAV8*1-01 F ATG CAC AGC CTC CTG GGG TTG TTG 650bp 1% 
R AAC AGC ACC GAA AGC CAC A 
PI1 F AGA CCT AGC ACC AGG CAA GTG T 970bp 1% 
R TTG GGC AGG AAG CAG AAT TCC AGA 
PI1-/- F GAG ATG CAA CCA GGT ATT 350bp 1% 
R CTA TCA GGA CAT AGC GTT 
PI2/PI2-/- 1 GGC AGA GAG GAG GTG CTT TG PI2: 400bp 
PI2-/-: 470bp 
 
3% 2 AGA AAA CCA GGG TAG TTA GC 
3 ATT GAC CGT AAT GGG ATA GG 
PI2tg F CCA CTG CCA AGG TCT GAA GGT CAC C 950bp 1% 
R TTG TTA ATT CTG CCT CAG TCT GCG 
Y16Atg F CTA TCT TCC AGG TCA ACT CG 318bp  
3% 
 
 
R ATC TAC AAT GCC ACG CTT CT 
ITC F CAA ATC TTG CTT GTC TGG TG 200bp 
ITC R GTC AGT CGA GTG CAC AGT TT 
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2.9.2.3.5 TCR CLONOTYPING AND BACTERIAL SEQUENCING PRIMER/OLIGO SEQUENCES 
PRIMER NAME SEQUENCE 5’-3’ FINAL CONCENTRATION SUPPLIER 
5’CDS PRIMER (T)25VN 10μM CLONTECH LABORATORIES 
SMARTer OLIGO AAG CAG TGG TAT CAA CGC AGA GTA CXX XXX 12μM CLONTECH LABORATORIES 
UNIVERSAL PRIMER 
MIX 
CTA ATA CGA CTC ACT ATA GGG CAA GCA GTG GTA 
TCA ACG CAG AGT 
 
CTA ATA CGA CTC ACT ATA GGG C 
0.08μM 
 
 
0.4μM 
 
CLONTECH LABORATORIES 
MuMBC PRIMER TGG CTC AAA CAA GGA GAC CT 5μM INVITROGEN 
MI3F PRIMER TTT TCC CAG TCA CGA C 1μM INVITROGEN 
MI3R PRIMER CAG GAA ACA GCT ATG AC 1μM INVITROGEN 
16S V2 rRNA 
FORWARD PRIMER 
CAT GCT GCC TCC CGT AGG AGT 0.24μM SIGMA-ALDRICH 
16S V2 rRNA REVERSE 
PRIMER 
CAG AGT TTG ATC CTG GCT CAG 0.24μM SIGMA-ALDRICH 
 
2.9.2.3.6 qPCR PRIMER DETAILS  
PRIMER NAME ASSAY ID AMPLICON 
LENGTH 
GAPDH Mm99999915_g1 VIC 107bp 
INSULIN 1 Mm01950294_s1 FAM 80bp 
INSULIN 2 Mm00731595_gH FAM 99bp 
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2.9.3 FLOW CYTOMETRY REAGENTS AND EQUIPMENT 
2.9.3.1 FLOW CYTOMETRY REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
DASATINIB AXON MEDCHEM 1392 
LYSIS BUFFER (10x) BD 349202 
RNAlater SIGMA-ALDRICH R0901 
SODIUM AZIDE SIGMA ALDRICH 438456 
 
2.9.3.2 NIH PROVIDED PEPTIDE:MHC BV421 TETRAMERS 
*This minimal binding insulin B15-23 peptide enables MHC loading due with 
Tyrosine at position 2 and provides optimal anchorage with Valine at position 9.  
 
2.9.3.3 FLOW CYTOMETRY-BASED ANTIBODY STAINING PANELS 
2.9.3.3.1 GENERALISED FLOW CYTOMETRY-BASED ANTIBODY STAINING 
PANELS 
FLOW CYTOMETRY PANEL NAME ANTIBODIES 
GENOTYPING ANTIBODY PANEL CD8 APC, CD19 PerCp/Cy5.5, TCRVα2 
FITC, TCRVα3.2 FITC, TCRVα8.3 FITC, 
TCRVα11.1 FITC, TCRVα11.2 FITC*, 
TCRVβ6 PE 
TRBV PHENOTYPING ORIGINAL 5-
COLOUR ANTIBODY PANEL 
CD4 APC, CD8 PE/Cy7, VIABILITY DYE 
eFluor780, CD19 PE, TCRVβ3-14 FITC** 
TRBV PHENOTYPING UPDATED 8-
COLOUR ANTIBODY PANEL 
CD8 BV510, CD4 PE/Cy7, VIABILITY DYE 
eFluor780 (WITH TCRVβ2-14, 17 AND 
CD19)*** 
CFDA-SE**** ANTIBODY PANEL CD4 BV421, CD8 V510, CD19 
PerCp/Cy5.5, CD44 APC, CD69 PE/Cy7, 
VIABILITY DYE eFluor780 
*All TCRVα antibodies are added in order exclude any mice that lack the fixed 
TCRCα-/-, as mice with the desired TCRCα-/- will have no staining for any 
TCRValpha and will have a small proportion of staining for TCRVβ6 (as the mice 
have endogenous TCRβ chains). 
** Individual TRBV FITC antibodies were added to each tube (12 tubes per tissue 
in total). All tubes received CD4, CD8, Live/Dead and CD19 antibodies. 
*** The TRBV and CD19 antibodies were split between 4 panels, using a number 
of different fluorochromes (2.9.3.3.3 and 2.9.3.3.4) 
**** CFDA-SE is detected in the FITC channel 
PEPTIDE SEQUENCE MHC RESTRICTION 
INSULIN B CHAIN 15-23 LYLVCGERG H2-Kd 
MINIMAL BINDING 
INSULIN B CHAIN 15-23 
AYAAAAAAV* H2-Kd 
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2.9.3.3.2 TRBV NOMENCLATURE 
CURRENT IMGT 
NOMENCLATURE 
PREVIOUS 
NOMENCLATURE 
TRBV1 TCRVβ2 
TRBV2 TCRVβ4 
TRBV3 TCRVβ16 
TRBV4 TCRVβ10 
TRBV5 TCRVβ1 
TRBV12-1 TCRVβ5.2 
TRBV12-2 TCRVβ5.1 
TRBV12-3 TCRVβ5.3 
TRBV13-1 TCRVβ8.3 
TRBV13-2 TCRVβ8.2 
TRBV13-3 TCRVβ8.1 
TRBV14 TCRVβ13 
TRBV15 TCRVβ12 
TRBV16 TCRVβ11 
TRBV17 TCRVβ9 
TRBV19 TCRVβ6 
TRBV20 TCRVβ15 
TRBV21 TCRVβ19 
TRBV23 TCRVβ20 
TRBV24 TCRVβ17 
TRBV26 TCRVβ3 
TRBV29 TCRVβ7 
TRBV30 TCRVβ18 
TRBV31 TCRVβ14 
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2.9.3.3.3 STANDARD TRBV PHENOTYPING FLOW CYTOMETRY MODIFIED 8-
COLOUR ANTIBODY PANEL 
ANTIBODY FLUOROCHROME PANEL 
1 
PANEL 
2 
PANEL 
3 
PANEL 
4 
CD4 PE/Cy7     
CD8 V500/V510     
Live/Dead eFluor 780     
CD19 eFluor 450/BV421     
TCRVβ2 AlexaFluor 647     
TCRVβ3 PE     
TCRVβ4 FITC     
TCRVβ5.1, 
Vβ5.2 
APC     
TCRVβ6 APC     
TCRVβ7 PE     
TCRVβ8.1, 
Vβ8.2 
FITC     
TCRVβ9 eFluor 450     
TCRVβ10b PE     
TCRVβ11 PerCp eFluor 710     
TCRVβ12 PerCp eFluor 710     
TCRVβ13 PerCp eFluor 710     
TCRVβ14 FITC     
TCRVβ17 FITC     
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2.9.3.3.4 PEYER’S PATCH TRBV PHENOTYPING FLOW CYTOMETRY 
MODIFIED 8-COLOUR ANTIBODY PANEL 
ANTIBODY FLUOROCHROME PANEL 
1 
PANEL 
2 
PANEL 
3 
PANEL 
4 
PANEL 
5 
CD4 eFluor 450      
CD4 APC      
CD8α V510      
CD8β PE/Cy7      
CD19 eFluor 450/BV421      
CD44 FITC      
CD62L PerCp/Cy5.5      
Live/Dead eFluor 780      
TCRVβ2 Alexa Fluor 647      
TCRVβ3 PE      
TCRVβ4 FITC      
TCRVβ5.1, 
Vβ5.2 
APC      
TCRVβ6 PE      
TCRVβ7 PE      
TCRVβ8.1, 
Vβ8.2 
FITC      
TCRVβ9 eFluor 450      
TCRVβ10b PE      
TCRVβ11 PerCp eFluor 710      
TCRVβ12 PerCp eFluor 710      
TCRVβ13 PerCp eFluor 710      
TCRVβ14 FITC      
TCRVβ17 FITC      
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2.9.3.3.5 PEPTIDE:MHC TETRAMER STAINING FLOW CYTOMETRY 
ANTIBODY PANELS 
ANTIBODY FLUOROCHROME STANDARD 
TETRAMER 
STAIN 1 
STANDARD 
TETRAMER 
STAIN 2 
PEYER’S 
PATCH 
TETRAMER 
STAIN 
CD4 APC    
CD4 PE/Cy7    
CD8α FITC    
CD8α BV510    
CD8β PE/Cy7    
CD11b APC    
CD19 eFluor 450    
CD19 PerCp/Cy5.5    
CD44 FITC    
CD62L PerCp/Cy5.5    
CD69 PE/Cy7    
TCRVβ6 PE    
TETRAMER APC    
TETRAMER BV421    
Live/Dead eFluor 780    
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2.9.3.4 FLOW CYTOMETRY NON-T CELL RECEPTOR ANTIBODY LIST 
ANTIBODY CLONE REACTIVITY SUPPLIER FLUOROCHROME CONCENTRATION DILUTION USE 
CD4 RM-5 
 
 
 
Rat α-mouse BioLegend 
eBioscience 
BV421 
APC 
eFluor 450 
PE/Cy7 
0.2mg/ml 
0.2mg/ml 
0.2mg/ml 
0.2mg/ml 
1:400 
1:400 
1:400 
1:400 
C 
T, TR 
TR 
T, TR 
CD8a 53-6.7 Rat α-mouse eBioscience 
BD 
 
 
BioLegend 
APC 
FITC 
PE/Cy7 
V500 
V510 
0.2mg/ml 
0.5mg/ml 
0.2mg/ml 
0.2mg/ml 
0.1mg/ml 
1:20 
1:200 
1:200 
1:200 
1:200 
G 
T 
TR 
TR 
C, T, TR 
CD8β YTS156.7.
7 
Rat α-mouse BioLegend PE/Cy7 0.2mg/ml 1:200 T, TR 
CD11b M1/70 Rat α-mouse BD APC 0.2mg/ml 1:200 T 
CD19 6D5 
1D3 
6D5 
Rat α-mouse BioLegend 
eBioscience 
BV421 
eFluor 450 
PerCp/Cy5.5 
0.025mg/ml 
0.2mg/ml 
0.2mg/ml 
1:200 
1:200 
1:20 
TR 
T, TR 
C, G, T 
CD44 IM7 Rat α-mouse BioLegend APC 
FITC 
0.2mg/ml 
0.2mg/ml 
1:200 
1:200 
C 
T, TR 
CD62L MEL-14 Rat α-mouse BioLegend PerCp/Cy5.5 0.2mg/ml 1:200 T, TR 
CD69 H1.2F3 Hamster α-
mouse 
BioLegend PE/Cy7 0.2mg/ml 1:200 C, T 
VIABILITY DYE N/A N/A eBioscience eFluor 780 N/A 1:1000 C, G, T, TR 
 
USE: C = CFDA-SE staining, G = Genotyping, T = Tetramer staining, TR = T cell Receptor Repertoire staining  
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2.9.3.5 FLOW CYTOMETRY T CELL RECEPTOR ANTIBODY LIST 
ANTIBODY CLONE REACTIVITY SUPPLIER FLUOROCHROME CONCENTRATION DILUTION USE 
TCRVα2 B20.1 Rat α-mouse BioLegend FITC 0.5mg/ml 1:100 G 
TCRVα3.2 RR3-16 Rat α-mouse BD FITC 0.5mg/ml 1:100 G 
TCRVα8.3 B21.14 Rat α-mouse BioLegend FITC 0.5mg/ml 1:100 G 
TCRVα11.1, Vα11.2 RR8-1 Rat α-mouse BD FITC 0.5mg/ml 1:100 G 
TCRVβ2 B20.6 Rat α-mouse BioLegend Alexa Fluor 647 0.5mg/ml 1:100 TR 
TCRVβ3 KJ25 Hamster α-mouse BD 
 
FITC 
PE 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ4 KT4 Rat α-mouse BD FITC 0.5mg/ml 1:200 TR 
TCRVβ5.1, Vβ5.2 MR9-4 Mouse α-mouse BioLegend 
BD 
APC 
FITC 
0.2mg/ml 
0.5mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ6 RR4-7 Rat α-mouse eBioscience 
BD 
BioLegend 
APC 
FITC 
PE 
0.2mg/ml 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
1:200 
TR 
TR 
G, T 
TCRVβ7 TR310 Rat α-mouse BD FITC 
PE 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ8.1, Vβ8.2 KJ16-133 Rat α-mouse eBioscience FITC 0.5mg/ml 1:200 TR 
TCRVβ9 MR10 Mouse α-mouse eBioscience 
BD 
eFluor 450 
FITC 
0.2mg/ml 
0.5mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ10b B21.5 Rat α-mouse BD 
eBioscience 
FITC 
PE 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ11 RR3-15 
123 
Rat α-mouse BD 
eBioscience 
FITC 
PerCp eFluor 710 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ12 MR11-1 Mouse α-mouse BD 
eBioscience 
FITC 
PerCp eFluor 710 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ13 MR12-3 Mouse α-mouse BD 
eBioscience 
FITC 
PerCp eFluor 710 
0.5mg/ml 
0.2mg/ml 
1:200 
1:200 
TR 
TR 
TCRVβ14 14-2 Rat α-mouse BD FITC 0.5mg/ml 1:200 TR 
TCRVβ17 KJ23 Mouse α-mouse BD FITC 0.5mg/ml 1:100 TR 
USE: G = Genotyping, T = Tetramer staining, TR = T cell Receptor Repertoire staining 
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2.9.4 TISSUE CULTURE REAGENTS AND EQUIPMENT 
2.9.4.1 TISSUE CULTURE REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
2-MERCAPTOETHANOL (50mM) LIFE TECHNOLOGIES 31350-010 
6-WELL PLATE THERMO SCIENTIFIC 140685 
12-WELL PLATE THERMO SCIENTIFIC 150628 
24-WELL PLATE THERMO SCIENTIFIC 142485 
25cm2 TISSUE CULTURE FLASK THERMO SCIENTIFIC 156340 
48-WELL PLATE THERMO SCIENTIFIC 152640 
75cm2 TISSUE CULTURE FLASK THERMO SCIENTIFIC 156472 
96-WELL PLATE THERMO SCIENTIFIC 163320 
DEAE FILTER MAT PERKIN ELMER 1450-522 
FETAL BOVINE SERUM (FBS) SIGMA-ALDRICH F7524 
GRANULOCYTE MACROPHAGE 
COLONY STIMULATING FACTOR 
(GM-CSF) 
WONG LAB N/A 
IL-2 SUPERNATANT WONG LAB N/A 
IL-7 R&D SYSTEMS 407-ML-005 
L-GLUTAMINE (200mM) LIFE TECHNOLOGIES 25030-024 
LIPOPOLYSACCHARIDES (LPS) 
E.coli 026:B6 
SIGMA-ALDRICH L2654 
MELTILEX FILTER WAX PERKIN ELMER 1450-441 
MR FROSTY FREEZING 
CONTAINER 
THERMO SCIENTIFIC 5100-0001 
NUNC CELL SCRAPER THERMO SCIENTIFIC 179693 
P815 CELLS WONG LAB N/A 
PENICILLIN-STREPTOMYCIN SIGMA-ALDRICH P0781 
RPMI 1640 GE HEALTHCARE E15-039 
THYMIDINE PERKIN ELMER NET027E001MC 
TOPRO-3 LIFE TECHNOLOGIES T3605 
 
2.9.4.2 TISSUE CULTURE EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
CELL HARVESTER 96 MACH TOMTEC 
CELL HARVESTER PUMPS DYMAX 30 CHARLES AUSTEN 
PUMPS 
HYBRIDIZATION OVEN N/A AMERSHAM LIFE 
SCIENCE 
MICROBETA COUNTER 2450 MICROPLATE 
COUNTER 
PERKIN ELMER 
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2.9.5 ELISA REAGENTS AND EQUIPMENT  
2.9.5.1 ELISA REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
2N SULPHURIC ACID (H2SO4) SIGMA-ALDRICH 35276 
96-WELL MAXISORP NUNC 
IMMUNO PLATE 
THERMO SCIENTIFIC 439454 
BOVINE SERUM ALBUMIN, 
FRACTION V 
SIGMA-ALDRICH 85040C 
CAPTURE ANTIBODY: 
RAT ANTI-MOUSE IFN-γ 
BD 551216 
CARBONATE-BICARBONATE 
BUFFER CAPSULES 
SIGMA-ALDRICH C3041-100CAP 
DETECTION ANTIBODY: 
BIOTIN RAT ANTI-MOUSE IFN-γ 
BD 554410 
STANDARD: RECOMBINANT 
MOUSE IFN-γ 
BD 555138 
STREPTAVIDIN-HORSE RADISH 
PEROXIDASE 
INVITROGEN SA1007 
TMB SUBSTRATE REAGENT SET BD 555214 
 
2.9.5.2 ELISA EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
ELISA PLATE READER MULTISKAN 
SPECTRUM 
THERMO 
LABORATORIES 
ELISA PLATE WASHER VP SERIES KNF NEUBERGER 
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2.9.5.3 ELISA ANTIBODY AND STANDARD CONCENTRATIONS 
ANTIBODY/STANDARD INITIAL CONCENTRATION DILUTION DILUENT FINAL CONCENTRATION 
CAPTURE ANTIBODY: 
RAT ANTI-MOUSE MIP-1β 
720μg/ml 1:180 1xPBS 4μg/ml 
CAPTURE ANTIBODY: 
RAT ANTI-MOUSE IFN-γ 
1mg/ml 1:500 CARBONATE 
BUFFER 
2μg/ml 
DETECTION ANTIBODY: 
BIOTINYLATED GOAT ANTI-
MOUSE MIP-1β 
144μg/ml 1:180 REAGENT DILUENT 0.8μg/ml 
DETECTION ANTIBODY: 
BIOTIN RAT ANTI-MOUSE IFN-γ 
0.5mg/ml 1:1000 REAGENT DILUENT 0.5μg/ml 
STANDARD: RECOMBINANT 
MOUSE MIP-1β 
0.11μg/ml 1:55 REAGENT DILUENT 0.002μg/ml* 
STANDARD: RECOMBINANT 
MOUSE IFN-γ 
1μg/ml 1:250 REAGENT DILUENT 0.004μg/ml** 
STREPTAVIDIN-HORSE RADISH 
PEROXIDASE FOR MIP-1β 
N/A 1:200 REAGENT DILUENT N/A 
STREPTAVIDIN-HORSE RADISH 
PEROXIDASE FOR IFN-γ 
N/A 1:4000 REAGENT DILUENT N/A 
 
*MIP-1β ELISA standard was serially diluted 1:2 with Reagent Diluent to generate a standard curve with standard concentrations at 0.002μg/ml 
(2000pg/ml), 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml and 31.25pg/ml. 
** IFN-γ ELISA standard was serially diluted 1:2 with Reagent Diluent to generate a standard curve with standard concentrations at 0.004μg/ml 
(4000pg/ml), 2000pg/ml, 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml and 62.5pg/ml. 
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2.9.6 HISTOLOGY REAGENTS AND EQUIPMENT 
2.9.6.1 HISTOLOGY REAGENTS  
REAGENT SUPPLIER ITEM NUMBER 
COVERSLIPS (24x50mm) VWR INTERNATIONAL 631-0147 
DPX SIGMA-ALDRICH 06522 
HAEMATOXYLIN VECTOR LABORATORIES H-3401 
HISTO-CLEAR NATIONAL DIAGNOSTICS HS-200 
HYDROGEN PEROXIDE 30% BDH LABORATORY 
SUPPLIES 
285194F 
L(+) LYSINE 
MONOHYDROCHLORIDE, 
99%+ 
ACROS ORGANIC 125221000 
LEVAMISOLE SOLUTION VECTOR LABORATORIES SP-5000 
OCT EMBEDDING MATRIX CELLPATH KMA-0100-00A 
PAP PEN (IMMEDGE PEN) VECTOR LABORATORIES H-4000 
RAT SERUM SIGMA-ALDRICH R9759 
SODIUM META-PERIODATE THERMO SCIENTIFIC 20504 
SODIUM PHOSPHATE DIBASIC SIGMA-ALDRICH S-0876 
SODIUM PHOSPHATE 
MONOBASIC 
SIGMA-ALDRICH S-0751 
SUCROSE FISHER SCIENTIFIC S/8600/60 
SUPERFROST PLUS SLIDES VWR 48311-703 
TISSUE MOULDS FISHER SCIENTIFIC 22-363-554 
TRIS BUFFER pH7.4 BRISTOL UNIVERSITY N/A 
TRIS BUFFER pH8.4 BRISTOL UNIVERSITY N/A 
TRITON X-100 SIGMA-ALDRICH X-100 
 
2.9.6.2 HISTOLOGY EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
CAMERA AXIOVISION LE ZEISS 
CRYOSTAT CRYOTOME FSE THERMO ELECTRON 
CORPORATION 
MICROSCOPE BX51 OLYMPUS 
 
2.9.6.3 HISTOLOGY BIOTINYLATED ANTIBODY LIST 
ANTIBODY CLONE REACTIVITY SUPPLIER CONCENTRATION DILUTION 
CD4 GK1.5 Rat α-mouse BioLegend 0.5mg/ml 1:10 
CD8a 53-6.7 Rat α-mouse BD 0.5mg/ml 1:10 
CD45R/ 
B220 
RA3-
6B2 
Rat α-mouse BD 0.5mg/ml 1:30 
RAT IgG2a λ 
ISOTYPE 
CONTROL 
B39-4 N/A BD 0.5mg/ml 1:10 
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2.9.7 INSULIN AUTOANTIBODY ASSAY REAGENTS AND EQUIPMENT 
2.9.7.1 INSULIN AUTOANTIBODY ASSAY REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
4 FAST FLOW PROTEIN G 
SEPHAROSE 
GE HEALTHCARE 17-0618-05 
5M HYDROCHLORIC ACID VWR 30018.360 
96-WELL 1.2ml MEGABLOCK 
PLATES 
SARSTEDT 82.1970.002 
ETHANOLAMINE SIGMA-ALDRICH E9508 
 
2.9.7.2 INSULIN AUTOANTIBODY ASSAY EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
DIGITAL PLATE SHAKER IKA MTS 2/4 IKA 
GAMMA COUNTER WALLAC WIZARD 1470 
AUTOMATIC GAMMA COUNTER 
PERKIN-ELMER 
PLATE WASHER HANDIWASH DYNATECH 
 
2.9.8 IN VIVO REAGENTS AND EQUIPMENT 
2.9.8.1 IN VIVO REAGENTS 
REAGENT SUPPLIER ITEM NUMBER 
BAYTRIL BAYER 
CORPORATION 
BABAY14 
BLOOD GLUCOSE STAT STRIPS NOVA BIOMEDICAL N/A 
CpG 1826 OLIGONUCLEOTIDES INVIVOGEN tlrl-1826-1 
D-(+)-GLUCOSE SOLUTION SIGMA-ALDRICH G8769 
DIASTIX (URINE STRIPS) BAYER 
CORPORATION 
2804 
INCOMPLETE FREUND’S 
ADJUVANT (IFA) 
SIGMA-ALDRICH F5506 
STERILE SODIUM CHLORIDE 
0.9% w/v (SALINE) 
BAXTER 
HEALTHCARE 
LIMITED 
FKE1323 
VYBRANT® CFDA-SE CELL 
TRACER KIT 
INVITROGEN V12883 
 
2.9.8.2 IN VIVO EQUIPMENT 
REAGENT SPECIFICATION SUPPLIER 
BLOOD GLUCOSE MONITOR STAT STRIP GLUCOSE 
XPRESS METER 
NOVA 
BIOMEDICAL 
WEIGHING SCALES CS SERIES OHAUS 
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FIGURE 9: TRAV8-1*01TRBJ9 (A22) NOD mice were crossed to TCRCα-/- (Cα-/-) 
NOD mice in the first generation to generate A22 and Cα-/- heterozygous mice 
(A22+/-Cα+/-). These mice were then fixed for the TCRCα-/- mutation through 
breeding A22+/-Cα+/- and TCRCα-/- (Cα-/-) NOD mice together. This produced A22+/-
Cα-/- mice, which could then be bred in the third generation to produce 25% of 
mice homozygous for both A22+/+ and Cα-/- (A22+/+Cα-/-). These mice could then be 
further crossed to produce offspring with 50% homozygosity for A22+/+ and Cα-/-. 
After successive generations, the A22 and Cα-/- genes were homozygous. 
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FIGURE 9: GENERATION OF THE SINGLE CHAIN TRAV8-1*01 TRANSGENIC 
(A22Cα-/-) NOD MICE  
FIRST GENERATION: 
 
 
 
 
 
 
SECOND GENERATION: 
 
 
 
 
 
THIRD GENERATION:
TRAV8-1*01TRAJ9 (A22) NOD 
X 
TCRCα-/- (Cα-/-) NOD 
A22+/-Cα+/- A22+/-Cα+/- 
 
A22+/-Cα+/- 
 
A22+/-Cα+/- 
A22+/-Cα+/- 
 
X 
TCRCα-/- (Cα-/-) NOD 
A22+/-Cα+/- 
 
A22+/-Cα-/- 
 
A22-/-Cα+/- 
 
A22-/-Cα-/- 
A22+/-Cα-/- 
 
X 
A22+/-Cα-/- 
 
A22+/+Cα-/- 
 
A22+/-Cα-/- 
 
A22+/-Cα-/- 
 
A22-/-Cα-/- 
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FIGURE 10: Single cell suspensions were prepared from thymi, spleen, pancreatic 
lymph nodes (PLN) and mesenteric lymph nodes (MLN). These cells were then 
stained with the TRBV phenotyping panels (see 2.9.3.3), fixed and measured on a 
BD FACS CANTO II. Data were analysed on Flowjo Version 7.6.5 software gating 
on cell populations for live single CD8+ T cells as shown above. The same gating 
was used for all strains and tissues except the thymus, where only the single 
positive CD4+ and CD8+ T cells were gated.   
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FIGURE 10: GATING STRATEGY FOR LIVE SINGLE CELL CD8+ T CELLS FOR TRBV REPERTOIRE 
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FIGURE 11: Single cell suspensions were prepared from thymi, spleen, pancreatic 
lymph nodes (PLN) and mesenteric lymph nodes (MLN). These cells were then 
stained with the TRBV phenotyping panels (see 2.9.3.3), fixed and measured on a 
BD FACS CANTO II. Data were analysed on Flowjo Version 7.6.5 software where 
cell populations were gated for live single CD8+ T cells as shown (FIGURE 10). 
Within the CD8+ T cell population, gates were assigned for each of the TCRVβ 
chains as shown above. The same gating was used for all strains and tissues. 
108 
 
FIGURE 11: GATING STRATEGY FOR CD8+ TRBV REPERTOIRE 
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FIGURE 12: Cells were isolated from the thymus, spleen, PLN, MLN or Peyer’s 
patches. Single cell suspensions were made and cells were counted. 1x106 cells 
were then aliquotted and cells were pre-incubated with Dasatinib for 30 minutes 
at 37°C. Cells were then washed and resuspended in Tetramer Wash Buffer 
containing 1μg of peptide:MHC tetramer. Cells were stained separately for Insulin 
B15-23:H2Kd tetramers and for the minimally binding peptide control 
AYAAAAAAV:H2Kd tetramer and incubated for 15 minutes at 37°C. Cells were 
then washed and stained for monoclonal antibodies to CD4, CD8, CD11b, CD19 
and viable cells for 30 minutes at 4°C, followed by cell fixation for a further 30 
minutes at 4°C. Cells were then washed and resuspended in Tetramer Wash 
Buffer and were measured on a BD FACS CANTO II. Data were subsequently 
analysed using Flowjo Version 7.6.5 software (Treestar) using the gating strategy 
shown to obtain live single cell CD8+CD19-CD11b-CD4-Tetramer+ T cells, with the 
Tetramer gate based on the G9C8 positive control. The minimally binding 
tetramer control was then deducted from the raw tetramer stain. Data shown are 
from a single male A22Cα-/-PI2-/- mouse PLN, however, it is representative of all 
mice and tissues stained. 
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FIGURE 12: GATING STRATEGY FOR LIVE SINGLE CELL CD8+CD19-CD11b-CD4-
TETRAMER+ T CELLS FOR IDENTIFYING INSULIN B15-23 REACTIVE CELLS 
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FIGURE 13: Splenocytes were harvested from mice and a single cell suspension 
was made. The cell suspension was then stained with Insulin B15-23 tetramer 
(13A) and/or monoclonal antibodies to CD4, CD8, CD11b, CD19, TCRVβ6 (TRBV19) 
and a viability marker (13A and 13B). 13A shows the gating for the tetramer-
based flow cytometry sorting on live single CD8+CD19-CD11b-CD4-Tetramer+ T 
cells into RNAlater from a male A22Cα-/-PI1-/-PI2-/-Y16Atg mouse PLN. 13B has the 
same gating strategy as 13A, whereby cells were gated on CD8+CD19-CD11b-CD4-, 
however, instead of tetramer, TCRVβ6+ T cells were gated and sorted into RPMI 
complete media. Sample 13B derives from a male A22Cα-/- mouse PLN. Both 
gating strategies are representative of all tetramer and antibody flow cytometry-
based cell sorting done.  
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FIGURE 13: FLOW CYTOMETRY BASED TETRAMER/TCRVβ ANTIBODY SORTING 
STRATEGY 
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FIGURE 14: Cells were isolated from the thymus, spleen, PLN or MLN. Single cell 
suspensions were made and cells were counted. CD8+ T cells were then isolated 
from the tissues using a MACS Miltenyi CD8+ Isolation kit. CD8+ T cells were then 
labelled with CFDA-SE at 37°C and washed to remove excess dye. Cells were then 
counted and resuspended at 10-20x106 per 200μl and transferred intravenously 
into NODPI2tg mice. Tissues were harvested four days later, single cell 
suspensions were made and cells were stained by monoclonal antibodies against 
CD4, CD8, CD19, CD44, CD69 and a viability marker for 30 minutes at 4°C. Cells 
were then fixed and washed prior to measurement on a BD FACS CANTO II. Post-
measurement, cells were analysed as outlined, gating live single cell CD8+CD4-
CFDA-SE+ T cells. Cells were then gated for proliferating CFDA-SE+ T cells (i.e. 
those with reduced CFDA staining). 
111 
 
FIGURE 14: GATING STRATEGY FOR CFDA-SE LABELLED CD8+ T CELL PROLIFERATION ASSAYS 
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CHAPTER 3: ANALYSIS OF THE T CELL RECEPTOR VARIABLE 
BETA CHAIN REPERTOIRE OF INSULIN B15-23 REACTIVE CD8+ 
T CELLS IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 
NOD MICE EXPRESSING VARYING LEVELS OF PROINSULIN 1 
AND 2 
3.1 INVESTIGATION OF THE T CELL VARIABLE BETA CHAIN 
RECEPTOR REPERTOIRE IN SINGLE CHAIN TRANSGENIC TRAV8-
1*01TRAJ9 NOD MICE EXPRESSING VARIABLE LEVELS OF 
PROINSULIN 
3.1.1 RATIONALE, AIMS & HYPOTHESIS 
The T cell receptor (TCR) repertoire is initially selected during thymic selection, 
with those TCRαβ chains that are able to strongly recognise tissue-restricted 
antigens being negatively selected. Furthermore, TCR repertoire selection also 
continues extra-thymically. There are many factors that are able to preferentially 
select specific TCR-expressing T cell responses and these apply to T cell responses 
to foreign antigens, tumour antigens and self-antigens. The main pressure on 
peripheral TCR repertoire is antigen expression. More specifically, the TCR 
repertoire is changed through the presence of antigen, preferentially selecting for 
the appropriate T cells to respond to the antigen (Cose et al., 1995, Hayashi et al., 
1995, Verdaguer et al., 1996, Wong et al., 2007b, Fanning et al., 2013, Koning et 
al., 2013, Sun et al., 2014), or promoting cross-reactive T cell responses (Smith et 
al., 2014, Nguyen et al., 2014). Furthermore, how the peptide is presented is also 
important (Messaoudi et al., 2002, Gras et al., 2009). In addition to antigen 
expression, peripheral regulation can also affect the TCR repertoire, for example 
through deletional tolerance (Fairchild et al., 1991) or through TCR repertoire 
biased regulatory T cell expansion (Quinn et al., 2001a, Sainz-Perez et al., 2012, 
Myers et al., 2013, Okuno et al., 2013). Interestingly, regulatory T cells have 
different TCR repertoires compared to conventional T cells, suggesting that 
conventional T cells are not converted into Tregs (Wong et al., 2007a, Hindley et 
al., 2011, Relland et al., 2012). There are also regional TCR repertoire differences 
found in the T cell populations (Weidmann et al., 1992, Halapi et al., 1993, 
Emerson et al., 2013, Sherwood et al., 2013). While some studies have shown 
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preferential TCR repertoire bias in the TCRα chain (Davies et al., 1991, Kobayashi 
et al., 2008), others have shown it is the TCRβ chain (Berschick et al., 1993, Cose 
et al., 1995, Hayashi et al., 1995, DiLorenzo et al., 1998, Quinn et al., 2001a), 
while some studies have shown no/little TCR repertoire bias (Lund et al., 1990, 
Olive et al., 1991, Sioud et al., 1992, Davies et al., 1992, Mathoulin et al., 1993, 
Parish et al., 1993). These differences are likely to have arisen due to the 
restricted availability of anti-TCR chain antibodies, particularly to the TCRVα chain 
(currently there are only 4 available antibodies), as well as the fact that TCR 
repertoire bias has been studied globally instead of investigating the antigen-
specific T cell populations. However, in order to maintain health, a diverse TCR 
repertoire is important, enabling T cells to stimulate a pathogenic or protective 
immune response as required (Ferreira et al., 2009, Manuel et al., 2012). This TCR 
diversity is affected by age (Naylor et al., 2005, Pfister et al., 2006, Yager et al., 
2008, Rudd et al., 2011, Vong et al., 2011, Britanova et al., 2014) and can make 
immunisations difficult, particularly in the elderly. However, some therapies have 
been developed using anti-TCRVβ monoclonal antibodies leading to protection 
from disease or disease reduction e.g. collagen-induced arthritis (Osman et al., 
1993), experimental autoimmune encephalomyelitis (EAE) (Zaller et al., 1990) 
and autoimmune diabetes (Edouard et al., 1993, Liu et al., 2012). Therefore, 
understanding how this TCR repertoire develops is important, not only for 
developing successful immunisations but it also enables investigators to identify 
factors that affect the promotion or reduction of T cell populations, based on 
their TCR, and how they impact disease survival or progression (reviewed by 
(Miles et al., 2011). 
As discussed earlier, antigen expression and presentation dictates the T cells, 
expressing a specific TCR, that are recruited during an immune response. In some 
studies, foreign antigens were expressed as self-antigens under the rat insulin 
promoter (Oldstone et al., 1991, Ohashi et al., 1991, Kurts et al., 1997). These 
studies highlighted the fact that auto-reactive CD8+ T cells were still selected, 
regardless of thymic antigen expression. However, the level of antigen expressed 
in the thymus dictated the avidity of the T cells selected (von Herrath et al., 1994, 
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Zehn and Bevan, 2006). Interestingly, these auto-reactive CD8+ T cells were 
unable to cause disease unless additional antigen was administered e.g. by 
infection in both polyclonal mice (Oldstone et al., 1991, Ohashi et al., 1991) and 
single TCRβ (Vβ5.2/TRBV12-1) transgenic mice (Dillon et al., 1994, Zehn and 
Bevan, 2006). These studies utilised a foreign antigen, expressed as a self-
antigen, and they may not be representative of T cell responses in a natural self-
antigen system such as the role of proinsulin expression on the development of 
an auto-reactive CD8+ TCR repertoire.  
In autoimmune diabetes, it has been shown that numerous TRBV chains may be 
important in disease, although many of these studies were done simply using 
flow cytometric methods and were non-antigen specific. However, with respect 
to insulin autoimmunity it has been shown that for insulin B9-23 reactive CD4+ T 
cells, the TCRα chain (TRAV5D-4*04) was shown to be important for conserving 
insulin autoimmunity, while able to pair to a number of TCRβ chains (Kobayashi 
et al., 2008, Zhang et al., 2009). This suggested a more permissive role for the 
TCRβ chain. However, it is unknown whether insulin-reactive CD8+ T cells show 
any TCR repertoire bias, with the only Insulin B15-23 reactive T cell known to 
utilise TRAV8-1*01TRAJ9 and TRBV19*01TRBD1-1TRBJ2-3 (previously named 
TCRVα15Jα8 and TCRVβ6Dβ1.1Jβ2.3 (Wong et al., 1996) and later, the TCRα chain 
was re-designated TCRVα18S1 (Wong et al., 1999)). 
In order to investigate the role of proinsulin expression in shaping the auto-
reactive CD8+ TCR repertoire, single chain transgenic mice were generated 
whereby the TCRα chain was restricted to the sole use of TRAV8-1*01TRAJ9 from 
the Insulin B15-23 reactive T cell, G9C8. As the TCRα chain in CD4+ Insulin B9-23 
reactive T cells dictated the development of insulin autoimmunity we chose to 
restrict the TCRα chain, allowing any endogenous TCRβ chains to pair (Kobayashi 
et al., 2008, Zhang et al., 2009). In addition, restriction of the TCRα chain also 
enabled us, in the first instance, to investigate the TCR repertoire by flow 
cytometry by using anti-TRBV antibodies, enabling us to identify the majority of 
TRBV chains (14 chains out of a total of 24). 
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HYPOTHESIS: 
Proinsulin expression will specifically alter the insulin-reactive CD8+ TCR 
repertoire, thus affecting the recognition of p:MHC, and the development of 
Insulin autoimmunity, including the ability to develop spontaneous autoimmune 
diabetes. 
AIMS:   
1. To investigate the total CD8+ T cell TRBV chain repertoire in single TRAV8-
1*01TRAJ9 chain transgenic mice aged 4-7 weeks, 8-10 weeks and 11-16 
weeks in the context of different levels of proinsulin 1 and 2 expression 
within the thymus and the periphery.  
2. To determine the frequency, the diabetogenicity and TCRβ chain 
repertoire of the Insulin B15-23 reactive CD8+ T cells in these mice 
expressing various levels of proinsulin 1 and 2 
The mice to be used for this investigation, including simplified names, which will 
be used throughout this work, are summarised in TABLE 5 below. 
TABLE 5: STRAIN NAMES AND INSULIN EXPRESSION OF MICE TO BE STUDIED  
NOD STRAIN NAME STRAIN 
SIMPLIFIED NAME 
PROINSULIN 
1 
PROINSULIN 
2 
TRAV8-1*01TRAJ9Cα-/-
PI1+/+PI2+/+ 
A22Cα-/- ++ ++ 
TRAV8-1*01TRAJ9Cα-/-
PI1+/+PI2+/+PI2tg 
A22Cα-/-PI2tg ++ +++ 
#TRAV8-1*01TRAJ9Cα-/-
PI1-/-PI2+/+ 
A22Cα-/-PI1-/- -- ++ 
TRAV8-1*01TRAJ9Cα-/-
PI1+/+PI2-/- 
A22Cα-/-PI2-/- ++ -- 
TRAV8-1*01TRAJ9Cα-/-
PI1-/-PI2-/-Y16Atg 
A22Cα-/-PI1-/-PI2-/-
Y16Atg 
-- -- 
 
#Note: The data generated for the TRAV8-1*01TRAJ9Cα-/-PI1-/-PI2+/+ (A22Cα-/-PI1-
/-) was generated in part by Miss Amy Phillips, an undergraduate, under my 
supervision. The designation A22 for the TCRα chain related to the selection of 
the transgenic mouse line 22 from a number of TCRα chain transgenic mice that 
had been generated. 
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3.2 PROINSULIN EXPRESSION IN POLYCLONAL NOD MICE  
During the development of the mice expressing varying levels of proinsulin, it was 
important to not only have genetic typing results but also to quantify the level of 
proinsulin expression. This provided useful data to confirm that the model was 
valid for further assessment as well as identifying any differences between the 
genders. Polyclonal NOD mice were used as a baseline for proinsulin expression. 
3.2.1 PROINSULIN 1 AND 2 ARE EXPRESSED IN THE THYMUS AND PLN 
NOD mice (both males and females) were investigated for the expression of 
proinsulin 1 and 2 within the thymus and the PLN. FIGURE 15 shows that the 
control GAPDH gene was present in all samples, with the largest amplification 
noted in the thymus, then the PLN and finally the islets. In all cases, both males 
and females were similar (thymus GAPDH amplification seen between cycles 20-
22 and PLN GAPDH between cycles 26-28) to each other suggesting similar 
amounts of RNA were present in the samples. In regard to proinsulin 1 and 2 
expression, the islets (positive control) highly expressed both proinsulin 1 and 2. 
The NOD mouse PLNs also expressed proinsulin 1 and 2; however, there was 
greater amplification of both proinsulin 1 and 2 in the males than in the female 
NOD PLN. As for thymus, proinsulin 1 was just detectable, with higher levels of 
proinsulin 2 noted. In both males and females, the thymic proinsulin expression 
was similar. This data derived from pooled tissues from 8-9 mice; however it is 
only representative of a single experiment, which could not be repeated at the 
point of writing this report, due to time restrictions. 
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FIGURE 15: Thymus and PLN were taken from polyclonal NOD male and female 
mice, separately, at 8 weeks of age (n=8-9). Thymus and PLN samples were 
homogenised/teased open to create a single cell suspension prior to enzymatic 
digestion at 37°C using Liberase/DNAse I enzymes. Post-digestion, cells were then 
depleted of CD45+ cells using a Miltenyi MACS kit and column (purity >99%) and 
frozen overnight in Tri Reagent at -80°C. The cells were defrosted and RNA was 
extracted. 2μg RNA was then used to make cDNA using Superscript VILO 
mastermix (Life Technologies). cDNA was then amplified for proinsulin 1, 2 and 
GAPDH using gene-specific primers and a Taqman mastermix (Life Technologies) 
on a Viia7 Real-Time PCR machine and analysed using ExpressionSuite software 
version 1.0.3. F=female, M=male. Control has everything except DNA. 
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FIGURE 15: PROINSULIN 1 AND 2 EXPRESSION WITHIN POLYCLONAL NOD 
ISLETS, THYMUS AND PANCREATIC LYMPH NODES (PLN) AS ASSESSED BY qPCR 
A: GAPDH 
 
 
 
 
 
 
 
B: PROINSULIN 1 
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3.3 THE EFFECT OF PROINSULIN EXPRESSION ON CELL 
POPULATIONS 
After confirmation of the models and documentation of the proinsulin expression 
levels, the next question to address was the role that proinsulin expression may 
have on the total population of T cells present in these mice. Therefore, lymphoid 
tissues were harvested and counted with single cell suspensions from the various 
lymphoid tissues analysed by flow cytometry for their CD4+ and CD8+ T cell 
populations. 
3.3.1 TOTAL CELL NUMBER IS INDEPENDENT OF PROINSULIN 
EXPRESSION  
Total thymi and splenocyte cells from mice aged 4-7 weeks, 8-10 weeks (see 
appendix) and 11-16 weeks were counted. The data in FIGURE 16 shows that at 4-
7 weeks, the A22Cα-/- mice had fewer cells in the spleen compared to A22Cα-/-PI1-
/-PI2-/-Y16Atg mice; however by 11-16 weeks there were no differences seen 
between the strains. In addition, there were a greater number of cells in the 
thymus of the NOD mice than in the TCR-restricted counterparts (apart from 
those over-expressing Proinsulin 2) by 11-16 weeks. Furthermore, all strains 
showed a significant change in thymic (p=<0.01) and splenic cell number 
(p=<0.01) with age, except for the spleen cell numbers for the A22Cα-/-PI2tg and 
the A22Cα-/-PI1-/-PI2-/-Y16Atg mice.  
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FIGURE 16: Thymocyte and splenocyte cells were harvested and homogenised. 
The red blood cells were lysed in the splenocyte populations and resuspended in 
10mls FACS Buffer for counting. Cell number was determined through exclusion 
of non-viable cells by Trypan blue using a haemocytometer. Data were analysed 
by ANOVA using R software. Data were shown to be significant (**) if it reached 
the p=<0.01 level; Thymocytes at 11-16 weeks: NOD vs A22Cα-/- p=0.0002996, 
NOD vs A22Cα-/-PI1-/- p=0.0000518, NOD vs A22Cα-/-PI2-/- p=0.0015271, NOD vs 
A22Cα-/-PI1-/-PI2-/-Y16Atg p=0.0000158, Splenocytes at 4-7 weeks: A22Cα-/- vs 
A22Cα-/-PI1-/-PI2-/-Y16Atg p=0.0091656. Each dot represents an individual mouse 
with the horizontal lines indicating the mean. 
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FIGURE 16: THYMOCYTE AND SPLENOCYTE TOTAL CELL COUNTS IN SINGLE 
CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING 
PROINSULIN LEVELS 
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3.3.2 CD4/CD8 T CELL RATIO IS AFFECTED BY PROINSULIN EXPRESSION 
The next question was to identify the role of proinsulin expression on the T cell 
compartment. Therefore, the proportion of CD4+ and CD8+ T cells were 
investigated by flow cytometric methods. FIGURE 17 illustrates the CD4+ (A&B) 
and CD8+ (C&D) T cell proportions at both 4-7 weeks and 11-16 weeks. 
Comparing the groups of 4-7 week old mice (17A), there were statistically 
significant differences in the CD4+ populations within the thymus between the 
A22Cα-/-PI2-/- mice, which had a greater proportion of CD4+ T cells, and both 
A22Cα-/-PI1-/- mice and A22Cα-/-PI1-/-PI2-/-Y16Atg mice; however by 11-16 weeks 
(17B) these differences were no longer seen. Interestingly, by 11-16 weeks the 
mice exhibited more statistically significant differences in the periphery, 
particularly when proinsulin 2 was deficient. Within the CD8+ T cell compartment 
there were only statistically significant differences between the A22Cα-/-PI2-/- 
mice, which have fewer CD8+ T cells, and the A22Cα-/-PI1-/- mice within the 
spleen, PLN and MLN and the A22Cα-/-PI1-/-PI2-/-Y16Atg mice within the Spleen at 
4-7 weeks of age (17C). However, these differences only appear in the young 
group. There were also no gender differences in the proportions of CD4+ or CD8+ 
T cells between these mice, and so males and females were grouped together. 
3.4 THE EFFECT OF PROINSULIN EXPRESSION ON TOTAL CD8+ T 
CELL VARIABLE BETA CHAIN RECEPTOR REPERTOIRE 
The next question to answer was - did the level of proinsulin expression have any 
effect on the CD8+ T cells selecting a specific TCRβ chain? For this, lymphoid 
tissues were harvested, stained with monoclonal antibodies using a multi-colour 
antibody staining panel (2.9.3.3 in Chapter 2), and analysed by flow cytometry. 
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FIGURE 17: CD4 and CD8 Single cell suspensions were prepared from thymi, 
spleen, pancreatic lymph nodes (PLN) and mesenteric lymph nodes (MLN). These 
cells were then stained with the TRBV phenotyping panels (see 2.9.3.3), fixed and 
measured on a BD FACS CANTO II. Data were analysed using Flowjo Version 7.6.5 
software and results were then collated for all mice. These box plots show the 
median with the first and third quartile indicated by the top and bottom of the 
box, with the maximum and minimum values indicated by the arms above and 
below the box. Strains were compared by ANOVA using R software with data 
shown to be statistically significant at the p=<0.05 (*) or at the p=<0.01 level (**). 
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FIGURE 17: CD4 & CD8 T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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3.4.1 TRBV19 EXPRESSING CD8+ T CELLS ARE REDUCED BY EXPRESSION 
OF BOTH PROINSULIN 1 AND 2  
One of the TRBV chains affected by proinsulin expression was TRBV19 (also 
known as TCRVβ6), as FIGURE 18 illustrates. This figure shows that when either 
Proinsulin 1 (A22Cα-/-PI1-/-), Proinsulin 2 (A22Cα-/-PI2-/-) or both (A22Cα-/-PI1-/-PI2-
/-Y16Atg) are absent, there is no change in the proportion of CD8+ T cells 
expressing TRBV19 with age. However, in mice that have normal levels of 
Proinsulin 1 and 2 (A22Cα-/-), there is a small decrease with age (n.s), but 
increasing the level of Proinsulin 2 results in a greater reduction and significant 
differences between the strains at both 4-7 weeks and 11-16 weeks. The 
differences between the A22Cα-/- mice and the other strains are summarised in 
TABLE 6. Interestingly, the TRBV19+ T cells in the A22Cα-/- mice differ significantly 
from only the A22Cα-/-PI2tg mice both at 4-7 and 11-16 weeks of age, with the 
differences limited to peripheral lymphoid tissues. The comparisons between the 
other strains are shown in the appendix, but the only significant differences 
observed were between the A22Cα-/-PI2tg mice and the mice lacking either or 
both of proinsulin 1 or proinsulin 2. In addition, there were no differences within 
the lymphoid tissues of each strain, no differences with age and, as mentioned 
previously, no gender differences. 
TABLE 6: SIGNIFICANT DIFFERENCES IN TRBV19 ASSOCIATION BETWEEN NATIVE 
PROINSULIN EXPRESSING SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD 
MICE AND ALL OTHER STRAINS EXPRESSING VARYING LEVELS OF PROINSULIN 
NOTE: All strains were compared for TRBV19 differences but only the A22Cα-/-
PI2tg mice were significantly different to the wildtype A22Cα-/- mice. For all other 
comparisons between the strains see the Appendix Tables. 
 
 
AGE 
(WEEKS) 
STRAIN NAME DIFFERENT TO TISSUE P VALUE 
4-7  
A22Cα-/- 
A22Cα-/-PI2tg PLN 0.0000004 
A22Cα-/-PI2tg MLN 0.0000000 
11-16 A22Cα-/-PI2tg Spleen 0.0000000 
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3.4.2 OTHER TRBV RESULTS 
TRBV19 showed the most dramatic TRBV repertoire changes in relation to 
proinsulin expression. However, proinsulin-specific effects were also seen with 
TRBV29 and TRBV16. In Proinsulin 2 deficient A22Cα-/-PI2-/- mice, the CD8+ T cells 
have an increased proportion of TRBV29 in the PLN, compared to all other 
strains, at 11-16 weeks, as shown in FIGURE 19. There were also significant 
differences between the tissues of the A22Cα-/-PI2-/- mice and the other strains, 
as shown. As for TRBV16, mice deficient in Proinsulin 1, Proinsulin 2 or both 
showed an increase in TRBV16 expression, as shown in FIGURE 20. As shown, at 
4-7 weeks, there is a significant difference between the mice lacking both 
Proinsulin 1 and 2 (A22Cα-/-PI1-/-PI2-/-Y16Atg) and those lacking Proinsulin 1 
(A22Cα-/-PI1-/-) when compared to the other strains, particularly in the PLN and 
MLN. At 11-16 weeks, those mice deficient in Proinsulin 2 (A22Cα-/-PI2-/-), also 
show significant differences to those mice expressing native levels of proinsulin 
(A22Cα-/-) and mice over-expressing proinsulin 2 (A22Cα-/-PI2tg) in the PLN and 
MLN. In addition to proinsulin-specific TRBV repertoire changes, significant 
changes were also noted with age. The proportion of TRBV4+ CD8+ T cells, shown 
in FIGURE 21, shows strain differences primarily in the thymus. However, it is the 
differences in the peripheral tissues between 4-7 weeks and 11-16 weeks, within 
each strain that show significant TRBV4 expansions (p=<0.01). 
The most striking results are discussed above, with the results for the other 
TCRVβ chains shown in the appendix. However, other statistically significant 
differences between the strains at different ages (TABLE 7 and TABLE 8), with age 
(TABLE 9) and between the tissues (TABLE 10 and TABLE 11) are shown below. In 
general, these results show greater variation between the strains at 4-7 weeks 
than at 11-16 weeks. In addition, these results also show that the thymus has the 
most significant differences when compared to the spleen or lymph nodes. 
Unfortunately, due to small numbers, the repertoire results for TRBV24 could not 
be compared. 
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FIGURE 18: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel, measured on a BD FACS CANTO II and analysed 
later using Flowjo Version 7.6.5 software. Data were then plotted using GraphPad 
Version 4 software. Each shape represents an individual mouse (n=8-13), with 
unfilled shapes representing those aged 4-7 weeks and filled shapes those aged 
11-16 weeks. The median is shown for each data set by a horizontal line with 
statistically significant differences at p=<0.05 (*) and p=<0.01 (**) between the 
strains shown following an ANOVA analysis using R software. 
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FIGURE 18: CD8+TRBV19+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 19: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel and measured on a BD FACS CANTO II to be 
analysed later using Flowjo Version 7.6.5 software. Data were then plotted using 
GraphPad Version 4 software. Each shape represents an individual mouse (n=8-
13), with unfilled shapes representing those aged 4-7 weeks and filled shapes 
those aged 11-16 weeks. The median is shown for each data set by a horizontal 
line with statistically significant differences at p=<0.05 (*) and p=<0.01 (**) 
between the strains shown following an ANOVA analysis using R software. 
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FIGURE 19: CD8+TRBV29+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 20: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel and measured on a BD FACS CANTO II to be 
analysed later using Flowjo Version 7.6.5 software. Data were then plotted using 
GraphPad Version 4 software. Each shape represents an individual mouse (n=8-
13), with unfilled shapes representing those aged 4-7 weeks and filled shapes 
those aged 11-16 weeks. The median is shown for each data set by a horizontal 
line with statistically significant differences at p=<0.05 (*) and p=<0.01 (**) 
between the strains shown following an ANOVA analysis using R software. 
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FIGURE 20: CD8+TRBV16+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
 
 
 
 
 
 
 
 
 
 
 
**  
THYMUS SPLEEN PLN MLN 
0
2
4
6
8
10
%
 C
D
8
+
 T
R
B
V
1
6
+
 T
 C
e
ll
s
*  
*  
**  
**  
**  
**  
**  
**  
**  
** 
**  
**  
*  
**  
**  
**  
**  
**  
**  
*  
**  
** 
**  
A22Cα
-/-
 A22Cα
-/-
PI2
tg
 A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα
-/-
PI1
-/-
 KEY A22Cα
-/-
PI2
-/-
 
Unfilled shapes = 4-7 weeks  Filled shapes = 11-16 
weeks
127 
 
FIGURE 21: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel and measured on a BD FACS CANTO II to be 
analysed later using Flowjo Version 7.6.5 software. Data were then plotted using 
GraphPad Version 4 software. Each shape represents an individual mouse (n=8-
13), with unfilled shapes representing those aged 4-7 weeks and filled shapes 
those aged 11-16 weeks. The median is shown for each data set by a horizontal 
line with statistically significant differences at p=<0.05 (*) and p=<0.01 (**) 
between the strains shown following an ANOVA analysis using R software. 
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FIGURE 21: CD8+TRBV4+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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TABLE 7: OTHER TRBV SIGNIFICANT DIFFERENCES BETWEEN SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING LEVELS OF 
PROINSULIN AT 4-7 WEEKS OF AGE 
 
TRBV CHAIN STRAIN DIFFERENT TO TISSUE P VALUE 
 
TRBV2 
A22Cα-/-PI2tg A22Cα-/-PI1-/- Spleen 0.0000005 
A22Cα-/-PI1-/-PI2-/-Y16Atg Spleen 0.0000001 
A22Cα-/-PI1-/-PI2-/-Y16Atg PLN 0.0000016 
TRBV13-2/13-3 A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/-PI2tg Thymus 0.0000000 
 
 
 
 
 
 
 
 
 
TRBV14 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
 
A22Cα-/- Thymus 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000004 
A22Cα-/- Spleen 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
A22Cα-/-PI1-/- A22Cα-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/- PLN 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
A22Cα-/-PI1-/- A22Cα-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/- MLN 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
A22Cα-/-PI1-/- A22Cα-/- 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
 
 
TRBV15 
A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/- MLN 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000001 
A22Cα-/-PI1-/- A22Cα-/- 0.0000000 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000000 
 
TRBV26 
A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/- Thymus 0.0000002 
A22Cα-/-PI2-/- 0.0000000 
A22Cα-/-PI2tg 0.0000003 
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TABLE 8: OTHER TRBV SIGNIFICANT DIFFERENCES BETWEEN SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING LEVELS OF 
PROINSULIN AT 11-16 WEEKS OF AGE 
 
 
 
 
 
 
 
TABLE 9: OTHER TRBV SIGNIFICANT DIFFERENCES WITHIN SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING LEVELS OF 
PROINSULIN WITH AGE 
 
 
TRBV CHAIN STRAIN DIFFERENT TO TISSUE P VALUE 
TRBV2 A22Cα-/-PI1-/- A22Cα-/- Spleen 0.0000009 
A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/- 0.0000002 
A22Cα-/-PI2tg 0.0000004 
A22Cα-/-PI2-/- A22Cα-/- 0.0000002 
A22Cα-/-PI2tg 0.0000004 
A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/- PLN 0.0000000 
A22Cα-/-PI2tg 0.0000004 
A22Cα-/-PI2-/- A22Cα-/- 0.0000000 
A22Cα-/- A22Cα-/-PI2-/- MLN 0.0000002 
A22Cα-/-PI1-/-PI2-/-Y16Atg 0.0000002 
TRBV12-2/12-1 A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/-PI2tg Spleen 0.0000002 
TRBV15 A22Cα-/-PI2tg A22Cα-/-PI1-/- PLN 0.0000001 
A22Cα-/-PI1-/-PI2-/-Y16Atg 0.0000000 
TRBV26 A22Cα-/-PI1-/-PI2-/-Y16Atg A22Cα-/-PI2-/- Spleen 0.0000000 
A22Cα-/-PI2tg 0.0000000 
A22Cα-/-PI1-/- A22Cα-/-PI2-/- 0.0000001 
A22Cα-/-PI2tg 0.0000000 
STRAIN TRBV CHAIN TISSUE P VALUE 
A22Cα-/-PI2tg TRBV15 PLN 
 
0.0000000 
TRBV31 0.0000018 
TRBV15 MLN 0.0000000 
TRBV17 0.0000000 
A22Cα-/-PI2-/- TRBV26 Thymus 0.0000002 
A22Cα-/-PI1-/-PI2-/-Y16Atg TRBV26 MLN 0.0000000 
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TABLE 10: OTHER TRBV SIGNIFICANT DIFFERENCES BETWEEN THE TISSUES IN 
SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING 
VARYING LEVELS OF PROINSULIN AT 4-7 WEEKS OF AGE 
 
 
 
STRAIN TRBV CHAIN TISSUE DIFFERENT 
TO 
P VALUE 
A22Cα-/- TRBV13-3/13-2 Thymus Spleen 0.0000000 
PLN 0.0000000 
MLN 0.0000000 
TRBV14 Spleen PLN 0.0000008 
MLN 0.0000015 
TRBV26 Thymus PLN 0.0000001 
MLN 0.0000000 
A22Cα-/-PI2tg TRBV13-3/13-2 Thymus Spleen 0.0000000 
PLN 0.0000000 
MLN 0.0000000 
TRBV26 Thymus PLN 0.0000000 
MLN 0.0000000 
A22Cα-/-PI1-/- TRBV13-3/13-2 Thymus Spleen 0.0000001 
PLN 0.0000000 
MLN 0.0000000 
A22Cα-/-PI2-/- TRBV13-3/13-2 Thymus Spleen 0.0000006 
TRBV26 Thymus PLN 0.0000000 
MLN 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg TRBV12-2/12-1 Thymus Spleen 0.0000000 
PLN 0.0000000 
MLN 0.0000000 
TRBV13-3/13-2 Thymus PLN 0.0000000 
MLN 0.0000000 
TRBV31 Thymus Spleen 0.0000001 
PLN 0.0000022 
MLN 0.0000001 
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TABLE 11: SIGNIFICANT DIFFERENCES BETWEEN THE TISSUES IN SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING LEVELS OF 
PROINSULIN AT 11-16 WEEKS OF AGE 
 
 
 
 
 
 
STRAIN TRBV CHAIN TISSUE DIFFERENT 
TO 
P VALUE 
A22Cα-/-PI2tg TRBV2 Spleen Thymus 0.0000000 
PLN 0.0000000 
MLN 0.0000000 
TRBV13-3/13-2 Thymus Spleen 0.0000000 
PLN 0.0000000 
MLN 0.0000000 
TRBV26 Thymus PLN 0.0000000 
MLN 0.0000000 
Spleen PLN 0.0000000 
MLN 0.0000000 
A22Cα-/-PI1-/- TRBV13-3/13-2 Thymus MLN 0.0000020 
A22Cα-/-PI2-/- TRBV13-3/13-2 Thymus Spleen 0.0000006 
PLN 0.0000001 
MLN 0.0000002 
A22Cα-/-PI1-/-PI2-/-Y16Atg TRBV13-3/13-2 Thymus Spleen 0.0000000 
PLN 0.0000000 
MLN 0.0000000 
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3.5 THE EFFECT OF PROINSULIN EXPRESSION ON INSULIN B15-23 
AUTOIMMUNITY IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 
NOD MICE 
The next question we wanted to address was whether the level of proinsulin 
expression had any effect on the development of insulin autoimmunity. This was 
addressed specifically, in the T cell compartment, by insulin B15-23 reactivity 
using peptide:MHC tetramers. 
3.5.1 THE EFFECT OF PROINSULIN EXPRESSION ON INSULIN B15-23-
REACTIVE CD8+ T CELL VARIABLE BETA CHAIN RECEPTOR REPERTOIRE 
The above sections report the results for total CD8+ TCRVβ chain repertoire in 
mice expressing the TRAV8-1*01TRAJ9, the TCRα chain from the G9C8 T cell 
clone (Wong et al., 1996), related to proinsulin expression. However, no 
knowledge was known of their antigen specificity and therefore given the antigen 
specificity of G9C8, we then sought to identify the TCRβ repertoire of the Insulin 
B15-23 reactive CD8+ T cells in these mice with different levels of proinsulin. 
3.5.1.1 PROINSULIN 1 AND 2 DEFICIENCY INCREASES THE PROPORTION OF 
INSULIN B15-23 REACTIVE CD8+ T CELLS WITHIN THE PLN IN SINGLE 
CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE  
Using insulin H-2Kd-B15-23 peptide tetramers (NIH tetramer facility), single cell 
suspensions from the thymus, spleen, pancreatic lymph node (PLN) and 
mesenteric lymph node (MLN) were stained. This allowed us to address the role 
of proinsulin expression on the development of those antigen-specific CD8+ T 
cells. Interestingly, when mice lacked Proinsulin 2 (A22Cα-/-PI2-/-), there was a 
significant increase in the proportion of insulin B15-23 reactive CD8+ T cells in 
comparison to the TCRα restricted mice (A22Cα-/-) expressing normal insulin 
levels within the spleen (p=0.0134) and the PLN (p=0.0466) as shown in FIGURE 
22. In addition, within the PLN there was also a significant increase in H-2Kd-B15-
23 peptide tetramer positive cells, seen in those mice deficient in Proinsulin 1 
(A22Cα-/-PI1-/-) and polyclonal NOD mice when compared to the A22Cα-/- mice 
(p=0.0296 and p=0.003 respectively). The A22Cα-/-PI2-/- mice also had a greater 
proportion of insulin B15-23 reactive CD8+ T cells within the thymus than the 
polyclonal NOD mice. There were no other significant differences in the thymus 
and none seen at all within the MLN. 
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FIGURE 22: PROINSULIN B15-23 REACTIVE CD8+ T CELL PROPORTIONS IN THE 
THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH 
NODE (MLN) IN POLYCLONAL NOD MICE AND SINGLE CHAIN TRANSGENIC 
TRAV8-1*01 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 22: Cells were harvested from thymus, spleen, PLN and MLN of mice aged 
4-8 weeks. These cells were stained using a multi-colour antibody staining panel 
(see 2.9.3.3) and measured on a BD FACS CANTO II to be analysed later using 
Flowjo Version 7.6.5 software. Data were then plotted using GraphPad Version 4 
software. Each shape represents an individual mouse (n=5-10). The median is 
shown for each data set by a horizontal line with statistically significant 
differences at p=<0.05 (*) and p=<0.01 (**) between the strains shown following 
a Mann Whitney comparison test between the strains. 
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3.5.1.2 SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXHIBIT 
INDIVIDUAL INSULIN B15-23 REACTIVE CD8+ T CELL CLONAL EXPANSIONS 
WITHIN THE PLN  
In order to isolate the insulin B15-23 reactive CD8+ T cells, cells from the PLN 
were harvested and sorted using a BD FACS ARIA for live single CD8+CD4-CD11b-
CD19-H-2Kd- B15-23 peptide Tetramer+ cells. These cells were then clonotyped for 
their TCRβ chain identifying the CDR3 region, which is used by the TCR to contact 
the peptide:MHC complex. 
Focussing initially on the TRBV chain, there were 14 different TRBV genes that 
pair with the specific TCRα chain in these insulin B15-23 reactive CD8+ T cells; 
however when analysed by strain, the TRBV gene selection was more restricted. 
As can be seen from FIGURE 23, although the numbers are small there was a 
trend with the greatest number of TRBV genes found in the Proinsulin 2 deficient 
mice (A22Cα-/-PI2-/-; n=6), then the A22Cα-/- mice (n=4), with the A22Cα-/-PI1-/-PI2-
/-Y16Atg mice following (n=3) and finally the A22Cα-/-PI2tg mice (n=1). 
Interestingly, the highest proportion of TRBV19+H-2Kd-B15-23 peptide tetramer+ 
cells was found in the mice deficient in both Proinsulin 1 and 2 (61%), followed by 
those that lack Proinsulin 2 (13%) and finally those with normal levels of 
proinsulin (4%) while not being detected in those mice over-expressing Proinsulin 
2. TRBV4 and TRBV13-2 were also shared by 3/4 of the strains analysed, while 
9/14 TRBV genes were restricted to only 1 strain. 
There are 14 TRBJ chains that can be used in conjunction with a TRBV chain and 9 
of these were identified by sequencing in these insulin B15-23 reactive CD8+ T 
cells. However, there were only 2 TRBJ segments that appeared in 3/4 strains of 
mice (see TABLE 12); these included TRBJ2-7 found in all strains except the 
A22Cα-/-PI2tg, and TRBJ1-1 found in all but the A22Cα-/-PI2-/- mice. TRBJ2-7 was 
the most prevalent in the A22Cα-/- mice (49.86%), the second most prevalent in 
the A22Cα-/-PI1-/-PI2-/-Y16Atg mice (30.49%) and the third in the A22Cα-/-PI2-/- mice 
(20.39%). The TRBJ2-3 utilised by the G9C8 T cell clone for recognition of insulin 
B15-23 was found in approximately the same proportion in both A22Cα-/- mice 
(12.97%) and the A22Cα-/-PI2-/- mice (12.94%) but not in the other strains. 
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FIGURE 23: Lymphoid cells were harvested from the PLN from individual mice 
aged 4-8 weeks, stained with H-2Kd-B15-23 peptide tetramer and sorted using a 
BD FACS ARIA. RNA was then extracted from the cells and TCRβ chain cDNA was 
generated, purified, cloned into a vector and amplified using recombinant E.coli. 
Individual colonies were then sequenced for their TCRβ chain. Data were then 
plotted as a percentage of all the sequences obtained within that strain, with 
each TCRβ chain colour coded to highlight similarities. Data shown are from 
A22Cα-/- (A – 2F & 2M), A22Cα-/-PI2tg (B – 1F), A22Cα-/-PI2-/- (C – 2F & 4M) and 
A22Cα-/-PI1-/-PI2-/-Y16Atg (D – 1F & 2M) mice. 
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FIGURE 23: PROINSULIN B15-23 REACTIVE CD8+ T CELL RECEPTOR VARIABLE BETA CHAIN PROPORTIONS SINGLE CHAIN TRANSGENIC TRAV8-
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TABLE 12: INSULIN B15-23 REACTIVE CD8+ T CELL RECEPTOR JOINING BETA 
CHAIN PROPORTIONS IN SINGLE CHAIN TRANSGENIC TRAV8-1*01 NOD MICE 
EXPRESSING VARYING PROINSULIN LEVELS 
 
 
 
 
 
 
 
TRBJ CHAIN STRAIN FOUND IN PROPORTION (%) 
TRBJ1-1 A22Cα-/- 
A22Cα-/-PI2tg 
A22Cα-/-PI2-/- 
17.29 
3.57 
19.08 
TRBJ1-3 A22Cα-/-PI2-/- 2.41 
TRBJ1-6 A22Cα-/-PI2tg 96.43 
TRBJ2-1 A22Cα-/- 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
12.68 
38.62 
TRBJ2-2 A22Cα-/- 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
0.58 
2.44 
TRBJ2-3 A22Cα-/- 
A22Cα-/-PI2-/- 
12.97 
12.94 
TRBJ2-4 A22Cα-/-PI2-/- 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
20.61 
28.46 
TRBJ2-5 A22Cα-/- 
A22Cα-/-PI2-/- 
6.63 
24.56 
TRBJ2-7 A22Cα-/- 
A22Cα-/-PI2-/- 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
49.86 
20.39 
30.49 
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Taking into account the entire clonotyping results i.e. the CDR3 sequence for 
individual mice within a strain, there was clearly an expansion of different 
clonotypes associated with the insulin B15-23 reactive CD8+ T cells. As TABLE 13 
and TABLE 14 show, each mouse has a different clonal expansion regardless of 
proinsulin expression with only 1 identical sequence found between the A22Cα-/- 
mice (1 male and 1 female) and one male A22Cα-/-PI2-/- mouse. This sequence was 
CASSLGGYEQY (highlighted in yellow), utilising TRBV15 and TRBJ2-7 and was the 
dominant clonotype within these mice. A similar clonotype to this sequence was 
found in a male A22Cα-/-PI2-/- mouse; however, the single amino acid difference 
was for a different amino acid group (E to G, see TABLE 15). The only other 
identical sequence identified was CASSRVPGEQY (highlighted in orange) and was 
found in 2 male A22Cα-/- mice as a sub-dominant clonotype utilising TRBV17 and 
TRBJ2-7. 2 clonotypes with 1 amino acid substitution were also found within a 
male A22Cα-/- mouse. While one of these substitutions involves a similar amino 
acid substitution (V to A), the other substitution is different (S to G). 
TABLE 15 shows that half of the single amino acid differences within the 
clonotype involved a similar valine to alanine substitution. Taking this into 
account identified 7 CDR3 sequences, which were shared or involved similar 
amino acid substitutions to another sequence. 
All the other clonotypes were unique with each mouse exhibiting a different 
dominant clonotype. Due to time restraints, the A22Cα-/-PI1-/- mice were not 
analysed.  
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TABLE 13: INSULIN B15-23 REACTIVE CD8+ T CELL RECEPTOR CDR3 CLONOTYPES FROM INDIVIDUAL SINGLE CHAIN TRANSGENIC TRAV8-
1*01TRAJ9 NOD MICE EXPRESSING NORMAL LEVELS OF PROINSULIN OR OVER-EXPRESSING PROINSULIN 2 
STRAIN GENDER TRBV CHAIN CDR3 SEQUENCE TRBJ CHAIN PROPORTION (%) TOTAL SAMPLES 
A22Cα-/- M 15 CASSLGGYEQY 2-7 47.78 43 
15 CASSQDRSNTEVF 1-1 27.78 25 
17 CASSRVPGEQY 2-7 22.22 20 
17 CASSRAPGEQY 2-7 1.11 1 
17 CAGSRVPGEQY 2-7 1.11 1 
12-1 CASLVETLY 2-3 48.89 44 
17 CASSRVPGEQY 2-7 32.22 29 
13-3 CASSDAWAGGQDTQY 2-5 21.11 19 
12-1 CASLAETLY 2-3 1.11 1 
F 15 CASSLGGYEQY 2-7 95.18 79 
13-2 CASGDWGGYQDTQY 2-5 4.82 4 
4 CASSFILGGYAEQF 2-1 54.32 44 
13-3 CASSDYGDANTEVF 1-1 23.46 19 
19 CASTRHHTEVF 1-1 19.75 16 
15 CASTGNTGQLY 2-2 2.47 2 
A22Cα-/-PI2tg F 3 CASRRDIYNSPLY 1-6 96.43 81.00 
13-2 CASGPGTGGFTEVF 1-1 3.57 3.00 
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TABLE 14: INSULIN B15-23 REACTIVE CD8+ T CELL RECEPTOR CDR3 CLONOTYPES FROM INDIVIDUAL SINGLE CHAIN TRANSGENIC TRAV8-
1*01TRAJ9 NOD MICE DEFICIENT IN PROINSULIN 2 OR LACKING BOTH NATIVE PROINSULIN 1 AND PROINSULIN 2 
STRAIN GENDER TRBV CHAIN CDR3 SEQUENCE TRBJ CHAIN PROPORTION (%) TOTAL SAMPLES 
A22Cα-/-PI2-/- M 19 CASSIRESGAETLY 2-3 65.56 59 
17 CASSRDNTEVF 1-1 12.22 11 
16 CASSLVSQDTQY 2-5 11.11 10 
13-2 CASGDAVEQY 2-7 11.11 10 
15 CASSLGGYEQY 2-7 65.96 62 
15 CASSLGGYGQY 2-7 22.34 21 
13-1 CASRSGGTGNTLY 1-3 10.64 10 
13-1 CASRSGGPGNTLY 1-3 1.06 1 
16 CASSLDRNQNTLY 2-4 100.00 94 
14 CASSYRGPNQDTQY 2-5 100.00 21 
F 4 CASSHRGNTEVF 1-1 93.42 71 
4 CVSSHRGNTEVF 1-1 5.26 4 
4 CASSHRGNTEAF 1-1 1.32 1 
13-1 CASSEGQGGDTQY 2-5 98.77 80 
13-1 CAGSEGQGGDTQY 2-5 1.23 1 
A22Cα-/-PI1-/-PI2-/-Y16Atg M 19 CASSPAGSTLY 2-4 92.11 70 
4 CASSLTGNTGQLY 2-2 7.89 6 
5 CASSPDNYEQY 2-7 83.91 73.00 
1 CTCSADYAEQF 2-1 16.09 14.00 
F 19 CASSGDYAEQF 2-1 97.59 81 
31 CAWSLAGGGQY 2-7 2.41 2 
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TABLE 15: INSULIN B15-23 REACTIVE CD8+ T CELL RECEPTOR CDR3 CLONOTYPE AMINO ACID COMPARISON FROM INDIVIDUAL SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING NORMAL PROINSULIN LEVELS OR DEFICIENT IN PROINSULIN 2 
*This CDR3 sequence also appears in another male A22Cα-/- mouse. 
 ** This CDR3 sequence also appears in one male and one female A22Cα-/- mouse. 
STRAIN GENDER CDR3 SEQUENCE 
FROM MOUSE 1 
CDR3 SEQUENCE 
FROM MOUSE 2 
SIMILAR/ 
DIFFERENT 
EXPLANATION OF SIMILARITY OR DIFFERENCE 
A22Cα-/- M CASSRVPGEQY* CASSRAPGEQY SIMILAR VALINE & ALANINE BOTH HAVE NONPOLAR SIDE CHAINS 
CASSRVPGEQY* CAGSRVPGEQY DIFFERENT SERINE HAS AN UNCHARGED POLAR SIDE CHAIN WHEREAS 
GLYCINE HAS A NONPOLAR SIDE CHAIN 
CASLVETLY CASLAETLY SIMILAR VALINE & ALANINE BOTH HAVE NONPOLAR SIDE CHAINS 
A22Cα-/-PI2-/- F CASSHRGNTEVF CVSSHRGNTEVF SIMILAR VALINE & ALANINE BOTH HAVE NONPOLAR SIDE CHAINS 
CASSHRGNTEVF CASSHRGNTEAF SIMILAR VALINE & ALANINE BOTH HAVE NONPOLAR SIDE CHAINS 
CASSEGQGGDTQY CAGSEGQGGDTQY DIFFERENT SERINE HAS AN UNCHARGED POLAR SIDE CHAIN WHEREAS 
GLYCINE HAS A NONPOLAR SIDE CHAIN 
M CASSLGGYEQY** CASSLGGYGQY DIFFERENT GLUTAMIC ACID HAS AN ACIDIC SIDE CHAIN WHEREAS 
GLYCINE HAS A NONPOLAR SIDE CHAIN 
CASRSGGTGNTLY CASRSGGPGNTLY DIFFERENT THREONINE HAS AN UNCHARGED POLAR SIDE CHAIN 
WHEREAS PROLINE HAS A NONPOLAR SIDE CHAIN 
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3.6 SPONTANEOUS DIABETES SEEN ONLY IN PROINSULIN 2 
DEFICIENT SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD 
MICE  
Having identified numerous clonotypes within the strains of mice, we asked 
whether any of these strains developed spontaneous autoimmune diabetes. 
Interestingly, no A22Cα-/- mice or A22Cα-/-PI2tg mice developed spontaneous 
autoimmune diabetes (n=20 males and females). However, as FIGURE 24 shows, 
3/12 A22Cα-/-PI2-/- male mice, but no females, developed spontaneous diabetes 
(p=0.0377). This onset was accelerated compared to polyclonal NOD female and 
male mice (10 weeks vs 17 and 19 weeks respectively) and reached 25% vs 
88.89% and 16.67% respectively. While the highest incidence of diabetes was 
seen in the NOD female mice overall, comparing the male A22Cα-/-PI2-/- and male 
NOD mice there is both an acceleration and an increase in incidence. 
3.7 ALL SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE 
DEVELOP INSULIN AUTO-ANTIBODIES WITH AGE 
Mice at 4-7, 8-10 and 11-16 weeks of age were investigated for the presence of 
insulin auto-antibodies in the serum. As FIGURE 25 shows there are similar insulin 
autoantibody results between male and female mice at all ages and the different 
strains of mice. Interestingly, the A22Cα-/-PI1-/-PI2-/-Y16Atg mice had the fewest 
number of mice with insulin auto-antibodies at 4-7 weeks with only 1/6 female 
mice and 0/6 male mice seen to have insulin auto-antibodies. However, insulin 
autoantibody prevalence in these mice had increased to 5/5 female and 3/3 male 
mice by 11-16 weeks. All mice shown in FIGURE 25 are non-diabetic, however 3/4 
male diabetic A22Cα-/-PI2-/- mice were shown to have insulin auto-antibodies 
present (see appendix). 
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FIGURE 24: THE INCIDENCE OF SPONTANEOUS DIABETES IN SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE DEFICIENT IN PROINSULIN 2 AND 
POLYCLONAL NOD MICE  
 
  
 
 
 
 
 
 
 
 
FIGURE 24: A22Cα-/-PI2-/- mice (12 males and 16 females) and NOD mice (6 males 
and 9 females) were placed into an observation group from weaning (3 weeks) 
and left to develop diabetes over a period of 20 weeks and 35-37 weeks 
respectively. Mice were tested bi-weekly for glycosuria and if positive were 
confirmed the next day by a blood glucose test. Diabetes was diagnosed only 
when the blood glucose level was above 13.9mmol/L. Data were then plotted 
using GraphPad Version 4 software. Survival curves were compared using a log 
rank test with significant differences at p=<0.05 between the A22Cα-/-PI2-/- male 
and female mice (* p=0.0377) and the NOD male and female mice (* p=0.0177). 
 
 
 
 
*  
*  
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FIGURE 25: THE PREVALENCE OF INSULIN AUTO-ANTIBODIES IN SINGLE CHAIN 
TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN 
LEVELS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 25: Serum was harvested from the blood from 4-7 week, 8-10 week 
(except the A22Cα-/-PI1-/-PI2-/-Y16Atg mice) and 11-16 week old mice. Insulin auto-
antibodies were then measured in a competitive insulin radioimmunoassay. Data 
were then plotted using GraphPad Version 4 software. Each shape represents an 
individual mouse (n=3-8 per group), with males and females shown separately. 
Anything above the dotted line (over 0.0103) was deemed positive. Positivity was 
based on the mean plus 3 standard deviations from control C57BL/6 serum. 
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FIGURE 26: CD8+ T CELL AND B CELL INFILTRATION IN THE PANCREATIC ISLETS 
OF DIABETIC A22Cα-/-PI2-/- MICE 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
FIGURE 26: Pancreata were taken from male diabetic A22Cα-/-PI2-/- mice at 10 
weeks and placed into PLP fixative overnight at 4°C. The next day samples were 
infused with 10% then 20% sucrose and frozen in OCT embedding matrix in an 
isopentane ice bath. 8μm sections were then cut and transferred onto histology 
slides. Sections were then stained for B220 (A) and CD8 (B) using biotinylated 
antibodies, which were detected using a streptavidin phosphatase. Slides were 
then counter-stained using haematoxylin and 1% ammonium chloride prior to 
dehydration in ethanol and Histo-clear. Coverslips were then mounted on the 
sections and once dry were imaged on an Olympus BX51 microscope using 
Axiovision LE Software (Zeiss). 
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3.8 PROINSULIN 2 DEFICIENT SINGLE CHAIN TRANSGENIC TRAV8-
1*01TRAJ9 NOD MICE EXHIBITED GREATER INSULITIS  
Observing that 25% of male Proinsulin 2 deficient mice only developed 
spontaneous diabetes, immunohistochemistry on frozen sections of pancreas was 
carried out to identify the degree on infiltration in the mice. As FIGURE 26 shows, 
both CD8 and B cell infiltration in A22Cα-/-PI2-/- mice was detected. However, only 
a small number of islets were analysed for pancreatic infiltrating cells and 
therefore the level of infiltration can not be compared between the strains. 
However, further investigation is needed to identify the difference in infiltration 
in relation to proinsulin expression between the mice, while also identifying the 
TCRβ chains of those infiltrating T cells. This may suggest differences in T cell 
recruitment and therefore the provide evidence for why some mice lacking 
proinsulin 2 develop diabetes while others do not. In addition, a full natural 
history study of these mice, identifying when they develop infiltration, would be 
useful as it may indicate if proinsulin expression can alter how quickly the 
pancreas becomes infiltrated. 
3.9 DISCUSSION 
In this chapter, three principal findings are reported. Firstly, proinsulin expression 
affected the CD8+ TRBV repertoire in mice that expressed a transgenic TCRα chain 
from an insulin-reactive CD8+ T cell clone. In particular CD8+TRBV19+ cells were 
reduced significantly upon exposure to both proinsulin 1 and 2, while removing 
either proinsulin gene alone did not change the frequency of this population. 
Other TRBV changes were also noted, including proinsulin specific effects on 
TRBV29 and TRBV16, with age-specific increases seen with TRBV4 expression. 
Secondly, in those mice lacking proinsulin 1 or 2 there were significant increases 
in insulin B15-23-reactive CD8+ T cells in the draining lymph node for the 
pancreas (PLN). However, thirdly, investigation of the CDR3β sequence of these 
cells identified minimal shared sequences between the different proinsulin-
expressing strains with each mouse having an individual dominant clonotype.   
This entire work takes into account thousands of data points and therefore when 
analysing the data for the TRBV repertoire work by ANOVA, it was decided to use 
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a stringent Bonferroni correction. This corrected for all the comparisons done, 
while also minimising any non-specific and spurious results. Therefore any data 
reported as significant at the p=<0.05 level, in fact had a p value of less than 
0.0000022907, while significance reported at the p=<0.01 level related to a p 
value less than 0.0000004581. While this means there was a 5% or 1% probability 
of this result being found by chance, it is important to remember that while 
something may not reach statistical significance it may be biologically relevant. In 
other data analysed, such as the cell counts and tetramer data, the uncorrected 
values were reported, as strain comparisons only were performed. In addition, 
for H-2Kd-B15-23 peptide tetramer staining, the data were corrected by 
subtracting the background staining using an irrelevant tetramer control.  
3.9.1 PROINSULIN EXPRESSION AND THE EFFECT ON CELL NUMBER 
The baseline of proinsulin 1 and 2 expression in the polyclonal NOD mice (all the 
animal models used in this study were developed on the NOD genetic 
background), was measured using qPCR. As the data showed, proinsulin 1 and 2 
were detectable at high levels in the islets, as expected. In the PLN, males had 
higher levels of proinsulin 1 and 2 than their female counterparts, even though 
they had similar levels of GAPDH. The result may suggest that the males express 
more proinsulin immunologically than the females, potentially providing more 
antigen to activate the T cells to cause diabetes, although this experiment needs 
to be repeated to draw this conclusion. In addition, the thymus was found to 
have low levels of proinsulin 1 and higher levels of proinsulin 2 with similar levels 
noted in males and females. This confirms previous findings suggesting proinsulin 
2 is predominantly expressed within the thymus (Chentoufi and Polychronakos, 
2002, Chentoufi et al., 2004, Palumbo et al., 2006); however, this study also 
shows minimal thymic proinsulin 1 expression. While some studies support 
proinsulin 1 expression in the thymus (Chentoufi and Polychronakos, 2002, 
Chentoufi et al., 2004, Palumbo et al., 2006), other studies report it is not present 
(Nakayama et al., 2005b). The presence of proinsulin 1 in the thymus is much 
discussed but from data generated here, it is clear there is a small amount 
present. In addition, the data shows there is more proinsulin 2 detectable than 
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proinsulin 1 in the periphery, which agrees with previous work (Chentoufi and 
Polychronakos, 2002, Chentoufi et al., 2004, Palumbo et al., 2006). Proinsulin 2 is 
known to be important from a tolerogenic perspective (French et al., 1997, 
Chentoufi and Polychronakos, 2002, Thébault-Baumont et al., 2003, Jaeckel et al., 
2004); however, it is also important metabolically, as NOD mice lacking proinsulin 
1 are protected from developing diabetes (Moriyama et al., 2003).  
In our model we investigated whether the expression of proinsulin altered the 
total cell numbers. Although we had not expected any differences between the 
single chain transgenic strains, we found that the wildtype A22Cα-/- mice had 
fewer spleen cells than the A22Cα-/-PI1-/-PI2-/-Y16Atg mice at 4-7 weeks. This 
difference was not seen in the older 11-16 week group. Although it is possible 
that the age at which the mice were studied was responsible, it is unlikely as the 
average age for each strain was 4.3 and 4.7 weeks respectively. Therefore, it is 
more likely that this effect was proinsulin-specific; expression of both proinsulin 1 
and 2 may have reduced the cell expansion in the periphery or may have induced 
deletion of T cells that have escaped negative selection. If this were the case, we 
would expect the Proinsulin 2 over-expressing mice to have even fewer cells. 
However, the numbers in the A22Cα-/-PI2tg mice were comparable, although this 
could be a compensatory change. As expected, at 11-16 weeks the polyclonal 
NOD mouse with no TCRα chain restriction had a greater number of thymic cells 
than the restricted TCRα mice. This is most likely to be due to the lack of TCR 
restriction in the polyclonal NOD mouse, producing many more different TCR 
combinations and thus the thymus atrophies at a slower pace, eventhough the 
NOD thymus is morphologically different and does not involute the same as other 
mice (Savino et al., 1991, Savino et al., 1993).  
3.9.2 PROINSULIN EXPRESSION AND THE CD4/CD8 T CELL RATIO 
Having restricted the TCRα chain from a proinsulin B15-23 reactive CD8+ T cell we 
investigated the effect on the CD4+ and CD8+ T cell populations within these 
different proinsulin-expressing mice.  At 4-7 weeks, the mice lacking proinsulin 2 
(A22Cα-/-PI2-/- mice) had a greater number of thymic CD4+ T cells than the A22Cα-
/-PI1-/- mice and the A22Cα-/-PI1-/-PI2-/-Y16Atg mice, while having decreased 
148 
 
peripheral CD8+ T cells when compared to the A22Cα-/-PI1-/- mice. However, at 11-
16 weeks the A22Cα-/-PI2-/- mice have more CD4+ T cells present in the spleen and 
MLN than the A22Cα-/-PI1-/- mice, while still showing a trend in the reduction in 
CD8+ T cells within the periphery compared to other strains. This difference in 
peripheral CD8+ T cells in the A22Cα-/-PI2-/- mice may be due to a lack of tolerance 
(lack of proinsulin 2) allowing auto-reactive CD8+ T cells to escape into the 
periphery and begin infiltrating the islets, resulting in a peripheral reduction in 
the 4-7 week old mice, as some of these mice developed spontaneous 
autoimmune diabetes. As for the peripheral expansion of CD4+ T cells in the 
A22Cα-/-PI1-/-PI2-/-Y16Atg mice compared to the A22Cα-/- mice, the A22Cα-/-PI2tg 
mice and the A22Cα-/-PI1-/- mice in the spleen, PLN and MLN, this may be due to a 
lack of antigen enabling more auto-reactive CD4+ T cells to develop (the original 
model was generated to study this), or it may be that CD4+ T cells are more 
resilient and receive non-antigen survival signals or that they can expand better 
than the CD8+ T cells. At 11-16 weeks, the A22Cα-/-PI2-/- mice have a non-
significant reduction in peripheral CD8+ T cells and an increased proportion of 
CD4+ T cells and therefore if those CD8+ T cells are entering the pancreas (as 
observed in the single chain TRBV13-3 transgenic NOD mouse recognising a 
peptide of IGRP (Verdaguer et al., 1996, Lieberman et al., 2003)), this may allow 
the CD4+ T cells to expand and “fill the space”.  It is noted, however, that in the 
TRBV13-3 transgenic NOD mouse, no differences were noted in the CD4+ T cell 
population (Verdaguer et al., 1996). 
3.9.3 THE EFFECT OF PROINSULIN ON TOTAL CD8+ TCR REPERTOIRE 
Within the CD8+ T cell population, the TRBV repertoire was investigated for any 
proinsulin-specific biases. Interestingly TRBV19, the same TRBV chain utilised by 
the G9C8 clone, was reduced in proportion with age but only when proinsulin 1 
and 2 were both present; when either or both genes were deleted, there was no 
effect on the population of TRBV19+CD8+ T cells. This reduction also correlated 
with the amount of antigen available, with a greater reduction seen in those mice 
which over-expressed proinsulin 2. TRBV19 has also been detected by 
clonotyping the CD8+ T cells in the A22Cα-/- mice, the A22Cα-/-PI2-/- mice and the 
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A22Cα-/-PI1-/-PI2-/-Y16Atg mice.  The role of proinsulin 2 has been established and 
shown to promote tolerance (French et al., 1997, Chentoufi and Polychronakos, 
2002, Jaeckel et al., 2004, Faideau et al., 2004) and when NOD mice are deficient 
in proinsulin 2, the mice develop accelerated diabetes (Thébault-Baumont et al., 
2003). However, NOD mice lacking proinsulin 1 do not develop autoimmune 
diabetes, believed to be due to the expression of proinsulin 2, tolerising the T 
cells (Moriyama et al., 2003), although this has not been fully investigated. The 
reduction in proportion of TRBV19 is seen in the thymus where proinsulin 2 is 
believed to be predominantly expressed; however, there is even more reduction 
within the periphery where proinsulin 1 and 2 are expressed (Chentoufi and 
Polychronakos, 2002, Chentoufi et al., 2004, Palumbo et al., 2006). This data 
suggests that both proinsulin 1 and 2 have tolerogenic properties and that they 
synergistically eliminate or prevent the development of T cells with potentially 
auto-reactive TCRs. While proinsulin 1 and 2 were able to reduce the proportion 
of CD8+TRBV19+ T cells by approximately 5% (in A22Cα-/- mice) in all tissues, 
fewer than 1% of the total CD8+ T cells were insulin B15-23 reactive with even 
fewer that expressed TRBV19 (shown by clonotyping). This non-specific TRBV19 
deletion may be due to potential tolerance. If the TCR CDR1 and CDR2 regions are 
important for MHC recognition with CDR3 important for dictating specificity, the 
combination of TRBV19 with the transgenic TCRα chain could result in the 
deletion of those G9-like CD8+ T cells. The level of proinsulin expressed may also 
contribute to the deletion of T cells with different avidity for the p:MHC complex. 
Numerous studies have shown that auto-reactive T cells with high avidity are 
deleted within the thymus, providing the antigen is expressed, while lower avidity 
T cells can escape into the periphery (Zehn and Bevan, 2006, Enouz et al., 2012). 
The spectrum of TCR avidity may therefore correlate to the level of antigen i.e. 
the more antigen that is expressed, the more likely the T cell will interact with it 
and therefore those with a lower avidity may also be deleted over time. In 
addition, it is possible that the expression of proinsulin 2 may increase the 
presence and function of regulatory cells to eliminate more auto-reactive T cells, 
but there is currently no evidence for this.  
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Proinsulin-specific effects were also seen in TRBV29 expression in the A22Cα-/-PI2-
/- mice. At 11-16 weeks, there was an increased TRBV29 proportion present in 
these mice when compared to all other strains within the PLN. In addition, the 
A22Cα-/-PI1-/- mice had statistically lower TRBV29 proportions in the thymus, 
spleen and MLN compared to the A22Cα-/-PI2-/- mice, while the A22Cα-/-PI1-/-PI2-/-
Y16Atg mice also had reduced TRBV29 proportions in the thymus and MLN in 
comparison to the A22Cα-/-PI2-/- mice. TRBV29 has not been identified as a 
proinsulin B15-23 reactive TRBV chain from the clonotyping or from previous 
data in NOD mice and is therefore likely to have arisen from a balancing effect in 
the TRBV repertoire; when one TRBV chain increases another is reduced.  
However, TRBV16 is increased when one or both proinsulins are deficient, while 
those mice with normal or over-expressed proinsulin levels do not show any 
expansion for TRBV16+ CD8+ T cells. Unlike TRBV29, clonotyping has shown that 
insulin B15-23 reactive CD8+ T cell receptors utilise TRBV16 In the A22Cα-/-PI2-/- 
mice. Therefore, this suggests when proinsulin is lacking; these auto-reactive 
CD8+ T cells are able to expand. TRBV4, on the other hand, expands in all strains, 
regardless of proinsulin expression, with age. Some of the increases in receptor 
frequencies are greater, whereas others show only a small rise. Therefore, there 
are factors in all these mice allowing the cells to expand. Interestingly, the 
clonotyping data revealed a proinsulin-reactive TRBV4+ clonotype. This expansion 
does not seem to be proinsulin-specific as it is seen in the A22Cα-/- mice, the 
A22Cα-/-PI2-/- mice and the A22Cα-/-PI1-/-PI2-/-Y16Atg mice, which lack native 
proinsulin expression. Although it is possible that these T cells are selected on a 
different proinsulin epitope, present in all the mice, it is more likely the T cells 
expand because of cross-reactivity to a different antigen. 
Investigating other TRBV repertoire differences revealed that the A22Cα-/-PI1-/-
PI2-/-Y16Atg mice appeared to be more different than any of the other strains, 
particularly at 4-7 weeks with significant differences reported with respect to 
TRBV13-2/13-3, TRBV14, TRBV15 and TRBV26. However, with age, these 
differences became less pronounced and there were fewer TRBV repertoire 
differences between the strains. While some of these differences were observed 
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in all the tissues, others tend to differ, particularly within the thymus. Within the 
strains there were also differences between the thymus and periphery, which is 
not surprising, given that the thymus is constantly changing and forming new T 
cells with different TCRs and both the thymus and periphery have different 
mechanisms to control the TCR repertoire.   
3.9.4 PROINSULIN EXPRESSION AND INSULIN B15-23 REACTIVE CD8+ T 
CELLS 
Given that these mice only have a restricted TCRα chain, but not TCRβ chain, and 
therefore a more polyclonal repertoire than TCRαβ transgenic mice, the 
proportion of those T cells that recognise insulin B15-23 are low and at similar 
levels to a polyclonal NOD mouse. This may suggest that this TCRα chain is 
utilised by many TCRs to recognise insulin B15-23 and would therefore agree with 
the Eisenbarth group suggesting that the TCRα chain is vital for insulin 
autoimmunity, although they investigated this in CD4+ T cells (Kobayashi et al., 
2008, Nakayama et al., 2012). However, it is also possible that forcing the TCR to 
have this TCRα chain also increases the proportion of the insulin B15-23 reactive 
T cells. When proinsulin 2 is deficient, these mice have significantly elevated 
levels of insulin B15-23 reactive CD8+ T cells in the thymus, spleen and PLN. Given 
that proinsulin 2 is important in central tolerance (Chentoufi and Polychronakos, 
2002, Chentoufi et al., 2004, Faideau et al., 2004, Palumbo et al., 2006), it is not 
surprising that the auto-reactive T cells are increased in these mice. Interestingly, 
in the PLN, the proinsulin 1 deficient mice also have increased proportions of 
proinsulin B15-23 reactive CD8+ T cells, providing further evidence that both 
proinsulin 1 and 2 may be important in tolerising auto-reactive T cells. 
3.9.5 PROINSULIN EXPRESSION AND THE TCRβ CHAIN REPERTOIRE OF 
INSULIN B15-23 REACTIVE CD8+ T CELLS 
By sorting these insulin B15-23 reactive CD8+ T cells and sequencing their CDR3β 
sequences, we learnt a number of important things. Firstly, while we may have 
expected TRBV19 to be predominantly expressed, it was only expressed in a small 
number of mice and was one of 14 TRBV chains utilised by the auto-reactive 
repertoire. This may be explained, as mentioned earlier, by the TCRα chain having 
greater importance in dictating insulin autoimmunity. Secondly, there was only 1 
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shared sequence between the strains and 1 other within a strain detected. 
Although more mice should be examined, the data shows that each mouse has its 
own individual clonal expansion. This is interesting as it illustrates how complex 
the interactions are in shaping the auto-reactive TCR repertoire. This data may 
also suggest a reason as why only some male proinsulin 2 deficient mice develop 
diabetes, because if one dominant clonotype can expand, it may be able to 
surmount the threshold of activation, leading to β cell specific destruction and 
the onset of autoimmune diabetes. However, the question to ask would be - 
what is driving that expansion of these individual clonotypes? One possibility 
addressed in Chapter 5, is the role of microbiota in the gut, which may influence 
the capabilities of these clonotypes to expand through molecular mimicry or in 
directly through the microbiota altering the metabolism and therefore changing 
the level of insulin produced. It could also be due to a diminished regulatory 
response in controlling the auto-reactive T cells; however, in the G9C8 transgenic 
mice, there were no additional regulatory populations found causing the lack of 
diabetes (Wong et al., 2009). However, the G9C8 transgenic mice also had a 
restricted TCRβ chain, whereas in the mice in this study, the TCRα chain can pair 
with any endogenous TCRβ chain and therefore direct comparison may not be 
applicable here. It is worth noting that the CD4+ T cells are also forced to have the 
same TCR that originates in a CD8+ T cell and therefore, in these single chain 
transgenic mice, the normal function of CD4+ T cells may be impeded and they 
may not function as normal polyclonal CD4+ T cells. 
Previous investigations of islet-infiltrating TRBV repertoire in NOD mice, indicated 
that TRBV12 coupled with TRBJ2-6 was important (Berschick et al., 1993); 
however, while TRBV12 was detected in this study, it was seen in association with 
TRBJ2-3. The same report also suggested TRBV13 was important, which is not 
surprising, given that this is the most common TRBV chain in the NOD mouse; 
however, they showed that there was no selection pressure on the TRBJ chain, 
similarly to this work. In addition, while data in the Bio-Breeding diabetes prone 
rat and Lewis rat showed treatment with anti-TRBV14 monoclonal antibodies was 
able to reduce and prevent autoimmune diabetes (Liu et al., 2012), it may also be 
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useful in the NOD mouse, as TRBV14 was the TCR found as the only insulin B15-
23 reactive clone in a male A22Cα-/-PI2-/- mouse. The previously published 
clonotyping data also revealed different TRBV chains associated with other auto-
reactive clones in diabetes. In addition to TRBV19, utilised by the insulin B15-23 
reactive G9C8 clone (Wong et al., 1996, Wong et al., 1999), TRBV1 was utilised by 
the AI4 T cell clone that recognises the insulin A chain (DiLorenzo et al., 1998, 
Lamont et al., 2014), TRBV16 was utilised by the NY8.2 T cell clone (Nagata et al., 
1994b), TRBV13-3 was utilised by the IGRP reactive NY8.3 CD8+ T cell clone 
(Nagata et al., 1994b, Lieberman et al., 2003) and TRBV13 was used by the islet-
reactive YNK1.3 T cell (Yoneda et al., 1997). While these clones used other TCRα 
chains and other TRBJ chains, except the G9C8 clone, a limited number of TRBV 
chains are found. This raises an interesting question as to whether some TCRβ 
chains form TCRs that are more auto-reactive, or even more promiscuous than 
others, or even that the level of proinsulin expression may be enough to drive 
other auto-reactive T cells to develop. However, it is important to clarify that the 
CDR3β repertoire work in this study refers solely to insulin B15-23 reactivity. 
The difference in immunodominance seen in each mouse from the CDR3β data 
may have arisen due to a difference in the amount of antigen present. In viral 
studies, the viral dose is associated with a change in the immunodominance and 
avidity of the T cell as well as antigen presentation and the number of viral 
reactive CD8+ T cells (Luciani et al., 2013). In relation to this work, metabolic 
insulin is dependent on the level of blood glucose, which can be affected by diet, 
exercise and environmental factors, which are different in each mouse. 
Therefore, individual mice may have different blood glucose levels, which result 
in increased insulin secretion, which in turn may provide additional antigen for 
presentation. The increase in insulin secretion may alter the immunodominance 
and avidity of those T cells present, enabling 25% of those male proinsulin 2 
deficient mice to develop autoimmune diabetes. 
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3.9.6 PROINSULIN EXPRESSION AND THE DEVELOPMENT OF INSULIN 
AUTOIMMUNITY AND DIABETES 
As mentioned, only a small proportion of male A22Cα-/-PI2-/- mice develop 
autoimmune diabetes. However, all mice regardless of proinsulin expression have 
detectable insulin auto-antibodies present and therefore exhibit insulin 
autoimmunity; however, this does not seem to be affected by the level of 
proinsulin expression. Insulin auto-antibodies in NOD mice are associated with 
islet inflammation but are not predictive of diabetes development (Robles et al., 
2003). Interestingly, previous work had shown NOD mice that lack native 
proinsulins but express the mutated Y16A transgene do not have any islet auto-
antibodies (Nakayama et al., 2005a). However, in the presence of a restricted 
TCRα chain, the A22Cα-/-PI1-/-PI2-/-Y16Atg mice have detectable insulin auto-
antibodies suggesting that this TCR chain may be important in inducing insulin 
autoimmunity and islet inflammation.  
The only TCRα chain transgenic mice here that developed spontaneous 
autoimmune diabetes, lacked proinsulin 2 and when the TCRα chain was not 
restricted in NOD mice, they develop accelerated diabetes with nearly 100% 
incidence in males and females (Thébault-Baumont et al., 2003, Moriyama et al., 
2003). This acceleration, due to a lack of proinsulin 2, may also explain the earlier 
onset of diabetes in the A22Cα-/-PI2-/- mice, which would enable high avidity auto-
reactive T cells to escape. As discussed the different dominant clonotypes may 
predispose/prevent those mice from developing diabetes. Unusually, there was a 
gender difference in diabetes development in these A22Cα-/-PI2-/- mice. While 
there were no gender differences in total TRBV repertoire, these T cells within 
these strains may function differently or may be better controlled. Interestingly, 
in data discussed in the fifth chapter, we noted males tended to have a higher 
blood glucose level than their female counterparts and when challenged with 
glucose in an intra-peritoneal glucose tolerance test, they appeared to take 
longer to return to normal. One may speculate that this difference could result in 
a greater amount of insulin being produced and therefore more antigen available 
to activate the T cells in the males; however, these experiments have not been 
done.  
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Investigation of the islet infiltrating T cells within the pancreas revealed some 
infiltration of CD4, CD8 and B cells in the islets. However, the degree of 
infiltration was quite small and the frequency of islets in the A22Cα-/-PI2-/- male 
mice was also reduced when compared to other strains. This is similarly seen in 
the G9 TCR transgenic mice deficient in PI2 (Terri Thayer, personal 
communication, manuscript in progress). This may suggest that the mice may be 
insulin resistant, although we are yet to formally test this with an insulin 
tolerance test (see Chapter 5), or that proinsulin 2 is important for islet 
development.  
3.9.7 SUMMARY 
Together, this data highlights that proinsulin expression is capable of altering the 
total and insulin B15-23 reactive TRBV repertoire and that these cells may have 
different functional capabilities given that 25% male A22Cα-/-PI2-/- mice develop 
diabetes. This has also raised questions as to the nature of factors other than 
antigen that may affect the development of the auto-reactive repertoire, in 
addition to the roles of both proinsulin 1 and 2 in shaping this repertoire. 
In this work, the TRBV repertoire, and more specifically, the CDR3β repertoire of 
insulin B15-23 reactive CD8+ T cells has been investigated. However, the 
functional capabilities of these cells in the different proinsulin environments have 
not been addressed in this chapter. As only 25% of the male A22Cα-/-PI2-/- mice 
develop diabetes, this warrants further investigation. In the next chapter, we ask 
what is the role of proinsulin expression in shaping the function of these insulin 
B15-23 reactive CD8+ T cells? 
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CHAPTER 4: THE EFFECT OF PROINSULIN EXPRESSION ON 
THE FUNCTION OF PROINSULIN-SPECIFIC CD8+ T CELL 
RESPONSES IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 
NOD MICE EXPRESSING VARYING LEVELS OF PROINSULIN 1 
AND 2 
4.1 AIMS, RATIONALE AND HYPOTHESIS 
Having investigated the repertoire of these insulin-specific CD8+ T cells, the 
question remained about if and how proinsulin expression affected the way the 
cells functioned.  
In the OT-1 RIPmOva model, the investigators showed that the CD8+ T cells 
escape negative selection. By expressing the ovalbumin antigen in Listeria and 
then infecting the mice with the antigen-expressing Listeria, the OT-1 cells 
became activated and caused diabetes (Zehn and Bevan, 2006, Zehn et al., 2009, 
Enouz et al., 2012). In addition, in this artificial self-antigen model, they showed 
that the T cells could become activated by weak interactions at a similar, or 
lower, affinity/avidity threshold to that used during thymic negative selection, 
but that strong and maintained TCR interactions were needed to enable the CD8+ 
T cells to expand (Zehn et al., 2009, Enouz et al., 2012). However, this model 
utilises a foreign antigen expressed as a self-antigen. Here, we studied how auto-
reactive CD8+ T cells developed and became activated in response to their native 
antigen. 
In a separate project using the transgenic G9C8 mice, whereby all the T cells 
express both the TCRα and β chain from the insulin B15-23 specific CD8+ T cell 
clone, functional differences in the G9C8 CD8+ T cells were found dependent on 
how much proinsulin was expressed (Terri Thayer, personal communication, 
manuscript in preparation). While the thymus was important, to some extent, the 
periphery had a greater role in continuing to shape the functional abilities of 
these T cells and their ability to respond to cognate peptide. The CD8+ T cells, 
which developed in the G9C8 mice that lacked both proinsulin 1 and 2 but had a 
mutant proinsulin expressed (Y16A transgene), showed that on encounter with 
insulin peptide, they responded significantly faster and stronger than the G9C8 
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CD8+ T cells that developed in proinsulin 1 and 2 sufficient mice. The G9C8 T cells 
from G9C8 transgenic mice lacking proinsulin 2 responded at levels between the 
mutant proinsulin mice and the wild type mice. Therefore, this indicated the 
importance of cognate antigen expression shaping the diabetogenic potential of 
an insulin-specific CD8+ T cell. 
As discussed in Chapter 3, 25% of TCRα chain transgenic male mice lacking 
proinsulin 2 (A22Cα-/-PI2-/- mice) developed spontaneous autoimmune diabetes, 
suggesting functional differences in the insulin B15-23-specific CD8+ T cells. This 
was similar to the diabetes incidence in male G9C8 transgenic mice discussed 
above. In this current study, as discussed in the previous chapter, there were 
multiple TCRs capable of recognising insulin B15-23 in the TCRα restricted mice 
and therefore the functional ability of these cells warrants investigation, as some 
may have had stronger or weaker functional avidities (i.e. the overall strength of 
the interaction between the TCR and p:MHC) than the clonotypic G9C8 TCR. 
 
Hypothesis: 
Alterations in endogenous proinsulin expression will alter the functional ability of 
the insulin B15-23-reactive CD8+ T cells. 
 
Aim: 
To assess the functional abilities, of the insulin B15-23 specific CD8+ T cells, both 
in vitro and in vivo, in single chain transgenic TRAV8-1*01TRAJ9 NOD mice 
expressing variable levels of proinsulin. 
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4.2 IN VITRO ASSESSMENT OF THE FUNCTION OF DIRECTLY EX VIVO 
ISOLATED CD8+ T CELLS FROM SINGLE CHAIN TRANSGENIC TRAV8-
1*01TRAJ9 NOD MICE EXPRESSING VARIABLE LEVELS OF PROINSULIN  
CD8+ T cells were isolated from mice expressing native proinsulin (A22Cα-/- mice), 
those over-expressing proinsulin 2 (A22Cα-/-PI2tg), those lacking proinsulin 2 
(A22Cα-/-PI2-/-) and those deficient in native proinsulin 1 and 2 (A22Cα-/-PI1-/-PI2-/-
Y16Atg) to assess their potential to recognise insulin B15-23 peptide and 
denatured whole insulin, directly ex vivo. The methods used to investigate this 
included 3H-thymidine incorporation proliferation assays, cytokine ELISAs and 
cytotoxicity assays. Due to time restrictions, no current functional data was 
obtained for the A22Cα-/-PI1-/- mice. 
4.2.1 INSULIN B15-23-REACTIVE CD8+ T CELL PROLIFERATIVE 
RESPONSES TO INSULIN B15-23 PEPTIDE OR DENATURED WHOLE 
INSULIN WERE NOT DETECTED IN WHOLE CD8+ T CELL POPULATIONS IN 
SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING 
VARYING LEVELS OF PROINSULIN 
In order to assess the functional capabilities of these insulin-reactive CD8+ T cells 
from the various TCRα chain transgenic mice upon cognate peptide recognition, 
CD8+ T cells were initially isolated and cultured in vitro to determine their 
proliferative ability through using a 3H-thymidine incorporation assay. As FIGURE 
27 shows, the proliferative responses to both insulin B15-23 peptide and 
denatured whole insulin were variable both within the spleen and the PLN. 
Insulin B15-23 peptide responses were seen at low levels at 0.04μg/ml insulin 
B15-23 peptide in all mice in the spleen but only the A22Cα-/-PI2-/- mice and the 
A22Cα-/-PI1-/-PI2-/-Y16Atg mice showed any response in the PLN. However, overall 
the counts per minute (cpm) were very low except at 5μg peptide in the A22Cα-/-
PI1-/-PI2-/-Y16Atg mice. As for whole denatured insulin responses, these were 
lower than with peptide in the spleen and PLN with the A22Cα-/-PI1-/-PI2-/-Y16Atg 
mice showing a greater response at 25μg/ml. In the PLN, the A22Cα-/-PI2-/- mice 
show a larger response at 0.2μg/ml, which was maintained at similar levels 
regardless of the concentration of denatured insulin. The data shown is from 1 
experiment; however, upon repeating and changing the peptide concentrations 
(titrating down as far as 0.0016μg/ml) the results were highly variable and failed 
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to show the same trend more than once. In all experiments, although no or low 
proliferative responses were seen to insulin or insulin peptide, α-CD3 stimulation 
was used as a positive control and on each occasion, proliferation was seen (cpm: 
50,000+). In addition, a G9C8 CD8+ T cell control was also included, showing 
proliferation of these cells with counts reaching as high as 120,000 cpm. 
Therefore, the proliferation responses were deemed too low in these single chain 
TRAV8-1*01TRAJ9 mice to detect the insulin-specific responses. 
4.2.2 NO DETECTABLE CYTOKINE RESPONSES TO INSULIN B15-23 
PEPTIDE OR DENATURED WHOLE INSULIN FROM WHOLE CD8+ T CELL 
POPULATIONS IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD 
MICE EXPRESSING VARYING LEVELS OF PROINSULIN 
Supernatants were removed 48 hours post-incubation from the proliferation 
assays and assessed for MIP-1β and IFN-γ production. As FIGURE 28 shows, MIP-
1β cytokine responses were produced at very low levels with a peptide 
concentration specific increase seen in all strains in response to denatured insulin 
and insulin B15-23 peptide; however the A22Cα-/-PI2tg mice exhibited no increase 
in response to insulin B15-23 peptide. The greatest MIP-1β production was seen 
in the A22Cα-/-PI2-/- mice reaching 175pg/ml at 25μg/ml of insulin B15-23 
peptide. The A22Cα-/-PI2-/- mice also produced the greatest amount of IFN-γ 
reaching approximately 1750pg/ml at 5μg of insulin B15-23 peptide. All other 
strains had much lower IFN-γ production in response to insulin B15-23 peptide 
compared to the A22Cα-/-PI2-/- mice. MIP-1β and IFN-γ responses were very 
similar in all the strains in response to insulin B15-23 peptide or to denatured 
insulin, although the A22Cα-/-PI2-/- mice had lower responses to denatured whole 
insulin when compared to insulin B15-23 peptide responses. The data in FIGURE 
28 shows the best responses detected but similar to the proliferation data, upon 
repeating these experiments and varying the peptide concentration; the results 
were variable and followed no general trend.   
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FIGURE 27: CD8+ T cells were isolated from the spleen (A & B) or the PLN (C & D) 
by magnetic negative selection from mice aged 4-8 weeks. T cells were then 
cultured with bone-marrow derived DCs at a 10:1 T cell:APC ratio with varying 
concentrations of Insulin B15-23 peptide (A & C) or denatured insulin (B & D). 
Cells were incubated at 37°C for 48 hours, then 120μl of supernatant was 
removed and 18.5KBq of thymidine was added to the plate which was incubated 
for a further 18 hours. Cells were then harvested onto a filter mat and counted in 
a Microbeta counter (Perkin Elmer). Mean data were then plotted using 
GraphPad Prism software where the counts per minute (cpm) were corrected for 
the background of proliferation without peptide.  
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FIGURE 27: THE EFFECT OF PROINSULIN EXPRESSION ON THE PROLIFERATIVE CAPABILITIES OF CD8+ T CELLS ISOLATED FROM THE SPLEEN OR 
PANCREATIC LYMPH NODE (PLN) FROM SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE  
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FIGURE 28: CD8+ T cells were isolated from the PLN by magnetic negative 
selection from mice aged 4-8 weeks. T cells were then cultured with bone-
marrow derived DCs at a 10:1 T cell:APC ratio with varying concentrations of 
Insulin B15-23 peptide (A & C) or denatured insulin (B & D). Cells were incubated 
at 37°C for 48 hours, then 120μl of supernatant was removed. Supernatants were 
tested for MIP-1β and IFN-γ production by ELISA (R&D Systems or BD ELISA kit). A 
plate reader was then used to detect the optical density (OD) values at a 
wavelength of 450nm with a reference at 570nm. Data were then plotted using 
GraphPad Prism Version 4 software where the OD values were used to generate a 
standard curve. The concentration of the samples were then calculated by a 
linear regression and corrected for the background without peptide.  
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FIGURE 28: THE EFFECT OF PROINSULIN EXPRESSION ON THE ABILITY TO PRODUCE PROINFLAMMATORY CYTOKINES IN RESPONSE TO 
DENATURED INSULIN AND INSULIN B15-23 PEPTIDE OF CD8+ T CELLS ISOLATED FROM THE PANCREATIC LYMPH NODE (PLN) FROM SINGLE 
CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE 
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4.2.3 NO DETECTABLE INSULIN B15-23-REACTIVE CD8+ T CELL 
CYTOTOXICITY IN RESPONSE TO INSULIN B15-23 PEPTIDE COATED 
P815 TARGETS FROM WHOLE CD8+ T CELL POPULATIONS IN SINGLE 
CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING 
VARYING LEVELS OF PROINSULIN 
Having seen no clear evidence for proliferative responses, the T cells were tested 
in a cytotoxicity assay for their ability to kill target cells expressing Insulin B15-23 
peptide. This assay utilised PKH-labelled P815 cells, a murine mastocytoma that 
expresses appropriate H-2Kd MHC to present insulin B15-23 as targets in a non-
radioactive assay adapted from the assay by Lee-MacAry and colleagues (Lee-
MacAry et al., 2001). As FIGURE 29 shows, the spontaneous lysis of the target 
cells (P815 cells) is low at approximately 5%. However, no T cells from any of the 
strains showed peptide-specific cytotoxicity with between 13-23% P815 lysis 
without peptide and between 12-25% with peptide. As discussed previously, 
repeating this experiment and altering the effector:target ratios and peptide 
concentrations yielded similar results to the data shown in FIGURE 29 where no 
consistent cytotoxicity was seen.  
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FIGURE 29: THE EFFECT OF PROINSULIN EXPRESSION ON THE CYTOTOXIC 
CAPABILITIES OF CD8+ T CELLS ISOLATED FROM THE SPLEEN FROM SINGLE 
CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE 
 
 
 
 
FIGURE 29: CD8+ T cells were isolated from the spleen by magnetic negative 
selection from mice aged 4-8 weeks. T cells were then cultured with P815 cells at 
a 20:1 effector:target ratio with varying concentrations of Insulin B15-23 peptide. 
Cells were incubated overnight for 16 hours at 37°C. Cells were then measured on 
a BD FACS CANTO II flow cytometer with the addition of TOPRO (a viability dye) 
20 seconds before cell acquisition on the cytometer. Data were then analysed 
using Flowjo Version 7.6.5 (gated on PKH+TOPRO+ P815s) and P815 lysis was 
plotted using GraphPad Prism 4 software.  
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4.3 IN VIVO ANTIGEN-SPECIFIC STIMULATION OF CD8+ T CELLS FROM 
SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING 
VARIABLE LEVELS OF PROINSULIN  
As no insulin-specific functional responses were detected in the earlier assays 
where CD8+ T cells were studied for insulin-specific responses directly ex vivo, 
CD8+ T cell responses were then studied post-immunisation with insulin B15-23 
peptide. CD8+ T cells were then isolated for adoptive transfer into NOD mice 
over-expressing proinsulin 2 (NODPI2tg), to amplify insulin-reactive CD8+ T cell 
responses. In the NODPI2tg mice, insulin-reactive T cells will proliferate wherever 
they encounter antigen-presenting cells, as the APCs constitutively express insulin 
on the MHCII promoter. This would provide insight into whether increased 
antigen and general inflammation were able to stimulate the insulin B15-23 
reactive CD8+ T cells in vivo. 
4.3.1 INSULIN B15-23 PEPTIDE IMMUNISATIONS BOOST THE T CELL 
COMPARTMENT NON-SPECIFICALLY BUT FAIL TO ACTIVATE INSULIN 
B15-23-REACTIVE CD8+ T CELLS 
In order to stimulate the insulin B15-23-reactive CD8+ T cells, young TCRα chain 
transgenic mice aged 4-8 weeks were immunised with 50μg CpG mixed with, 50μl 
Incomplete Freund’s Adjuvant with or without 50μg Insulin B15-23 peptide. 
Control mice were immunised with CpG and IFA without peptide. The mice were 
analysed at various times post-immunisation including days 2, 4, 6 and 9. The 
results at post-immunisation day 2 (TABLE 16) and day 6 (TABLE 17) showed the 
most difference and therefore day 4 and 9 results have not been shown. As 
TABLE 16 and TABLE 17 show, between days 2 and 6 post-immunisation, there 
was an increase in the proportion of CD8+ T cells present in the ILN (Inguinal 
lymph node), PLN (pancreatic lymph node) and spleen in both controls and those 
receiving peptide. This increase in CD8+ T cells was also associated with an 
increase in CD44 expression, while those cells expressing CD69 decreased by 
approximately 50%. In addition by day 6 post-immunisation, the total proportion 
of Insulin B15-23-reactive CD8+ T cells was increased, with a small increase seen 
in those expressing CD44 and CD69, however, these still remained at low levels 
(less than 5%). However, there was no difference between the controls and those 
receiving peptide. The A22Cα-/-PI2-/- mice and the A22Cα-/-PI1-/-PI2-/-Y16Atg mice 
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receiving peptide had the greatest proportion of Insulin B15-23 reactive CD8+ T 
cells present. However, there were also no differences seen in responses 
between peptide-immunised and the control mice. 
4.3.2 NO PROLIFERATION OF TOTAL CD8+ T CELLS ISOLATED FROM 
SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING 
VARIOUS PROINSULIN LEVELS UPON ADOPTIVE TRANSFER INTO NOD 
MICE OVER-EXPRESSING PROINSULIN 2 
A different method of amplifying any insulin-reactive CD8+ T cells from these 
single chain TRAV8-1*01TRAJ9 transgenic mice expressing variable levels of 
proinsulin was tested next. CD8+ T cells were harvested from the spleen from 
immunised or control mice expressing different proinsulin levels and stained with 
CFDA-SE. 15x106 CD8+ T cells from each strain were then intravenously injected 
into NODPI2tg mice that over-express proinsulin 2 under the MHCII promoter. 
Peripheral tissues including spleen, PLN and MLN were then harvested 4 days 
post-transfer. As TABLE 18 shows there were no detectable differences in the 
proportion of total CD8+ T cells in the NODPI2tg mice between the cells from 
control mice and cells from immunised mice. However, there was greater 
variation in total CD8+ T cell proportion within the PLN (9.72-11.3% in the spleen, 
16.5-21.4% in the PLN and 17-18.8% in the MLN). In addition, while the 
proportions are small and the data was not significantly different, in the NODPI2tg 
mice receiving cells from immunised A22Cα-/- donor mice, there were more 
CD8+CFDA-SE+ T cells present in all tissues compared with the NODPI2tg mice 
receiving control A22Cα-/- donor cells. This trend was reversed in both the 
NODPI2tg mice receiving A22Cα-/-PI2tg or A22Cα-/-PI1-/-PI2-/-Y16Atg cells where 
there were fewer CD8+CFDA-SE+ T cells present in all tissues when the labelled 
donor cells were derived from mice that had been immunised prior to transfer. 
Functional investigations of these transferred CD8+ T cells by observing CD69 
upregulation revealed no proportional differences between the control and the 
immunised cells with few cells expressing CD69. As mentioned previously, there 
were no differences between the cells from the different strains.  
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TABLE 16: THE EFFECT OF INSULIN B15-23 IMMUNISATION ON TOTAL AND INSULIN B15-23-REACTIVE CD8+ T CELLS 2 DAYS POST-
IMMUNISATION FROM THE SPLEEN, INGUINAL LYMPH NODE (ILN) AND PANCREATIC LYMPH NODE (PLN) IN SINGLE CHAIN TRANSGENIC 
TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARIABLE PROINSULIN LEVELS 
STRAIN TISSUE CD8+ (%) CD8+TETRAMER+ (%) CD8+CD44+ (%) *CD8+CD44+TETRAMER+ (%) CD8+CD69+ (%) *CD8+CD69+TETRAMER+ 
(%) 
A22Cα-/- 
Control  
ILN 
PLN 
SPLEEN 
37.7 
40.5 
25.3 
0.28 
2.33 
0.83 
5.34 
4.05 
8.44 
1.3 
3.5 
1.21 
11.5 
11.5 
13.4 
0.85 
3.01 
1.41 
A22Cα-/- 
Imm 
ILN 
PLN 
SPLEEN 
37.85 
40.45 
25.75 
0.455 
0.64 
0.345 
4.495 
3.795 
7.94 
1.455 
0.905 
0.935 
13.65 
10.975 
11.62 
0.435 
0.715 
0.39 
A22Cα-/-
PI2tg 
Control  
ILN 
PLN 
SPLEEN 
36.4 
36.5 
27.8 
0 
0.13 
0.56 
6.63 
5.27 
7.24 
0 
0 
0.02 
7.16 
4.4 
4.91 
0.38 
0 
0.31 
A22Cα-/-
PI2tg 
Imm 
ILN 
PLN 
SPLEEN 
36.45 
36.1 
24.6 
0.5 
1.105 
0.79 
4.725 
4.67 
8.645 
1.3 
1.095 
1.915 
13.235 
7.38 
8.02 
1.18 
1.505 
0.86 
A22Cα-/-PI2-
/- 
Control  
ILN 
PLN 
SPLEEN 
29.4 
31.4 
14.6 
0 
0.21 
0.22 
9.83 
5.61 
16.2 
0 
0.98 
0.05 
5.84 
3.62 
4.61 
0 
0.65 
0 
A22Cα-/-PI2-
/- 
Imm 
ILN 
PLN 
SPLEEN 
35.7 
31.4 
22.5 
0.17 
0.88 
0.01 
7.08 
6.78 
11.9 
0.8 
0.47 
1.65 
7.8 
6.27 
7.43 
0.34 
0.24 
1.47 
A22Cα-/-PI1-
/-PI2-/-Y16Atg 
Control  
ILN 
PLN 
SPLEEN 
28.4 
30.9 
23.8 
0.2 
1 
0.51 
4.51 
5.59 
9.67 
0.28 
1.15 
1.11 
6.57 
4.02 
4.77 
0 
0.8 
1.22 
A22Cα-/-PI1-
/-PI2-/-Y16Atg 
Imm  
ILN 
PLN 
SPLEEN 
30.9 
30.7 
23.45 
0.11 
0.31 
0.48 
5.205 
5.665 
9.66 
0.89 
0.615 
1.03 
9.54 
6.525 
6.85 
0.52 
0.41 
1.11 
*CD8+CD44+TETRAMER+ T cells (%) refers to the percentage of the CD8+CD44+ T cells (%) that were tetramer positive. Likewise, the CD8+CD69+TETRAMER+ 
T cells (%) refers to the percentage of the CD8+CD69+ T cells (%) that were tetramer positive.  
NOTE: Control refers to mice not receiving peptide (n=1 per group), whereas Imm, short for immunised, refers to those mice receiving peptide (n=2 per 
group). 
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TABLE 17: THE EFFECT OF INSULIN B15-23 IMMUNISATION ON TOTAL AND INSULIN B15-23-REACTIVE CD8+ T CELLS 6 DAYS POST-
IMMUNISATION FROM THE SPLEEN, INGUINAL LYMPH NODE (ILN) AND PANCREATIC LYMPH NODE (PLN) IN SINGLE CHAIN TRANSGENIC 
TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARIABLE PROINSULIN LEVELS 
STRAIN TISSUE CD8+ (%) CD8+TETRAMER+ (%) CD8+CD44+ (%) *CD8+CD44+TETRAMER+ (%) CD8+CD69+ (%) *CD8+CD69+TETRAMER+ 
(%) 
A22Cα-/- 
Control  
ILN 
PLN 
SPLEEN 
55.7 
51.7 
31.9 
1 
2.03 
1.54 
19.2 
11.5 
21.5 
1.01 
1.76 
1.01 
6.34 
3.52 
2.65 
1.28 
2.16 
0.64 
A22Cα-/- 
Imm 
ILN 
PLN 
SPLEEN 
54.55 
53.4 
32.65 
0.395 
1.695 
0.11 
15.95 
12.45 
22.5 
0.2 
1.47 
0.25 
5.675 
5.04 
3.175 
0.485 
1.535 
0 
A22Cα-/-PI2tg 
Control 
ILN 
PLN 
SPLEEN 
52.1 
51.6 
31.2 
1.44 
0.43 
0 
13.3 
9.89 
19.4 
1.41 
0.26 
0 
4.96 
3.27 
2.09 
1.64 
0.58 
0 
A22Cα-/-PI2tg 
Imm 
ILN 
PLN 
SPLEEN 
53.7 
54.4 
33.9 
0 
1.4 
0 
12.9 
8.95 
15.6 
0 
1.63 
0 
4.24 
2.96 
1.7 
0 
1.82 
0 
A22Cα-/-PI2-/- 
Control 
ILN 
PLN 
SPLEEN 
37 
38.5 
20.5 
1.09 
0 
1.77 
15.7 
13.1 
19.1 
1.75 
0 
0 
1.75 
2.78 
0.894 
1.45 
0 
0 
A22Cα-/-PI2-/- 
Imm 
ILN 
PLN 
SPLEEN 
42.2 
39.4 
19.6 
2.27 
0.57 
2.8 
19.5 
9.84 
24.1 
3.88 
2.72 
2.44 
1.91 
1.87 
0.901 
4.22 
1.83 
5 
A22Cα-/-PI1-/-
PI2-/-Y16Atg 
Control 
ILN 
PLN 
SPLEEN 
47.8 
38.2 
21 
1.9 
1.87 
0.63 
23.8 
15.3 
30.3 
1.59 
1.75 
0.42 
4.92 
2.92 
1.82 
1.62 
1.55 
0.47 
A22Cα-/-PI1-/-
PI2-/-Y16Atg 
Imm 
ILN 
PLN 
SPLEEN 
46.6 
45.05 
24.75 
1.52 
1.345 
1.92 
23.5 
11.9 
20.85 
1.32 
1.195 
1.76 
4.87 
2.82 
2.23 
1.385 
1.655 
2.95 
*CD8+CD44+TETRAMER+ T cells (%) refers to the percentage of the CD8+CD44+ T cells (%) that were tetramer positive. Likewise, the CD8+CD69+TETRAMER+ 
T cells (%) refers to the percentage of the CD8+CD69+ T cells (%) that were tetramer positive. 
NOTE: Control refers to mice not receiving peptide (n=1 per group), whereas Imm, short for immunised, refers to those mice receiving peptide (n=2 per 
group). 
 
168 
 
 
TABLE 18: THE EFFECT OF INSULIN B15-23 IMMUNISATION ON CD8+ T CELL PROLIFERATION AND ACTIVATION FROM SINGLE CHAIN 
TRANSGENIC TRAV8-1*01 NOD MICE EXPRESSING VARIOUS PROINSULIN LEVELS POST-ADOPTIVE TRANSFER INTO NODPI2tg MICE OVER-
EXPRESSING PROINSULIN 2 
NOTE: Control refers to mice not receiving peptide, whereas Imm, short for immunised, refers to those mice receiving peptide. Data above represents the 
mean from 2 NODPI2tg mice per donor except the A22Cα-/-PI2tg Imm which is from a single mouse. 
DONOR TISSUE CD8+ (%) CD8+CFDA+ (%) CD8+CFDA+CD69+ 
(%) 
A22Cα-/- Control SPLEEN 
PLN 
MLN 
11.3 
16.5 
17 
0.406 
0.502 
0.438 
4.2 
3.91 
2.56 
A22Cα-/- Imm SPLEEN 
PLN 
MLN 
10.65 
18.6 
17.85 
1.16 
1 
1.03 
4.01 
3.18 
2.92 
A22Cα-/-PI2tg Control SPLEEN 
PLN 
MLN 
9.72 
21 
18.8 
1.13 
1.32 
1.15 
4.14 
2.51 
1.8 
A22Cα-/-PI2tg Imm SPLEEN 
PLN 
MLN 
10.95 
21 
18.65 
0.779 
0.978 
0.754 
4.24 
3.67 
7.94 
A22Cα-/-PI1-/-PI2-/-Y16Atg Control SPLEEN 
PLN 
MLN 
11.1 
21.4 
17.4 
0.577 
0.676 
0.586 
3.39 
1.79 
1.35 
A22Cα-/-PI1-/-PI2-/-Y16Atg Imm SPLEEN 
PLN 
MLN 
11.6 
18.7 
17.3 
0.348 
0.442 
0.353 
2.34 
2.22 
0.938 
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4.4 EX VIVO EXPANSION OF CD8+TRBV19+ T CELLS FROM SINGLE CHAIN 
TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARYING 
LEVELS OF PROINSULIN  
In spite of detection of insulin-reactive CD8+ T cells in the different proinsulin-
expressing mice shown in Chapter 3, insulin-reactive responses were not seen 
either in vivo or in vitro, in proliferative or cytotoxic responses in the total CD8+ T 
cell populations isolated from the single chain TRAV8-1*01TRAJ9 transgenic mice. 
Therefore, we embarked on a cloning procedure, by limiting dilution, to identify 
and expand those specific Insulin B15-23-reactive CD8+ T cells. To do this CD8+ T 
cells were sorted by flow cytometry for TRBV19+ expression (using an anti-
TCRVβ6 antibody) and grown in culture with irradiated splenocytes, bone-
marrow derived DCs, Insulin B15-23 peptide and IL-2. IL-7 was also added to help 
promote survival (Tsuda et al., 2000). Cells were then replated at 1, 3, 10 and 30 
cells per well using limiting dilution, enabling isolation of (oligo)clonal lines. A 
total of 40 cell lines were established through this cloning procedure (TABLE 19). 
TABLE 19: TOTAL OLIGOCLONAL CD8+TRBV19+ INSULIN B15-23-REACTIVE T CELL 
LINES ISOLATED 
 
4.4.1 CD8+TRBV19+ T CELL LINES FROM SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARYING LEVELS OF 
PROINSULIN ARE CYTOTOXIC TO INSULIN B15-23 LOADED P815 
TARGETS 
In order to assess the function of the expanded oligoclonal CD8+TRBV19+ T cell 
lines, the cells were tested for their ability to destroy insulin B15-23 loaded P815 
MOUSE STRAIN CELL LINE ID 
A22Cα-/- 10E5, 10F3, 10F11, 10F12 
30B6, 30B7, 30C2, 30C4, 30D7, 30F7, 30F11 
A22Cα-/-PI2-/- 1C5, 1F9, 1H9 
10F10 
30A4, 30A5, 30A6, 30B9, 30D1, 30D4, 30D8, 30E2, 30F6, 30H3 
A22Cα-/-PI1-/-PI2-/-Y16Atg 1G3 
3D7, 3F11, 3G5 
10A12, 10G2 
30A8, 30B7, 30B8, 30D9, 30E2, 30E8, 30G3, 30G7, 30H1 
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target cells. As FIGURE 30 shows, most of the oligoclonal lines were able to lyse 
Insulin B15-23 loaded targets specifically with cytotoxic activity seen at 0.2μg/ml 
of peptide and above. The expanded CD8+TRBV19+ T cells derived from the 
A22Cα-/- mice or A22Cα-/-PI1-/-PI2-/-Y16Atg mice responded similarly from around 
0.2μg peptide with 70-90% lysis and 50-90% lysis at 5μg peptide respectively. 
Interestingly, the A22Cα-/-PI2-/- 1F9 oligoclonal line (30B) responded at a lower 
concentration of 0.04μg/ml peptide and is the most sensitive oligoclonal line. 
While the A22Cα-/-PI2-/- 1F9, 30D4 and 30A6 lines responded similarly to the other 
strains, the oligoclonal lines 1C5, 30B9 and 30D8 respond much more weakly. In 
addition, the A22Cα-/-PI2-/- 30H3 line peaked at 1μg/ml peptide (~40% lysis) prior 
to a decreased cytotoxic response at 5μg/ml peptide.  
4.4.2 CD8+TRBV19+ T CELL LINES FROM SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARYING LEVELS OF 
PROINSULIN PRODUCE PROINFLAMMATORY CYTOKINES IN RESPONSE 
TO INSULIN B15-23 PEPTIDE PRESENTATION  
The cytotoxicity results showed that many oligoclonal lines responded specifically 
to peptide, and were further tested for production of proinflammatory MIP-1β 
and IFN-γ cytokines. FIGURE 31 shows the highest secreting cytokine oligoclonal 
lines for both MIP-1β (A) and IFN-γ (B). Oligoclonal lines A22Cα-/- 10F3, A22Cα-/-
PI2-/- 1H9, 30D1 and 30E2 and A22Cα-/-PI1-/-PI2-/-Y16Atg 30G7 showed high 
cytokine production for both MIP-1β and IFN-γ. However, some oligoclonal lines 
secreted more MIP-1β than IFN-γ and vice versa. Interestingly, more oligoclonal 
lines derived from A22Cα-/-PI2-/- mice produced higher concentrations of IFN-γ 
and more oligoclonal lines derived from A22Cα-/-PI1-/-PI2-/-Y16Atg mice produced 
higher concentrations of MIP-1β. Similarly to the cytotoxicity results, the 
oligoclonal lines produced cytokines at either 0.2 or 1μg/ml of peptide. All 
oligoclonal results for MIP-1β or IFN-γ production are shown in TABLE 20 and 
TABLE 21 respectively. This data shows that all oligoclonal lines, regardless of 
strain origin, had similar cytokine responses. 
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FIGURE 30: CD8+TRBV19+ T cells were isolated from A22Cα-/- mice (A), A22Cα-/-
PI2-/- mice (B) or A22Cα-/-PI1-/-PI2-/-Y16Atg mice (C) by flow cytometric sorting 
using a BD FACS ARIA. These cells were then expanded ex vivo with the addition 
of IL-2, IL-7 and 1μg/ml of Insulin B15-23 peptide and supported by irradiated 
splenocytes and bone-marrow derived DCs. Expanded cells were then removed, 
washed three times, counted and then cultured with P815 cells at a 10:1 
effector:target ratio with varying concentrations of Insulin B15-23 peptide. Cells 
were incubated overnight for 16 hours at 37°C. Cells were then run on a BD FACS 
CANTO II flow cytometer with the addition of TOPRO-3 (a viability dye) 20 
seconds before each tube was run. Data were then analysed using Flowjo Version 
7.6.5 (gated on PKH+TOPRO+ P815 cells) and P815 lysis was corrected for the 
background (using 0μg/ml) and results analysed using GraphPad Prism 4.  
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FIGURE 30: THE CYTOTOXIC CAPABILITIES OF CD8+TRBV19+ T CELLS EXPANDED 
EX VIVO FROM SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE 
EXPRESSING VARIOUS LEVELS OF PROINSULIN 
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FIGURE 31: CD8+TRBV19+ T cells were isolated from A22Cα-/- mice, A22Cα-/-PI2-/- 
mice or A22Cα-/-PI1-/-PI2-/-Y16Atg mice by flow cytometric sorting using a BD FACS 
ARIA. These cells were then expanded ex vivo with the addition of IL-2, IL-7 and 
1μg/ml of Insulin B15-23 peptide and supported by irradiated splenocytes and 
bone-marrow derived DCs. Expanded cells were then removed, washed three 
times, counted and then cultured with bone-marrow derived DCs at a 10:1 T 
cell:APC ratio with varying concentrations of Insulin B15-23 peptide. Cells were 
then incubated at 37°C for 48 hours then supernatant was removed. 
Supernatants were tested for MIP-1β (A) and IFN-γ (B) production by ELISA. A 
plate reader was then used to detect the optical density (OD) values at a 
wavelength of 450nm with a reference at 570nm. Data were then plotted using 
GraphPad Prism 4 where the OD values were used to generate a standard curve. 
The concentration of the samples were then calculated by a linear regression and 
corrected for the background cytokine production in the absence of peptide.  
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FIGURE 31: MIP1β AND IFNγ CYTOKINE PRODUCTION FROM CD8+TRBV19+ T 
CELLS EXPANDED EX VIVO FROM SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC 
NOD MICE EXPRESSING VARIOUS LEVELS OF PROINSULIN 
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TABLE 20: MIP-1β CYTOKINE PRODUCTION FOR ALL OLIGOCLONAL CD8+TRBV19+ T CELL LINES EXPANDED EX VIVO FROM SINGLE CHAIN 
TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARIOUS LEVELS OF PROINSULIN 
NT = Not Tested at 5μg/ml of Insulin B15-23 peptide 
DONOR STRAIN ID INSULIN B15-23 PEPTIDE CONCENTRATION (μg/ml) 
0.04 0.02 1 5 
 
 
 
A22Cα-/- 
10F11 0.00 0.00 0.00 144.22 
10F12 0.00 0.00 17.67 413.45 
30B6 0.00 0.00 0.00 35.04 
30C2 6.60 22.45 269.34 NT 
30D7 11.12 11.12 48.91 211.21 
30F7 11.17 4.96 17.37 80.65 
 
 
 
A22Cα-/-PI2-/- 
1C5 0.00 0.00 0.00 40.00 
1F9 0.00 0.00 27.59 288.14 
30A6 9.24 9.24 50.17 NT 
30B9 0.00 0.00 0.00 226.10 
30D4 0.00 0.00 57.37 135.53 
30F6 0.00 0.00 0.00 151.18 
 
 
 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
3F11 0.00 0.00 0.00 169.03 
30A8 0.00 0.00 0.00 213.70 
30B7 6.60 33.01 698.44 NT 
30B8 0.00 0.00 0.00 123.13 
30D9 0.00 0.00 0.00 306.75 
30E2 0.00 18.48 179.56 662.21 
174 
 
TABLE 21: IFN-γ CYTOKINE PRODUCTION FOR ALL OLIGOCLONAL CD8+TRBV19+ T CELL LINES EXPANDED EX VIVO FROM SINGLE CHAIN 
TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARIOUS LEVELS OF PROINSULIN 
NT = Not Tested at 5μg/ml of Insulin B15-23 peptide 
DONOR STRAIN ID INSULIN B15-23 PEPTIDE CONCENTRATION (μg/ml) 
0.04 0.02 1 5 
 
 
A22Cα-/- 
30B6 0.00 0.00 275.14 5015.86 
30C2 0.00 0.00 393.77 NT 
30C4 0.00 141.59 1203.24 2210.29 
30D7 0.00 0.00 0.00 670.18 
30F7 0.00 0.00 32.52 2607.10 
 
 
A22Cα-/-PI2-/- 
30A6 0.00 0.00 23.29 NT 
30D4 0.00 0.00 239.22 2604.63 
30D8 0.00 169.61 1122.29 2656.61 
30F6 0.00 0.00 91.40 955.55 
30H3 0.00 0.00 691.16 446.06 
 
 
 
 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
1G3 0.00 0.00 113.57 2368.02 
3F11 0.00 0.00 1109.66 2383.26 
3G5 0.00 0.00 45.08 1737.98 
10G2 0.00 0.00 116.69 2251.52 
30A8 0.00 0.00 391.80 2602.83 
30B7 0.00 0.00 1421.17 NT 
30B8 0.00 0.00 381.79 NT 
30E2 0.00 0.00 241.22 762.00 
30H1 0.00 0.00 51.31 2473.78 
175 
 
4.4.3 EX VIVO EXPANSION OF CD8+TRBV19+ T CELLS FROM SINGLE 
CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING 
VARYING LEVELS OF PROINSULIN IDENTIFY OLIGOCLONAL CD8+ T CELL 
LINES THAT UTILISE TRBV19 IN CONJUNCTION WITH TRBJ2-3  
Functional analysis had shown that some of the oligoclonal T cell lines responded 
better than others. In order to address whether these oligoclonal T cell lines were 
clonal or not, we investigated the TCR clonotype of these cells. As can be seen 
from TABLE 22 and TABLE 23, there are 9/20 clonal lines, with 6 shared CDR3 
sequences across all strains and 5 unique CDR3 sequences. Two of these were 
identified in the A22Cα-/- derived 30B6 and 30D7 lines and 3 in the A22Cα-/-PI2-/- 
derived 30B9, 30D4 and 30D8 lines. There were no unique CDR3 sequences in the 
A22Cα-/-PI1-/-PI2-/-Y16Atg derived lines. In addition, it should be noted that there 
were 2 non-TRBV19 sequences in the 30F7 line derived from the A22Cα-/- mice 
using TRBV24 and the 3F11 line derived from the A22Cα-/-PI1-/-PI2-/-Y16Atg mice 
utilising TRBV4. Interestingly, all the lines utilise TRBJ2-3 except one clone within 
the 30D7 oligoclonal line (from the A22Cα-/- mice) which utilises TRBJ2-7. All the 
clones identified that use TRBV19 and TRBJ2-3 express 4 amino acids between 
the TRBV and TRBJ chain in the motif CASS-XXXX-GAETLY. 
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TABLE 22: THE TCR CDR3 CLONOTYPE FOR ALL OLIGOCLONAL CD8+TRBV19+ T CELL LINES EXPANDED EX VIVO FROM SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARIOUS LEVELS OF PROINSULIN 
DONOR STRAIN ID TRBV CDR3 SEQUENCE TRBJ FREQUENCY (%) 
 
 
 
 
 
A22Cα-/- 
10F11 19 CASSIRTGGAETLY 2-3 100 
10F12 19 CASSMRQGGAETLY 2-3 100 
30B6 19 CASSIRQGGAETLY 2-3 94.74 
19 CASSIRQGDAETLY 2-3 5.26 
30C4 19 CASSMRQGGAETLY 2-3 88.89 
19 CASSRRDRGAETLY 2-3 11.11 
30D7 19 CASSSGLEQY 2-7 93.75 
19 CASSFREEGAETLY 2-3 6.25 
30F7 19 CASSIRTGGAETLY 2-3 94.12 
24 CASSRDSDTEVF 1-1 5.88 
 
 
 
 
 
 
A22Cα-/-PI2-/- 
1F9 19 CASSIRQGGAETLY 2-3 96 
19 CASSFREEGAETLY 2-3 4 
30A6 19 CASSFREEGAETLY 2-3 100 
 
30B9 
19 CASSMRQGGAETLY 2-3 69.23 
19 CASSFREEGAETLY 2-3 23.08 
19 CASSIREGGAETLY 2-3 7.69 
30D4 19 CASSIRQGGAETLY 2-3 94.12 
19 CASSVRQGGAETLY 2-3 5.88 
 
30D8 
19 CASSFREEGAETLY 2-3 50 
19 CASSIRQGGAETLY 2-3 25 
19 CASSFRQEGAETLY 2-3 16.67 
19 CASSMRQRGAETLY 2-3 8.33 
30H3 19 CASSIRQGGAETLY 2-3 100 
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TABLE 23: THE TCR CDR3 CLONOTYPE FOR ALL OLIGOCLONAL CD8+TRBV19+ T CELL LINES EXPANDED EX VIVO FROM SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE EXPRESSING VARIOUS LEVELS OF PROINSULIN 
DONOR STRAIN ID TRBV CDR3 SEQUENCE TRBJ FREQUENCY (%) 
 
 
 
 
 
 
 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
1G3 19 CASSMRQGGAETLY 2-3 100 
 
3F11 
19 CASSMRQGGAETLY 2-3 63.64 
19 CASSRRDRGAETLY 2-3 31.82 
4 CASSQDGQDTQY 2-5 4.55 
3G5 19 CASSIRQGGAETLY 2-3 100 
 
10G2 
19 CASSMRQGGAETLY 2-3 58.33 
19 CASSFREEGAETLY 2-3 33.33 
19 CASSFRQEGAETLY 2-3 8.33 
30A8 19 CASSMRQGGAETLY 2-3 100 
30B8 19 CASSMRQGGAETLY 2-3 100 
 
30E2 
19 CASSIRTGGAETLY 2-3 61.90 
19 CASSMRQGGAETLY 2-3 33.33 
19 CASSFREEGAETLY 2-3 4.76 
30H1 19 CASSIRQGGAETLY 2-3 100 
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4.5 DISCUSSION 
To summarise, functional insulin B15-23-reactive T cell responses, including 
proliferation, cytokine production and cytotoxicity assays, could not be detected 
within the heterogeneous population of CD8+ T cells, regardless of the proinsulin 
expression, in the different single chain TRAV8-1*01TRAJ9 transgenic NOD mice. 
Immunisation, to pre-activate insulin B15-23 responses, was also not effective in 
expanding the cells sufficiently to detect the population by the standard 
methods. Therefore a cloning procedure to amplify the insulin B15-23 responses 
was done. Through the generation of many TRBV19+ (oligo)clonal lines, insulin 
B15-23 responses were detected by many clones with low avidity. Clonotyping of 
these cell lines revealed a requirement, in almost all insulin B15-23 reactive 
responses, for TRBV19 to be associated with TRBJ2-3, the same TCRβ chain 
utilised by the original G9C8 T cell clone. Investigation of the CDR3β chain also 
revealed a conserved 4 amino acid motif between the TCRVβ and TCRJβ chains 
that seemed to be important for insulin B15-23 recognition. At position 2 of this 
sequence, arginine was required in all cases. 
4.5.1 INSULIN B15-23 FUNCTIONAL RESPONSES WITHIN A 
HETEROGENEOUS CELL POPULATION 
While proinsulin expression can alter the proportion of Insulin B15-23-reactive 
CD8+ T cells in single chain TRAV8-1*01TRAJ9 transgenic NOD mice, those cells 
are still a small proportion (generally less than 0.5% of the total CD8+ T cells). 
Therefore, when assessing the functional capabilities of the insulin B15-23-
reactive CD8+ T cell population, we aimed to detect and study the insulin-specific 
responses above the background level. However, the results were variable for all 
the strains and there was not any consistent peptide-specific proliferative, 
cytotoxic or cytokine responses. This may not be surprising as the frequency is 
low and therefore we may not be able to detect the insulin-specific responses 
with methods at the limit of sensitivity. In addition, each mouse stained using 
Insulin B15-23 H2Kd tetramers had a different proportion of insulin B15-23-
reactive CD8+ T cells, as well as having different TCR repertoires. As we were 
unable to detect consistent responses in any of the strains including those lacking 
either one or both proinsulin genes, it may suggest that these CD8+ T cells are of 
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low avidity or are tolerised. In addition, the individual dominance in the insulin 
B15-23 reactive TCR repertoire, coupled with only 25% of male A22Cα-/-PI2-/- mice 
developing diabetes, may suggest that the variable responses seen depend on 
which specfic T cell clone or clones expand in any given mouse. Therefore, the 
lack of response may be due to the diabetes-causing clones not being present in 
the small number of individual mice studied.  
Insulin B15-23-reactive G9C8 CD8+ T cells that develop in the G9C8 transgenic 
mouse are relatively naïve in phenotype and fail to develop spontaneous 
diabetes (Wong et al., 2009). However, other TCR transgenic mice such as those 
specific for IGRP (NY8.3) can develop spontaneous autoimmune diabetes 
(Verdaguer et al., 1997). This may suggest that these insulin B15-23-reactive  
CD8+ T cells are more difficult to activate than other T cells. In addition, the 
insulin B15-23-reactive T cells are proportionally reduced with age in the 
unmanipulated NOD mouse (Wong et al., 1999), whereas the IGRP206-214-reactive 
T cells become dominant (Lieberman et al., 2004). This suggests that there may 
be different intrinsic mechanisms controlling these antigen-specific T cells and 
their development, which may be related to the level of antigen e.g. proinsulin 
expressed and may suggest why some A22Cα-/-PI2-/- mice develop diabetes. 
Proinsulin is known to be expressed ectopically (Anderson et al., 2002, Yip et al., 
2009) and this may have an effect to generate peripheral tolerance. However the 
NY8.3 T cells do not appear to be tolerised by peripheral antigen expression 
(Wang et al., 2012b). This may be due to the high avidity that these NY8.3 T cells 
have for IGRP and therefore the individual T cell clone avidity/affinity for antigen 
is another contributing factor to differences in antigen-specific responses. 
Currently, although it is clear that there are factors controlling the expansion of 
these insulin B15-23-reactive CD8+ T cells, the nature of these has not been 
elucidated.  
4.5.2 IN VIVO IMMUNISATIONS TO AMPLIFY THE INSULIN B15-23-
REACTIVE T CELLS 
Through immunisations with insulin peptide or protein, we aimed to provide a 
stronger stimulus to the T cells in the various strains of TCRα transgenic mice to 
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raise them over their activation threshold and identify their functional responses. 
However, this also failed to yield any reproducible results, with many non-specific 
effects seen and very few peptide-specific effects noted. By measuring CD69 
expression, an early T cell activation marker (Testi et al., 1989), we saw a 
decrease in expression over time, post-immunisation. This may have been due to 
the activated T cells migrating to tissues that were not examined in this study e.g. 
the pancreas or may be due to peripheral control, preventing T cell activation. 
With respect to the G9C8 T cell, CD69 expression is not seen prior to activation as 
the cells are naïve, but once activated, expression is upregulated (Wong et al., 
2009). In contrast, CD44 was seen to increase. This was not surprising given that 
CD44 is a memory marker, which in conjunction with CD62L and CCR7, can 
distinguish between effector memory (CD44+CD62L-CCR7-) and central memory T 
cells (CD44+CD62L+CCR7+)  (Sallusto et al., 1999); in activated G9C8 T cells CD62L 
was shown to be decreased (Wong et al., 2009). This may suggest that it is more 
difficult to raise auto-reactive T cells over their activation threshold, potentially 
due to better peripheral control and therefore multiple immunisations may be 
required in order to enable the T cells to respond in a proinflammatory manner. 
In addition, some vaccinations poorly activate naïve T cells prior to memory T cell 
development (Lauvau et al., 2001) and therefore this may be what occurs in our 
model. In the G9C8 transgenic mouse model approximately 70% of mice 
developed spontaneous autoimmune diabetes after two immunisations (Wong et 
al., 2009) and therefore more immunisations may be required. In addition, other 
investigators had shown that immunisation with insulin, the insulin B chain or 
epitopes B9-23 did not stimulate detectable insulin-specific responses, although 
their study focused on CD4+  T cells (Daniel and Wegmann, 1996, Halbout et al., 
2002). 
In the RIPmOva model, ovalbumin, a foreign antigen, is expressed as a self-
antigen in the thymus and pancreas under the rat insulin promoter. Infection of 
these mice with OVA-expressing Listeria monocytogenes or vesicular stomatitis 
virus, increases antigen availability, enabling developing T cells to bypass negative 
selection and become activated by their antigen at avidities similar to, or lower, 
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than thymic negative selection to cause disease (Enouz et al., 2012). This 
contrasts with the work we have done. However, in this current study we are 
using a naturally expressed self-antigen system whereas the RIPmOva model is 
artificial and therefore the T cells that can respond to Ova antigen may have a 
higher avidity than normal self-antigen-reactive CD8+ T cells and subsequently 
may be capable of getting over the activation threshold more easily or have a 
lower activation threshold. In addition, if we had substituted the native insulin 
B15-23 peptide for a heteroclitic peptide e.g. the LYLVCGERV variant, we may had 
greater functional responses, as seen with the clonotypic G9C8 T cell clone (Wong 
et al., 2002). However, as this peptide is not naturally expressed, we refrained 
from using this peptide as we wanted our results to show the T cells activated 
with the native peptide. 
Studying the CD8+ T cells in the single chain TRAV8-1*01TRAJ9 transgenic NOD 
mice, both directly ex vivo and following immunisation, had failed to reliably test 
the functional capabilities of any insulin B15-23-reactive CD8+ T cells. Therefore, 
we decided to sort antigen-specific TRBV19+ CD8+ T cells by flow cytometry to 
amplify proinsulin-specific T cells for further study. In addition, this was also the 
TRBV chain used by the clonotypic G9C8 T cell clone in conjuction with TRBJ2-3 
(Wong et al., 1996). By culturing these cells with IL-2, IL-7 and Insulin B15-23 
peptide, the Insulin B15-23-reactive CD8+ T cells expanded well, enabling 
functional responses to be evaluated.   
4.5.3 CLONING TRBV19+ INSULIN B15-23 REACTIVE T CELLS  
The oligoclonal lines, generated from the different strains of mice, exhibited 
peptide-specific cytotoxic behaviour to Insulin B15-23 peptide-loaded P815 
targets and were capable of secreting proinflammatory MIP-1β and IFN-γ 
cytokines. Each oligoclonal line responded to the presence of insulin B15-23 
peptide. From the cytotoxicity results, the majority of oligoclonal lines responded 
similarly to higher concentrations of Insulin B15-23 peptide, with three of the 
oligoclonal lines having minimal cytolytic capability (A22Cα-/- derived 30F7 line 
and the A22Cα-/-PI2-/- derived 30B9 and 30D8 lines).  All the other oligoclonal lines 
were capable of causing specific lysis of peptide-coated targets above 40% and as 
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high as 90% at 5μg/ml of Insulin B15-23 peptide, as shown by the G9C8 CD8+ T 
cell clone (Wong et al., 1999). The finding that most of the oligoclonal lines did 
not respond to lower peptide concentrations supports the notion that these 
CD8+TRBV19+ T cells, recognising Insulin B15-23, were of low functional avidity. It 
is worth noting that these T cells were isolated from the spleen and therefore it is 
possible that higher avidity T cells may have been found in the pancreatic lymph 
nodes. There are several other possibilities for our observation that only low 
functional avidity T cells were isolated. 1. Higher avidity T cells may have already 
been activated by the target antigenic peptide and infiltrated the pancreas, 
destroying the insulin producing β cells. 2. High avidity insulin B15-23 reactive 
CD8+ T cells were negatively selected in the thymus, similarly to the OVA-reactive 
CD8+ T cells (Zehn and Bevan, 2006). Expression of one proinsulin gene is 
sufficient to select against these high avidity T cells, resulting in only low avidity T 
cells surviving in the different strains of mice due to the presence of one or both 
proinsulin genes as in the A22Cα-/-, A22Cα-/-PI1-/-, A22Cα-/-PI2tg or A22Cα-/-PI2-/- 
mice. These possibilities do not apply to the A22Cα-/-PI1-/-PI2-/-Y16Atg mice, which 
lack both native proinsulin genes (with a mutated proinsulin gene expressed). 
Here, of all the mice, we might have expected development of higher avidity 
insulin-reactive CD8+ T cell clones. However, in these mice, the insulin B15-23 
peptide is mutated and thus, any higher avidity T cells that may initially develop, 
may not be maintained in the periphery due to a lack of antigen. By creating a 
conditional native insulin knock out model, where both insulin 1 and 2 are 
deficient but are prevented from developing metabolic diabetes by expression of 
Y16A transgene, the insulin 1 and/or 2 genes can be re-expressed at later time 
points. This would allow T cells to develop without encountering antigen until the 
proinsulin genes are activated and may identify if high avidity T cells, reactive to 
Insulin B15-23, can develop but fail to be maintained if the antigen is not 
expressed. 
A number of the oligoclonal lines produced cytokines – the highest 
concentrations were secreted from the A22Cα-/-PI1-/-PI2-/-Y16Atg derived 30G7 
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line, closely followed by the A22Cα-/- derived 10F3 line and the A22Cα-/-PI2-/- 
derived 1H9 line.  
Interestingly, there were more A22Cα-/-PI1-/-PI2-/-Y16Atg derived lines that 
produced higher MIP-1β cytokine production than from any other mouse strains 
and likewise there are more A22Cα-/-PI2-/- derived lines that produced higher 
quantities of IFN-γ. Whilst it is possible that this is simply due to biological 
variation, it may suggest a potential role of antigen expression on the 
proinflammatory cytokine bias found within these oligoclonal lines derived from 
the different proinsulin expressing TRAV8-1*01TRAJ9 NOD mice. However, the 
number of oligoclonal lines is small and this suggestion therefore remains 
speculative, but from the results it may suggest proinsulin 1 expression may 
enable greater IFN-γ production and proinsulin 2 expression may enable greater 
MIP-1β production. This functional difference may also be associated with the 
presence of other clones in the oligoclonal line, different TRBJ usage and 
differences within the CDR3 region that contact the insulin B15-23 p:MHC 
complex. Therefore, we went on to investigate the clonality and repertoire of 
these insulin B15-23-reactive T cell lines to address these questions. 
4.5.4 CLONOTYPING OF THE CD8+TRBV19+ OLIGOCLONAL LINES 
From data obtained from the clonotyping of these oligoclonal lines, it was clear to 
see that in order for the insulin B15-23-reactive CD8+ T cells to recognise the 
auto-antigenic peptide using TRBV19, in almost all cases, TRBJ2-3 was selected, 
which is the same TRBV and TRBJ chains as the G9C8 T cell clone (Wong et al., 
1996). Therefore, there is an importance in these two chains associating to allow 
the insulin peptide to be recognised and that TRBJ2-3 has to be used to stimulate 
a proinflammatory response. There was one oligoclonal line, the A22Cα-/- derived 
30D7, that used TRBJ2-7 instead of TRBJ2-3; however, the production of MIP-1β 
and IFN-γ in response to Insulin B15-23 peptide was quite low and therefore this 
may suggest that while the T cells may recognise insulin using this TRBJ chain, the 
interaction is too weak to elicit the functional response. Interestingly, all lines 
derived from all of the mice have the same TRBJ chain suggesting that these TCRs 
form regardless of thymic proinsulin expression - even in the A22Cα-/- mice 
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expressing native proinsulin, as well as in the polyclonal NOD mouse from which 
the G9C8 T cell clone was originally derived. This G9C8 T cell clone was isolated 
from islets of a 7 week old pre-diabetic NOD female (Wong et al., 1996) 
suggesting that in mice with normal proinsulin expression the T cells expressing 
TRBV19 in conjunction with TRBJ2-3 fail to be tolerised and are capable of 
infiltrating the islets to cause diabetes.  
When compared to the TCR repertoires of insulin B15-23 tetramer-sorted cells 
described in the previous chapter, the TRBV19 expressing T cell clones also 
associated with TRBJ1-1, TRBJ2-1 and TRBJ2-4, as well as the TRBJ2-3, suggesting 
TRBV19 is the most important part of the TCRβ chain in recognising insulin B15-
23. Therefore, while other TRBJ chains can be used to recognise insulin, only the 
TRBJ2-3 cells were detected through ex vivo expansion. Whilst remaining to be 
confirmed at this stage, possible reasons for finding this could be: 1. T cell clones 
using the other TRBJ chains may have a higher avidity and therefore using 1μg/ml 
of Insulin B15-23 peptide may have resulted in too strong a stimulation and may 
have caused deletion of high avidity cells. 2. The culture conditions may have 
limited the expansion of other TRBJ expressing T cells and favoured those of a 
lower avidity expressing TRBJ2-3, although this does not seem likely.   
While some of the oligoclonal lines were in fact clonal, others were not, and 
there did not seem to be any functional enhancement if only one T cell clone was 
present or not. The presence of more than one clone in each line is not surprising 
as limiting dilution was used as a standard cloning procedure and usually requires 
more than one limiting dilution procedure to isolate a clone. However, there 
were two lines containing non-TRBV19 T cells. These were the A22Cα-/-  derived 
30F7 (using TRBV24) and the A22Cα-/-PI1-/-PI2-/-Y16Atg derived 3F11 (utilising 
TRBV4). This growth of non-TRBV19+ T cells may have arisen because of 
incomplete exclusion in the initial TRBV19 sorting of the cloned lines to remove 
contaminated APCs prior to clonotyping. However, it is currently unknown if 
either of these T cell clones recognise Insulin B15-23, given that these T cells 
were not sorted using the insulin B15-23 peptide:MHC tetramers and therefore 
testing the clones for their ability to individually recognise insulin B15-23 will 
185 
 
need to be done. While TRBV24 has not been identified in the previous Insulin 
B15-23-reactive CD8+ T cell repertoire work, TRBV4 was found in conjunction with 
TRBJ1-1 or TRBJ2-2 in the A22Cα-/-PI2-/- mice and the A22Cα-/-PI1-/-PI2-/-Y16Atg 
mice respectively.  
It was shown in Chapter 3 that only one male A22Cα-/-PI2-/- mouse examined had 
insulin-reactive tetramer positive CD8+ T cells utilising the TRBV19 and TRBJ2-3 
chains and that utilised a CDR3β sequence of CASSIRESGAETLY. This sequence 
also fits with the 4 amino acids found between CASS and the GAETLY sequence in 
all of the TRBV19 expanded T cell lines. While the initial G9C8 T cell clone used 
the 4 amino acid sequence IRDR and the tetramer-sorted clone used IRES, neither 
of these sequences were identified in the expanded TRBV19+ oligoclonal lines. 
Instead, IREG, IRQG, IRTG, FREE, FRQE, MRQG, RRDR and VRQG were found. In all 
of these CDR3β sequences, arginine was conserved in the second position, likely 
providing a very important contact with the insulin B15-23 peptide. In the first 
position, non-polar side chain amino acids were preferred (with the exception of 
arginine), while at the third position either an amino acid with an acidic side chain 
(aspartic acid (D) or glutamic acid (E)) or an uncharged polar side chain 
(Glutamine (Q) or Threonine (T)) were preferred, with the last position having 
little preference for an amino acid type. This demonstrates the potential 
importance of these amino acids in this CDR3β region for dictating peptide 
specificity. It is currently unknown as to how these amino acid differences 
interact with the peptide and if there is an optimal CDR3β sequence. 
Unlike the TCR repertoire from Insulin B15-23 tetramer sorted cells discussed in 
the previous chapter, there are many TRBV19+ expanded oligoclonal lines that 
have shared CDR3β sequences across all the strains regardless of proinsulin 
expression. Of the 20 clones sequenced for their CDR3β region, there are 6 
shared CDR3β sequences across all strains and 5 unique CDR3 sequences. Two of 
these unique sequences were identified within the A22Cα-/- derived 30B6 and 
30D7 lines and 3 within the A22Cα-/-PI2-/- derived 30B9, 30D4 and 30D8 lines. This 
sequence homology between strains provides further evidence of an intrinsic 
selection for particular sequences, following the aforementioned motif, which 
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appears to be essential when using TRBV19 and TRBJ2-3 for recognising insulin 
B15-23. It should also be noted that these results are from a selection of the 
more rapidly growing lines, and not all oligoclonal lines could be tested 
functionally or sequenced for the CDR3β region due to time restrictions.   
4.5.5 SUMMARY 
To summarise, this study demonstrated a lack of peptide-specific responses from 
investigation of total CD8+ T cell populations, from the lymphoid tissues of the 
various TCRα chain restricted, proinsulin-expressing mice. However, when a 
subset expressing TRBV19 were expanded, insulin B15-23 responses were 
identified. A number of oligoclonal lines were isolated that were cytotoxic for 
targets presenting the auto-antigenic peptide, and produced proinflammatory 
cytokines. Through sequencing the CDR3β region of these oligoclonal lines, we 
identified a requirement for TRBJ2-3 for insulin recognition with the fixed TRAV8-
1*01TRAJ9 and TRBV19. In addition, the oligoclonal lines use the same TRBV and 
TRBJ chain as the G9C8 T cell clone and showed similarities in a 4 amino acid 
motif to the other insulin B15-23-reactive TRBV19 expressing cells in the previous 
tetramer based repertoire work. This study has shown that regardless of 
proinsulin expression, the insulin B15-23-reactive CD8+ T cells still develop and 
have a similar avidity for their peptide when they express TRBV19. 
4.6 FUTURE WORK 
This investigation has yielded many more questions to answer. Firstly, it is 
important that more data is obtained both in terms of functional assays and in 
terms of CDR3β clonotyping in order to confirm if the trends identified are 
confirmed but also to identify any other T cell clones not yet seen i.e. such as 
those expressing alternative TRBJ chains in the cells sorted by Insulin B15-23 
tetramer binding in Chapter 3.  In addition, the oligoclonal lines with more than 
one clone would also need to be further cloned in order to obtain clonal 
populations. 
Secondly, while we initially flow cytometrically sorted for TRBV19-expressing 
CD8+ T cells, due to the selection pressure placed on that TRBV chain by 
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proinsulin expression, isolating Insulin B15-23-reactive CD8+ T cells by virtue of 
their insulin B15-23 reactivity, rather than by TCRβ chain, and studying their TCR 
repertoires should also be conducted. This would identify other TRBV chains 
capable of recognising the insulin B15-23 peptide, providing more data on the 
selection of auto-reactive CD8+ T cells and whether there are other T cell clones 
of higher avidity that can be activated at lower peptide concentrations. It is 
possible that TRBV19 itself places limitations on the avidity of interaction with 
the insulin peptide. Understanding how both the TRBV19 and other TRBV chain 
expressing insulin B15-23-reactive CD8+ T cells develop would allow comparisons 
to be made between the chains identifying any common motifs within the CDR3 
region. Once these cells have been isolated, the role of proinsulin 1 and 2 may 
then be fully explored in terms of their ability to expand and transfer diabetes in 
mice with altered proinsulin levels.    
Thirdly, this data focuses on the selection of the TRBV repertoire and therefore 
we do not fully understand if the TCRα chain makes important contacts within 
the peptide:MHC and therefore, it would be important to also examine the TCRα 
restriction in mice expressing various proinsulin levels. While there are few flow 
monoclonal antibodies against the TCRα chain, sorting for those insulin B15-23-
reactive CD8+ T cells with tetramer would enable the T cells to be investigated for 
their TRAV and TRAJ chains as well as the CDR3α sequence. If insulin B15-23-
reactive CD8+ T cells from TRBV19*01TRBD1TRBJ2-3 restricted mice had similar 
CDR3α sequences to the G9C8 TCRα chain sequence, then this would suggest the 
TCRα chain is more important for recognising the insulin peptide than the TCRβ 
chain. The data generated from this prospective study would also enable 
investigation into how auto-reactive T cells develop and escape negative 
selection due to the TCRα pairing, and whether high avidity T cells can develop 
with only the TCRβ chain restricted. In addition, this work would aid our 
understanding as to the strength of the interaction the TCRα and TCRβ chains 
individually contribute in recognising Insulin B15-23. 
Fourthly, since the immunisation work failed to sufficiently expand the insulin 
B15-23-reactive CD8+ T cells to facilitate study of the cells from in vivo activation, 
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it may be worth attempting additional immunisations in order to see if these T 
cells can be stimulated above their threshold. During this work, it would also be 
useful to identify which cells are capable of preventing these T cells from 
responding, providing a therapeutic target to enrich in preventing autoimmune 
diabetes. 
Finally, as mentioned in this work and the previous chapter, these mice have a 
variable proportion of insulin B15-23-reactive CD8+ T cells with individual 
dominant TCR repertoires. These individual clones may be important functionally 
as we found that only 25% of male A22Cα-/-PI2-/- mice developed spontaneous 
autoimmune diabetes. Therefore, investigating this difference in incidence and 
whether it is linked to specific higher avidity clonotypes remains to be tested.  
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CHAPTER 5: THE EFFECT OF ANTIBIOTICS AND THE GUT 
MICROBIOTA ON THE INCIDENCE OF DIABETES  
5.1 AIMS, RATIONALE AND HYPOTHESIS 
In order to fight an infection, the immune system relies on interactions between 
the invading foreign organism and the innate immune system. This interaction is 
initially mediated through pattern recognition receptors that include toll-like 
receptors (TLRs), found on many cell types, of which TLR 3, 7, 8 and 9 are found 
intracellularly and TLR 1, 2, 4, 5 and 6 are found extracellularly (reviewed by 
(Akira et al., 2006)). These TLRs signal downstream through an adaptor protein 
called MyD88, stimulating upregulation of proinflammatory cytokines and 
costimulation molecules. These TLRS bind specific ligands, known as pathogen-
associated molecular patterns, to induce a specific immune response e.g. TLR4 
recognises lipopolysaccharides in the Gram-negative bacterial envelope, in 
conjunction with the co-receptor MD-2, in a species-specific manner which is 
dictated by differences in TLR4 ligand binding (Shimazu et al., 1999, Hajjar et al., 
2002, Ohto et al., 2012). In addition, signalling specificity is mediated by TIRAP, an 
adaptor molecule, which can impair TLR1, 2, 4 and 6 signalling responses (Horng 
et al., 2002). 
Through TLR signalling, the innate immune response can protect against invading 
and commensal microbiota, maintaining gut homeostasis (Cario et al., 2004, 
Fukata et al., 2006, Shang et al., 2008, Mukherji et al., 2013). Interestingly, when 
these TLRs were deficient, as in knock out mice, homeostasis was disrupted. In 
TLR2-/- mice, bacterial loads and bacteria-associated pathology were increased 
(Wooten et al., 2002, Echchannaoui et al., 2002), while the proinflammatory 
responses in diabetic nephropathy (Devaraj et al., 2011c) and liver fibrosis (Ji et 
al., 2014) were decreased. In addition TLR2-/- mice, on the NOD genetic 
background, were also shown to be protected from the development of diabetes 
(Kim et al., 2007) and, through TLR2 signalling, tolerance can be established 
through boosting regulatory T cells and reversing the hyperglycaemia in recent-
onset diabetic mice (Burton et al., 2010, Kim et al., 2012). This indicates that 
while the host became susceptible to infection; autoimmunity, fibrosis and non-
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infectious disease-related complications were decreased. Therefore, 
understanding how all these factors shape the innate immune response is 
important. 
Through TLR signalling, the innate immune response begins and invokes the 
adaptive immune response through antigen presentation. Interestingly, the 
adaptive immune response can be dictated by the presence, or lack, of TLR 
signalling. TLR deficiencies reduce antigen-specific T cell proliferation and 
activation (Vallois et al., 2007, Gonnella et al., 2008, Zhang et al., 2010, Kim et al., 
2012), while signalling through TLRs can boost immunosuppressive cell 
populations (Burton et al., 2010, Tai et al., 2013). This indicates that TLR signalling 
can promote autoimmunity, while protecting against infection. 
In addition, to the TLR deficient mice, the effects of altering downstream 
signalling were also investigated e.g. in MyD88-/- mice. Following an LCMV 
infection in the MyD88-/- mouse, virus-specific CD8+ T cells could not be activated 
(Zhou et al., 2005), and CD4+ T cells could not differentiate into virus-specific T 
cells (Zhou et al., 2009). Furthermore, MyD88-/- NOD mice, were protected from 
diabetes (Wen et al., 2008), as were C57BL/6 MyD88-/- mice that over-expressed 
islet costimulatory molecules (Alkanani et al., 2014). The NOD MyD88 deficient 
mice were only protected from the development of diabetes when they were 
reared in specific pathogen-free mouse facilities, as when the mice were 
rederived in a germ-free environment, nearly all mice developed diabetes by 30 
weeks of age (Wen et al., 2008). This suggested a role for bacteria in shaping the 
immune response and upon transfer of gut microbiota from protected 
NODMyD88-/- mice into wildtype NOD mice, insulitis and diabetes were delayed 
(Peng et al., 2014). This altered disease phenotype corresponded to changes in 
the gut microbiota, increases in TGF-β and IgA secretion and the number of 
CD8+CD103+ T cells. Altered gut microbiota were also found in TLR-deficient mice 
(Fukata et al., 2005, Vijay-Kumar et al., 2010). Furthermore, gut microbiota 
differences were also identified in another spontaneous autoimmune diabetes 
model, the Bio-Breeding rat, where the rats susceptible to disease had different 
gut microbiota to those rats protected from disease (Roesch et al., 2009). The gut 
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microbiota were also shown to be different between individuals with type 1 
diabetes/β cell autoimmunity and the gut microbiota from healthy controls 
(Giongo et al., 2011, de Goffau et al., 2013). 
The finding that gut bacteria modify disease susceptibility to autoimmune 
diabetes promoted the interest in using antibiotics to investigate how that would 
affect the microbiota and diabetes development. In the NOD mouse model, 
antibiotics have been shown both to reduce (Hansen et al., 2012) and increase 
(Tormo-Badia et al., 2014) diabetes incidence depending on the antibiotic(s) 
used. In addition, the time of administration also appeared to be important in 
providing this protective or pathogenic response. Furthermore, the altered gut 
microbiota can be transmitted to the foetus and can impact the development of 
the gut (Ubeda et al., 2012, Tormo-Badia et al., 2014). 
Gut microbiota have also been modified by treatment with bacteria such as 
Lactobacillus casei and other probiotic bacteria corresponding with reduced 
incidence of diabetes (Matsuzaki et al., 1997, Calcinaro et al., 2005). 
Furthermore, genetic modification of Lactobacillus lactis to secrete IL-10 with 
human proinsulin or GAD65, two auto-antigens in diabetes, coupled with low-
dose α-CD3 treatment reversed diabetes in some NOD mice (Takiishi et al., 2012, 
Robert et al., 2014). Interestingly, in experimental autoimmune 
encephalomyelitis (EAE) (Ochoa-Repáraz et al., 2010a, Ochoa-Repáraz et al., 
2010b) and intestinal inflammatory disease (Mazmanian et al., 2008), 
polysaccharide A, a bacterial component, was able to prevent  disease. However, 
in diabetes, no single microbial factor has, as yet, been identified.  
Other factors, such as androgen levels, have recently been identified to be 
altered when the gut microbiota are modified. Normally female NOD mice have a 
higher incidence of diabetes than male NOD mice; however, when the mice are 
germ-free, or the males are castrated, the incidence of diabetes is similar 
(Yurkovetskiy et al., 2013). In addition, faecal transfer from male NOD mice into 
young female NOD mice was able to protect the recipient mice from diabetes, by 
inducing changes to the gut microbiota and increasing the testosterone level, 
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which was associated with decreased islet inflammation (Markle et al., 2013a). 
This indicates that both the gut microbiota and androgens are capable of shaping 
the immune response. 
While these studies have shown gut microbial differences between mice that 
were susceptible to disease development and those protected from disease, they 
focused predominantly on the development of diabetes in polyclonal mice, rats 
or individuals with a large T cell receptor diversity encompassing diverse antigen 
specificities. Therefore, work investigating specific antigen-specificities is required 
to identify any direct or indirect roles the gut microbiota may have on the 
individual antigen-reactive T cells. 
During investigation of diabetes incidence in the single chain TRAV8-1*01TRAJ9 
transgenic NOD mice, it was shown 25% of male mice lacking proinsulin 2 
developed spontaneous disease, similarly to male G9C8 TCR transgenic mice 
lacking proinsulin 2 (Terri Thayer, personal communication, manuscript in 
progress). This observation was made when the mice had prophylactic, 
intermittent broad-spectrum antibiotics administered for prevention of rectal 
prolapse. However, it was observed that when the single chain TRAV8-1*01TRAJ9 
transgenic NOD mice were not given antibiotics in their drinking water, they were 
protected from developing diabetes. Therefore, further studies were initiated to 
formally assess the effect of antibiotic administration on the development of 
diabetes in single chain TRAV8-1*01 transgenic NOD mice, deficient in proinsulin 
2. More specifically, the gut bacteria, the TCR repertoire and the insulin B15-23-
reactive T cells were investigated following different antibiotic regimes for any 
identifiable differences that contributed to this altered diabetes incidence.   
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Hypothesis: 
Antibiotics will alter the gut microbiota, and associated with this, the activation of 
insulin-reactive CD8+ T cells and consequently affect the incidence of diabetes. 
 
Aims: 
1. To investigate the effect of antibiotic administration on the development 
of autoimmune diabetes in the single chain TRAV8-1*01TRAJ9 transgenic 
NOD mice deficient in proinsulin 2, and investigate cellular phenotypic 
and functional changes responsible for any differences. 
2. To investigate the TRBV repertoire in single chain TRAV8-1*01TRAJ9 
transgenic NOD mice deficient in proinsulin 2 given different antibiotic 
regimes. 
3. To investigate the development of insulin B15-23-reactive CD8+ T cells in 
these single chain TRAV8-1*01TRAJ9 transgenic NOD mice, deficient in 
proinsulin 2, following antibiotic administration. 
4. To investigate the composition of the gut microbiota in single chain 
TRAV8-1*01TRAJ9 transgenic NOD mice deficient in proinsulin 2 following 
antibiotic administration.  
5. To study glucose tolerance in single chain TRAV8-1*01TRAJ9 transgenic 
NOD mice.  
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5.2 ANTIBIOTIC ADMINISTRATION AFFECTS THE DEVELOPMENT 
OF SPONTANEOUS DIABETES IN SINGLE CHAIN TRAV8-1*01TRAJ9 
TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
Historically, the A22Cα-/-PI2-/- mice had been treated with intermittent antibiotics 
as a prophylaxis against rectal prolapse, which may be a problem in TCRCα-/- 
mice. As shown in Chapter 3, a proportion of the mice developed autoimmune 
diabetes. However, on observing a group of mice off antibiotics, it was noted that 
the diabetes incidence was reduced. Therefore, the studies reported in this 
chapter were conducted to further examine this phenomenon. In all these 
experiments outlined, Baytril, a fluoroquinolone containing enrofloxacin as the 
active ingredient, was added to the drinking water. This is a broad-spectrum 
antibiotic targeting both Gram-positive and Gram-negative bacteria. It should be 
noted at the outset that rectal prolapse did not develop in these mice and any 
changes in diabetes was not related to rectal prolapse. 
5.2.1 ANTIBIOTICS ADMINISTERED POST-WEANING AFFECT THE 
INCIDENCE OF AUTOIMMUNE DIABETES IN SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
In the initial experiment 8 female and 19 male mice were observed for the 
development of autoimmune diabetes. All A22Cα-/-PI2-/- mice received Baytril 
treatment every other week during pregnancy and up to the age of weaning (3 
weeks). These mice were then divided into different treatment groups where 
they received Baytril (14 males, 8 females) or were not treated with Baytril (5 
males). Baytril was administered either intermittently or constantly but as no 
differences emerged between the two groups, the data were combined. In 
addition, no spontaneous diabetes was observed in any of the female A22Cα-/-
PI2-/- mice, therefore only the data from male mice are shown. As FIGURE 32 
shows, the incidence of diabetes in male A22Cα-/-PI2-/- mice that received Baytril 
reached 43% (6/14 mice). This was higher than the incidence in those male 
A22Cα-/-PI2-/- mice which were not treated with Baytril post-weaning (20%, 1/5 
mice). Diabetes was observed as early as 36 days (approximately 6 weeks of age) 
in those male mice that received Baytril constantly compared to 55 days in the 
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single mouse which developed diabetes without Baytril treatment, post-weaning. 
While there was a trend towards an increase in diabetes incidence with Baytril 
administration, the numbers were small and the data were not significantly 
different. 
5.2.2 ANTIBIOTICS ADMINISTERED PRE-PREGNANCY AFFECT THE 
INCIDENCE OF AUTOIMMUNE DIABETES IN SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
Having identified a difference in diabetes incidence in the small cohort of mice 
treated post-weaning, the question arose as to whether treating these mice 
earlier i.e. from birth would alter the incidence of diabetes. Therefore, breeder 
trios (2 females and 1 male) were set up and treated as before with either Baytril 
constantly in the water, Baytril every other week or no Baytril at all. The pups, up 
to 3 weeks of age, received the same treatments as their breeder parents. Upon 
reaching 3 weeks, mice were sexed and divided into cohorts to receive Baytril 
constantly or not at all (see FIGURE 33). A total cohort of 33 female and 34 male 
A22Cα-/-PI2-/- mice were observed for diabetes up to 12 weeks. As mentioned 
previously, any mice that received Baytril from 3 weeks were grouped together as 
no differences between the groups were observed. FIGURE 34 shows diabetes in 
male A22Cα-/-PI2-/- mice started from 6 weeks of age, as previously mentioned. 
However, in the group without Baytril treatment, 1/5 mice (20%) became 
diabetic at a later time point (10 weeks). The incidence of diabetes reached 43% 
in those male mice that received Baytril treatment, similarly to the previous 
study. However, there were no statistically significant differences between the 
two cohorts. In addition, no diabetes was recorded in any of the female A22Cα-/-
PI2-/- mice. 
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FIGURE 32: THE EFFECT OF ANTIBIOTIC (BAYTRIL) ADMINISTRATION POST-
WEANING ON THE INCIDENCE OF SPONTANEOUS AUTOIMMUNE DIABETES IN 
SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN 
PROINSULIN 2 
 
 
FIGURE 32: Male A22Cα-/-PI2-/- mice were treated with Baytril every other week 
during pregnancy and weaning (up to 3 weeks of age). After weaning, mice were 
placed into cohorts to receive Baytril in their water (n=14) or no Baytril (n=5). 
Mice were observed for 10 weeks with bi-weekly urine tests for glycosuria. If 
positive, the reading was confirmed the next day by testing blood glucose. 
Diabetes was diagnosed when blood glucose was above 13.9mmol/L. Data were 
plotted using GraphPad Prism Version 4 software. Survival curves were compared 
using a log rank test, where no significant differences were detected between the 
no Baytril and Baytril treated group (p=0.3222). 
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FIGURE 33: ANTIBIOTIC TREATMENT GROUPS FOR A22Cα-/-PI2-/- MICE FROM 
BIRTH  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 33: Male and Female A22Cα-/-PI2-/- mice (n=34 and 33 respectively) were 
treated with Baytril constantly, every other week or not at all during pregnancy 
and weaning (up to 3 weeks of age). After weaning, mice were placed into 
cohorts to receive Baytril or not at all in their water.  
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FIGURE 34: THE EFFECT OF ANTIBIOTIC (BAYTRIL) ADMINISTRATION PRE-
PREGNANCY ON THE INCIDENCE OF SPONTANEOUS AUTOIMMUNE DIABETES IN 
SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN 
PROINSULIN 2 
 
 
FIGURE 34: Male A22Cα-/-PI2-/- mice were treated with Baytril constantly, every 
other week or not at all during pregnancy and weaning (up to 3 weeks of age). 
After weaning, mice were placed into cohorts to receive Baytril constantly (n=29) 
or not at all in their water (n=5). Mice were observed for 12 weeks with bi-weekly 
urine tests for glycosuria. If positive, the reading was confirmed the next day by 
testing blood glucose. Diabetes was diagnosed when blood glucose was above 
13.9mmol/L. Data were plotted using GraphPad Prism Version 4 software. 
Survival curves were compared using a log rank test where no significant 
differences were detected between the groups (p=0.3284). 
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5.3 THE CD8+ TCR REPERTOIRES IN SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
ARE UNAFFECTED BY THE DIFFERENT ANTIBIOTIC REGIMES 
To test whether the difference in incidence of diabetes was due to a specific TCR 
repertoire expansion or loss, the CD8+ TCR repertoire was investigated in these 
male and female mice A22Cα-/-PI2-/- mice either at the time they developed 
diabetes or at the end of the period of observation if no diabetes occurred (10-12 
weeks). 
5.3.1 ANTIBIOTIC TREATMENT OF SINGLE CHAIN TRAV8-1*01TRAJ9 
TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 DOES NOT AFFECT 
THE NUMBER OF CD4+ OR CD8+ T CELLS 
Peyer’s patches (PP), mesenteric lymph nodes (MLN) and pancreatic lymph nodes 
(PLN) were isolated from the A22Cα-/-PI2-/- mice, from which single cell 
suspensions were stained using antibodies against CD4, CD8 and the TRBV chains 
(2.9.3.3). Live single CD4+ and CD8+ T cells were gated. FIGURE 35 shows the 
average T cell numbers stained in each antibody panel from each tissue with an 
average of 1000-2000 CD4+ T cells in the Peyer’s patches compared to 6000-8000 
CD4+ T cells within the MLN or PLN. The CD8+ T cell counts were similar to the 
CD4+ T cells. There were no statistically significant differences between mice on 
or off Baytril treatment, those mice that became diabetic vs non-diabetic or 
between males and females and therefore males and female results were 
combined.  
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FIGURE 35: Peyer’s patches, PLNs and MLNs were isolated from single chain 
TRAV8-1*01TRAJ9 transgenic NOD mice, deficient in proinsulin 2, receiving 
various antibiotic regimes. Mice were studied either at the time diabetes was 
diagnosed or at the end of the observation period (12 weeks). Single cell 
suspensions were stained with a panel of antibodies against CD4 and CD8 and 
measured on a BD FACS CANTO II. Data were then analysed using Flowjo Version 
7.6.5 software where live single CD4+ T cells (A) or CD8+ T cells (B) were gated. 
This proportion was then converted to a cell number using the total live cell 
number. The CD4+ or CD8+ T cell count from each staining panel for each tissue 
was then used to create an average value. Data were then plotted using 
GraphPad Version 4 software. The horizontal lines on the dot plot represent the 
median, while each individual shape represents an individual mouse. There were 
no statistical differences identified by ANOVA using R software and therefore 
male and female data were combined. Diabetic data only include male A22Cα-/-
PI2-/- mice as no females became diabetic. 
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FIGURE 35: T CELL NUMBERS IN SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC 
NOD MICE DEFICIENT IN PROINSULIN 2 THAT RECEIVED ANTIBIOTIC 
TREATMENT OR DID NOT 
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5.3.2 ANTIBIOTIC TREATMENT OF SINGLE CHAIN TRAV8-1*01TRAJ9 
TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 DOES NOT AFFECT 
THE TOTAL CD8αβ+ TCR REPERTOIRE 
CD8+ TCR repertoire was investigated by flow cytometry using a modified TRBV 
repertoire panel used in Chapter 3 (2.9.3.3). TABLE 24 summarises the PLN TRBV 
repertoire data in cell number per 10,000 CD8αβ+ T cells, to allow for direct 
comparison of CD8+ T cells in the Peyer’s patches, MLN and PLN. The PLN data is 
shown, as no differences were seen between the lymph nodes and Peyer’s 
patches and the results are therefore representative also of the MLN and Peyer’s 
patches. This data is presented as those receiving Baytril (regardless of if pre or 
post-weaning) and those not treated with Baytril, combining both males and 
females. A full table broken down by treatment group and gender is presented in 
the appendix. From this data, TRBV13 is the most prevalent followed by TRBV19 
then TRBV4. There were no differences between any of the antibiotic treatment 
groups, between genders or between those diabetic and those non-diabetic. 
However, the numbers of male diabetic A22Cα-/-PI2-/- mice studied were small 
(n=1-3). 
5.3.3 ANTIBIOTIC TREATMENT OF SINGLE CHAIN TRAV8-1*01TRAJ9 
TRANSGENIC NOD MICE, DEFICIENT IN PROINSULIN 2, DOES NOT 
AFFECT THE PROPORTION OF TOTAL CD8αβ+ MEMORY T CELLS 
Although TCR repertoire changes were not identified, we also asked whether 
there was a difference in memory phenotype of the CD8αβ+ T cells in these 
A22Cα-/-PI2-/- mice dependent on antibiotic treatment. The CD8+ T cells were 
isolated from the Peyer’s patches, MLN and PLN and stained with antibodies 
against CD8α, CD8β, CD44 and CD62L, to enable classification of central memory 
or effector memory T cells. FIGURE 36 shows CD44+CD62L+ central memory T 
cells were increased in the MLN and PLN in comparison to the Peyer’s patches; 
however, this trend was reversed for the CD44+CD62L- effector memory T cell 
populations where there were more present in the Peyer’s patches than the 
lymph nodes. Analysis of the data by ANOVA revealed no statistically significant 
differences between the treatment groups or gender.  
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TABLE 24: PLN CD8αβ+ TRBV REPERTOIRE IN SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 SHOWN 
BY ANTIBIOTIC TREATMENT 
 
Data shown refer to the average from all treatment groups whether the mice received Baytril or not. Data is representative of 56 mice 
receiving Baytril (27 females and 29 males) and 11 mice not treated with Baytril (6 females and 5 males).  
ANTIBIOTIC 
TREATMENT 
TRBV 
1 
TRBV 
2 
TRBV 
4 
TRBV 
12 
TRBV 
13 
TRBV 
14 
TRBV 
15 
TRBV 
16 
TRBV 
17 
TRBV 
19 
TRBV 
24 
TRBV 
26 
TRBV 
29 
TRBV 
31 
BAYTRIL TREATED 250 279 1206 347 2867 299 157 321 70 1737 3 212 13 480 
NO BAYTRIL 233 274 1212 346 2769 292 171 333 62 1751 3 204 18 478 
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FIGURE 36: Peyer’s patches, PLNs and MLNs were isolated from single chain 
TRAV8-1*01 transgenic NOD mice deficient in proinsulin 2 receiving various 
antibiotic regimes. Mice were studied either at the time diabetes was diagnosed 
or at the end of the observation period (12 weeks). Single cell suspensions were 
stained with a panel of antibodies against CD4, CD8α, CD8β, CD44 and CD62L and 
measured on a BD FACS CANTO II. Data were then analysed using Flowjo Version 
7.6.5 software where live single CD8αβ+CD44+CD62L+ or CD8αβ+CD44+CD62L- T 
cells were gated. This proportion was then converted to a cell number per 104 
CD8αβ+ T cells. Data were then plotted using GraphPad Version 4 software. The 
horizontal lines on the dot plot represent the median, while each individual shape 
represents an individual mouse. There were no statistical differences identified 
by ANOVA using R software and therefore male and female data were combined. 
Diabetic data only includes male A22Cα-/-PI2-/- mice as no females became 
diabetic. 
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FIGURE 36: TOTAL NUMBERS OF CD8αβ+CD44+CD62L+ CENTRAL MEMORY AND 
CD8αβ+CD44+CD62L- EFFECTOR T CELLS PRESENT IN THE PEYER’S PATCHES, 
MESENTERIC LYMPH NODE (MLN) AND PANCREATIC LYMPH NODE (PLN) OF 
SINGLE CHAIN TRAV8-1*01 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
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5.4 INSULIN B15-23-REACTIVE CD8+ T CELLS IN SINGLE CHAIN 
TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN 
PROINSULIN 2 WERE UNAFFECTED BY DIFFERENT ANTIBIOTIC 
REGIMES 
Having observed no broad CD8+ TCR repertoire changes with different antibiotic 
treatment regimes, the insulin B15-23 reactive CD8+ T cells were investigated, to 
establish whether there were any changes in this specific CD8+ T cell population.  
5.4.1 FREQUENCY OF INSULIN B15-23-REACTIVE CD8+ T CELLS WAS 
UNAFFECTED BY ANTIBIOTIC TREATMENT OF SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2  
Using Insulin B15-23 peptide:MHC tetramers, insulin-reactive CD8+ T cells could 
be identified within the Peyer’s patches, the MLN and the PLN from A22Cα-/-PI2-/- 
mice. FIGURE 37 shows in mice treated without antibiotics, the Peyer’s patches 
had the largest number of insulin B15-23-reactive CD8+ T cells (not significant) 
and were shown to decrease in the MLN and PLN (not significant). However, in 
those mice treated with antibiotics, the numbers of insulin B15-23-reactive CD8+ 
T cells comparing the Peyer’s patches and the MLN were more similar, while 
showing a reduction in the PLN. Furthermore, there was no numerical difference 
between the insulin B15-23-reactive CD8+ T cells in the diabetic A22Cα-/-PI2-/- 
mice compared to non-diabetic mice. Although, there was a trend for the number 
of insulin B15-23-reactive CD8+ T cells to be decreased in the Peyer’s patches, 
while increased in the MLN and PLN when mice were treated with antibiotics 
compared to those without antibiotics, the numbers are small and the data were 
not significantly different. In addition, only males were analysed for the insulin 
B15-23-reactive CD8+ T cells and therefore cannot be compared to the female 
A22Cα-/-PI2-/- mice. 
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FIGURE 37: TOTAL NUMBER OF INSULIN B15-23 REACTIVE CD8+ T CELLS PER 104 
CD8αβ+ T CELLS IN MALE SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD 
MICE DEFICIENT IN PROINSULIN 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 37: Cells were harvested from Peyer’s patches, mesenteric lymph nodes 
(MLN) and pancreatic lymph nodes (PLN) from mice aged 6-12 weeks. These cells 
were then stained using a multi-colour antibody staining panel (see 2.9.3.3) and 
measured on a BD FACS CANTO II, to be analysed later using Flowjo Version 7.6.5 
software. Background was subtracted from all tissues, using a minimally binding 
peptide:MHC tetramer. Data were then plotted using GraphPad Version 4 
software. Each shape represents an individual mouse (n=3-11). The median is 
shown by the horizontal line. 
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5.4.2 ANTIBIOTIC TREATMENT OF SINGLE CHAIN TRAV8-1*01TRAJ9 
TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 DOES NOT AFFECT 
THE NUMBER OF INSULIN B15-23-REACTIVE MEMORY CD8+ T CELLS 
Although no statistically significant differences were noted in the number of 
memory T cells between mice receiving treatment or those without antibiotic 
treatment, the insulin B15-23-reactive CD8αβ+ T cells were investigated for their 
memory status as central or effector memory T cells. FIGURE 38 shows that there 
were similar numbers of central memory and effector memory T cells and that 
these results were similar between the tissues. The number of effector memory T 
cells (CD8αβ+CD44+CD62L-) within the Peyer’s patches compared to the MLN and 
PLN, in A22Cα-/-PI2-/- mice not treated with antibiotics, was increased from a 
median value of 5 per 10,000 cells (in the MLN and PLN) to 27 per 10,000 cells in 
the Peyer’s patches. Interestingly, in those mice treated with antibiotics, the 
median number of effector memory T cells remained at approximately 5 per 
10,000 cells in all tissues. However, the numbers are small and only males were 
analysed for the insulin B15-23-reactive CD8+ T cells and therefore cannot be 
compared to female A22Cα-/-PI2-/- mice. 
5.5 ANTIBIOTIC ADMINISTRATION ALTERED GUT MICROBIOTA IN 
SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE 
DEFICIENT IN PROINSULIN 2 
Administration of antibiotic regimes to A22Cα-/-PI2-/- mice altered the incidence of 
diabetes observed; however, it was unknown if the gut microbiota played a role 
in shaping the onset of diabetes. To investigate this, faecal pellets were collected 
weekly from all mice individually, from weaning to termination; DNA was 
subsequently extracted and sequenced for known bacteria. This enabled 
identification of bacterial differences between the treatment groups. This 
bacterial sequencing was performed by Dr Li Wen and her colleagues at Yale 
University. 
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FIGURE 38: Cells were harvested from Peyer’s patches, mesenteric lymph nodes 
(MLN) and pancreatic lymph nodes (PLN) from mice aged 6-12 weeks. These cells 
were then stained using a multi-colour antibody staining panel (see 2.9.3.3) and 
measured on a BD FACS CANTO II. Data were then analysed using Flowjo Version 
7.6.5 software where live single CD8αβ+CD44+CD62L+ or CD8αβ+CD44+CD62L- T 
cells were gated. This proportion was then converted to a cell number per 104 
CD8αβ+ T cells. Data were then plotted using GraphPad Version 4 software. The 
horizontal lines on the dot plot represent the median, while each individual shape 
represents an individual mouse. 
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FIGURE 38: TOTAL NUMBERS OF INSULIN B15-23-REACTIVE CD8αβ+CD44+CD62L+ 
CENTRAL MEMORY T CELLS AND CD8αβ+CD44+CD62L- EFFECTOR MEMORY T 
CELLS PRESENT IN THE PEYER’S PATCHES, MESENTERIC LYMPH NODE (MLN) 
AND PANCREATIC LYMPH NODE (PLN) OF MALE SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
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5.5.1 GUT MICROBIOTA IS ALTERED BY ANTIBIOTICS IN SINGLE CHAIN 
TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
Faecal pellets from A22Cα-/-PI2-/- mice were sequenced for bacteria present at 3 
weeks of age (before the change in antibiotics at weaning) and at 6 weeks of age 
(at the time spontaneous diabetes was observed). A principal component analysis 
(PCA) was conducted on the sequenced bacteria to compare the variation 
between individual mice sequenced as shown in FIGURE 39. This data shows that 
all mice have similar bacteria present at 3 weeks. However, the mice treated with 
Baytril from weaning tended to have the most variation between each other. 
Interestingly, most of the data showed clustering between the different antibiotic 
treatment groups with a few samples, including some samples from mice that 
would become diabetic at 6 weeks, separated from the main cluster. By 6 weeks, 
there were more differences in the gut microbiota between the groups. It can be 
seen that the mice which did not receive treatment, are found to the left, the 
Baytril-treated from birth mice cluster in the centre and the Baytril-treated from 
weaning A22Cα-/-PI2-/- mice are mainly found to the right. The most striking 
difference is seen in those diabetic male mice, which cluster together. Of these 
diabetic mice, 4 were treated with antibiotics from weaning and 1 was treated 
with Baytril from birth. Only 1 diabetic mouse fell outside this cluster. 
Interestingly, there was a gender difference within the antibiotic treatment 
cohorts as the males and females tended to cluster separately. 
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FIGURE 39: Faecal pellets from antibiotic treated A22Cα-/-PI2-/- mice, aged 3 and 6 
weeks, were collected and bacterial DNA extracted. DNA was then sequenced 
and known bacteria were identified through sequence homology. Bacterial 
variation between mice was identified through a principal component analysis 
(PCA). Males (n=3-4) and females (n=2-3) treated in the antibiotic regimes – 
Baytril from birth, Baytril from weaning (3 weeks) and no Baytril are shown. In 
addition bacterial DNA from faecal pellets from diabetic A22Cα-/-PI2-/- mice were 
also sequenced (n=2 treated from birth, n=4 treated from weaning). Male mice 
shown by outlined squares (in blue or orange) were identified to be diabetic at 6 
weeks after two consecutive positive glycosuria results and blood glucose over 
13.9mmol/L.  
 
 
 
209 
 
FIGURE 39: GUT MICROBIOTA VARIATION BETWEEN SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 
GIVEN DIFFERENT ANTIBIOTICS REGIMES AT 3 AND 6 WEEKS OF AGE 
 
KEY:  Males = Squares   (Pre)Diabetic Male = Outlined squares  Females = Circles 
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5.5.2 GUT MICROBIOTA DIVERSITY DECREASED WITH AGE IN SINGLE 
CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE, DEFICIENT IN 
PROINSULIN 2, AND WAS INDEPENDENT OF ANTIBIOTIC TREATMENT 
Identification of the total gut microbiota differences between the A22Cα-/-PI2-/- 
mice receiving different antibiotic treatments revealed greater differences at 6 
weeks. However, when the bacteria were subdivided by phylum, there was a 
considerable decrease in microbial diversity in all mice. FIGURE 40 shows all 
treatment groups had a predominant Firmicute population at 3 weeks (45-64%), 
which expands to approximately 90-98% of the entire bacteria sequenced. At 3 
weeks, the mice, in all groups, had a greater bacterial diversity, particularly the 
no antibiotics group and the antibiotic-treated group from weaning. The Baytril 
treated group from birth predominantly comprised firmicutes and bacteroidetes 
(making up over 99%) at 3 weeks but by 6 weeks, the firmicutes had expanded 
and the bacteroidetes populations decreased from 38% to just over 1%. The 
bacteroidetes, proteobacteria, tenericutes and deferribacteres are all decreased 
in proportion from 3 to 6 weeks of age. However, the actinobacteria population 
increased in those mice treated with Baytril from birth and Baytril from weaning 
from 0.6% and 2.53% to 2.53% and 5.25% respectively. The mice in the antibiotic-
treatment from weaning maintained the largest diversity at 6 weeks. This 
decrease in gut microbial diversity was antibiotic treatment-independent as all 
groups were similarly affected. 
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FIGURE 40: Faecal pellets from antibiotic-treated A22Cα-/-PI2-/- mice, aged 3 and 6 
weeks, were collected. DNA was then extracted, sequenced and compared to 
known bacteria testing for sequence homology. Bacteria were then identified and 
grouped by phylum, with all mice receiving the same treatment grouped together 
(males and females). Each group comprised 6-8 mice with the proportions in 
percentages shown in bold on the pie charts. 
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FIGURE 40: GUT MICROBIOTA DIVERSITY AT THE PHYLUM LEVEL PRESENT IN 
SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN 
PROINSULIN 2 AT 3 AND 6 WEEKS OF AGE  
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5.6 MALE SINGLE CHAIN TRAV8-1*01TRAJ9 TRANSGENIC NOD 
MICE DEFICIENT IN PROINSULIN 2 HAD IMPAIRED GLUCOSE 
TOLERANCE COMPARED TO FEMALE MICE 
While investigations into the gut microbiota revealed a dramatic decrease in 
bacterial diversity, this raised the question as to how this might affect the role 
microbiota play in metabolism. Therefore, male single chain TRAV8-1*01TRAJ9 
transgenic NOD mice were investigated for their ability to respond to a glucose 
stimulus i.e. through insulin production. Mice were fasted overnight prior to the 
glucose challenge, with blood glucose levels taken at 0 minutes, then every 15-30 
minutes. FIGURE 41 shows that blood glucose was raised within 15 minutes of 
glucose challenge in all mice. In the male (A) and female (B) NOD mice at 6 weeks 
of age, blood glucose peaked at 17-18mmol/L at 15 minutes and took less than 
60 minutes to fall below the threshold for diabetes (13.9mmol/L). This was 
similarly seen in the female A22Cα-/-PI2-/- mice at 6 weeks; however, the single 
female 12 week old A22Cα-/-PI2-/- mouse appeared to have better glucose 
tolerance than the mice at 6 weeks (B). In contrast to the female A22Cα-/-PI2-/- 
mice at 6 weeks, the male mice, both at 6 and 12 weeks (A), failed to reduce their 
blood glucose levels within 90 minutes of a glucose challenge. While the 12-week 
old male A22Cα-/-PI2-/- mice appeared to have a marginally improved glucose 
tolerance compared to the 6-week old males, the male mice remained glucose 
intolerant over the period of this test.  
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FIGURE 41: 6-12 week old single chain TRAV8-1*01TRAJ9 transgenic NOD mice 
and polyclonal NOD mice were fasted overnight. A baseline blood glucose reading 
was taken and then the mice were challenged intra-peritoneally with 1.5g glucose 
per kg of weight. Blood glucose readings were then taken at 15 minutes, 30 
minutes, 60 minutes and 90 minutes post-glucose challenge. Mean data and 
range were then plotted using GraphPad Prism Version 4 software. Data are 
representative of 4 independent experiments whereby A shows data from the 
male mice and B shows data from the female mice. Data are representive of 9 
male and 7 female 6-week old A22Cα-/-PI2-/- mice (M6 and F6 respectively), 1 
male and 1 female 12-week old A22Cα-/-PI2-/- mice (M12 and F12 respectively) 
and 4 male and female 6-week old NOD mice (M6 and F6 respectively).  
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FIGURE 41: GLUCOSE TOLERANCE TEST RESULTS IN SINGLE CHAIN TRAV8-
1*01TRAJ9 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 AND 
POLYCLONAL NOD MICE 
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5.7 DISCUSSION 
To summarise, more male single chain TRAV8-1*01TRAJ9 transgenic NOD mice 
deficient in proinsulin 2 developed spontaneous autoimmune diabetes on 
antibiotic administration, whether treated pre- or post-weaning. However, no 
female A22Cα-/-PI2-/- mice developed diabetes regardless of antibiotic treatment 
(consistent with data in Chapter 3). In addition, these male A22Cα-/-PI2-/- mice 
showed impaired glucose tolerance, reducing blood glucose levels more slowly 
post-glucose challenge compared with NOD mice, while the female A22Cα-/-PI2-/- 
mice reduced the blood glucose level more rapidly. Investigation into the gut 
microbiota revealed greater differences between the antibiotic treatment groups 
at 6 weeks, with the bacterial species of many of the male diabetic mice 
clustering together. Upon further investigation at the phylum level, it was noted 
that all the mice had a greatly reduced bacterial diversity with Firmicutes 
comprising over approximately 90% of the total bacterial populations, whether 
they received antibiotics or not. Therefore, bacteria may be important in shaping 
the insulin B15-23-reactive CD8+ T cell response while also affecting glucose 
metabolism. Further work identifying specific bacterial species will help resolve 
the role of bacteria in the development of diabetes. 
5.7.1 STUDY LIMITATIONS 
It is important to note that the numbers in each group are small and therefore a 
greater number of mice need to be enrolled in the study. In addition, mice were 
cohoused at 3 weeks even if they had derived from different initial antibiotic 
treatment groups and therefore it is possible that bacteria were transferred 
between mice and thus reduced the differences between the mice. However, 
whether this protected mice or aided diabetes progression is unknown. 
While many environmental factors were controlled for e.g. preparing fresh 
antibiotic-containing water bi-weekly, sterilisation of bottles etc. many could not 
be controlled for such as the amount of antibiotic-containing water each mouse 
drank, the food each consumed etc. It should also be mentioned that as 
illustrated in Chapters 3 and 4, although genetically identical, there was individual 
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mouse variation in the number of insulin B15-23-reactive CD8+ T cells and 
therefore this could also not be controlled for. 
5.7.2 BAYTRIL AND DIABETES INCIDENCE 
Baytril containing enrofloxacin, a fluoroquinolone, is capable of destroying 
bacteria through inhibiting enzymes involved in bacterial DNA replication. More 
specifically, it preferentially targets Topoisomerase II (also known as DNA gyrase) 
in Gram-negative bacteria and Topoisomerase IV in Gram-positive bacteria, 
stabilising the complexes preventing DNA replication (Hooper, 2000). Through 
administration of this antibiotic post-weaning, incidence almost doubled from the 
previously observed 25% in male A22Cα-/-PI2-/- mice (see Chapter 3) to 43% when 
receiving antibiotics. This suggested that potentially changes to the gut 
microbiota were affecting the development of autoimmune diabetes. 
Interestingly, the diabetes was even more accelerated in these studies compared 
to the incidence reported in Chapter 3 (6 weeks vs 10 weeks).  
Only 1 of 5 male mice that did not receive any antibiotics developed diabetes, 
compared with 6 of 14 mice that were given antibiotics. The diabetes incidence 
may therefore be affected by the antibiotics circulating in the mouse and also the 
duration of administration may also play a role in promoting increased 
diabetogenicity. The antibiotics may also cause preferential expansion of disease-
inducing bacteria or a decrease in the disease-preventing bacteria. While these 
incidence curves were not statistically significantly different, a clear trend was 
seen.  
When the mice were treated in a larger cohort from birth to 3 weeks with 
different antibiotic regimes and then split into those mice receiving or not 
receiving Baytril post-weaning (after 3 weeks of age), the incidence was also 
affected.  
The mice from breeders that were treated with antibiotics had a similar age of 
onset of diabetes (6 weeks) and similar level of diabetes incidence (43%) to that 
seen when the mice were treated post-weaning. Interestingly, 1/5 mice receiving 
no antibiotics, developed diabetes but at a delayed time of 10 weeks of age. 
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During the design of the experiment, breeders and litters from birth were treated 
with different antibiotic regimes, and when the mice reached 3 weeks, they were 
divided and placed into other treatment cohorts. At this point, mice were 
cohoused with other mice that had previously received other treatment regimes 
and therefore, it is possible that mice were capable of transferring/protecting 
mice from disease through coprophagic behaviour. Therefore, when designing 
future experiments, mice will be housed separately to ensure the true incidence, 
without any other influencing factors, will be observed. It is known 
environmental factors can influence diabetes including viruses (Atkinson et al., 
1994, Drescher et al., 2004), bacteria (Wen et al., 2008, Hansen et al., 2012, 
Alkanani et al., 2014, Peng et al., 2014, Tormo-Badia et al., 2014), diet (Giulietti et 
al., 2004, Schmid et al., 2004, Marietta et al., 2013), the pH of drinking water (Sofi 
et al., 2014) etc. and therefore cohousing mice and transfer of microbiota may 
explain the diabetes observed in the mouse not treated with antibiotics.  
As observed previously, no female A22Cα-/-PI2-/- mice developed diabetes 
regardless of the antibiotic regime they received. This difference between the 
gender may have arisen due to the presence of sex hormones whereby in these 
mice oestrogen or progesterone may protect the females while testosterone may 
make the males more susceptible in contrast to the roles of these hormones in 
polyclonal NOD mice (Yurkovetskiy et al., 2013). Yurkovetskiy and colleagues also 
showed that androgens and gut microbiota are connected and that disease 
susceptibility can be altered through modifying these factors. In addition, these 
mice developing diabetes at 6 weeks correlates with the time they begin to 
sexually mature. Therefore, the gut microbiota may also be interacting with the 
hormones enabling preferential survival of diabetes causing/preventing bacteria. 
Unlike treatment with Vancomycin (Hansen et al., 2012), or with an antibiotic mix 
during pregnancy (Tormo-Badia et al., 2014), Baytril (containing enrofloxacin) 
treatment of mice has induced similar increases in incidence when mice were 
treated either neonatally or post-weaning. In addition, antibiotics administered 
during pregnancy were shown to increase diabetes incidence. Therefore, it is 
possible that the gut microbiota in these mice are different and that the 
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dominant, and potentially protective, Akkermansia muciniphila species in the 
Verrucomicrobia phylum is not found within these TCR restricted A22Cα-/-PI2-/- 
mice. Species identification would help resolve this question. 
5.7.3 BAYTRIL TREATMENT AND TCR REPERTOIRE  
To further explore the factors that contributed to the altered diabetes incidence, 
the TCR repertoire was examined to investigate whether expansion/deletion of a 
specific T cell population was involved in preventing or causing disease. The 
Peyer’s patches, MLNs and PLNs were isolated and investigated for the TCR 
repertoire. Interestingly, no differences were observed in the CD4+ or CD8+ T cell 
number and no differences were seen in the global CD8αβ+ TCR repertoire 
between any mice regardless of antibiotic treatment. Even though the TCRα 
chain is restricted, the T cells can still respond to a variety of antigens and it 
appears that the antibiotics are not having global effects on the TCR repertoire. 
However, it did not preclude small changes in antigen-specific populations i.e. 
bacteria-specific or insulin-specific T cells.  
CD8αβ+ T cells were also investigated for the expression of CD44 and CD62L, 
identifying subsets of memory T cells. Interestingly, increased numbers of 
CD44+CD62L+ central memory T cells but decreased numbers of CD44+CD62L- 
effector memory T cells were found in the MLN and PLN when compared to the 
Peyer’s patches. Given that M cells within the Peyer’s patches are constantly 
sampling the contents of the gut, it is not surprising that there are fewer central 
and more effector CD8αβ+ T cells in the Peyer’s patches. This increased activation 
within the Peyer’s patches may also stimulate antigen-specific T cells i.e insulin-
reactive T cells whether directly or indirectly. It is known that lymphocytes 
isolated from the gut-associated lymph nodes can transfer diabetes into 
immunocompromised NOD.scid mice (Jaakkola et al., 2003). Therefore, the 
insulin B15-23-reactive CD8+ T cells from the Peyer’s patches were further 
investigated.   
A similar number of insulin B15-23-reactive CD8αβ+ T cells were identified in all 
lymphoid tissues in all male mice regardless of antibiotic treatment. However, 
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there was a trend to decreasing insulin B15-23-reactive CD8+ T cells from the 
Peyer’s patches to the MLNs to the PLNs in mice not treated with antibiotics. In 
those treated with antibiotics, the numbers of insulin B15-23-reactive CD8+ T cells 
were similar between the Peyer’s patches and the MLN but reduced in the PLN. It 
was possible that these auto-reactive CD8+ T cells were trafficking from the 
Peyer’s patches/MLNs upon activation, noted to be important in the early stages 
of diabetogenic T cell development through a mucosal addressin molecule 
(Hänninen et al., 1998). However, investigation into the memory subset of these 
cells revealed similar low numbers of central and effector memory T cells across 
all tissues. Once again, this suggested that these T cells were being maintained 
peripherally at low levels and had encountered antigen but were difficult to 
activate/expand, as seen in Chapter 4. This may be due to a higher activation 
threshold for these T cells and therefore may only become activated upon 
increased antigen exposure. In addition, these T cells may be regulated effectively 
through the presence of regulatory cells. However, few mice have been studied 
and therefore more data are required to gain better insight into this 
phenomenon. 
It should also be noted that these data were generated from a comparison of 
mice diabetic at 6 weeks or upon termination at 12 weeks of age and thus have 
not developed diabetes. Therefore, there may be a greater difference between 6-
week old mice that do or do not develop diabetes and these mouse groups 
should be investigated in the future. 
5.7.4 BAYTRIL AND GUT MICROBIOTA 
In this study we showed that at 3 weeks of age (up to weaning), the differences in 
bacteria present in the different antibiotic treated cohorts, as analysed by a 
principal component analysis, are small. However, by 6 weeks, differences 
emerged between the treatment groups, with the majority of mice in the 
different groups clustered together. Given that the antibiotic administered 
affects both Gram-positive and Gram-negative bacteria it is not surprising that 
there were differences in the gut microbiota between the groups. Even more 
interesting was that the diabetic mice tended to fall within the same area 
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suggesting that these mice had similar bacteria present. Therefore, this shows 
that the bacteria present within these mice are likely to be important in the 
development of diabetes. However, whether the bacteria have a direct or 
indirect role in T cell activation has yet to be identified.  
There was more gut bacterial diversity at the phylum level in the mice at 3 weeks. 
However, as these mice reached 6 weeks they had a significant decrease in 
diversity with approximately 90% of the bacteria identified to be members of the 
phylum firmicutes. This effect was found to be antibiotic independent and 
therefore suggests it is either due to the TCRα chain restriction enforced in these 
A22Cα-/-PI2-/- mice or due to the lack of proinsulin 2. Both of these factors raise 
interesting questions as it has been reported that, to maintain health, a diverse 
TCR repertoire is required and therefore if the repertoire is restricted, control of 
the bacterial composition may be affected. In addition, gut microbiota are 
required to maintain health and when the bacterial diversity is greatly reduced it 
can increase insulitis in germ-free NOD mice (Alam et al., 2011). This may be why 
the firmicutes increase dramatically as the immune system is less able to control 
the bacteria. Alternatively, proinsulin 2 may be important for the survival of 
bacteria from a metabolic point of view. While proinsulin 1 is largely expressed in 
the periphery, proinsulin 2 is believed to be important in tolerance. However, 
NOD mice deficient in proinsulin 1 do not develop metabolic or autoimmune 
diabetes and therefore proinsulin 2 must also be metabolically active. Thus, 
bacteria may require insulin for signalling and growth or the innate immune 
system may require insulin signalling to function accordingly.  
The phylum firmicutes contains many species, some of which are known to be 
protective and others which may be more damaging. Within the phylum 
firmicutes are probiotic bacteria including lactobacillus. Therefore, it is possible 
that these also expand to prevent T cells from causing diabetes. Lactobacillus 
casei, VSL#3 (containing Lactobacilli) and genetically-modified Lactobacillus lactis 
secreting human proinsulin or GAD65 have all been shown to be important in 
reducing diabetes incidence and reverting pre-existing diabetes (Matsuzaki et al., 
1997, Calcinaro et al., 2005, Takiishi et al., 2012, Robert et al., 2014). However, 
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identifying causal or protective bacteria would be important in order to devise a 
more successful therapeutic treatment, minimising the activation of diabetogenic 
T cells while increasing the regulation of these cells.   
Alternatively, if a species of firmicutes were expanding within the gut of these 
mice due to an inability of the immune system to effectively target these 
bacteria, it is possible they could be damaging the gut wall and thus making it 
leakier. This could allow auto-antigens to escape and be presented to T cells and 
stimulate the immune processes leading to the activation of diabetogenic T cells. 
However, as yet, we have no data to support this. 
As previously mentioned, Vancomycin treatment of NOD mice created a 
dominant Akkermansia muciniphila species in the Verrucomicrobia phylum 
(Hansen et al., 2012), however, this was not found in these TCR restricted A22Cα-
/-PI2-/- mice. As the antibiotics have different mechanisms of action, it may not be 
surprising to have different dominant species. Therefore, it may be worth in 
future investigating the role of other antibiotic treatments on the development of 
insulin B15-23-reactive CD8+ T cells, the gut microbiota and diabetes. 
While it has been reported the pH of drinking water can affect the gut microbiota 
and incidence of autoimmune diabetes (Sofi et al., 2014), it is unlikely to have any 
effect in our study as all mice received the same water. 
5.7.5 IMPAIRED GLUCOSE TOLERANCE IN MALE MICE 
Gut bacteria have numerous roles in metabolism. The restricted gut microbiota 
present in these single chain TRAV8-1*01TRAJ9 transgenic mice may have 
exerted a metabolic effect. Therefore, we tested the response of these mice to a 
glucose challenge, requiring the production and secretion of insulin from the 
pancreas in order to maintain homeostasis. 
Using intraperitoneal glucose tolerance tests, it was shown that the male and 
female polyclonal NOD mice responded well and were capable of reducing their 
blood glucose within 30 minutes. However, in the single chain TRAV8-1*01TRAJ9 
transgenic NOD mice deficient in proinsulin 2, there was a difference in the 
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metabolic response between males and females, with younger male mice 
appearing to have reduced functional response. This suggested that it was not 
the TCR restriction that was causing an impaired glucose response. However, it 
does suggest that androgens may be important factors and, as seen previously, it 
may be that the difference in gut microbiota may also be responsible. It has 
previously been shown in NOD mice that gut bacteria, androgens and the 
immune system are all important factors in shaping the onset of diabetes. It is 
not surprising that the A22Cα-/-PI2-/- mice, which may develop diabetes were the 
ones that had a less efficient response to a glucose challenge. This may be due to 
a lack of proinsulin 2 in these mice resulting in less insulin being produced; 
however, the female mice do not have any metabolic defects. Most likely, as 
these mice develop diabetes, they may already have infiltration in the pancreas 
and therefore there may be fewer insulin producing cells available. As Chapter 3 
showed, there was some infiltration in the A22Cα-/-PI2-/- male mice; however, it 
was unlike NOD infiltration that is quite robust. In addition, pups born to NOD 
mice that had been treated in pregnancy, had fewer islets infiltrated compared to 
NOD litters that had not received any antibiotics (Tormo-Badia et al., 2014). 
Therefore, it is highly likely that both of these contribute to the male A22Cα-/-PI2-
/- mice developing diabetes. 
Also, it may be possible that the β cells in the pancreas produce a lower amount 
of insulin. However, currently, there is no data to suggest this or any factors that 
may reduce insulin production other than β cell destruction. 
Gut microbiota can produce short chain fatty acids to be used by the host as an 
energy source through the receptor GPR43, which can suppress insulin-mediated 
fat accumulation (Kimura et al., 2013). However, in this study we have altered the 
gut microbiota and therefore it is possible that lower amounts of short chain fatty 
acids are made by the restricted bacteria resulting in greater fat deposition and 
thus insulin resistance. While the male mice are marginally larger than the 
females, no studies have been carried out on the fat or fatty acid chains in these 
mice. 
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Interestingly, treatment with the antibiotics, ampicillin, neomycin and 
metronidazole in Swiss mice revealed a decrease in the firmicutes and 
bacteroidetes phyla resulting in increased insulin signalling and sensitivity 
(Carvalho et al., 2012). In the A22Cα-/-PI2-/- mice, firmicutes were shown to be 
dominant, encompassing over 90% of the detectable microbiota; therefore the 
presence of these bacteria, through contact or secretary mechanisms, may also 
be making the mice less glucose tolerant. However, for future work, insulin 
measurements as part of the glucose tolerance tests as well as insulin tolerance 
tests should be performed, which will provide more information on this 
phenomenon.  
5.7.6 SUMMARY 
As discussed in Chapter 5, the administration of antibiotics appears to increase 
the incidence of diabetes by altering the gut microbiota, but does not affect the 
TCR repertoire. In addition, it is highly likely that androgens such as testosterone 
are also involved. However, as of yet, the role of the microbiota and androgens in 
the activation of the insulin B15-23-reactive CD8+ T cells is not fully understood 
and therefore warrants further investigation. 
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CHAPTER 6: FINAL DISCUSSION AND FUTURE WORK 
 
6.1 THESIS RESULTS SUMMARY 
The aim of this work was to investigate the development of insulin B15-23-
reactive CD8+ T cells in different proinsulin-expressing single chain TCRα (TRAV8-
1*01TRAJ9) transgenic NOD mice. Initial studies revealed phenotypic differences 
in the TRBV repertoire, particularly in relation to TRBV19, the same TRBV chain 
utilised by the insulin B15-23-reactive G9 T cell clone (Wong et al., 1996). Further 
investigation into the TRBV repertoire of the insulin B15-23-reactive T cells 
revealed individual clonal expansions, with minimal CDR3 sequence overlap 
between the different proinsulin-expressing mice. In addition, proinsulin 
expression did not affect the total proportion of insulin B15-23-reactive T cells.  
The role of proinsulin expression in shaping the functional ability of the insulin 
B15-23-reactive T cells was subsequently assessed using proliferation, cytokine 
production and cytotoxicity assays. However, due to the low frequency of insulin 
B15-23-reactive T cells, peptide-specific responses could not be detected in the 
proinsulin-expressing single chain TCRα (TRAV8-1*01TRAJ9) transgenic NOD 
mice, above the level of assay sensitivity. Therefore, TRBV19+CD8+ T cells were 
expanded in vitro and cloned by limiting dilution. Interestingly, the majority of 
(oligo)clonal T cell lines utilised TRBJ2-3 (the same junctional region found in the 
G9C8 clone from which the TCRα chain was derived), in conjunction with TRBV19, 
indicating the importance of this configuration in the TCR pairing for insulin B15-
23 recognition. In addition, while a minority of (oligo)clonal lines responded at 
lower concentrations of insulin B15-23 peptide, most were shown to be of low 
functional avidity, regardless of proinsulin expression, if they express TRBV19. 
This was demonstrated in Chapter 4 where the T cell (oligo)clonal T cells 
responded to antigen, only at high peptide concentrations (1-5μg/ml peptide). 
The result suggested that the TCR interaction with p:MHC was weak, resulting in 
low T cell activity, indicating low functional avidity of the p:MHC:TCR interaction. 
However, while these T cell responses were low, it may not be related to avidity, 
it could be that these T cells, having been expanded and grown with peptide, may 
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be more tolerised to the insulin B15-23 peptide, than the directly ex vivo isolated 
insulin B15-23-reactive T cells and therefore these T cells, when assessed, exhibit 
low functional activity to peptide below 1μg/ml. The different proinsulin-
expressing single chain TCRα (TRAV8-1*01TRAJ9) transgenic NOD mice did not, in 
general develop autoimmune diabetes. However, 25% of male proinsulin 2 
deficient mice developed spontaneous autoimmune diabetes. There were a 
number of possible explanations for this. One possibility was that the insulin-
reactive T cells were more functionally active. Another was that higher avidity T 
cells were present, although there is no current data to support this. A further 
suggestion could be that due to the expansion of different immunodominant 
insulin B15-23-reactive CD8+ T cells in each different proinsulin-expressing mouse 
that some T cells may be able to overcome tolerance easier. Further 
investigations into the development of autoimmune diabetes in these mice 
revealed antibiotic-mediated effects on gut microbiota were capable of 
influencing the development of diabetes, independent of TCR repertoire. In 
addition, the role of proinsulin 2, while important for thymic and peripheral 
selection is also important metabolically. This was demonstrated in the single 
chain TCRα (TRAV8-1*01TRAJ9) transgenic NOD mice deficient in proinsulin 2 in 
Chapter 5 in relation to the intraperitoneal glucose tolerance tests. This showed 
that NOD male and female mice, and the female single chain TCRα NOD 
transgenic mice deficient in proinsulin 2 were able to control their blood glucose 
sufficiently below the threshold for diabetes within 30-60 minutes. However, in 
the male single chain TCRα NOD transgenic mice deficient in proinsulin 2, they 
were not able to reduce their blood glucose, following a glucose bolus, below the 
threshold for diabetes by 90 minutes, indicating signs of glucose intolerance. This 
may be due to a lack of insulin secretion and therefore an inability to quickly 
control the glucose bolus or it may be due to a form of insulin-resistance present 
in these mice, which results in the insulin not working as effectively on the target 
tissues and therefore it takes more insulin to be produced to enable the glucose 
uptake. However, insulin levels in this study were not investigated and therefore 
the precise reason for these mice having signs of glucose intolerance is unknown. 
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Thus the work in this thesis has suggested that proinsulin expression alters the 
functional status of insulin B15-23-reactive CD8+ T cells, independently of TCR 
repertoire, with individual TCRβ chain clonal expansions identified in each mouse. 
This data indicates other mechanisms impacting the development of insulin B15-
23 auto-reactivity other than antigen expression exist and may include a role for 
gut microbiota. 
6.2 THESIS RESULTS FUTURE WORK 
6.2.1 THE ROLE OF PROINSULIN EXPRESSION 
Proinsulin is a precursor protein of the metabolically active hormone insulin. NOD 
mice express two proinsulin proteins called proinsulin 1 and 2, which only vary by 
2 amino acids in the B chain and 3 amino acids in the C chain. Proinsulin 2 is 
believed to be important in inducing tolerance, as NOD mice lacking proinsulin 2 
develop robust accelerated diabetes (Thébault-Baumont et al., 2003) and 
proinsulin 2 expression is capable of reducing and preventing diabetes (French et 
al., 1997, Faideau et al., 2004, Faideau et al., 2006). On the other hand, proinsulin 
1 deficiency prevents the development of diabetes (Moriyama et al., 2003) 
believed to be mediated by the difference in the location of the expression of the 
two genes. This study, in agreement with other work, showed proinsulin 2 is 
predominantly expressed within the thymus with lower levels of proinsulin 1 
(Chentoufi and Polychronakos, 2002, Chentoufi et al., 2004, Palumbo et al., 
2006); however, some report that proinsulin 1 is not expressed in the thymus 
(Deltour et al., 1993, Derbinski et al., 2005, Nakayama et al., 2005b). Yet, all agree 
that both proinsulin 1 and 2 are expressed in the pancreas. 
This study is the first antigen-specific study investigating how antigen expression 
affects the development of Insulin-reactive T cells at both a TCR repertoire and 
functional level. This study has shown that both proinsulin 1 and 2 are important 
in shaping TCR repertoire. Native proinsulin expression and proinsulin 2 over-
expression induced decreases in the TRBV19 chain usage on a global repertoire 
basis. In addition, when mice were deficient in either proinsulin 1 or 2, the 
proportion of TRBV19+ CD8+ T cells was increased. However, while this data 
shows an importance of proinsulin expression in TCR repertoire composition, only 
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the proinsulin 2 deficient mice developed diabetes. In this study there appeared 
to be no functional differences in T cell responses to insulin B15-23 peptide, but 
only those T cells expressing TRBV19 were evaluated. However, functional 
investigations in the clonotypic G9 TCRαβ transgenic mouse revealed that when 
proinsulin 1 and 2 are lacking and the G9 T cells develop in the absence of 
proinsulin that cells can recognise (due to the mutation in the proinsulin 
transgene (Nakayama et al., 2005a)), they exhibit the greatest insulin B15-23 
proliferative and cytotoxic response, closely followed by proinsulin 2 deficient 
mice and then the native proinsulin-expressing G9 mice (Terri Thayer, personal 
communication, manuscript in progress). This data highlights the importance of 
these models in assessing the development of antigen-specific T cell populations. 
However, understanding how proinsulin 1 deficiency affects the G9 T cells will 
need to be investigated. 
In this study, utilising single chain TCRα transgenic NOD mice (using the TCRα 
chain from the G9C8 clone) and in the study involving G9 TCRαβ double 
transgenic mice, all crossed to various proinsulin-expressing backgrounds, it has 
been shown proinsulin expression is capable of affecting the development of 
these T cells and their ability to cause diabetes. By focusing on a single T cell 
clone, as in the G9C8 transgenic NOD mice, larger functional T cell differences, 
from the different proinsulin-expressing mice, could be seen in response to 
peptide; however, in both this study and the G9 transgenic mouse study only 
mice deficient in proinsulin 2 developed spontaneous diabetes. While the single 
chain TCRα transgenic NOD mice studies reported here revealed that multiple 
insulin B15-23-reactive CD8+ TCRβ chains could be used for antigen recognition, 
functional differences in the insulin-reactive CD8+ T cells could not be detected in 
this study between the different proinsulin-expressing mice. This may be due to 
the presence of multiple insulin B15-23-reactive T cells, which due to the various 
TCRβ chains they express, may recognise antigen differently and therefore 
respond in a different manner to the single T cell clone in the G9 TCR transgenic 
mouse work. However, no study to date has investigated the insulin-reactive 
CD8+ T cell populations in polyclonal mice. Therefore for continued work in this 
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field, polyclonal NOD mice expressing proinsulin 1 and/or proinsulin 2, and 
proinsulin 1 and 2 deficient mice, should be investigated for their TCR repertoire, 
and the presence of other antigen-specific T cells in order to gain insight into how 
antigen-expression affects insulin-specific CD8+ T cells (both Insulin B15-23 and 
Insulin A14-20 (Wong et al., 1996, Lamont et al., 2014)) and how this 
subsequently affects other non-insulin auto-reactive CD8+ T cell populations such 
as IGRP (Lieberman et al., 2003), which are dependent on insulin autoimmunity 
(Krishnamurthy et al., 2008), over time. For CD8+ T cells, MHC:tetramers can be 
used to ask such questions; however, for CD4+ T cells, there are few tetramers 
available. 
In this study, proinsulin-specific effects on TCR repertoire changes were found at 
a global T cell level. However, how does this expression of proinsulin 1 and 2 
affect the repertoire? In relation to TRBV19 expression, a proportional reduction 
with age in those mice expressing native proinsulin or over-expressing proinsulin 
2 would suggest that those CD8+ T cells are likely to have been deleted. This may 
suggest both proinsulin 1 and 2 have tolerogenic properties - if proinsulin 2 was 
solely responsible for tolerance, then the TRBV19+ CD8+ T cell proportion in the 
single chain TCRα transgenic NOD mice deficient in proinsulin 1 would have been 
reduced to a similar level seen in the native proinsulin-expressing mice. This 
suggests that both proinsulin 1 and 2 ensure protection from insulin B15-23 
autoimmunity and may act either additively or independently from each other. 
However, proinsulin expression may mediate functional tolerogenic effects and 
therefore not detected by TCR repertoire. These could include induction of 
anergy, where the T cell is unresponsive to antigen. Therefore, while we have 
only seen a small number of TCR repertoire effects, it is possible that other forms 
of tolerance are operating and therefore the total effect of proinsulin expression 
on tolerance cannot be assessed in this study. While some studies, including this 
one, have identified a tolerogenic role for proinsulin 2 (Chentoufi and 
Polychronakos, 2002, French et al., 1997, Jaeckel et al., 2004, Thébault-Baumont 
et al., 2003), the role of proinsulin 1 has not been fully established. The only 
investigation in NOD mice showed that proinsulin 1 deficient mice are protected 
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from the development of diabetes (Moriyama et al., 2003). Interestingly, on a 
non-autoimmune background (129/SV), mice deficient in proinsulin 2, showed 
increased insulin 1 gene transcripts as well as increased beta cell mass to 
compensate for lower insulin production, indicating the importance of proinsulin 
1 in metabolism (Leroux et al., 2001). In addition, in NOD mice, proinsulin 1 and 2 
peptide immunisations identified proinsulin 1-reactive T cells cross-reacted with 
proinsulin 2 epitopes and vice versa, with proinsulin 2 9-23 (B chain) peptide able 
to induce proliferation in proinsulin 1-reactive NOD T cells and proinsulin 1 9-23 
and 49-66 (C chain) peptides able to induce proliferation of proinsulin 2-reactive 
NOD T cells (Jaeckel et al., 2004). This suggested that these TCRs are selected for 
by proinsulin 2 and that both proinsulins can facilitate proinsulin-specific 
populations to be expanded. In addition, work by Halbout and colleagues 
identified even more proinsulin 1 epitopes in NOD mice following peptide 
immunisation (Halbout et al., 2002). Therefore further work to assess the relative 
contributions of both proinsulin 1 and 2 in shaping tolerance and diabetogenicity 
of insulin B15-23-reactive CD8+ T cells is needed. 
In addition to this work investigating the repertoire and antigen-specific 
populations, further qPCR work would need to be done to study the level of 
proinsulin 1 and 2 in all the mutated mice, including those deficient in either or 
both proinsulin genes. This may identify if there is a required threshold for the 
level of proinsulin expressed in order to mediate tolerogenic effects. Additionally, 
it may identify a role for proinsulin 1 in shaping the diabetogenic TCR repertoire 
and may elucidate which antigen-specific populations, if any, are affected by 
proinsulin 1 expression.  
While investigations into genetically modified polyclonal mice that express 
proinsulin 1 and/or 2 genes would reveal how auto-reactive T cell populations 
develop, further understanding in this area may be helped by the generation of 
mice containing proinsulin genes under controlled reporter genes. By switching 
on or turning off the proinsulin genes, it would enable us to understand how 
these T cells develop and how they may be manipulated post-development to 
alter the auto-reactive T cell development.  
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6.2.2 THE ROLE OF MICROBIOTA IN INSULIN B15-23 AUTOIMMUNITY 
Gut microbiota play a role in both health and disease (reviewed by (Sekirov et al., 
2010). For maintenance of health, a diverse gut microbiota is beneficial and when 
the gut microbiota is imbalanced, opportunistic pathogens can cause infections. 
Through gut microbial interactions with the innate immune system, tolerance 
and protection can be generated to commensals and potential pathogens. 
Interestingly, some studies have shown that gut microbiota may be causal or 
protective in disease and autoimmunity and genetic manipulation of these 
bacteria may enhance protective responses (Matsuzaki et al., 1997, Calcinaro et 
al., 2005, Takiishi et al., 2012, Robert et al., 2014). In addition, the gut microbiota 
can be altered through defects in the innate immune system such as TLRs and 
their signalling molecules (Echchannaoui et al., 2002, Wooten et al., 2002, Wen et 
al., 2008, Peng et al., 2014). In addition, there are broad effects on microbiota 
through treatment with antibiotics (Hansen et al., 2012) and the presence of 
androgens (Yurkovetskiy et al., 2013, Markle et al., 2013a). Antibiotic effects can 
be caused both by broad-spectrum agents, whereby both Gram-positive and 
Gram-negative bacteria are affected or they can more specifically target 
individual types of bacteria. However the antibiotics work, they reduce the 
particular bacteria, disrupting the natural homeostasis of commensal bacteria, 
enabling other bacteria to compete to fill the space. On the other hand, 
androgens enable the preferential survival and expansion of particular bacteria 
over others. Therefore, both antibiotic and androgen mediated effects on the 
microbiota may then disrupt the TLR signalling on the innate immune and 
subsequently may change their function from pro-tolerogenic to pathogenic or 
vice versa. In addition, the altered bacteria may produce new molecules, which 
mimic self-antigens. These may then be presented to antigen-specific T cells, 
which may cross-react with the self-antigen, leading to the destruction of the 
bacteria and self-antigen expressing cells, referred to as molecular mimicry. In 
addition, the bacteria may non-specifically induce a proinflammatory 
environment leading to bystander activation of the T cells, which, when 
activated, may promote antigen-specific T cell effects leading to recognition of 
self-antigen targets. 
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In the study reported in this thesis, treatment of single chain TCRα transgenic 
NOD mice deficient in proinsulin 2, with an enrofloxacin-containing antibiotic 
known as Baytril, was used. This increased the incidence of diabetes in the male 
proinsulin 2 deficient mice, while not affecting the lack of diabetes in the female 
mice. Further investigations, revealed the development of diabetes was 
independent of TCR repertoire and insulin B15-23-reactive T cells but partly 
dependent on gut microbiota changes by 6 weeks, as diabetic mice had similar 
gut microbiota in comparison to those non-diabetic. As the principal component 
analysis data showed in Chapter 5, the majority of diabetic mice at 6 weeks were 
found to cluster together and therefore have similar gut bacteria to one another. 
At that point, the results suggested that the gut bacteria were involved in 
increasing the incidence of diabetes. However, if the diabetic mice were also 
found to have similar bacteria to the non-diabetic mice then it would have been 
less likely that the increase in diabetes incidence was caused by bacteria. By 
sequencing the gut microbiota, significant expansion of the Firmicutes phylum 
and a marked decrease in gut microbial diversity was seen with age in all the 
mice. Interestingly, the male proinsulin 2 deficient single TCRα chain transgenic 
NOD mice were also generally shown to be glucose intolerant. Therefore, gender, 
metabolism and the microbiota appeared to be interconnected in shaping the 
development of insulin autoimmunity in an indirect manner. 
To further investigate the findings, more single chain TRAV8-1*01TRAJ9 
transgenic NOD mice deficient in proinsulin 2 should be studied, increasing the 
numbers. Additionally, in the experiments shown in this thesis, while some male 
mice were investigated for the number of insulin B15-23-reactive T cells, female 
mice were not investigated. Although no difference was noted in the number of 
insulin B15-23-reactive T cells between the male mice whether they were or were 
not treated with antibiotics, there may be a functional difference identified when 
male and female mice are compared. This also links with previous work 
identifying gender biases in the microbiota caused by the presence of androgens 
(Yurkovetskiy et al., 2013, Markle et al., 2013a). In the present study both male 
and female mice had similar gut microbiota composition, with the diabetic mice 
231 
 
exhibiting different microbial composition. In addition, this study looked at 
restricted TCRα chain transgenic mice, and therefore is not fully comparable to 
studies investigating the effects in polyclonal mice. Furthermore, as the total 
number of CD8+ T cells was unaffected by treatment with antibiotics, it suggests 
other innate immune cells or regulatory cells may be directly affected by 
antibiotic treatment and therefore other cell populations will need to be 
investigated.  
As mentioned, a proportion of male proinsulin 2 deficient mice developed 
diabetes; however, it is unknown whether the development of diabetes was 
mediated by T cells expressing the G9 TCRβ chain or other TCRβ chains. 
Therefore, investigations into which specific T cell clone(s) are affected by 
antibiotic administration should be identified to address whether this is an effect 
on all insulin B15-23-reactive T cells or an effect mediated by a specific-TCR, 
perhaps recognising a bacterial component due to TCR cross-reactivity. To assess 
this G9 TCR transgenic mice deficient in proinsulin 2 could be investigated, 
identifying whether T cells exhibiting a single TCR are similarly influenced by 
antibiotic administration.  
While bacterial sequencing revealed that bacteria from the phylum firmicutes 
were increased with age and this was the predominant phylum in all mice, 
irrespective of antibiotic treatment, sequencing at the species level was not 
carried out. Therefore, further work investigating the species present may help to 
identify the presence of bacteria with known probiotic activity while also 
providing information on which bacterial species are expanding or decreasing and 
whether that is different in those developing diabetes and not. In addition, 
bacterial transfer studies could also be carried out for direct causal roles in 
shaping the auto-reactive environment, similar to the work by Peng and 
colleagues (Peng et al., 2014). 
Having shown that some male mice, deficient in proinsulin 2, were glucose 
intolerant, this phenomenon should also be further investigated. In addition to 
glucose tolerance, measurements of insulin levels would be important (this had 
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been attempted but the sensitivity of the assay was insufficient to give conclusive 
results), as well as insulin tolerance tests. These measurements coupled with an 
in-depth histology study, would provide information on if insulin production is 
decreased in the male mice compared to females, and if the lack of proinsulin 2 
reduces the number of islets that develop as well as the degree of infiltration in 
these mice, confirming if these mice have an intrinsic insulin deficiency or some 
degree of insulin resistance. In addition, bacterial species sequencing may also 
identify bacteria that affect metabolism and therefore, the level of insulin 
produced or degree of insulin resistance may be affected by the presence of 
particular microbiota (Caricilli et al., 2011, Carvalho et al., 2012).  
In addition, while this work has focussed on the use of an enrofloxacin containing 
antibiotic, which has a large impact on both the Gram-positive and Gram-
negative bacteria, other antibiotics, such as Vancomycin (Hansen et al., 2012), 
may be utilised in the future to gain better insight into the collection of 
microbiota present in the gut. This may also enable larger collections of bacteria 
to be investigated to see if and how they may alter disease development. 
While this work is the first to investigate Insulin B15-23-reactive CD8+ T cells, 
specifically in relation to the effect of gut microbiota on shaping the auto-reactive 
environment and diabetes, more work needs to be done to identify if the insulin 
B15-23-reactive T cells have a direct or indirect role in the onset of diabetes both 
in these mice and in TCR polyclonal mice.  
6.2.3 FINAL SUMMARY 
While it was initially hypothesized that proinsulin expression would alter the 
repertoire of insulin B15-23-reactive CD8+ T cells and their functional ability to 
respond to insulin peptide, we did not observe any antigen-specific T cell 
repertoire changes; however, there were functional changes associated with the 
ability to cause diabetes when proinsulin 2 was deficient. Furthermore, we found 
different insulin B15-23-reactive CD8+ T cell clonal immunodominance in the 
different proinsulin-expressing mice, with minimal shared clones, due to different 
CDR3 sequences, identified between them. This suggests, while proinsulin 
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expression is important in aiding thymic negative selection and peripheral 
selection on a global TCR level, that the specific clonal expansion is independent 
of proinsulin expression. Interestingly, proinsulin 2 over-expression has been able 
to reduce and prevent diabetes (French et al., 1997, Jaeckel et al., 2004), as seen 
in this study. However, a minority of mice were still able to develop spontaneous 
diabetes, albeit at a much later time point (Jaeckel et al., 2004). This suggests that 
while proinsulin expression may shape tolerance, there are still auto-reactive T 
cells that escape and become activated. Therefore, in order to develop a therapy 
targeting these insulin B15-23-reactive CD8+ T cells, other mechanisms 
influencing clonal selection operate in the periphery and need to be identified. In 
mice expressing an artificial self-antigen, such as those expressing ovalbumin, T 
cells can escape central tolerance and only become active when antigen 
expression is increased. Zehn and Bevan showed this when they expressed ova 
peptide in Listeria and infected a group of mice (Zehn and Bevan, 2006). While 
bacterial infection with Listeria alone, without the self-antigen, was unable to 
cause disease, the infection with ovalbumin-expressing Listeria may have 
changed the context in which the artificial self-antigen (ovalbumin) was 
expressed in and thus trigger disease. Therefore, self-antigen expression in an 
artificial self-antigen system may influence selection but other factors may 
mediate post-selection development or function. However, it is important to 
remember that each TCR potentially recognises different antigens, with a 
different strength of interaction with the p:MHC and therefore what may affect 
one TCR may not be directly translatable to another. In this study, we showed the 
sequence of the TCR of the insulin B15-23-reactive T cells were individual to each 
mouse and therefore, while antigen expression (i.e. proinsulin) may not affect the 
TCR repertoire selection overall in these mice, it may not be the same for other 
TCRs. In addition, while it is possible the level of antigen is capable of changing 
the function of the T cells, only TRBV19 expressing insulin B15-23-reactive T cells 
were investigated here and proinsulin expression did not appear to affect the 
function of those. However, how proinsulin expression affects the other insulin 
B15-23-reactive TRBV expressing T cells remains to be studied. Therefore any 
future work requires the level of antigen expression on individual TCRs to be 
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investigated, as each TCR is different, whether functionally or from a TCR 
repertoire perspective. 
While the diabetes incidence in the mice that were deficient in proinsulin 2 was 
affected by antibiotics, it still remains unknown as to the exact reason for the 
increase in diabetes incidence. While initial observations were made that 
antibiotic administration to the breeders during pregnancy, or from birth, did not 
affect the diabetes incidence, it is possible that there are other immunological 
changes dependent on when antibiotics are administered (Tormo-Badia et al., 
2014). While this study used an enrofloxacin-containing antibiotic, other 
antibiotics, may have a greater or a lesser impact on the development of 
autoimmunity in these mice. Therefore, it is important to identify the specific 
affects the antibiotics have and how that specifically affects antigen-specific 
populations leading to the onset of or protection from autoimmunity or disease. 
In this study it was known that diabetes only occurred in male mice from 
approximately 6 weeks, coinciding with the time the mice reached sexual 
maturity, therefore, while it still remains untested, it is likely androgens have 
some effect on the diabetes incidence in this study, as observed by others 
(Yurkovetskiy et al., 2013, Markle et al., 2013a). While this gut microbiota 
mediated study has begun investigations into the shaping of insulin B15-23-
reactive T cells, there is still much more work to be done. However, if bacterial 
species can be identified that are capable of mediating protective or activating T 
cell responses, then targeted specific therapies, through antibiotic administration 
or probiotic-containing drinks may be developed enabling the beneficial bacteria 
to boost T cell immunoregulation and thus delay, reduce or prevent diabetes.  
Finally, together this data provides an insight into the development of insulin 
B15-23-reactive T cells, utilising a single TCRα chain, which only when coupled to 
TRBV19, do we see any TCR repertoire selection effects. However, clonal 
expansion is individual, and therefore, while antigen expression is important; 
other mechanisms of control are involved in shaping the insulin B15-23 
autoimmunity. Therefore, these mechanisms need to be identified in order to 
develop therapeutic strategies capable of preventing the onset of insulin B15-23 
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reactivity. This will not only be beneficial from an animal model perspective but 
may be similar in human disease, providing key insights into preventing diabetes. 
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CHAPTER 7: APPENDIX 
7.1 APPENDIX TABLES 
 
 
TABLE 25: SIGNIFICANT DIFFERENCES BETWEEN SINGLE CHAIN TRANSGENIC 
TRAV8-1*01TRAJ9 NOD MICE EXPRESSING TRBV19 IN MICE WITH VARYING 
LEVELS OF PROINSULIN 
 
 
 
 
AGE 
(WEEKS) 
STRAIN NAME DIFFERENT TO TISSUE P VALUE 
 
 
 
4-6 
 
 
 
 
 
 
 
 
 
 
A22Cα-/-PI2tg 
A22Cα-/- PLN 0.0000004 
A22Cα-/-PI1-/- PLN 0.0000001 
A22Cα-/-PI2-/- PLN 0.0000009 
A22Cα-/-PI1-/-PI2-/-Y16Atg PLN 0.0000000 
A22Cα-/- MLN 0.0000000 
A22Cα-/-PI1-/- MLN 0.0000000 
A22Cα-/-PI2-/- MLN 0.0000001 
A22Cα-/-PI1-/-PI2-/-Y16Atg MLN 0.0000000 
 
 
 
 
 
 
11-16 
 
 
 
 
 
 
 
A22Cα-/-PI1-/- Thymus 0.0000008 
A22Cα-/-PI2-/- Thymus 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg Thymus 0.0000000 
A22Cα-/- Spleen 0.0000000 
A22Cα-/-PI1-/- Spleen 0.0000000 
A22Cα-/-PI2-/- Spleen 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg Spleen 0.0000000 
A22Cα-/-PI1-/- PLN 0.0000000 
A22Cα-/-PI2-/- PLN 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg PLN 0.0000000 
A22Cα-/-PI1-/- MLN 0.0000000 
A22Cα-/-PI2-/- MLN 0.0000000 
A22Cα-/-PI1-/-PI2-/-Y16Atg MLN 0.0000000 
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TABLE 26: PLN CD8αβ+ TRBV REPERTOIRE IN SINGLE CHAIN TRAV8-1*01 TRANSGENIC NOD MICE DEFICIENT IN PROINSULIN 2 SHOWN BY 
ANTIBIOTIC TREATMENT AND GENDER 
Data were collated from CD8αβ+ TRBV repertoire staining of the PLN (pancreatic lymph nodes) from single chain TRAV8-1*01TRAJ9 NOD 
transgenic mice deficient in proinsulin 2. Data shown is representative of 4-7 mice per group except the two diabetic groups (in red) which 
compile data from 1-3 mice. n/a = data unavailable. No differences were found between any of the groups or genders.
ANTIBIOTIC 
TREATMENT 
SEX TRBV 
1 
TRBV 
2 
TRBV 
4 
TRBV 
12 
TRBV 
13 
TRBV 
14 
TRBV 
15 
TRBV 
16 
TRBV 
17 
TRBV 
19 
TRBV 
24 
TRBV 
26 
TRBV 
29 
TRBV 
31 
PRE-
WEANING 
POST-
WEANING 
ON ON M 194 236 1214 367 2841 292 160 312 72 1709 1 215 12 480 
ON ON F 295 267 1289 351 2895 290 98 305 73 1741 6 208 22 514 
ON OFF M n/a 268 1232 345 2877 307 153 319 70 1679 1 224 14 458 
ON OFF F 377 267 1258 328 2932 307 176 297 60 1712 5 185 26 502 
ON/OFF ON M 230 313 1118 363 2948 331 158 354 59 1738 2 218 7 457 
ON/OFF ON F 266 313 1223 329 2906 298 166 316 72 1763 4 194 6 496 
ON/OFF OFF M 197 317 1173 341 2933 288 142 338 71 1792 6 230 6 467 
ON/OFF OFF F 309 291 1244 325 2858 304 163 308 64 1746 4 210 13 513 
OFF ON M 287 263 1158 356 2643 292 165 328 71 1776 1 227 8 479 
OFF ON M 130 258 1078 374 2706 293 172 368 89 1704 1 216 10 445 
OFF ON F 214 271 1280 338 3001 286 172 290 69 1745 4 205 18 469 
OFF OFF M 262 252 1199 360 2746 280 165 334 67 1721 3 206 16 483 
OFF OFF M 193 280 1173 357 2746 304 176 364 58 1802 2 208 14 447 
OFF OFF F 245 289 1263 321 2815 292 173 300 60 1729 4 199 24 505 
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7.2 APPENDIX FIGURES 
 
FIGURE 42: THYMOCYTE AND SPLENOCYTE TOTAL CELL COUNTS IN SINGLE 
CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING 
PROINSULIN LEVELS AT 8-10 WEEKS OF AGE 
 
 
 
 
 
 
 
 
 
 
 
KEY 
 
 
FIGURE 42: Thymocyte and splenocyte cells were harvested and homogenised. 
The red blood cells were lysed in the splenocyte populations and the splenocytes 
resuspended in 10mls FACS Buffer for counting. Cell number was determined 
through exclusion of non-viable cells by Trypan blue using a haemocytometer. 
Data were analysed by ANOVA using R software. Data shown were not significant 
at the p=<0.01 level. Each dot represents an individual mouse with the horizontal 
lines indicating the mean. 
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FIGURE 43: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software. 
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FIGURE 43: CD8+TRBV1+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 44: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software.
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FIGURE 44: CD8+TRBV2+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 45: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software. 
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FIGURE 45: CD8+TRBV12+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 46: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software. 
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FIGURE 46: CD8+TRBV13+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 47: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software.
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FIGURE 47: CD8+TRBV14+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
 
 
 
 
 
 
 
 
**  
A22Cα
-/-
 A22Cα
-/-
PI2
tg
 
A22Cα-/-PI1-/-PI2-/-Y16Atg 
A22Cα
-/-
PI1
-/-
 KEY 
A22Cα
-/-
PI2
-/-
 
Unfilled shapes = 4-7 weeks  Filled shapes = 11-16 weeks 
THYMUS SPLEEN PLN MLN 
**  
**  
**  
**  
**  **  
**  
**  
**  
**  **  
**  
**  
**  
**  **  
**  
**  
244 
 
FIGURE 48: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software.
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FIGURE 48: CD8+TRBV15+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 49: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software.
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FIGURE 49: CD8+TRBV17+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 50: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software.
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FIGURE 50: CD8+TRBV26+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 51: Lymphoid cells were harvested from thymus, spleen, PLN and MLN of 
mice aged 4-7 weeks or 11-16 weeks. These cells were stained using a multi-
colour antibody staining panel (see 2.9.3.3) and measured on a BD FACS CANTO II 
to be analysed later using Flowjo Version 7.6.5 software. Data were then plotted 
using GraphPad Version 4 software. Each shape represents an individual mouse 
(n=8-13), with unfilled shapes representing those aged 4-7 weeks and filled 
shapes those aged 11-16 weeks. The median is shown for each data set by a 
horizontal line with statistically significant differences at p=<0.05 (*) and p=<0.01 
(**) between the strains shown following an ANOVA analysis using R software.
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FIGURE 51: CD8+TRBV31+ T CELL PROPORTIONS IN THE THYMI, SPLEEN, PANCREATIC LYMPH NODE (PLN) AND MESENTERIC LYMPH NODE 
(MLN) IN SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD MICE EXPRESSING VARYING PROINSULIN LEVELS 
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FIGURE 52: THE PREVALENCE OF INSULIN AUTO-ANTIBODIES IN MALE DIABETIC 
POLYCLONAL NOD MICE, MALE DIABETIC NOD MICE DEFICIENT IN PROINSULIN 
2 AND MALE DIABETIC SINGLE CHAIN TRANSGENIC TRAV8-1*01TRAJ9 NOD 
MICE DEFICIENT IN PROINSULIN 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 52: Serum was separated from the blood of diabetic male mice. Insulin 
auto-antibodies were then measured in a competitive insulin radioimmunoassay. 
Data were then plotted using GraphPad Version 4 software. Each shape 
represents an individual mouse (n=4-6 per group), with only males shown. 
Anything over the dotted line (over 0.0103) was deemed positive. Positivity was 
based on the mean plus 3 standard deviations from antibody measurements of 
control C57BL/6 mice. 
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